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ABSTRACT
Antibody directed enzyme prodrug therapy (ADEPT) is a two-step targeting 
system, which utilises pretargeting of antibody-enzyme to tumour followed by 
administration of a prodrug, which is converted to an active cytotoxic by the 
enzyme at tumour sites. This system aims to overcome cancer resistance 
mechanisms by the tumour specific generation of large quantities of a cytotoxic 
agent.
ADEPT is a complex therapeutic strategy as it involves multiple components, 
each of which has their own unique requirements for the system as a whole to be 
successful. It is hypothesised that by measuring mechanism in a clinical trial 
setting, a greater understanding of ADEPT can be achieved. Additionally, 
rational modifications can be determined and implemented, thereby accelerating 
the development process.
This thesis demonstrates how mechanistic data attained from one phase I/II 
ADEPT clinical trial lead to the development of a novel genetically engineered 
antibody-enzyme fusion protein for ADEPT, which was shown in a second 
clinical trial to have enhanced features for tumour targeting in ADEPT. The 
metabolic assessment of tumours using [F-18] FDG PET was assessed during 
both ADEPT trials and shown to provide additional information when compared 
with conventional response assessment, particularly in the assessment of patients 
with radiological stable disease. As the data generated on ADEPT from both 
preclinical and clinical development is large, and the possibilities for 
modification to the system are numerous, an Ontology and Conceptual Model 
have been developed to organise the data attained on ADEPT.
This thesis demonstrates that although ADEPT is a complex therapeutic strategy 
it can be successfully studied in a clinical setting using mechanistic clinical trial 
design, rational modifications can be made and data can be organised to facilitate 
development for the future.
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1 Introduction
1.1 Background
Cancer is the second largest cause of death in developed countries and its 
incidence is continuing to rise. Cancer currently causes 25% of all deaths in the 
United Kingdom (Cancer Research UK, 2002). Despite the recent vast increase 
in research into new chemotherapy agents including combination regimens, high 
dose therapies and novel strategies, few have made significant advances in the 
cure or long term survival of patients with advanced or metastatic solid tumours. 
Drug resistance remains a significant obstacle to therapy (Pastan and Gottesman, 
1987; Juranka et al, 1989; Kaye, 1998; Gottesman et al, 2002). The maximum 
dose of chemotherapy is limited by the development of systemic toxicities due to 
treatments not being tumour specific. One strategy to overcome resistance 
mechanisms is to specifically target tumour cells, thereby limiting systemic 
effects and increasing therapeutic potential. This forms the basic principle of 
antibody directed enzyme therapy (ADEPT), which is the focus of this thesis. A 
successful treatment requires a detailed understanding of the condition it is 
directed against, and the in vivo effects of the treatment on both tumour and 
normal tissues. From this information therapeutic strategies may be modified and 
developed with the aim of constructing a cure for a complex and serious disease.
1.1.1 Colorectal cancer
Colorectal cancer is the main solid tumour discussed throughout this thesis. It is a 
leading cause of cancer death in the UK, being responsible for 11% of all cancer 
deaths (second only to lung cancer), and resulting in nearly 17 000 deaths per 
annum in England and Wales (Quinn et al, 2001). The incidence of colorectal 
cancer is 48 cases /100 000 people per year in the UK (Quinn et al, 2001). The 
current 5-year survival for patients with colorectal cancer (all stages) is 40%. 
Once metastases develop the median survival for a patient is 11 months 
(Advanced Colorectal Cancer Meta-analysis Project, 1992). Conventional 
chemotherapy is unable to cure patients with advanced or metastatic disease, so 
there is an urgent need to develop novel therapies.
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5Fluorouracil (5FU) has historically been the mainstay of chemotherapy for 
colorectal cancer, with maximum response rates of approximately 20-30% in 
metastatic disease (Lokich et al, 1989; Advanced Colorectal Cancer Meta­
analysis Project, 1992; Meta-analysis Group in Cancer, 1998). It is an anti­
metabolite with predominantly S-phase activity. Infiisional regimens have been 
compared to bolus administration and are associated with an increase in response 
rate and a different toxicity profile, with a slight increase in overall survival 
(Lokich et al, 1989; Meta-analysis Group in Cancer, 1998). Bolus 5FU is 
associated with more haematological toxicities (grade III or IV in 31% of 
patients) compared with infusional schedules (grade III or IV in 4% of patients), 
however the occurrence of plantar-palmer syndrome is higher in infiisional 
schedules (34%) compared with bolus administration (13%) (Meta-analysis 
Group in Cancer, 1998). Diarrhoea, nausea and vomiting, or mouth ulcers occur 
in approximately 15% of patients for both schedules (Meta-analysis Group in 
Cancer, 1998). Many centres have undertaken trials using variations on 
infiisional or bolus regimens, with or without the addition of biomodulating 
agents (e.g.: folinic acid), with little impact on overall survival (Advanced 
Colorectal Cancer Meta-analysis Project, 1992; Leichman et al, 1995; Rougier et 
al, 1997).
Recently two new chemotherapeutics have been shown to have efficacy in 
advanced colorectal cancer. These are irinotecan (CPT11), a topoisomerase I 
inhibitor, and oxaliplatin, a synthetically derived platinum. Single agent 
irinotecan has an objective response rate of 13% as second line treatment for 
metastatic disease, with another 40-50% of patients achieving stable disease 
(Rougier and Mitry, 2000). An increased median survival of approximately 2 
months has been shown in two randomised controlled trials comparing single 
agent irinotecan administered after the failure of 5FU compared to best 
supportive care or an infusional 5FU regimen (Cunningham et al, 1998; Rougier 
et al, 1998). As a first line treatment for metastatic colorectal cancer, irinotecan 
in combination with 5FU has a response rate of 39-41% compared to 21-23% 
with 5FU alone, with a statistically significant improvement in time to 
progression and overall survival (Douillard et al, 2000; Saltz et al, 2000). The 
side-effects associated with irinotecan are diarrhoea, myelosuppression
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(neutropaenia), acute cholinergic syndrome, nausea and vomiting. Grade 3 or 4 
diarrhoea has been reported in 20-40% of patients with single agent irinotecan or 
irinotecan in combination with 5FU (Cunningham et al, 1998; Douillard et al, 
2000; Saltz et al, 2000). Grade 3 or 4 neutropaenia has been reported in up to 
54% of patients (Saltz et al, 2000).
Single agent oxaliplatin used as first line chemotherapy for metastatic colorectal 
carcinoma has a response rate of approximately 22%, which is comparable with 
single agent 5FU(Armand et al, 2000). Significant synergy has been shown in 
vitro between oxaliplatin and 5FU, so most clinical trials have utilised this 
combination. In first-line therapy for metastatic disease the combination of 
oxaliplatin with 5FU has resulted in a response rate of approximately 50% (de 
Gramont et al, 2000; Giacchetti et al, 2000). The toxicities seen include 
neutropaenia, diarrhoea, peripheral neuropathy, nausea and vomiting (de 
Gramont et al, 2000; Giacchetti et al, 2000). There were improvements seen in 
time to progression, but overall survival was not significantly improved by the 
addition of oxaliplatin to a 5FU regimen (de Gramont et al, 2000; Giacchetti et 
al, 2000).
Despite the introduction of both irinotecan and oxaliplatin into the management 
of advanced colorectal cancer and the increased response rates that have been 
seen, these treatments have remained essentially palliative and long-term cures 
have not been achieved. Improvements in survival have, in some trials, been 
attained, but these improvements have been in terms of months, rather than 
years. Also, these treatments are associated with significant toxicities for 
patients, which is not only undesirable but also limits the dose of chemotherapy 
that can be administered. The need therefore remains for a more effective and 
tumour specific treatment.
1.2 Antibody therapies for cancer
Antibody targeted therapy has the promise of the ‘magic bullet’ proposed by Paul
Ehrlich almost a century ago. The aim is to develop a system that will target
therapeutic agents to specific tissues such as tumours to maximise effect, while at
the same time reducing systemic toxicity. Since the 1980’s monoclonal antibody
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therapy, either alone or conjugated to therapeutic agents such as radionuclides, 
drugs, toxins, enzymes or growth factors have been recognised as emerging 
agents for the diagnosis and treatment of cancer.
Antibody therapy for cancer was used as early as 1895 when Hericourt and 
Richet immunized animals with human tumour extracts and gave the serum to 
patients resulting in some tumour responses (Hericourt and Richet, 1895). 
Polyclonal antibodies were used from the 1940’s and shown to react with tumour 
antigens (for review - Boschoff and Begent, 1996). However, the development of 
hybridoma technology in 1975 by Kohler and Milstein allowed for the first time 
the generation of monoclonal antibodies with defined specificities (Kohler and 
Milstein, 1975). More recently techniques such as the development of phage 
technology for generating large libraries of monoclonal antibodies with the 
ability to select for desirable characteristics have further expanded the 
possibilities of monoclonal antibody therapy (Huse et al, 1989).
A normal immune response to a foreign antigen involves the activation of B- 
lymphocytes to secrete antibodies that bind to various epitopes of the antigen. 
This polyclonal antibody response has heterogeneous specificities and affinities. 
Each ‘batch’ of polyclonal antiserum made to an antigen is also variable. 
Monoclonal antibodies, however, bind to the antigen (a defined epitope) with one 
specificity and one affinity, and can be manufactured in large amounts in the 
laboratory under standard conditions. This ‘uniformity’ makes them more 
suitable for therapeutic use.
Genetic engineering has lead to the design of various antibody-derived molecules 
(Hawkins and Chester, 1996). A whole IgG antibody is 150kDa and consists of 2 
variable light chains ( V l ) ,  2 variable heavy chains (V h ), 2 constant light chains 
(C l)  and 6 constant heavy chains (2 xC h1, 2 xC h2 , 2 xCh3) (f ig u re  1). The 
domains of V l ,  V h , C l  and C hI make up the antigen-binding end of the molecule 
(Fab). The Ch2 and Ch3 domains comprise the Fc portion, which is important in 
recruitment of the host immune response and persistence of the antibody in the 
circulation.
24
Figure 1: Schematic diagram of whole IgG
,Vh
Fab
Diagrammatic representation o f IgG, which consists o f 2 variable light chains 
(V l) , 2 variable heavy chains (V h ), 2 constant light chains ( C l)  and 6 constant 
heavy chains (2x C hI, 2x C h2, 2x C h3). The Fab region o f the molecule is 
associated with antigen interaction, and the Fc portion is involved in recruitment 
o f effector cells.
Single chain Fv (scFv) are the smallest antibody fragments retaining full 
antibody specificity, but only remain stable if the Vh and V l chains are joined by 
a flexible linker (Huston et al, 1988). A scFv has a molecular weight of 27kDa 
(figure 2).
Figure 2: Schematic diagrams of whole antibody and antibody
fragments
Diagrammatic representation o f IgG, with the antibody fragments F(ab)2, and 
scFv. The F(ab)2, fragment consists o f 2 variable light chains (V l) ,  2 variable 
heavy chains (V h) ,  2 constant light chains (C l)  and 2 constant heavy chains 
(C h I)-  S cF v  consists o f 1 variable light chain (Vl) ,  and 1 variable heavy chain 
(V h)  with a flexible linker.
F(ab’)2
lOOkDa
Single chain Fv
27kDa
IgG
150kDa
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The two main methods of generating monoclonal antibodies are hybridoma 
technology and combinatorial phage libraries. Kohler and Milstein developed the 
hybridoma technique in 1975 (Kohler and Milstein, 1975). It involves the 
immunization of mice against a target antigen and then immortalizing the 
antibody producing B cells by fusing with myeloma cells to produce a 
hybridoma. The resultant hybridoma produces uniform antibodies of a single 
specificity. The hybridoma cell line can potentially produce a large quantity of 
antibody indefinitely; however, the method has the limitation that only a small 
amount of an antibody repertoire can be examined because each clone must be 
studied separately for its specificity. Combinatorial phage libraries have 
developed more recently as a result of the ability to purify antibody variable 
region genes from populations of B cells by polymerase chin reaction (PCR) 
using specific primers. Copy deoxyribonucleic acid (cDNA) encoding Fab or VH 
and Vl joined by a synthetic linker, is cloned into a bacteriophage genome where 
it encodes the antibody protein. If filamentous phage are used, the protein 
product can be displayed on the cell surface, therefore allowing the 
bacteriophage to be used directly to select for required specificity and binding 
characteristics (f ig u re  3 ) (Huse et al, 1989; McCafferty et al, 1990; Chester et al, 
1994; Verhaar et al, 1995).
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Figure 3: Combinatorial phage library
X N i r  Lymphocytes
VH Linker VL
RN A
1. Immunise with Antigen
cDNA
2 .Antibody V genes PCR 
amplified and randomly linked
5 .Subclone; express soluble scFv
Phage
Streptavidin coated
magnetic bead «l
p  p
Biotinylated Antipin ^  p
3 .Linked genes cloned into phage 
to create scFv library
4. Select target antigen reactive phage
Schematic representation o f generation o f a combinatorial phage library 
Abbreviations: RNA- ribonucleic acid; cDNA-copy deoxyribonucleic acid; scFv- 
single chain variable fragment; Vn-variable heavy fragment; VL-variable light 
fragment (reproduced with permission from K  Chester).
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The advantages of phage libraries over hybridoma technology are listed in Table 
1.
Table 1: The advantages of phage libraries compared to
hybridoma technology for the production of monoclonal antibodies
■ 1    .    "T^T'    ' ' """ *1 A  .Able to produce large quantities (10 ) of antibody clones (hybridoma 10 -10 )________
V h and VLare randomly recombined in scFv, giving a potentially broader repertoire than
occurs naturally___________________________________________________________
Selection for a desired characteristic can be made from the whole library, whereas
hybridomas are screened clone by clone_______________________________________
Production is commonly via bacterial or yeast cells and not by mammalian cells
eliminating the risk of mammalian virus and DNA contamination.___________________
Production is relatively low cost_____________________________________________
Antibodies are cloned facilitating generation of engineered antibodies and fusion proteins
1.2.1 Factors that influence tumour targeting by antibodies
Selective tumour targeting of antibodies may be influenced by both the 
characteristics of the antibody and characteristics of the antigen.
Antibody characteristics
Molecular size
The molecular weight of an antibody influences both the penetration of the 
antibody into a tumour and the rate of clearance from the circulation. Large 
antibodies, such as IgG, escape from the vasculature into the tumour slowly and 
penetrate through the tumour slowly (Russell et al, 1992). They therefore tend to 
remain in peripheral areas of the tumour close to blood vessels (Buchegger et al,
1983; Pedley, 1996). Their larger molecular size reduces their renal clearance 
and they remain in the systemic circulation for longer. They have low tumour: 
blood ratios over the first 4-48 hours after administration, with peak tumour: 
blood ratios usually occurring at 72-96 hours post administration (Lane et al,
1994; Behr et al, 1995). Smaller fragments (scFv or Fab fragments) penetrate 
further into the tumour (Buchegger et al, 1983; Russell et al, 1992; Yokota et al,
1992; Begent et al, 1996). They also circulate systemically for shorter periods of
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time due to rapid renal filtration (Colcher et al, 1990; Milencic et al, 1991; 
Verhaar et al, 1995; Begent et al, 1996). Positive tumour: blood ratios occur 
earlier than with whole antibodies, however, the rapid clearance from the 
circulation results in less total antibody available for tumour binding and lower 
absolute tumour antibody levels (Yokota et al, 1992, Pedley et al, 1993, Behr et 
al, 1995).
Affinity and avidity
Affinity is a measure of the strength of the bond between antigen and antibody. 
Measurements of affinity relate to equilibrium conditions, and can be expressed 
by a kinetic ‘on-rate’ and ‘off rate’. The affinity of an antibody for its antigen is 
important for targeting especially when antigen concentration is low within a 
tumour. High affinity antibodies often have a slow ‘off rate’ (ie: once they bind 
antigen they remain bound to it) (Adams et al, 2001). These antibodies have been 
shown to deposit heavily in areas closely adjacent to tumour vasculature, with 
very little diffusion through the tumour (Adams et al, 2001). This phenomenon 
has been theorized to be due to a ‘binding site barrier’, which proposes that 
macromolecular ligands are prevented from penetrating tumours by their 
successful binding to their receptor (Fujimori et al, 1990; Weinstein and van 
Osdol, 1992). The barrier is greater with higher affinity antibodies. This may be 
overcome to some degree by increasing the administered dose of antibody or by 
prolonging the infusion time, but this may result in lower tumour to blood ratios 
as more antibody is present systemically (Fujimori et al, 1990). Low affinity 
antibodies, with a rapid off rate, diffuse further into the tumour, but are not 
retained for as long as higher affinity antibodies (Adams et al, 2001). They 
therefore do not achieve as selective targeting.
Affinity describes a univalent interaction, however natural antibodies are
polyvalent (i.e.: have more than one binding site), which results in a much more
stable interaction. Avidity is used to describe a monovalent or polyvalent
interaction; the latter can result in a large improvement in functional affinity. For
example, IgG, which is a bivalent molecule, has an approximately 1000-fold
increase in functional affinity in comparison to a single Fab fragment (Hawkins
and Chester, 1996). It has been demonstrated, using image registration
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techniques to correlate radiolabelled antibody tumour distribution with tumour 
morphology, that bivalent and trivalent antibodies have longer retention in viable 
tumour areas compared to monovalent antibodies (Chester et al, 2000; Flynn et 
al, 2002).
Specificity and selectivity
The specificity of an antibody for its antigen will influence its biodistribution. 
Specific antibodies bind to the antigen within tumour areas and are retained for a 
period of time, whereas non-specific antibodies do not bind and are therefore not 
retained. The tumour to normal tissue ratio of specific antibody therefore steadily 
increases with time, whereas for a non-specific antibody the ratios will remain 
low. Microdistribution studies have shown that specific antibodies remain 
retained for longer in viable tumour areas, whereas non-specific antibodies pass 
quickly through to the necrotic centre of tumours, where there is little therapeutic 
potential (Flynn et al, 1999).
The selectivity of an antibody for its antigen will determine the likelihood of 
cross-reactivity with normal tissue. Cross-reactivity is undesirable as it results in 
unwanted toxicity and unfavourable targeting ratios.
Immunogenicity
Murine antibodies are immunogenic in humans and in the presence of an intact 
immune system lead to the production of human anti-mouse antibodies (HAMA). 
Repeated administration results in progressively shorter circulating half-life of 
the antibody, with poor tumour localisation and retention. It may also lead to 
immune reactions such as anaphylaxis and serum sickness. The development of 
chimeric antibodies with murine variable regions and human constant regions has 
greatly reduced problems of immunogenicity (Boulianne et al, 1984; Neuberger 
et al, 1985). ‘Reshaped’ or ‘humanised’ antibodies have also been developed, in 
which only the antigen binding site, rather than the whole variable domain, is 
transplanted from rodent antibodies onto human antibodies, with the advantage 
of potentially even further reduced immunogenicity (Riechmann et al, 1988). 
Chimeric or humanised antibodies can be given repeatedly usually with no
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significant reduction in circulating half-life. The half-life of chimeric antibodies 
in humans is much longer than murine antibodies, with half-lives in serum of 10 
days or longer being reported (Begent et al, 1990; Amlot et al, 1995). It also 
appears that having a human effector Fc arm of the antibody results in better 
recruitment of the host immune response in particular, cell mediated immunity. It 
is possible to develop human antibodies to chimeric antibodies -  either to the 
murine variable region (anti-idiotypic antibodies) or to the human constant 
regions, although in clinical practice to date this has not frequently been a 
significant problem.
Other methods of reducing immunogenicity to murine antibodies include using 
smaller antibody fragments, adding polyethylene glycol or glycosylations to the 
antibody or suppressing the immune system with drugs such as cyclosporin.
Antigen characteristics
Tumours may express certain antigens that differentiate them from normal cells 
and therefore provide targets for therapy. Important characteristics of a target 
antigen include its tumour specificity, the presence of a soluble form, the 
antigen’s normal function and the distribution of the antigen in the tumour 
(Chester and Hawkins, 1995; Hawkins and Chester, 1996).
Tumour specificity o f target antigen
Tumour antigens may be unique to the tumour or they may be in relative 
abundance in tumours compared to normal tissues. Antigens that are unique to 
tumour cells are less common, and include immunoglobulin idiotypes in B cell 
lymphomas and mutated cellular proteins such as mutated epidermal growth 
factor in gliomas and non-small cell lung cancer (Garcia de Palazzo et al, 1993; 
Weiner, 1999).
B cell lymphoma/ leukaemia result from the abnormal proliferation of a single 
clone of transformed cells (Levy et al, 1977). These transformed cells all express 
a cell surface immunoglobulin that contains a unique epitope that may be used to 
differentiate the cancer cell from other normal cells (Levy et al, 1977). It is a
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very specific target as there is no normal tissue expression, however therapies 
against this target must be tailor-made as the epitope is also unique to individual 
patients. Polyclonal anti-idiotype sheep antibodies were used in an attempt to 
treat chronic lymphocytic leukaemia as early as 1979 (Hamblin et al, 1980; 
Gordon et al, 1984). Although tumour shrinkage was not seen, there was a 
transient fall in peripheral lymphocyte count with therapy (Hamblin et al, 1980; 
Gordon et al, 1984). The first example of an anti-idiotype murine monoclonal 
antibody being used therapeutically in a patient with poorly differentiated 
lymphocytic lymphoma was reported in 1982 (Miller et al, 1982). After being 
treated with 400mg of anti-idiotype antibody the patient obtained a complete 
remission from their disease (Miller et al, 1982). This remission lasted for 6lA 
years (Brown et al, 1989). Many other patients have since received anti-idiotype 
therapy with reproducible anti-tumour effects (Brown et al, 1989).
Immunotherapy using anti-idiotype scFv fragments has also been used as a 
treatment strategy. V-region sequences encoding idiotypic antigen are isolated 
from tumours and then assembled as scFv (± Fc antibody fragment) and 
incorporated into an adenovirus vector (Armstrong et al, 2002). The recombinant 
vector is then administered and is used to produce host- generated anti-idiotypic 
antibody and T cell mediated tumour cytotoxicity (Armstrong et al, 2002).
Initially the generation of anti-idiotype antibodies took approximately 1 year for 
each patient, which limited their clinical applicability (Brown et al, 1989). 
Advancements in phage technology have greatly reduced the time for individual 
antibodies to be developed and this improves the likelihood of anti-idiotype 
therapy becoming more widely available (Miller et al, 1989).
Most tumour antigens are not tumour specific, but are present in much higher
quantities in tumour than in normal tissues. Examples of these include oncofetal
antigens (carcinoembryonic antigen, a fetoprotein), growth factor receptors (her-
2 neu, epidermal growth factor receptor), differentiation antigens (CD20, CD25,
CD33), stromal antigens (integrins, fibroblast activation markers) and antigens
associated with hypoxia or neovascularisation (HIFa, vascular endothelial
growth factor -VEGF). New targets are constantly being identified from the
study of mutations, gene expression profiling and as a result of a proteomic
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studies (Alizadeh et al, 2000; Martin et al, 2000; Vogelstein et al, 2000; 
Reidhaar-Olson and Hammer, 2001). Tumour targeting can occur with these 
antigens, if the normal tissue expression is minimal, in non-essential tissues or is 
inaccessible to antibodies. Several antibodies have shown efficacy and have now 
been licensed for therapy against these ‘relatively’ tumour-specific antigens. 
These include rituximab anti-CD20 antibody (Rituxan® Genentech Inc. and 
IDEC Pharmaceuticals Corporation) and trastuzumab anti-Her-2 neu antibody 
(Herceptin® Genentech Inc).
Circulating antigen
Some tumour antigens have a circulating form in addition to the tumour-bound 
component. This has proved useful in the clinical situation for monitoring 
conventional chemotherapy, or for screening for primary or recurrent cancer 
(Bidart et al, 1999). Tumour antigens which are commonly used for this purpose 
include carcinoembryonic antigen, a fetoprotein and human chorionic 
gonadotrophin. It can however pose problems in antibody targeting as circulating 
antibody binds the secreted antigen systemically, making less available for 
tumour localisation (Martin et al, 1984; Pedley et al, 1989; Boxer et al, 1992).
Cellular function o f antigen
Antigens may be derived from molecules which have a cellular function, such as 
a growth factor receptor or a tyrosine kinase enzyme. The binding of antibody to 
antigen may therefore result in the ‘switching-off (blocking antibodies) or 
‘switching-on’ (activating antibodies) of this function. Overexpressed growth 
factor receptors or constitutively expressed tyrosine kinase enzymes will lead to 
abnormal cellular regulation, and have been recognised as one of the steps of 
cancer development. Blocking growth factor receptors or enzymes may therefore 
control tumour growth. In addition the binding of an antibody to a receptor and 
activating it to cause down-stream signalling may be another method of attaining 
cytotoxic effect.
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Antigen location and accessibility
Antigens are cell surface bound, or intracellular. Intracellular antigens require 
internalisation of the antibody for efficacy. Cell surface antigens are therefore 
more accessible for targeting. The distribution of the antigen within the tumour is 
also important as antigens expressed adjacent to tumour vasculature are more 
accessible from the systemic circulation than antigens in the deeper parenchymal 
region (Boxer et al, 1992; Russell et al, 1992).
Antigens are often heterogeneously expressed within a solid tumour (Hockey et 
al, 1984; Chung et al, 1994; Boxer et al, 1999; Flynn et al, 2001). A therapy or 
targeting system that relies upon each target cell expressing the antigen will 
therefore lead to selective therapy to antigen expressing cells, with a proportion 
of cells escaping. Antibody therapies that exert a bystander effect onto 
neighbouring cells are therefore theoretically more likely to be efficacious.
1.2.2 Therapeutic approaches using antibodies
Antibodies can be used as molecules that influence biological processes, or as 
targeting moieties, used to deliver radiation, toxins, cytotoxics or enzymes 
specifically to a tumour site.
Antibodies as biomodulators
The interaction of an antibody with its antigen may produce biological effects 
that can be exploited for therapeutic purposes. Antibodies may block access of 
growth factors, cytokines or other soluble factors by either binding directly to the 
soluble factor itself or by binding to its receptor (Glennie and Johnson, 2000). 
They thereby interrupt the growth stimulus to a cancer cell. Antibodies may also 
mark the antigen-expressing cell for activation of complement and recruitment of 
cellular effectors against the target cell (Glennie and Johnson, 2000). An 
example of this is the anti-CD20 antibody rituximab, which activates antibody- 
directed cellular cytotoxicity (ADCC) killing of the target lymphoma cells. A 
third mechanism of action may be through signalling pathways that occur when 
antibodies crosslink the target molecule and deliver transmembrane signals that
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control cell division. Rituximab also appears to have a direct cell-signalling role 
in CD20 positive cells (Johnson and Glennie, 2001). These more complex 
interactions often rely on the Fc arm of the antibody for effector function and do 
not function as effectively when antibody fragments are used (Glennie and 
Johnson, 2000).
Antibodies as targeting agents
Antibodies also can be used as targeting vehicles to deliver radiation, toxins, 
cytotoxics or enzymes to tumours.
Radioimmunotherapy
Radioimmunotherapy utilises antibodies to deliver radioactivity, usually in the 
form of p emitting radioisotopes, to tumours. This has been an encouraging 
strategy in the treatment of radiosensitive tumours, such as lymphoma, where 
sustained tumour responses have been observed. High dose radioimmunotherapy 
with autologous bone marrow rescue using and an iodine-131 labelled anti- 
CD20 antibody produced a complete response rate of 84% and partial response 
rate of 10% in 19 patients with relapsed B cell lymphoma (Press et al, 1993). 
Many of these patients were heavily pre-treated, and the responses were often 
sustained, with a progression free survival of 62% after 2 years. These results 
suggest that some of the patients may have been cured by the high dose therapy, 
which illustrates the potential of radioimmunotherapy.
Zevalin® (Biogen Idee), Y-90-ibritumomab tiuxetan, is an yttrium labelled 
murine anti-CD20 antibody, which is the first agent used for 
radioimmunotherapy to receive Food and Drug Administration (FDA) approval 
in the USA. Ibritumomab is the murine parent of rituximab, and forms the 
antibody component of Zevalin®. Zevalin® is indicated in the treatment of 
patients with relapsed or refractory low-grade, follicular, or transformed CD20 
positive B-cell non-Hodgkin's lymphoma, including patients with rituximab 
refractory follicular non-Hodgkin's lymphoma. The overall response rate in 
patients receiving Zevalin® was 80%, compared to those randomised to receive 
rituximab alone who had a response rate of 56% (]Witzig et al, 2002). Duration
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of response was not significantly different between the two groups, and survival 
data has not yet matured. Non-haematological toxicity was similar between the 
two groups (lWitzig et al, 2002). In addition a study was performed in patients 
refractory to rituximab, which found that there was a 74% response rate to 
Zevalin® in this patient group (2Witzeg et al, 2002).
Radioimmunotherapy has been used in phase I/II clinical trials for the treatment 
of common solid tumours. It has, however, generally been associated with a 
much lower response rates than when haematological malignancies are treated 
(Lane et al, 1994). Responses appear more likely when smaller volumes of 
disease are treated (Behr et al, 2002).
Radioimmunotherapy has the advantage of a bystander effect, in that targeted 
radiation may cause DNA damage and cell death to antigen positive cells as well 
as adjacent antigen negative cells. However biodistribution and dosimetry studies 
reveal that it takes up to 24 hours until maximum antibody accumulation in 
tumour occurs and several days until background antibody clears and positive 
tumour to normal tissue antibody ratios are achieved. The absolute amounts of 
antibody retained in the tumour areas have been shown to be low when a 
radiolabelled antibody has been administered and tumour tissue radioactivity 
subsequently measured directly. One study showed that 0.001 of the total 
administered radioactivity was found in human tumours resected at an average of 
five post radiolabelled antibody administration (correction applied for 
radioactivity decay only) (Mach et al, 1980). A pre-clinical study showed that 
that the absolute amount of radioactivity in tumour after administration of 
tumour specific antibody was 0.015% of the injected dose per gram of tissue 
(Epenetos et al, 1986). The average tumour to normal tissue ratio obtained has 
been shown to be 5:1 -10:1 (Mach et al, 1980; Lane et al, 1994; Wagner et al, 
2002). Consequently a large amount of radiation may also be distributed 
elsewhere in the body resulting in haematological and other toxicities.
Depending on the radioisotope chosen, radioimmunotherapy may also be 
associated with logistical problems such as the requirement for patients to be 
treated in specialist centres with appropriate radiation protection procedures in 
place.
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Immunotoxins
Immunotoxins consist of an antibody linked to a cellular toxin, which is usually 
plant or animal derived. The antibody replaces the toxin’s normal cell binding 
and internalisation domains in order to allow specific targeting of the toxin to an 
appropriate antigen on a cancer cell. The immunotoxin must usually be 
internalised into the cell for therapy as the toxin acts on intracellular targets such 
as ribosomes (Byers and Baldwin, 1988). These toxins have a very high potency 
and only a few molecules need to be internalised for effect. There is, however, no 
bystander effect, so theoretically each tumour cell must be targeted in order to 
produce ‘cure’. A phase I study of an anti CD22 murine antibody linked to the 
immunotoxin, ricin A, was performed in 26 patients with refractory B cell 
lymphoma (Amlot et al, 1993). In 24 evaluable patients there was one complete 
response and five partial responses at 1 month (overall response rate 25%). The 
main side-effects were vascular leak syndrome and myalgia. The vascular leak 
syndrome was dose limiting. Responses were rapid (37.5% of patients had a > 
50% reduction in size of tumours at 1 week) but generally not sustained (30-78 
days for responders at 1 month). Vascular leak syndrome can be a serious 
problem, particularly when it involves the lungs and causes pulmonary oedema, 
which may be fatal.
More encouraging results were seen with BL22, which is an anti-CD22 Fv fused 
to a truncated pseudomonas exotoxin. When used in refractory hairy cell 
leukaemia eleven of sixteen patients attained a complete response, and a further 
two patients attained a partial response (Kreitman et al, 2001). The treatment was 
reasonably well tolerated, with only one patient developing a cytokine release 
syndrome (subsequent patients were pretreated with a cox-2 inhibitor and an 
anti-TNF antibody to prevent further episodes), and two patients developed 
haemolytic uremic syndrome (Kreitman et al, 2001).
Antibody-cytotoxic immunoconjugates
Antibodies may be used to target chemotherapeutics specifically to tumours. 
Initially it was hoped that this would improve the specificity of commonly used 
cytotoxics, however clinical trials to date with this approach have not been
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encouraging (Tjandra et al, 1989; Elias et al, 1990; Tolcher et al, 1999). High 
potency cytotoxics, such as calicheamicin, conjugated to antibodies have, 
however, been more promising. CMA-676 (gemtuzumab ozogamicin; Mylotarg 
® Wyeth Ayerst) is an immunoconjugate of a humanised anti-CD33 antibody 
with calicheamicin, which has be shown in clinical trials to produce responses in 
patients with refractory acute myeloid leukaemia (Sievers et al, 1999; Bernstein,
2000). It has recently been licensed for use in USA for the treatment of relapsed 
CD33 positive acute myeloid leukaemia in patients aged over 60.
Pretargeting strategies
Pretargeting strategies have been developed to improve therapeutic ratios 
between tumour and normal tissues. This is achieved in two or more steps. First, 
a targeting vehicle, which consists of an antibody with a tag attached, is 
administered. Once the tagged antibody has reached the tumour, a second 
conjugate is administered which will recognise the tag on the first antibody- 
complex (Stoldt et al, 1997). Ideally at this time the first antibody complex will 
be localised in the tumour, with minimal systemic retention. The second 
component is used to administer a cytotoxic effect, such as the delivery of 
radioactivity.
In a 2-step system the first antibody is allowed to clear by itself, and in a 3-step 
system a ‘chaser’ is given to accelerate systemic clearance of the first antibody. 
Without the use of a ‘chaser’ the antibody may take many days to clear to 
sufficient levels to administer the second molecule.
Pretargeting allows the generation or retention of high concentrations of the 
therapeutic molecule specifically in the tumour with reduced levels in normal 
tissues when compared with direct delivery systems such as 
radioimmunotherapy. Pretargeting systems have therefore the advantage of 
improved therapeutic ratios, with potentially less toxicity to normal organs. It has 
been predicted in mathematical models that the increase is up to 200% in tumour 
to background ratio (Zhu et al, 1998). The disadvantage is their added 
complexity and the requirement for careful timing and dosing in order to achieve 
high therapeutic targeting (Goodwin and Meares, 1997; Goldenberg, 2002).
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Avidin-biotin systems, or streptavidin-biotin systems have been used for 
pretargeting and have feasibility for radioimmunotherapy and 
radioimmunoscintigraphy. Magnani et al demonstrated in patients undergoing 
enucleation for uveal melanoma using single photon emission computerised 
tomography (SPECT) imaging that the 3-step avidin-biotin system resulted in an 
increased tumour-to-nontumour ratio of 3.1 versus 1.5 for conventional 
radioimmunoscintigraphy (Magnani et al, 1996). Tumour responses have been 
demonstrated in patients treated with avidin-biotin or streptavidin-biotin 
pretargeting strategies (Stoldt et al, 1997; Paganelli et al, 1998; Grana et al, 
2002). Avidin and streptavidin are, however, both immunogenic and 
opportunities for repeated therapy may be limited.
ADEPT is a pretargeted strategy, which utilises an antibody tagged with an 
enzyme as its first step, and a prodrug activation system as its effector function. 
Prodrug strategies are discussed in more detail below and ADEPT is further 
expanded in section 1.4.
1.3 Prodrug therapies for cancer
Anticancer prodrugs were being developed by Ross and Warwick as early as 
1955 at Chester Beatty Research Institute (Bagshawe, 1987). The prodrugs were 
designed to be activated in vivo by enzymatic cleavage to release powerful 
alkylating agents. It was proposed that tumour specificity could be obtained by 
the cleavage of prodrugs by enzymes that were present in much higher 
concentrations in tumour than normal tissues (Connors, 1978; Carl et al, 1980).
One of their prodrugs, CB1954 (5-aziridinyl-2,4-dinitrobenzamide), displayed 
impressive preclinical activity specifically in the Walker 256 rat carcinoma 
model (Cobb et al, 1969; Connors and Melzak, 1971). This tumour was found to 
express high levels of the enzyme, DT diaphorase, which activated the prodrug, 
CB1954 by a 2-electron reduction (Denny et al., 1996). Unfortunately CB1954 
was subsequently found to be a much poorer substrate for human than rat DT 
diaphorase, which has limited its clinical applicability (Boland et al, 1991). 
CB1954 in the Walker rat carcinoma model however established the principle of 
tumour specific prodrug activation.
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Aniline mustards were subsequently shown to produce ‘cures’ in established 
plasma cell tumours in mouse models (Whisson and Connors, 1965). Further 
investigation revealed that the therapeutic effect of aniline mustards were related 
to the enzyme, P glucuronidase, which was present at a 5 times greater 
concentration in the plasma cell tumours than in the normal mouse liver 
(Connors and Whisson, 1966). It was concluded that the therapeutic effect of the 
aniline mustards was as a consequence of glucuronide formation in the liver 
followed by the breakdown of the glucuronide-aniline mustard by p 
glucuronidase in the tumour to form a cytotoxic agent (Connors and Whisson, 
1966). The high concentrations of p glucuronidase in the plasma cell tumours 
resulted in efficacy of the aniline mustard, whereas tumours with lower 
expression of p glucuronidase (sarcoma 180 and NK lymphoma) were more 
resistant to aniline mustard therapy (Connors and Whisson, 1966).
Bioreductive drugs are prodrugs that are selectively metabolised to cytotoxic 
agents in hypoxic areas (Connors, 1996; Denny et al, 1996). Tumours are known 
to have hypoxic regions, which are generally radioresistant and chemoresistant. It 
was initially proposed that bioreductive drugs would be activated in hypoxic 
conditions and kill hypoxic cells selectively. Subsequently it was suggested that 
if bioreductive drugs release a diffusible cytotoxic agent then a bystander effect 
could ensure a greater therapeutic potential by also having cytotoxic effects on 
surrounding normoxic tumour cells (Denny and Wilson, 1993). The activation of 
bioreductive prodrugs in hypoxic conditions may occur as a result of low pH, 
availability of oxygen for inactivation of chemical intermediates by chemical 
oxidation or by the presence of hypoxia specific enzymes, such as DT diaphorase 
(Denny et al, 1996). Mitomycin C is an example of a chemotherapeutic 
selectively activated by the enzyme DT diaphorase, which is present in hypoxia 
(Ross et al, 1993).
Capecitabine is a prodrug with tumour specific activation that has recently been 
developed and is in clinical use. Capecitabine is a fluoropyrimidine carbamate 
prodrug of 5FU. It is administered orally, is rapidly and almost completed 
absorbed in the upper gastrointestinal tract as an intact molecule, and is then 
converted by a 3 step enzymatic pathway to 5FU preferentially in tumour tissue
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(Miwa et al, 1998; Judson et al, 1999; Twelves and Anthoney, 2000; Venturini et 
al, 2002). The first two enzymes involved in the conversion of capecitabine to 
5FU, carboxylesterase and cytidine deaminase, are expressed mainly in the liver 
(Miwa et al, 1998). The final step depends on thymidine phosphorylase (TP), an 
enzyme that is present at higher concentrations in tumours than in normal tissues 
(Miwa et al, 1998). TP (also known as platelet-derived endothelial-cell growth 
factor; Pd-EGCF) expression in tumours is related to angiogenesis, enhanced 
tumour growth and invasion (Brown and Bicknell, 1998; Fox et al, 2001). It 
appears to be up-regulated by hypoxia and low pH, which are found in poorly 
perfused areas of tumours (Griffiths et al, 1997). It has been correlated with a 
poor prognosis in patients with colorectal cancer, non-Hodgkin’s lymphoma, 
breast cancer, non small cell lung cancer and gastric cancer (Maeda et al, 1996; 
Takebayashi et al, 1996; Brown and Bicknell, 1998). TP activity measured in 
various types of human tumour tissues has been found to be 3-10 times higher in 
tumours than in normal tissue adjacent to the tumour (Miwa et al, 1998). The 
exception to this is the liver, where the enzyme activity was higher than in the 
other normal tissues. It has been demonstrated in mouse xenograft models of 
human breast and colorectal cancer that exposure to chemotherapeutic agents 
(paclitaxel, docetaxel, mitomycin C or cyclophosphamide) increases tumour TP 
activity 4-8 fold (Sawada et al, 1998; Endo et al, 1999). An increase in TP 
activity in tumours exposed to radiotherapy has also been shown (Sawada et al,
1999).
The tumour selectivity of capecitabine has been demonstrated in a study of 19 
patients who had either primary tumours or liver metastasis resected after 5-7 
days of oral capecitabine. In primary colorectal tumours the mean 5FU 
concentration was 3.2 times higher in tumour than in surrounding normal tissues 
(p=0.002), and tumour to plasma concentrations of 5FU exceeded 20 to 1 
(Schuller et al, 2000). The ratio of 5FU concentration in colorectal tumours 
compared to other normal tissues was 8-10 to 1 (Schuller et al, 2000). The ratio 
of 5FU concentration in liver metastasis compared to adjacent normal liver was 
only 1.4 to 1 (p=0.49, not significant) (Schuller et al, 2000). This result confirms 
the colorectal tumour selective activation of capecitabine by TP. This effect is
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much less pronounced in the liver where TP activity is approximately equal in 
tumour and normal liver.
Pharmacokinetic studies have shown that the maximum plasma concentration for 
both capecitabine and 5FU occurs at approximately 2 hours after oral 
administration (Reigner et al, 2001). The half-life of 5FXJ in plasma was 
approximately 0.75-1.15 hours (Reigner et al, 2001). This indicates that although 
5FU may be preferentially formed in tumours it does circulate systemically. The 
area under the curve (AUC) for 5FU after administration of capecitabine is lower 
than after continuous 5FU infusion, however, it is likely that this circulating 5FU 
is resulting in toxicity to normal tissues which limits further dose escalation 
(Reigner et al, 2001).
Clinical studies have been performed with capecitabine and these have shown 
that the toxicities experienced were similar to those associated with infusional 
5FU and included hand-foot syndrome, diarrhoea, nausea, vomiting, and 
stomatitis (Van Cutsem et al, 2000). Two large randomized phase III trials 
totalling 1207 patients have been undertaken to assess the efficacy of 
capecitabine compared to 5FU (Mayo regimen) for first line treatment of 
metastatic colorectal cancer (Hoff et al, 2001; Van Cutsem et al, 2001). 
Capecitabine showed a superior response rate (25.7% vs 16.7%, p<0.0002) with 
equivalent time to progression (4.6 months vs 4.5 months) and survival (12.9 
months vs 12.8 months) when compared to 5FU (Twelves, 2002).
The efficacy of capecitabine is however limited by several factors. There is 
considerable variability in TP expression in colorectal tumours between patients. 
One study, in which TP expression by immunohistochemistry was measured in 
resected colorectal tumours (primary and liver metastasis) and adjacent normal 
tissue, showed that only 80% of patients had higher TP expression in the 
colorectal primary than in surrounding normal mucosa (Collie-Duguid et al,
2001). The range of tumour to normal tissue TP expression was 0.06-150.3 to 1 
(Collie-Duguid et al, 2001). Normal liver has a higher level of TP activity than 
other tissues, resulting in lower ratios of TP for liver metastasis from colorectal 
cancer to background normal liver. The mean ratio of TP measured in liver
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metastasis to background liver in the same study was 1.78:1 (range 0.35-17.23) 
(Collie-Duguid et al, 2001).
The rate limiting enzyme for the catabolism of 5FU is dihydropyrimidine 
dehygrogenase (DPD). DPD expression in colorectal tumours tends to be 
decreased compared to surrounding normal tissues, although, again, significant 
patient variability has been demonstrated (Collie-Duguid et al, 2001). 
Intratumoural gene expression of DPD has been shown to be inversely correlated 
with response to 5FU chemotherapy and to patient survival (Salonga et al, 2000). 
The efficacy of capecitabine has been shown in pre-clinical models to correlate 
very well with the ratio of TP:DPD levels (Ishikawa et al, 1998). This variability 
in both TP and DPD expression may therefore lead to a significant impact on 
efficacy of capecitabine in individual patients.
TP has been shown histologically to be concentrated in areas adjacent to necrotic 
tissue, where there is a low oxygen tension and low pH (Griffiths et al, 1997). 
This has implications for its effectiveness as a prodrug-activating enzyme. There 
may be problems with poor accessibility to systemically administered prodrug, 
and once the activated drug is formed the hypoxic and acidic environment may 
adversely affect its efficacy. Also the maximal drug concentrations will be 
formed in parts of the tumour where there are large numbers of cells that may 
already be dead, with less drug theoretically available to surrounding viable 
cancer cells.
5FU is an anti-metabolite with broad-ranging effects. It utilizes the same cellular 
transport and activation pathways as uracil, and once activated has effects on 
both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) (Sobrero et al,
2000). DNA synthesis is disrupted through inhibition of thymidine synthase (S 
phase specific effect). Incorporation of 5FU metabolites into both DNA and 
RNA results in alterations in its processing and function (non cell cycle 
dependent). Determinants of the factors important for sensitivity to 5FU are 
therefore complex, which leads to difficulties in the prediction of sensitivity and 
toxicity of 5FU in individual patients (Sobrero et al, 2000).
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Drug resistance to 5FU has been identified. The resistance mechanisms that have 
been described include overexpression of thymidine synthase and reduced drug 
transport across the cell membrane, as well as increased DPD enzyme (Hughes 
and Calvert, 1999). The emergence of drug resistance to 5FU may reduce the 
effectiveness of capecitabine.
Capecitabine is therefore an example of a therapeutically useful prodrug, 
however its efficacy is limited by the low ratios of tumour to normal tissue 
enzyme levels. A strategy that can increase the tumour to normal tissue enzyme 
ratios may thereby result in improved efficacy for a prodrug system.
1.4 Antibody directed enzyme prodrug therapy (ADEPT)
1.4.1 Background
Antibody directed enzyme prodrug therapy (ADEPT) uniquely combines the 
advantages of antibody targeting therapies with those of tumour specific prodrug 
systems. It is a two-step pretargeting approach. The first step involves 
administration of an antibody-enzyme. The antibody is used to localise an 
enzyme specifically to a tumour. Once antibody-enzyme has cleared from the 
circulation an appropriate prodrug is administered. The prodrug is activated by 
enzyme at the tumour site, resulting in tumour specific therapy (Bagshawe, 1987; 
Bagshawe etal, 1988; Senter et al, 1988; Senter, 1990; bagshawe, 1994; 
2Bagshawe, 1994; ^lakey et al, 1995; Niculescu-Duvaz and Springer, 1995; 
Senter and Springer, 2001) (figure 4).
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Figure 4: Schematic representation of ADEPT
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ADEPT is a pretargeting strategy, in which an antibody-enzyme complex is used 
to localise to tumour areas (a). This is followed by the administration o f a 
prodrug, which becomes activated by enzyme at the tumour site (b).
ADEPT has several potential therapeutic advantages over conventional 
chemotherapy. It utilises antibody targeting to achieve tumour specificity. The 
two-step approach allows clearance of background enzyme to occur before the 
effector (prodrug/drug) is administered, further increasing tumour specificity and 
reducing the likelihood of systemic toxicity. One enzyme molecule can activate 
many molecules o f prodrug thereby creating an amplification effect, which 
results in large amounts o f drug being generated in the tumour. As active drug is 
generated extracellularly it can diffuse to neighbouring cells, resulting in 
cytotoxicity to both antigen positive and antigen negative cells (bystander effect). 
The amount o f active cytotoxic generated at the tumour site should be much 
greater than could be administered systemically, consequently therapeutic 
efficacy should be improved and resistance mechanisms may potentially be 
overcome. The toxicity associated with conventional chemotherapy should be 
greatly reduced by targeting the treatment to tumours.
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The disadvantage of ADEPT is that it is a complex multi-step treatment. The 
timing and dose of each component is crucial, and assessing the ability of each 
step to function as designed in a clinical setting is difficult. The possible choices 
of and modifications to each component (antibody, enzyme and prodrug) are vast 
and require a detailed understanding to make rational design choices. Despite this 
complexity ADEPT has been shown to be a promising therapeutic strategy, in 
both the preclinical and clinical setting (Bagshawe et al, 1988; Bagshawe et al, 
1995; Napier et al, 2000).
ADEPT systems
The first example of antibody-enzyme conjugate being used to generate a 
cytotoxic agent was by Philpott in 1973 (Philpott et al, 1973). An antihapten 
antibody was conjugated to glucose oxidase and, in the presence of 
lactoperoxidase and iodide, was shown to result in selective iodination and cell 
killing of hapten substituted tumour cells. This effect was shown in a cell culture 
system only.
An ADEPT system was reported in a human xenograft model in i988 (Bagshawe 
et al, 1988). The F(ab')2 fragment of an anti-human chorionic gonadotrophin 
antibody (W14) was chemically conjugated to the bacterial enzyme 
carboxypeptidase G2 (CPG2). This was administered to mice bearing human 
choriocarcinoma xenografts (Bagshawe et al, 1988). After sufficient time to 
allow accumulation in tumour and clearance from peripheral tissues, a benzoic 
acid mustard prodrug was administered. This prodrug was rapidly converted to 
drug by the CPG2 enzyme. Marked suppression of tumour growth was shown to 
occur after only one treatment, which was greater than achieved with commonly 
used cytotoxic agents (Bagshawe et al, 1988).
Senter also described an antibody directed prodrug system in 1988 (Senter et al, 
1988). Anti-tumour monoclonal antibodies were covalently liked to alkaline 
phosphatase, and directed against antigen expressing tumour cells. Alkaline 
phosphatase was then used to convert relatively non toxic etoposide phosphate to 
the active cytotoxic, etoposide (Senter et al, 1988). In xenografts this system
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showed delivery of the enzyme alkaline phosphatase to tumour, and, efficacy, 
with rejection of established tumours (Senter et al, 1988).
Many ADEPT systems have since been described utilizing different antibodies, 
enzymes and prodrugs (table 2). They may be classified according to the type of 
enzyme used, which may be non-mammalian or mammalian. Non-mammalian 
enzymes do not usually have human substrates, and so there are few problems 
with endogenous activation in non-target tissue. They are, however, 
immunogenic which may limit repeated exposure. Examples of non-mammalian 
enzymes used in ADEPT include CPG2, (3-lactamase, penicillin G amidase and 
cytosine deaminase (Senter and Springer, 2001). Mammalian enzymes have 
problems with endogenous activation, which may reduce tumour specificity. 
However, they have fewer problems with immunogenicity than non-mammalian 
enzymes, and may be used in repeated therapies. Examples of mammalian 
enzymes used in ADEPT include alkaline phosphatase, carboxypeptidase A and 
p-glucoronidase (Senter and Springer, 2001).
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Table 2: ADEPT systems
Enzyme Drug formed Reference:
N on-mammalian 
enzymes
Carboxypeptidase G2 nitrogen mustards (Bagshawe etal, 1988; 
Eccles etal, 1994; 
Bagshawe et al, 1995; 
Niculescu-Duvaz and 
Springer, 1995; Blakey et 
al, 1996; Napier et al, 2000)
p-lactamase nitrogen mustard (Vrudhula et al, 1993)
doxorubicin (Svensson et al, 1995)
mitomycin (Vrudhula et al, 1997)
vinca alkaloids (Meyer etal, 1993)
paclitaxel (Rodrigues et al, 1995)
platinums (Hanessian and Wang, 
1993)
penicillin G amidase doxorubicin,
melphalan
(2Vrudhula et al, 1993)
palytoxin (Bignami etal, 1992)
cytosine deaminase 5FU (Wallace etal, 1994)
Mammalian enzymes
alkaline phosphatase doxorubicin (Senter, 1990)
etoposide (Senter etal, 1988)
mitomycin (Senter et al, 1989)
phenol mustard (Wallace and Senter, 1991)
carboxypeptidase A methotrexate (Vitols et al, 1995; Perron 
and Page, 1996)
antifolates (Springer et al, 1996)
P-glucoronidase doxorubicin (Bosslet etal, 1992; Bosslet 
et al, 1994; Houba et al, 
2001)
phenol mustard (Cheng et al, 1999)
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Alternative enzvme-prodrug delivery systems
The use of an antibody to direct enzyme to tumour has some potential problems. 
The conjugation of the antibody to the enzyme may result in a large molecule, 
which will hamper penetration through tumour. Tumours are heterogeneous in 
their antigen expression and this may also reduce the likelihood of sufficient 
enzyme delivery. Also the conjugation process may either damage or result in 
conformal change in the antibody, which may affect subsequent antigen binding, 
and tumour specificity. Immunogenicity of non-human antibodies or enzymes 
will limit treatment repeatability.
The majority of these obstacles may conceivably be overcome with the 
development of genetic engineering techniques resulting in rationally designed 
genetic fusion proteins of antibody fragments with enzyme. Smaller, more stable 
and potentially less immunogenic molecules may be developed.
Several alternative strategies for delivering enzyme and prodrug selectively to 
tumours have also been developed, included the delivery of genetic code for 
enzymes to tumour cells, and the use of polymers as an alternative to antibody 
delivery systems.
VDEPT/ GDEPT
Virus-directed enzyme prodrug therapy (VDEPT) was first described in 1991 
(Huber et al, 1991). It consists of a construct containing a tumour-specific 
transcriptional regulation sequence linked to the protein coding domain of a non­
mammalian enzyme, which is delivered to tumour areas by a replication deficient 
retroviral vector (Huber et al, 1991). The transcriptional regulation sequence is 
used to allow selective expression the non-mammalian enzyme in tumour cells.
A prodrug is then administered systemically and becomes activated in the tumour 
by the expressed enzyme. Huber described the system in hepatoma cells, with a 
varicella zoster virus tyrosine kinase being selectively expressed in a-fetoprotein 
positive cells (Huber et al, 1991). The prodrug used was araM, which was
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converted by the varicella zoster vims tyrosine kinase to form araATP (Huber et 
al, 1991).
Gene directed enzyme prodrug therapy (GDEPT) similarly involves the tumour 
directed delivery of a gene encoding a foreign enzyme followed by 
administration of a suitable prodrug which is activated locally by the expressed 
enzyme. The delivery of the gene construct in GDEPT is usually via liposomal 
delivery systems (Xu and McLeod, 2001). Both VDEPT and GDEPT have 
inherent difficulties of vector delivery, and with expression of adequate amounts 
of DNA and consequently enzyme (Xu and McLeod, 2001). Most VDEPT/ 
GDEPT systems rely on the intracellular expression of enzyme and subsequent 
conversion of prodrug to drug. This may limit any bystander effect, unless the 
converted drug is able to diffuse out of the cell and act locally, or be transferred 
to adjacent cells through gap junctions or apoptotic vesicles (Greco and Dachs,
2001). The bystander is particular important in VDEPT/ GDEPT systems as it is 
unlikely that greater than 10% transfection rate of tumour cells will occur (Greco 
and Dachs, 2001).
Preclinical and clinical trials have been performed in GDEPT/VDEPT using the 
gene for herpes simplex vims thymidine kinase as the enzyme and with 
ganciclovir as the prodrug. Ganciclovir is converted 1000 fold more efficiently to 
its monophosphate form by herpes simplex vims thymidine kinase than by 
mammalian nucleoside monophosphate kinase (Greco and Dachs, 2001). 
Ganciclovir phosphate is then catalysed further by cellular enzymes to form toxic 
metabolites that interfere with DNA synthesis. Ganciclovir is S-phase specific so 
it is necessary that targeted cells are actively dividing for effect. The cytotoxic 
active metabolites of ganciclovir are highly charged and insoluble in lipid 
membranes -  making cell-cell diffusion difficult (Greco and Dachs, 2001). This 
strategy has been promising in preclinical models, however in the clinical setting 
it has been less successful. This may be due to insufficient gene transfer 
throughout the tumour, the S phase specific effect of ganciclovir or to the dose 
limiting bone marrow effects of ganciclovir, preventing higher doses being 
administered (Greco and Dachs, 2001).
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GDEPT has been studied in the preclinical setting using the bacterial enzyme 
CPG2 in combination with the mustard alkylating prodrug, 4-[2-chloroethyl)(2- 
mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA) (Marias etal, 1996). 
This is the same combination that has been successfully used in ADEPT (section 
1.4.2). It was shown that in cell culture of a variety of different cell lines, total 
cell kill could occur when only 4-12% of cells expressed CPG2 enzyme, 
indicating a substantial bystander effect (Marias et al, 1996). Three newer 
mustard prodrugs have recently been assessed in combination with CPG2 for 
GDEPT using preclinical human tumour xenografts in nude mice (Friedlos et al,
2002). These have shown improved potency over CMDA, and again 
demonstrated that if low cell transduction rates are attained, a large bystander 
effect is required for efficacy (Friedlos et al, 2002). One of the prodrugs used 
was a bisiodophenol mustard, ZD2767P, which is the prodrug used in the 
ADEPT clinical trials described in this thesis (chapter 2 and 4). ZD2767P was 
found to be the most potent of the three prodrugs used, however had less 
bystander effect. It was therefore most efficacious when there was a high 
proportion of cells expressing CPG2 (Friedlos et al, 2002).
PDEPT/MDEPT
Polymer-directed enzyme prodrug therapy (PDEPT) utilizes polymer-enzyme 
complexes and polymer prodrugs. MPEG -directed enzyme prodrug therapy 
(MDEPT) utilises methoxypolyethylene glycol (MPEG) coated enzyme for 
tumour specific delivery. Polymer coated drugs and proteins may passively 
accumulate in tumours because of the leaky vasculature and poor lymphatic 
drainage of tumours (Satchi et al, 2001). This is referred to as the enhanced 
permeability and retention effect of tumours (Matsumura and Maeda, 1986). 
PDEPT/ MDEPT strategies do not require individualisation to tumours 
expressing different antigens and polymerized products tend to be non or 
minimally immunogenic. Early preclinical studies have shown minor therapeutic 
benefit, although further optimization is required (Satchi et al, 2001).
ADEPT, GDEPT/ VDEPT and PDEPT/ MDEPT are all based on the principle of
delivery of enzyme to tumour, followed by administration and activation of
prodrug. The mechanism of delivering enzyme differs for each system. Enzyme
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may be delivered as a functioning protein (ADEPT, PDEPT), or its DNA may be 
delivered, and subsequently transcribed to functioning enzyme (GDEPT, 
VDEPT). The delivery of functioning enzyme obviates the complex process of 
transfection and subsequent transduction of DNA to protein in target cells, with 
all its associated problems. However there is the opportunity for greater tumour 
selectivity with GDEPT/ VDEPT as both selective gene delivery and selective 
promoter gene expression can be used to ensure tumour specificity. With 
ADEPT/ PDEPT if the targeting of functioning enzyme to tumour is poor, 
enzyme will be present in non-tumour sites and non-specific activation of 
prodrug will result in toxicity.
The advantages of using antibody to deliver enzyme to tumour over VDEPT/ 
GDEPT or PDEPT/ MDEPT strategies are summarised in table 3. The main 
advantages with antibodies are that there is the potential for good tumour 
targeting due to the specificity of antibody-antigen interaction. Intact enzyme is 
delivered, which obviates the need for complicated cellular DNA delivery and 
subsequent transfection and transcription. Enzyme is present extracellularly, 
rather than being generated intracellularly, which improves the availability to 
prodrug and increases the likelihood of a bystander effect. In addition, as will be 
outlined in section 1.4.2, significant progress has already been made towards the 
development of a successful ADEPT strategy in the clinical setting using a 
bacterial CPG2 enzyme, and mustard prodrug alkylating agents.
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Table 3: Comparison of enzyme-prodrug systems
ADEPT VDEPT/ GDEPT PDEPT/MDEPT
Enzyme delivery 
system
Antibody Viral vector or 
liposomal delivery 
system
Polymer or MPEG
Mechanism of 
attaining tumour 
specificity
Antibody-antigen
interaction
Tumour specific 
transcriptional 
regulation 
sequences
Passive
accumulation
(leaky
vasculature, poor 
lymphatics)
Enzyme
functional status 
on delivery
Delivered intact 
and functional
Needs to be 
transcribed
Delivered intact 
and functional
Site of enzyme Extracellular Intracellular Extracellular
Potential for 
bystander effect
High (enzyme 
accessible)
Low due to 
reduced 
accessibility of 
enzyme
High (enzyme 
accessible)
Potential for 
non-target tissue 
activation
Moderate due to 
potential for 
cross-reactivity or 
if poor systemic 
clearance
Low if both 
selective gene 
delivery and 
selective 
promoters used
High due to non­
specific delivery 
system of active 
enzyme
1.4.2 ADEPT -  A5CP in combination with CMDA
ADEPT with A5B7 F(ab ')2 antibody chemically conjugated to the bacterial 
enzyme CPG2 (termed ‘ A5CP’) in combination with benzoic acid prodrugs was 
first developed for colorectal tumours in 1989 (Bagshawe, 1989). This ADEPT 
system will be examined in some detail as it forms the basis for two subsequent 
ADEPT clinical trials that are the focus of this thesis.
The ADEPT system consists of four essential components: the target, the 
antibody, the enzyme and the prodrug/drug. Each of these components are 
expanded below for ADEPT with A5CP in combination with the benzoic acid 
prodrug, CMDA,
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Target antigen - CEA
Carcinoembryonic antigen (CEA) is a cell surface glycoprotein expressed by 
most colorectal tumours, and a proportion of other common epithelial 
malignancies such as breast, pancreatic, gastric, lung and ovarian carcinomas 
(Hammarstrom, 1999). It is an oncofetal antigen, which was first described and 
characterised by Gold and Freedman in 1965 (Gold and Freedman, 1965). It is a 
member of the immunoglobulin gene superfamily and is composed of a single 
polypeptide chain of approximately 688 amino acids and is highly glycosylated 
(Mitchell, 1998). It has one V-type and six C2-type immunoglobulin domains. 
The molecular weight of CEA is approximately 180kDa. The gene for CEA is on 
chromosome 19 (Hammarstrom, 1999).
Attempts to crystallize CEA have been thwarted by its high carbohydrate 
content; however, its structure has been further elucidated by small angle Xray, 
neutron scattering and modelling (Boehm et al, 1996). Its length was found to be 
27-33nm, and it was shown to be arranged with its seven domains (CEA 1-7) in 
an extended linear zig-zag pattern (Boehm et al, 1996; Boehm and Perkins, 
2000).
CEA is expressed in normal adult tissue, with the main site being in the ‘fuzzy 
coat’ (glycocalyx) of the luminal surface on the top of the microvilli of the 
columnar epithelium of the colon (Benchimol et al, 1989; Hammarstrom, 1999). 
It is also present to a small degree in the mucosa of the stomach, the squamous 
epithelial cells of the tongue, oesophagus and cervix, in sweat glands and in the 
epithelial cells of the prostate (Hammarstrom, 1999). In a normal healthy adult 
approximately 50-70mg of CEA is released a day into the colon (Hammarstrom, 
1999). The normal function of CEA is not clear. Its strategic location and its 
structure suggest it may have a role in the maintenance of innate immunity. CEA 
may trap microorganisms in the glycocalyx and prevent them from invading the 
luminal gut cells (Hammarstrom, 1999).
In colon cancer tumour cells lose their polarity and CEA is expressed on all 
surfaces (not just the luminal surface) (Benchimol et al, 1989; Hammarstrom, 
1999). CEA has been shown in tumour cell lines to act as an intercellular
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adhesion molecule and may have a role in the metastatic potential of malignant 
cells (Benchimol et al, 1989). It has been proposed that overproduction of CEA 
leads to disruption of normal intercellular adhesion forces, which may contribute 
to tumourogenesis by creating abnormal tissue architecture or increasing 
metastatic potential (Benchimol et al, 1989; Ordonez et al, 2000).
Systemically administered anti-CEA antibodies are not able to penetrate through 
to the luminal surface of the normal intestine due to the presence of tight 
junctions between cells. Consequently specific tumour targeting can be achieved.
CEA -related antigens occur in several tissues and cross-reactivity can be a 
problem with non-specific anti-CEA antibodies. The most common sites of cross 
reactivity are with granulocytes, monocytes, Kupffer cells, bile canaliculi, 
pancreatic acini and lymphocytes (Nap et al, 1992). This cross-reactivity has 
been shown to be as a result of shared epitopes between and CEA and these 
tissues (Nap et al, 1992). This cross-reactivity is independent of affinity (Nap et 
al, 1992). Most specific antibodies do not, however, have this cross-reactivity.
CEA also has a secreted form, which is released into the systemic circulation. 
Circulating serum CEA levels are used clinically to monitor response of patients 
to therapy, and for early detection of tumour relapses (Minton et al, 1985; 
Fletcher, 1986; Ward etal, 1993; Mitchell, 1998; Bidart etal, 1999). Raised 
circulating CEA levels at the time of surgical resection have also been shown to 
be an independent prognostic factor for survival (Lindmark et al, 1995;
1 Compton et al, 2000). The extent to which CEA is secreted into the systemic 
circulation varies for individual patients. A very high circulating CEA level may 
lead to reduced targeting efficiency of anti-CEA antibodies, as they bind to 
accessible CEA in the circulation, and are less available for binding to cell 
surface CEA in tumour areas (Boxer et al, 1992). In one study, serum CEA 
levels of > 2000pg/L was associated with the lowest amounts of tumour anti- 
CEA radiolabelled antibody localisation (Boxer et al, 1992).
CEA expression within tumours is heterogeneous, and antibody binding 
throughout tumours has been shown to be non-uniform (Boxer et al, 1992). This 
heterogeneity has proved to be a limiting factor for therapies that require
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antibody internalisation, or utilise antibody-effector systems, as areas of the 
tumour may be unaffected. The bystander effect of ADEPT, provided by the 
diffusion of active drug locally in the tumour, has been designed to overcome 
this problem as it can result in cytotoxic effects to both antigen positive and 
antigen negative tumour cells.
In summary, CEA has the advantage of being a common target, present in the 
majority of patients with colorectal cancer, as well as some other solid tumour 
types (breast, pancreatic, gastric, lung and ovarian carcinomas). It is often 
abundantly expressed in tumour tissue. It is easily identifiable as a target on 
tumour tissue by immunohistochemistry on resected tumour specimens. It is 
expressed on some normal tissues, in particular on normal bowel epithelium, 
however this expression is on the luminal side of mucosal cells, which is 
inaccessible to systemically administered antibodies. The limitations of using 
CEA as a target includes its secreted form, which may lead to sequestration of 
antibody in the circulation with reduced tumour targeting, and its heterogeneous 
tumour expression, which may lead to inadequate tumour targeting. The first 
limitations may be minimised if patients with high serum CEA levels are 
excluded from treatment, and the second limitation may be overcome to some 
degree by the bystander effect of ADEPT, which will lead to cytotoxicity to both 
antigen negative and antigen positive cells.
Antibodv-A5B7
A5B7 is an IgGl murine antibody to CEA (Harwood et al, 1986; Pedley et al, 
1987). The F(ab')2 fragment of A5B7 has a molecular weight of lOOkDa and is 
derived from whole A5B7 by enzymatic digestion with pepsin (Lamoyi and 
Nisonoff, 1983).
A5B7 whole IgG and F(ab')2 fragment have been used extensively both 
preclinically and in clinical trials of radioimmunotherapy (RIT), 
radioimmunoscintigraphy and radioimmunoguided surgery (Blair et al, 1990; 
Dawson et al, 1991; Pedley et al, 1993; Lane et al, 1994). Preclinical studies of 
radioimmunotherapy demonstrated that twice the activity of 1-131 radiolabelled 
antibody must be administered to produce the same therapeutic effect if the
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F(ab')2 fragment is used compared to whole antibody (Pedley et al, 1993). This is 
due to rapid circulatory clearance of the F(ab')2 fragment which results in lower 
absolute amounts of radiolabelled antibody delivered to tumour. However, more 
favourable tumour to normal tissue ratios were attained with the F(ab')2  
fragment, in particular with less potential toxicity to bone marrow (Pedley et al, 
1993).
Clinical trials have confirmed that A5B7 both as whole antibody and F(ab')2 
fragment localise effectively to CEA expressing tumours (Dawson et al, 1991; 
Lane et al, 1994). Gamma camera imaging was utilised to quantify 
biodistribution of radioimmunotherapy with 1-131 radiolabelled A5B7 whole IgG 
and F(ab')2 fragment (Lane et al, 1994). It was found that whole IgG A5B7 
reached peak tumour concentrations of antibody at 27 hours, whereas the F(ab')2  
fragment reached peak tumour concentration approximately 4 hours after 
administration (Green et al, 1990; Lane et al, 1994). Tumour responses were 
seen in both patient groups (Lane et al, 1994).
As A5B7 is a murine antibody it is immunogenic in humans. Without the 
concurrent administration of immunosuppressive drugs only one administration 
is usually possible before HAMA form (Ledermann et al, 1991). The presence of 
HAMA may lead to rapid clearance of the administered murine antibody by the 
immune system, with inadequate tumour targeting, and may result in more 
serious complications including serum sickness or anaphylaxis.
The combination of the smaller molecular size of the F(ab ')2 fragment of A5B7 
and its rapid tumour penetration made it suitable for combining with an enzyme 
to form an antibody-enzyme molecule for ADEPT.
Enzyme -  CPG2
A number of bacterial and mammalian enzymes have been used experimentally 
in ADEPT systems (see table 2). As discussed previously, mammalian enzymes 
(alkaline phosphatase or p-glucuronidase) are usually non-immunogenic and 
therefore can be used repeatedly. They have the disadvantage, however, that, as 
they have human equivalents, endogenous enzyme may lead to non-specific
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activation of prodrug and subsequent toxicity. Bacterial enzymes, such as 13- 
lactamase and carboxypeptidase G2 (CPG2) have no human equivalent, so there 
should be very little chance of endogenous activation of prodrug. However 
bacterial enzymes are immunogenic, which limits the number of ADEPT 
treatments that can be administered.
CPG2 is a bacterial zinc metalloenzyme derived from Pseudomonas sp strain 
RSI6 (Sherwood etal, 1985; Bagshawe, 1987). CPG2 catalyses the hydrolysis of 
folates to pteroates and L-glutamic acid (Sherwood et al, 1985). CPG2 is active 
in vivo as a dimer of 83 kDa (Sherwood et al, 1985; 2Bagshawe, 1994). There is 
no known human equivalent. In addition to being a useful enzyme for therapeutic 
ADEPT systems, it also can be used to metabolise methotrexate to 4-(vV(2,4- 
diamino-6-pteridinyl methyl)amino) benzoic acid. This has been used clinically 
in the treatment of methotrexate toxicity. The rate of formation of the metabolite 
from methotrexate can be used to estimate CPG2 enzyme activity in vivo 
(plasma or tissue samples), by correlating known CPG2 enzyme levels with the 
rate of metabolism of methotrexate (Blakey et al, 1996; Martin et al, 1997).
Antibodv-enzvme conjugate -  A5CP
A chemical conjugate was formed of the F(ab')2 fragment of the murine anti- 
CEA antibody, A5B7, linked by a stable thio-ether bond to CPG2 (A5CP) 
(Melton et al, 1983). A5CP has a molecular weight of 180 kDa. The chemical 
conjugation process can result in some reduction in antibody binding or to 
enzyme activity and may lead to the formation of a heterogeneous product.
Preclinical studies were performed using A5CP in LS174T human CEA 
colorectal mouse xenograft models. This is a model with tumour CEA 
expression, with no circulating CEA. These preclinical studies indicated that 
clearance of A5CP from plasma was slow, and that a safe level of plasma CPG2 
activity (<0.3U/mL) only occurred after 6-7 days, by which time tumour enzyme 
levels had also fallen (Bagshawe, 1989; Sharma et al, 1990; Sharma et al, 1991). 
The administration of prodrug before this time was fatal, due to high plasma 
CPG2 enzyme levels leading to systemic activation of prodrug.
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A galactosylated murine IgG antibody directed to the active site of CPG2, SB43- 
gal, was therefore used to accelerate clearance of A5CP from the circulation 
(Sharma et al, 1990; Sharma et al, 1994). The mechanism by which SB43 
inactivates CPG2 appears to involve binding at or near the active site of the 
enzyme, or at a distant site resulting in conformational change in CPG2 (Sharma 
et al, 1990). In order to prevent SB43 inactivating CPG2 in tumour sites, it was 
galactosylated, which allowed it to be cleared rapidly from the circulation by 
hepatic galactose-specific receptors (Thornburg etal, 1980; Bagshawe, 1989; 
Sharma et al, 1990; 2Bagshawe, 1994; Pharma, 1996). It was demonstrated that 
using SB43-gal, CPG2 enzyme could be cleared from the peripheral circulation, 
without significantly altering enzyme levels in the tumour or the amount of drug 
generated in the tumour (Rogers et al, 1995; Pharma, 1996;). The administration 
of SB43 allowed prodrug to be given as early as 24 hours after A5CP without 
toxicity ^Sharma, 1996).
Prodrug
Ideally a prodrug for ADEPT should be a compound of low toxicity, which is 
converted, only by the action of one specific enzyme, to a highly cytotoxic active 
drug (Bagshawe, 1987). The active drug should be a small molecule, which is 
highly diffusible through a tumour (Bagshawe, 1987). Mustard alkylating agents 
have several properties that make them a rational choice as the drug/prodrug 
system for ADEPT. Their cytotoxicity is not cell-cycle specific so they have 
activity against both proliferating and quiescent cells. Solid tumours have large 
numbers of quiescent cells, which can be problematic for cell cycle specific 
drugs. Alkylating agents have activity against both well-oxygenated and hypoxic 
cells, which, due to the known poor perfusion of solid tumours, is again 
advantageous (Bagshawe, 1989). Low levels of resistance have been reported 
against alkylating agents by tumour cells, as they are not subject to multi-drug 
resistance (Frei et al, 1988; Ford and Hait, 1990). Alkylating agents exhibit dose 
dependent effects, which may be an advantage as ADEPT aims to selectively 
deliver much higher doses of drug to tumour sites than can be achieved with 
systemic chemotherapy (Frei et al, 1988). Chemical deactivation of mustard 
alkylating agents is feasible by using functional groups that are cleavable by
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appropriate enzymes (Bagshawe, 1987; Bagshawe et al, 1988). These 
modifications can lead to > 100 fold differences in chemical reactivity between 
prodrug and drug ^Springer et al, 1991; Springer et al, 1995).
Benzoic acid mustard prodrugs that could be activated by CPG2 were developed 
for ADEPT. The chemical design required an aromatic ring to be linked to a 
glutamic acid moiety by an amide bond (Niculescu-Duvaz and Springer, 1995). 
This system minimises prodrug uptake into cells due to the two acidic functional 
groups, however, once the glutamate is cleaved and the drug is formed, it is 
much more lipophilic, and readily taken up into cells (Niculescu-Duvaz and 
Springer, 1995).
CMDA is a benzoic acid mustard prodrug which is activated by cleavage of a 
glutamate by CPG2. Its pharmacokinetic parameters are an IC50 of IOOjjM, Km of 
3pM and kcat of 700s’1. (Niculescu-Duvaz and Springer, 1995; Senter and 
Springer, 2001). CMDA showed encouraging preclinical activity against both 
choriocarcinoma and colorectal human tumour xenografts (Bagshawe, 1989; 
2Springer et al, 1991; Blakey et al, 1993; !Blakey et al, 1995). It was therefore 
chosen as the first prodrug to be used in clinical trials of ADEPT.
1.43  ADEPT Clinical Trials with A5CP in combination with CMDA
Two clinical trials of ADEPT have been performed using A5CP in combination 
with CMDA for CEA expressing advanced colorectal tumours (Bagshawe et al, 
1995; Napier et al, 2000). The galactosylated clearing enzyme, SB43, directed 
against the active site of CPG2 was used to accelerate clearance of A5CP from 
the peripheral circulation prior to prodrug administration.
The first clinical trial of this ADEPT system established that A5CP could be 
safely administered to patients at doses of 5000U-20 000U/ m2 (Bagshawe et al,
1995). CMDA prodrug when administered alone to seven patients was inert and 
non-toxic, other than nausea and vomiting which may have been in part 
attributable to dimethylsulphoxide, in which CMDA had to be administered 
(Bagshawe et al, 1995). No active drug could be measured in serum when
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CMDA was given alone, indicating that, as hypothesised, no endogenous 
activation was occurring.
An administration schedule was developed which involved infusing A5CP over 2 
hours, followed 24 hours later by the clearing antibody, SB43-gal, as a 
continuous infusion. At 48 hours the CMDA prodrug was given as repeated 
bolus injections over 1-5 days (Bagshawe etal, 1995).
Myelosuppression was the main toxicity seen from ADEPT (Bagshawe et al,
1995). Active drug could be measured in plasma, which was thought to have 
been due either to leak-back of activated drug from tumour sites, or residual 
enzyme in the peripheral circulation, which may have activated CMDA 
peripherally (Springer et al, 1993). Plasma enzyme, at the time of prodrug 
administration, was below the detectable limit by spectrophotometric 
methotrexate reduction assay (0.02U/mL) (Bagshawe et al, 1995).
The bacterial enzyme CPG2, and the murine antibody, A5B7 were immunogenic, 
with all patients developing an immune response by day 10 unless 
immunosuppression with cyclosporin was given. The administration of 
cyclosporin allowed up to three cycles of ADEPT to be given over a 21 day 
period (Bagshawe et al, 1995).
Tumour responses were seen -  in seventeen patients who received ADEPT, there 
were four partial responses, one mixed response and three minor responses or 
disease stabilisations (Bagshawe et al, 1995). Response appeared to depend more 
on prodrug dose ratio than on plasma enzyme levels (Begent and Bagshawe,
1996)
The second clinical trial of ADEPT was a mechanistic study using fixed doses of 
A5CP, SB43-gal and CMDA (Napier et al, 2000). Ten patients with advanced or 
metastatic colorectal cancer who had previously received standard chemotherapy 
were treated with ADEPT. A5CP was administered at a dose of 10 000U/m2. 24 
hours later SB43-gal was administered as a constant infusion for 4 days, and 
CMDA was administered at a dose of200mg/m2 as a bolus injection at 48 hours, 
72 hours and 96 hours after commencement of A5CP. The components of
ADEPT were measured in tumour and normal tissues in order to gain an 
understanding of whether effective conditions for therapy were met. Standard 
toxicity and response evaluations were also made.
The components of ADEPT measured were:
- Serum CPG2 enzyme levels measured by spectrophotometric and 
HPLC methotrexate reduction assay
- Tumour CPG2 enzyme levels from tumour biopsy specimens measured 
by methotrexate reduction assay on HPLC
- 1-131 radiolabelled A5CP biodistribution in tumour and normal tissues 
assessed by quantitative SPECT analysis
- Prodrug and drug concentrations measured in plasma by high 
performance liquid chromatography (HPLC)
- HAMA and human anti-CPG2 antibody (HACPG2A) by enzyme 
linked immunosorbance assay (ELISA)
It was possible to demonstrate that at the time of prodrug administration the 
tumour: serum CPG2 enzyme levels exceeded 10 000:1 (Napier et al, 2000). Five 
patients had tumour biopsies performed with direct measurement of CPG2 
enzyme levels, and these confirmed that tumour enzyme estimations by SPECT 
analysis of radiolabelled A5CP were valid. Median CPG2 enzyme concentration 
in tumour by HPLC (tumour biopsies) was 0.47U/g (range 0.32-0.62 U/g), and 
by SPECT it was 0.34U/g (range 0.19-0.63U/g). Figure 5 shows the distribution 
of CPG2 enzyme in plasma and tumour after the administration of A5CP.
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Figure 5: CPG2 enzyme levels in tumour and blood after
administration of A5CP
♦ —  T u m o u r  
B i o p s y  
A —  B l o o d
s
1  a
3
a
N
C 0.01
W
0.1
0.001
20 1000 40 60 80
Tim e (hours)
Biodistribution o f A5CP after administration in ADEPT trial. SB43, a clearing 
antibody, was administered at 24 hours. CPG2 enzyme activity was measured in 
blood by spectrophotometric analysis (methotrexate reduction assay). Tumour 
A5CP localisation was measured by serial SPECT imaging o f 1-131 
radiolabelled A5CP and confirmed in a small number o f patients with tumour 
biopsies, in which CPG2 enzyme activity was measured on HPLC (methotrexate 
reduction assay). (Napier et al, 2000)
The plasma elimination half-life o f CMDA prodrug was 18 ± 8mins (Martin et 
al, 1997) The active drug was measurable in plasma and had a biological half-life 
of 36 ± 14 minutes (Martin et al, 1997).
ADEPT was well tolerated with dose-limiting toxicity consisting of 
myelosuppression. Four patients had common toxicity criteria (CTC) grade 3 or 
4 neutropaenia or thrombocytopaenia. The median times to nadir were for 35 
days for neutropaenia and 25 days for thrombocytopaenia (Napier et al, 2000). 
This was thought to be due to the presence of active drug in the circulation, 
which was likely to have occurred from leak-back after activation in tumour 
areas. It was unlikely to have been due to activation of CMDA by CPG2 enzyme 
in plasma, as at the time of prodrug administration plasma CPG2 enzyme levels
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were undetectable (less than 0.001 U/mL by HPLC) (Martin et al, 1997; Napier et 
al, 2000).
A5CP was, as expected, found to be immunogenic, with all patients developing 
HAMA and HACPG2A by 14 days. ADEPT showed evidence of efficacy, with 1 
patient attaining a partial response lasting 4 months, 6 patients had stable disease 
with a median progression free survival of 4 months, and 3 patients had disease 
progression.
These two clinical trials of ADEPT have therefore shown evidence of tumour 
response, however, effectiveness was thought to be limited by the long half-life 
of the activated drug, which was likely to have to diffused back into the 
circulation and caused myelosuppression (Martin et al, 1997; Napier et al, 2000). 
This limited further dose-escalation of prodrug. In addition the drug generated 
from CMDA is of low potency, and high CPG2 enzyme levels were required in 
the tumour to create tumoricidal concentrations of drug. A prodrug that generated 
a more potent drug may not require such high levels of tumour CPG2 enzyme.
The targeting system used in these trials gave high tumour to blood ratios of 
antibody-enzyme conjugate (>10,000:1), and high tumour CPG2 enzyme levels 
at the time of prodrug administration (0.47U/g), however it required additional 
administration of a clearing antibody directed to the active site of CPG2. This 
adds a further level of complexity to the ADEPT system, and requires the 
addition of a potentially immunogenic antibody.
1.4.4 ADEPT -  the next step
The experience gained in the clinical trials of ADEPT using A5CP in 
combination with CMDA indicated that in order to improve efficacy and reduce 
toxicity with ADEPT it was desirable to develop a new prodrug-drug system. In 
particular the drug formed from the activation of prodrug by CPG2 should have a 
short half-life to prevent ‘leak-back’ of activated drug into the systemic 
circulation. In addition it was hypothesised that if the drug formed from the 
activation of prodrug was of high potency that a tumoricidal effect may occur at 
lower tumour enzyme concentration than was required for CMDA. The clearing
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antibody approach was a requirement when CMDA was used as a prodrug, as 
high tumour enzyme concentrations were required for efficacy. The clearing 
antibody allowed prodrug to be administered at 48 hours after antibody-enzyme, 
when high tumour enzyme levels were still present. Without a clearing antibody 
many days may be required for systemic CPG2 enzyme levels to fall to levels 
safe enough to allow administration of prodrug without systemic activation. 
Tumour enzyme concentrations will also fall during this time. A more potent 
drug should be tumoricidal at lower drug concentrations, and the tumour CPG2 
enzyme levels attained at later timepoints without a clearance system, may be 
adequate to generate a sufficient concentration of drug for efficacy. This would 
obviate the need for the clearing antibody system, which is undesirable as it adds 
a further levels of complexity to an already complicated therapy, and introduces 
another immunogenic protein into ADEPT.
These were the working hypotheses that lead to the development of the ADEPT 
clinical trial outlined in chapter 2. The design of the clinical trial was carefully 
constructed in order to incorporate mechanistic measures to try and ascertain 
whether the components of ADEPT were functioning as designed on the clinical 
setting. The issues surrounding the design of mechanistic phase I/II clinical trials 
are discussed below.
1.5 Phase I/II clinical trial design
Phase I clinical trials of anti-cancer treatments conventionally aim to assess 
toxicity of a new treatment and to define the maximum tolerated dose (MTD) of 
the drug being tested. The standard pharmacokinetic profiles of the new drug are 
also assessed. A preliminary phase II component may also been included once a 
MTD has been defined. This will consist at looking at the efficacy of the agent in 
a small number of patients.
Patients who participate in phase I/II trials usually have incurable advanced
cancer and have already pursued conventional treatment options. Some of these
patients will have been very heavily pre-treated with chemotherapy and/ or
radiotherapy, likely to make them more vulnerable to the side-effects of new
therapies and less likely to respond to them. As the chance of a patient receiving
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a therapeutic benefit during a phase I/II trial is minimal as few patients as 
possible should be treated.
1.5.1 Issues in the design of phase I/II clinical trials of anti-cancer 
therapies
Designing phase I/II clinical trials of anti-cancer drugs holds many challenges 
both practically and ethically. Basic issues which need consideration include the 
start dose, the dose escalation scheme, the number of patients required, the type 
of patient required (inclusion and exclusion considerations), and issues regarding 
patient information and informed consent.
Start dose and dose escalation scheme
In the majority of phase I clinical trials an agent being tested would not have 
previously been used in humans. Consequently, although the side-effect profile 
may be to some degree predicted from preclinical studies, the safety of the agent 
cannot be guaranteed and the dose that may cause toxicity is uncertain. Most 
phase I clinical trials conventionally will commence at a dose level which is 
thought to be very unlikely to cause toxicity. This is usually at a dose 1/10th of 
the mouse dose required to be lethal to 10% (LDio) from preclinical studies 
(Newell et al, 1999; Eisenhauer et al, 2000). At such a low dose there is a low 
chance of toxicity, however there is also a low likelihood of efficacy.
Until recently the standard method for escalation from the starting dose was by 
treating three patients at each dose level, and to use a ‘Modified Fibonacci’ dose 
escalation schema to direct further dose increments. An example of this schema 
is shown in table 4. Once any grade 3 or 4 toxicity is experienced, the cohort is 
expanded to 6 patients. Once 2 of 6 patients develop grade 3 or 4 toxicity dose 
escalation is stopped and dose limiting toxicity defined (DLT).
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Table 4: Modified Fibonacci dose escalation schema
dose level % increase in dose actual dose (mg/m2)
1 (start dose) 20 mg/m2
2 100% 40 mg/m2
3 50% 60 mg/m2
4 33% 80 mg/m2
5 25% 100 mg/m2
This is an example o f a modified Fibonacci dose escalation schema. A minimum 
o f 3 patients are treated at each dose level -  resulting in at least 15 patients 
being treated to take the dose from 20mg/m2 to lOOmg/m2
There has however, more recently, been criticism of this dose schema as it is 
likely that many patients will be treated at subtherapeutic doses with very little 
chance of benefit, and lengthy trials result which slow down the development 
process of novel agents (Ratain et al, 1993; Mani and Ratain, 1997; Eisenhauer 
et al, 2000). Although the response rates in phase I clinical trials are low, the 
majority of them occur within 80%-120% of the recommended phase II dose 
(Von Hoff and Turner, 1991).
An accelerated titration design has been proposed as an alternative to standard 
Modified Fibonacci escalation schemas. This involves an accelerated phase of 
dose escalation in which only one patient is treated in each cohort and dose 
escalations of 100% are made until grade 2 drug related toxicity is attained 
(Simon et al, 1997). After this the dose escalation is slowed and between three 
and six patients may be treated at each dose level. This was simulated and 
effectively shown to reduce the number of patients undertreated and to speed up 
the completion of phase I studies (Simon et al, 1997). Using dose doubling and 
one patient at each dose level commencing at 20mg/m2 as in table 4, providing 
there was no dose limiting toxicity, four patients would be treated in order to 
reach a dose of 160mg/m2. Using the Modified Fibonacci schema displayed, at 
least fifteen patients were required to be treated to reach a dose of 100mg/m2. 
This highlights the advantages of accelerated titration schemas, as fewer patients 
are required to be treated at potentially subtherapeutic doses.
The disadvantage of this system is that little data is collected at the earlier 
timepoints, and therefore information on interpatient variability in toxicity or 
pharmacokinetics is not obtained (Eisenhauer et al, 2000). In addition, more
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information than just toxicity may be useful, and will be unlikely to be collected 
in sufficient amounts by just treating one patient at each dose level. This may be 
important when an understanding of mechanism is part of the trial design. 
Accelerated dose escalation may also be problematic if the drug has a narrow 
therapeutic window. It is usually recommended that pharmacokinetic modelling 
is performed concurrently to try and minimise the likelihood of unexpected drug 
accumulation and subsequent toxicity (Cavalli and Sessa, 1999; Emilien et al, 
2000).
The MTD is a dose below the DLT, at which toxicity is predictable and 
manageable. This is the dose that is usually recommended for phase II testing of 
efficacy. In reality an initial Phase II component is often incorporated into Phase 
I trials in order to obtain a preliminary idea of efficacy. Usually this will involve 
treating 14 patients at MTD. If no patient responds the investigator may conclude 
with 95% probability that the drug being tested has a response rate of less than 
20% in the population tested (Ratain et al, 1993). If one or more patients respond 
the group is usually expanded to 25 patients in order further define efficacy.
Patient selection
The target group for a phase I/II clinical trial needs consideration. The trial 
should be performed in a tumour type for which the chance of therapeutic benefit 
is maximal. However, restricting the tumour type may reduce the rate of accrual 
and lengthen the development time (Mani and Ratain, 1997). As efficacy is not a 
primary endpoint of phase I clinical trials it may be argued that restricting the 
tumour type should be applied only to phase II trials, in which the assessment of 
efficacy is of primary importance.
For therapeutic strategies designed against a specific target or mutation, the 
presence of that target is an inclusion requirement. As ADEPT is a targeted 
strategy against CEA, it is required that patients have CEA expressing tumours. 
This may be assessed by immunohistochemistry of tumour resection or biopsy 
specimens, or by measuring serum CEA levels. Immunohistochemistry involves 
ascertaining the presence of CEA on tumour cells by using an anti-CEA antibody 
on fixed specimens. The amount of CEA present cannot be accurately quantified.
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Measuring CEA in the blood is possible as CEA is a secreted protein. It is 
measured quantitatively by radioimmunoassay or ELISA, and expressed as 
micrograms per litre (jig/L). Low levels of CEA are found in the blood normally, 
however greater than 10 pg/L is considered abnormal. ADEPT is unlikely to be 
effective if there are very high levels of circulating CEA, as this will inhibit 
tumour targeting, and reduce antibody circulation time due to the formation of 
antigen-antibody complexes in the circulation (Boxer et al, 1992). Therefore the 
ADEPT trials are restricted to patients with a serum CEA level of less than 1000 
Hg/L.
Due to the uncertainty of both toxicity profiles and efficacy of agents in phase I 
trials, it is a usual requirement that patients who participate in them have locally 
advanced or metastatic cancer which is not curable by conventional treatments.
In addition patients should have been offered standard chemotherapy or 
radiotherapy regimens. Some patients will prefer to try ‘experimental’ therapies 
in preference to conventional treatments and so may participate in phase I trials 
fairly early in their disease course, whereas other patients may only consider 
phase I/II clinical trials after they have exhausted all conventional treatment 
options.
Most phase I/II clinical trials will exclude patients with abnormal renal or hepatic 
function, as this may disrupt the metabolism of the agent being tested, leading to 
an increased likelihood of toxicity. In addition patients should have normal 
haematological parameters as they may otherwise be more vulnerable to 
myelosuppression. It is usually required that all toxicities from a previous 
chemotherapy regimen have resolved prior to commencing the phase I/II trial. 
Patients are excluded if they have a concurrent medical illness that could reduce 
their ability to tolerate the treatment or the trial protocol. It is usually stipulated 
that the life-expectancy of patients participating in phase I or II trials is at least 3- 
4 months, in order that they may be expected to complete the treatment and 
follow-up period. In addition patients are required to have a good performance 
status to be included in a phase I/II trial. Patients with a poor performance status 
are less likely to complete the trial and may be more at risk of serious toxicities.
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Although efficacy is not a primary endpoint of phase I clinical trials, it is usually 
an inclusion requirement that patients have measurable disease according to 
standard criteria. Response assessments are included in the trial protocol and 
response data is collected. In addition the protocol will stipulate that patients 
should not be concurrently on any anti-cancer treatment and that a specified 
period of time should have elapsed between the completion of a previous therapy 
and the commencement of the clinical trial. This is to reduce the likelihood of 
additive toxicities and to ensure no confusion over the cause of a particular 
response.
Patient Information and Informed Consent
It is important that adequate patient information and informed consent are 
provided in Phase I clinical trials. It is therefore also a requirement that only 
patients who are able to understand the complexities of the trial and the 
information provided may enter the study. Information must be provided in a 
way that patients can comprehend. It is a difficult concept to have patients fully 
understand that phase I clinical trials are not focussed on efficacy, as it is this 
which is a patient’s usual motivation for entering a trial. It is also difficult to 
obtain consent from a patient when the toxicities of a treatment are not yet 
known. It may be argued that part of informed consent should include updating 
patients with the progress of the trial to date, toxicities experienced and efficacy 
assessments (Ratain et al, 1993). This could be done verbally or with regularly 
updated patient information sheets or consent forms (Ratain et al, 1993). Another 
ethical concern is how to obtain consent from patients who are treated at the first 
few dose levels, when the therapeutic will almost certainly be ineffective. It must 
be recognised that the population in whom phase I/II cancer clinical trials are 
conducted are a vulnerable group as they have incurable cancer with a limited 
life expectancy, but a good performance status. Obtaining true informed consent 
may therefore be very difficult, as the agenda of the patient and the investigator 
may be quite different.
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1.5.2 Mechanistic clinical trial design for ADEPT
The ADEPT system has been thought of as complex, as it involves the 
combination of antibody targeting, an enzyme activation system and a 
prodrug/cytotoxic drug system. Each of these components has their own unique 
requirements in order for the system as a whole to be successful, and 
understanding this system may only be possible when each component can be 
investigated individually. A mechanistic clinical trial design involves 
quantitatively measuring each component of ADEPT in order to ascertain if 
ADEPT is functioning as designed. It is hypothesised that by measuring 
mechanism, a greater understanding of ADEPT can be achieved. Additionally, 
rational modifications can be determined and implemented, thereby accelerating 
the development process. The collection of quantitative data is important, so that 
estimations of the amount of improvement required in order to attain efficacy can 
be expressed in numerical terms.
Designing phase I clinical trials to measure mechanism of a therapy may result in 
an increased number of interventions for each patient. This may be from an 
increase in number of blood tests to more invasive investigations such as 
complex radiological or isotope imaging studies or even tumour biopsies. 
However, the increased data obtained from each individual patient should ensure 
that overall fewer patients are required to be treated to ascertain if a new 
treatment is functioning as hypothesised.
In ADEPT the components of the mechanism that are essential for efficacy 
include the antibody mediated selective delivery of functional enzyme to tumour, 
the conversion of prodrug to drug, and the cytotoxic effect of activated drug. It 
would be desirable to be able to quantitatively measure each of these steps in a 
clinical setting. The ADEPT trials discussed within this thesis have utilised 
mechanistic studies in order to be able to make these quantitative measurements. 
The mechanistic studies are discussed in detail in the context of the clinical trials 
in this thesis.
A large amount of data may be acquired by undertaking mechanistic studies in a 
clinical trial. Interpreting the data may become difficult due to the volume of data
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collected and the number of co-existing variables which may occur in each 
patient. A relational ontology is one means of organising this data in a logical 
way, to aid in interpretation of the data. An ontology for clinical trials of ADEPT 
has been developed using Protege, which is a hierarchical Ontology tool. This 
subsequently may be used as a platform for developing a database to store the 
data or as a foundation for a model of ADEPT, which characterises the 
relationship between each of the components of the ADEPT treatment within a 
patient. The model may be defined mathematically, using either measured 
clinical data, predicted data based on experience acquired with ADEPT, or on 
preclinical data. The aim of collecting and organising all of this data is that it aids 
interpretation of ADEPT and should accelerate development of ADEPT by 
directing rational changes to the ADEPT system. These concepts are discussed in 
detail and applied in Chapter 7.
1.6 [F-18] FDG PET for response assessment
The ability to objectively measure response of a tumour to therapy is an essential 
element of clinical trials designed to assess efficacy of new cancer therapies, as 
well as being part of standard patient care. Assessments of response have been 
conventionally based on changes in dimensional measurements of tumours on 
standard radiological imaging modalities, such as CT scans. Although this is 
widely accepted and almost universally adopted, it is plagued by several 
limitations, which are discussed in detail below. Particularly problematic is the 
assessment of novel therapies, as the patient group in which they are tested are 
often heavily pre-treated and their biological mechanism may not be likely to 
attain more than disease stabilisation. A potentially promising agent may thereby 
be misleadingly discounted as ‘non-efficacious’.
Previous trials of ADEPT have been associated with many patients with ‘stable 
disease*. It is unclear whether this ‘stable disease’ represents ‘some therapeutic 
effect’ or ‘no therapeutic effect’. As ADEPT is a treatment with very low 
systemic toxicity, the attainment of stable disease may be an acceptable endpoint, 
if the stable disease was actually as a result of some therapeutic effect. It is clear 
that a more sensitive method of assessment of therapeutic effect is required.
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[F-18] fluorodeoxyglucose positron emission tomography ([F-18] FDG PET) has 
attracted considerable interest recently, particularly in the field of Oncology. It 
already has a role in the staging of patients prior to potentially curative surgical 
resections, and in the differentiation of benign from malignant lesions (Hustinx et 
al, 2002). However, it may also have an additional role, in the assessment of 
response to therapy.
1.6.1 ‘Conventional’ response assessment
Phase II clinical trials of novel chemotherapeutics or other anti-cancer strategies 
rely upon objective evidence of response before they can proceed further in their 
development. Phase I clinical trials are now frequently adopting a phase II 
component in order to gain preliminary evidence of efficacy once safety had 
been established and the MTD has been defined. Additionally, in everyday 
Oncology practice in order to make an informed decision regarding a patient’s 
response to chemotherapy, a formal response assessment is usually required.
The World Health Organization (WHO) in 1979, and Miller et al in 1981 
published criteria for assessment of response based on radiological imaging or 
clinical findings in an attempt to standardise the reporting of response to cancer 
therapies (WHO, 1979; Miller et al, 1981). These criteria defined four terms 
which describe response to therapy; complete response (CR), partial response 
(PR), stable disease (SD) and progressive disease (PD). The method 
recommended use of bi-dimensional measurements of lesions, before and after 
treatment, to quantify change.
Over time it became clear that there were some areas of ambiguity in these 
criteria for response assessment and a new system, termed Response Evaluation 
Criteria in Solid Tumours (RECIST) was developed (Therasse et a/,2000). The 
RECIST criteria are based on using the sum of maximal unidimensional 
measurements of tumours. These criteria more clearly define the ‘measurability’ 
of lesions, response criteria, recommended frequency of response assessments, 
response reporting and specifications for radiological imaging (Therasse et al, 
2000).
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Unfortunately there are limitations associated with these current methods of 
response assessment. The information displayed from conventional radiological 
imaging, such as CT scans, is anatomical. However, tumours are heterogeneous, 
and contain viable and necrotic regions (Flynn et al, 1999). These are not well 
accounted for on CT scans, Xray or MRI. An efficacious therapy should have an 
effect on the viable area of tumours, and it would be advantageous to be able to 
image and assess this. Current radiological techniques may lead to the 
misinterpretation of an area of necrosis as tumour, thereby under-representing an 
actual tumour response.
Problematic areas for accurate radiological measurements include skeletal 
metastasis, pleural or pericardial effusions or ascites, meningeal disease, 
inflammatory masses (eg: inflammatory breast tumours), interpretation of lesions 
which lie within previous radiotherapy fields, defining tumour from post-surgical 
or post-radiotherapy fibrosis, and diffuse tumours, such as pleural thickening or 
omental masses. Another problem area is the interpretation of lymphadenopathy, 
whether it is malignant or reactive, and defining ‘complete response’, as a 
residual lymph node mass usually remains post treatment. A method of assessing 
response that can identify tumour areas from non-tumour may overcome some of 
these problems.
Current radiological techniques, and the response criteria, assess tumours as two- 
dimensional objects, whereas in reality they have 3 dimensions (volumes). This 
may lead to misinterpretation of changes in size of lesions, due to a change in 
shape, or due to technical issues such as slice thickness for CT scans. A small 
lesion imaged on CT scan may be misinterpreted due to slice thickness, which 
may determine whether the lesion is imaged through its middle, or at its upper or 
lower edge.
It is also well recognised that in the treatment of solid tumours it may take many
weeks for radiological imaging to show a reduction in size of a tumour. It is
recommended that an assessment be undertaken at least 6-8 weeks after
commencing a therapy (Therasse et al, 2000). Common practice is to assess for
response after approximately 3 months of treatment. This may result in patients
being exposed to potential toxicities from several cycles of treatment, before a
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response evaluation can be made. An effective therapy, however, will be causing 
cytotoxicity and resultant tumour damage within hours of administration, and 
these effects should be assessable earlier than 6-8 weeks. Radiological imaging is 
insensitive to biological effects of treatment, and it is only when very significant 
changes have occurred in tumour size that they will be recognised.
Although the RECIST criteria have now much more clearly defined the 
procedure for radiological and clinical response assessment, the measurements 
do remain somewhat subjective, and inter-user variability can be problematic. It 
is recommended that for trials in which objective response rate is a primary 
objective, all responses be confirmed by an expert (Therasse et al, 2000).
In summary the limitations of conventional response assessment to therapy 
include not being able to define viable tumour from necrotic tissue or fibrosis, 
difficulty with measuring lesions that are poorly delineated, problems with 
representing three dimensional tumour volumes in two dimensions, insensitivity 
to the biological anti-tumour effect of treatments and measurement 
inconsistencies. These limitations are even more problematic when attempts are 
made to assess the effect of novel biological therapies, in which the aim may be 
for disease stabilisation, with minimal toxicity, rather than tumour shrinkage. In 
addition, patients who undertake phase I/II trials are often heavily pre-treated and 
the likelihood of them attaining a response to therapy maybe reduced. Therefore 
there is a need for a method of response assessment that reflects the biological 
change within tumours, rather than just tumour dimensions.
1.6.2 Positron Emission Tomography
Positron emission tomography (PET) utilises cyclotron produced proton rich 
radionuclides, which decay by positron emission. The nuclear conversion of a 
proton to a neutron releases a positron (a positively charged electron). This 
positron has kinetic energy and travels a small distance from the parent nucleus 
and then reacts with a neighbouring electron, resulting in an annihilation 
reaction. This releases energy according to E=mc2, and thereby produces two 
photons each with an energy of 51 IkeV at 180°to each other (Budinger, 1998) 
(Figure 6). Detectors placed around a patient will record ‘co-incidences’, which
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are photon pairs that arrive simultaneously. The origin of the positron emitter 
must be along the line o f the co-incidence. Computational reconstruction is then 
required to form a 3 dimensional image of the distribution of the emitter.
Figure 6: Diagrammatic representation of a positron emitting
radionuclide
511 keV
e+  ► e+ e-
511 keV
The nuclear conversion o f a proton (P+)  to a neutron (N) is associated with the 
release o f a positron (e+), which leaves the nucleus and travels a short distance 
randomly in the surrounding tissue. It then collides with a neighbouring electron 
(e~), and an annihilation reaction forms, which results in the release o f 2 photons 
o f energy o f 511 keV at 180° to each other. This can be recorded as a 
‘coincidence ’ by surrounding detectors.
PET imaging has increased sensitivity over SPECT imaging, as there is no need 
for collimation to determine the line of source of the photon, this is instead 
determined by the path o f the coincidence. Scattered and random events do 
occur, however they present less o f a problem than with SPECT. Compton 
scatter may occur if a photon is deflected from its original path, with the resultant
76
effect of an inaccurate path of coincidence. This deflection results in loss of 
energy of the photon and consequently large deflections may be eliminated by 
energy windowing. Random events may result from coincident detection of two 
unrelated photons.
1.6.3 [F-18] Fluoro-2-deoxy-D-glucose ([F-18] FDG
Fluorine-18 is a positron-emitting radioisotope with a half-life of 110 minutes. 
[F-18] FDG is an analogue of glucose, which competes for the same transport 
into cells as glucose, however once it is phosphorylated by the enzyme 
hexokinase, it cannot be metabolised further, and becomes trapped (Gallagher et 
al, 1978) (Figure 7). It therefore accumulates in tissues at a rate proportional to 
glucose utilisation.
It has been observed that cells that have undergone malignant transformation 
have an increase in glycolysis, which is related to tumour growth rate (Warburg, 
1956; Weber, 1977). The mechanism for this is not well understood, however, is 
thought to be as a result of an increase in transmembrane glucose transporters 
(GluT) and in hexokinase activity (Weber, 1977; Brown et al, 1999). [F-18] FDG 
is therefore taken up into malignant cells and retained, resulting in metabolic 
images of tumour glucose metabolism. [F-18] FDG that is not phosphorylated by 
hexokinase is excreted via the kidneys, unlike glucose, which is actively 
reabsorbed by the renal proximal tubule (Gallagher et al, 1978). Consequently 
background levels of FDG are lower than would be expected, and excellent 
tumour signal to background noise ratios can be attained.
The use of [F-l 8] FDG is originally derived from the work of Sols and Crane 
who studied carbon-14 [C-14] 2-deoxyglucose, and showed that 2-deoxyglucose 
was transported into cells in a similar way to glucose, but then becomes 
metabolically trapped (Sols and Crane, 1954). Sokoloff developed a three 
compartment model of regional glucose metabolism in the brain using [C-14] 2- 
deoxyglucose and autoradiography (Sokoloff et al, 1977). The principles of this 
work continue to be used today with dynamic cerebral [F-18] FDG PET kinetic 
modelling.
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Figure 7: Representation of the metabolism of glucose and [F-18]
FDG
a)
GluT
glucose
hexokinase 
-► glucose ► Glucose-6-P
Glu-6-
phosphatase
I
b)
GluT
FDG
hexokinase 
>  FDG < = £ >  FDG-6-P
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The differences in metabolism between (a) glucose and (b) [F-18] FDG are 
shown diagrammatically. [F-18] FDG is taken up into tumour cells by glucose 
transporters (gluT) in the same way as glucose, and is phosphorylated by 
hexokinase to form [F-18] FDG-6-phosphate. However, it is then trapped within 
the cell and cannot enter further metabolic pathways. There is very little 
dephosphorylation o f [F-18] FDG-6-phosphate by the enzyme glucose-6- 
phosphatase, further increasing its intracellular accumulation. Glucose is 
actively reabsorbed by the proximal convoluting tubules o f  the kidney, however 
free [F-18] FDG is not, leading to rapid urinary clearance, and lack o f  
accumulation in the systemic circulation and non-metabolising tissues.
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[F-18] FDG has become the most widely used positron-emitting tracer in 
Oncology. This is due to its good imaging properties, its applicability to a wide 
range of tumour types, its versatility and to its convenient half-life making it 
suitable for offsite production. It has been used in Oncology for staging of 
tumours, grading of tumours, differentiation of benign and malignant lesions, 
early detection of tumour recurrence and more recently, for assessment of 
response to therapy (Brock et al, 1997; Hoh et al, 1997; Bomanji et al, 2001; 
Hustinx et al, 2002).
[F-18] FDG PET has several features that provide additional benefits over 
conventional radiological imaging (Table 5). [F-18] FDG PET scans represent 
the biological process of glucose metabolism, and therefore provide both 
anatomical and functional information. Viable tumour areas may be 
differentiated from necrotic areas or fibrosis. The data is quantitative and can be 
analysed as both ‘intensity’ and as volumes. The disadvantage of [F-18] FDG as 
a tracer is that it is not specific for malignancy. Increased uptake can also be 
found in inflammatory conditions, infections and granulomatous disease. [F-18] 
FDG is also taken up in some normal tissues, including brain, heart, skeletal 
muscle and bowel. Excretion is via the urinary tract, and high tracer levels can be 
problematic in the bladder or renal pelvises. Patients must fast prior to [F-18] 
FDG injection as [F-18] FDG competes with glucose, and high circulating 
glucose levels will lead to poor tumour resolution due to high background [F-18] 
FDG levels and low tumour uptake (Lindholm et al, 1993; Diederichs et al,
1998; Langen et al, 1993). The scanning of patients with diabetes may be 
problematic. Patients must also be rested after injection, as skeletal muscle 
uptake can make interpretation of scans difficult. An awareness of these 
limitations is therefore very important and careful patient preparation is required 
for optimal results.
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Table 5: Comparison between CT scans and [F-18] FDG PET
scans
CT scan [F-181 FDG PET scan
Image type Anatomical Anatomical and functional
Data set 2 dimensional data 
collected in representative 
slices
3 dimensional volume data 
(entire data set acquired)
Lesion Resolution 1-2 mm (depends on lesion 
size and location)
4-5 mm (depends on lesion 
size, location and metabolic 
activity)
Quantitation Measurable by dimensions Quantitative by intensity and 
volume
Patient preparation Fast 2 hours 
Oral/iv contrast
Fast 4-6 hours
Rest after injection (1 hour)
Consider iv frusemide
Scan time 10-20 mins 45min-l hour
False positives Necrosis
Post surgical fibrosis 
Post radiotherapy fibrosis
Infection 
Inflammation 
Granulomatous disease 
Normal tissues -  heart, 
skeletal muscle, bowel, 
urinary tract
1.6.4 Gamma camera PET/ Coincidence PET
Full ring PET scanners are very expensive, and are not routinely accessible to 
most Cancer Centres. There are presently only nine PET centres in the United 
Kingdom. Also they can only be used for PET and not for any other form of 
imaging. Gamma cameras, however, are widely available and are commonly 
used in routine Nuclear Medicine Departments. Modification of gamma cameras 
in order that they may be used for PET imaging may allow greater accessibility 
and affordability to PET. This is especially relevant with [F-18] FDG as its 110 
minute half-life makes it suitable for off-site production. In addition the high 
resolution of dedicated full ring PET scanners may not be required for all 
imaging indications. The serial assessment of response of tumour lesions that are 
detectable by CT scans may, it is proposed, be adequately assessed by a lower 
resolution PET scanner.
In 1994 AD AC Laboratories developed a system to detect 511 keV photons by a 
SPECT scanner without a lead collimator (Wagner, 1998). This was termed
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‘Molecular Co-Incidence Detection’ (MCD). It utilises 2 detectors that rotate 
around the patient and detect ‘coincidences’ of 51 IkeV photons that arrive 
simultaneously (within 15 nanoseconds). New high count rate digital electronics 
were required to transmit this information, and they allowed the use of thicker 
crystals (5/8 inch) without compromising the performance of the camera in 
SPECT mode (Patton and Turkington, 1998; Wagner 1998). Most radioisotopes 
used for SPECT imaging have low energy emissions (<200keV), compared to the 
high energy emissions of positron emitting radionuclides, and allowance for 
imaging of both high and low energy emissions had to be incorporated into the 
design.
Attenuation correction using Caesium-137 (Cs-137) point sources has been 
developed to allow attenuation correction to be applied to the emission scans. 
This greatly improves the image quality, especially in the thorax, where 
attenuation is non-uniform, due to the low density of lung tissue.
One of the limitations of gamma camera PET is reduced sensitivity compared to 
full ring PET. This is attributed to by the loss of coincidences that occur between 
the 2 detector heads, and the mechanics of the detector system used which is not 
as efficient as those used in full ring PET scanners. There is a problem with 
‘dead time’ which is the recovery time required of the crystals before another co­
incidence can be registered. Imaging of high levels of radioactivity will lead to 
flooding of the detectors and the relationship between activity and detected co­
incidences becomes non-linear. This also results in poor image resolution.
The low count rate capability of gamma camera PET systems requires that less 
[F-18] FDG be administered compared to dedicated full ring systems. Usually 
370-500MBq of [F-18] FDG is administered to patients who are having full ring 
PET, and, in comparison, 100-185MBq of [F-18] FDG is administered to patients 
having gamma camera PET. This is an advantage with respect to radiation 
protection for patients and staff, but a disadvantage for image quality.
Many studies have now been performed comparing gamma camera PET to 
dedicated PET systems for detection of malignant lesions (Shreve et al, 
1998;Tatsumi et al, 1999; Landoni et al, 1999). A recent review concluded that
for tumours >15mm, the detection rate for gamma camera PET is fairly similar to 
dedicated PET (Ak et al, 2001). However, for lesions <15mm, the sensitivity of 
gamma camera PET is only approximately 80% compared to dedicated PET (Ak 
et al, 2001). This limits the usefulness of gamma PET for staging, as a number of 
small lesions may be missed. However, gamma camera PET is satisfactory and 
cost-effective in situations where the detection of small lesions is not required. 
This includes the differentiation of benign from malignant lesions, providing the 
lesion to be examined is >2cm, and for monitoring response to therapy, where a 
change in size or intensity of a lesion is important, rather than the detection of 
small lesions.
1.6.5 [F-18] FDG PET for response assessment
[F-18] FDG PET scans reflect the metabolic process of glucose metabolism 
occurring within cells, and therefore may provide a better indicator of tumour 
viability with treatment than conventional radiological imaging. There are an 
increasing number of papers being published in which [F-18] FDG PET scans 
have been used to assess response to cancer therapies (Table 6). Evidence is 
emerging that [F-18] FDG PET scans are a valid measure of tumour response. It 
is also apparent that [F-18] FDG PET scans are more sensitive predictors of 
response to therapy than radiological imaging. In particular, changes in tumour 
[F-18] FDG uptake with therapy precede, by weeks to months, any radiological 
changes. Studies have confirmed that response to chemotherapy may be 
predicted after 1 cycle of treatment (<3 weeks), as opposed to conventional 
response assessment with radiological imaging, which is usually performed after 
2-3 months of treatment. Some studies are now suggesting that a reduction in [F- 
18] FDG uptake may commence in the first 24 hours after treatment (Demetri et 
al, 2002).
Response assessment by [F-18] FDG PET in a clinical trial setting is, however,
currently limited by a lack of agreed standard assessment criteria or procedures.
The timing of a [F-18] FDG PET assessment, the frequency of assessments,
details of patient preparation parameters and scanning protocols have not been
standardised. In addition, the method of quantitative analysis has not been
agreed. Even less has been published with response assessment using gamma
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camera PET than dedicated PET, with, to date, only one published trial utilising 
gamma camera PET for assessing response to therapy. This was a visual study, 
and was not quantitative (Kostakoglu et al, 2002). There is a need, therefore, for 
a standardised approach for response assessment with [F-18] FDG PET. In 
addition, a method of quantitative response assessment with [F-18] FDG PET 
using a gamma camera PET system is required, in order for it to become 
established as a possible means of assessing response to therapy in clinical trials.
In chapter 5 a novel method for defining and quantifying change in tumour [F- 
18] FDG uptake using gamma camera [F-18] FDG PET is developed. This 
methodology is validated in 31 patients receiving standard first or second line 
chemotherapy for metastatic disease, and compared with conventional response 
assessment. Chapter 6 outlines the application of quantitative gamma camera 
[F-18] FDG PET to the phase I/II ADEPT clinical trials and its role in the 
interpretation of radiological stable disease in this setting.
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Table 6: [F-18] FDG PET studies of response of tumours to therapy.
Tumour type No. of 
patients
Timing of PET Method Comment Reference
Breast 30 Before the first, second and 
fifth courses o f  chemo, and 
at the end (neoadjuvant)
Kinetic analysis 
(Patlak) and SUV
PET after 1 course o f  chemo able to predict a 
complete pathological response (sensitivity o f  90%, 
specificity 74%)
(Smith et al, 2000)
Breast 11 Pre, day 8, day 21, day 45 
and day 63 after chemo/ 
hormone Rx 
(neoadjuvant)
Kinetic analysis and 
SUV
Reduction in tumour [F-18] FDG uptake in 
responders antedated any reduction in anatomical 
size o f  lesions
(Wahl etal, 1993a)
Breast 8 Pre, after Is* and 3rd /4th 
cycles o f  chemo
SUV Reduction in tumour [F-18] FDG uptake occurs after 
first cycle o f  chemo
(Jansson et al, 1995)
Oesophageal 40 Pre chemo, and 14 days post 
chemo (neoadjuvant)
SUV Reduction in tumour [F-18] FDG uptake at 14days 
correlated with histopathological response to 
chemotherapy, and survival
(Weber et al, 2001)
Oesophageal 36 Pre CRT and 1 month after 
CRT (neoadjuvant)
Visual
Tumour to liver ratio 
(T :L ratio)
PET response correlated strongly with pathological 
response and survival
(Flamen et al, 2002)
Oesophageal 10 Pre CRT and 2 weeks after 
CRT (neoadjuvant)
SUV Reduction in tumour [F-18] FDG uptake after 
therapy predicted responders
(Kato et al, 2002)
Colorectal 20 Pre chemo, 1-2 weeks and 
4-5 weeks post chemo
SUV 
T :L ratio
Reduction in T:L ratio at 1-2 weeks and reduction in 
T:L ratio and SUV at 4-5 weeks correlated with 
response.
(Findlay et al, 1996)
Germ cell tumours 23 Pre and after 2-3 cycles o f  
induction chemo (prior to 
HD)
SUV Reduction in tumour [F-18] FDG uptake predicted 
response to HD therapy, and correlated with survival
(Bokemeyer et al, 2002)
Lymphoma 24 Pre, after 3 cycles induction 
chemo, before and after 
HDT
SUV Reduction in tumour [F-18] FDG uptake during 
induction chemo correlated with survival
(Cremerius et al, 2002)
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Lymphoma 30 Pre chemo 
After 1 cycle
After completion o f  chemo
Visual analysis Gamma camera coincidence PET 
Residual disease on PET after 1 cycle o f  
chemotherapy strongly correlated with early relapse, 
and complete response on PET correlated with 
prolonged progression free interval
(Kostakoglu et al, 2002)
Lymphoma 11 Pre chemo, 1 week and 6 
weeks after chemo
Kinetic analysis 
(Patlak) and SUV
Responders had reduction in [F-18) FDG uptake at 1 
week and 6 weeks. 6week [F-18] FDG PET 
predicted long-term outcome
(Romer et al, 1998)
NSCLC 32
(16 had
pre+post
scans)
Pre chemo and 2 weeks 
after completion CRT 
(neoadjuvant)
Kinetic analysis Model used to correlate residual tumour glucose 
metabolism with pathological complete response
(Choi et al, 2002)
NSCLC 15 Pre chemo and after 3 
cycles o f  chemo 
(neoadjuvant)
SUV [F-18] FDG PET accurately assessed mediastinal 
lymph node downstaging post chemo and correlated 
with survival
(Vansteenkiste et al, 
1998)
Paediatric bone 
sarcoma
26 Pre chemo and after 
completion chemo 
(neoadjuvant)
SUV Tumour [F-18] FDG uptake correlated with 
histological response to chemo
(Hawkins et al, 2002)
Mixed 26 1 week before
2 weeks after completion o f  
treatment
Tumour to muscle 
ratio (static scans) 
TUR (dynamic scans 
10-60mins)
Some correlation with CT response found (Ichiya etal, 1991)
This table outlines fifteen studies that have been performed to assess the utility o f [F-18] FDG PET in the assessment o f response to 
chemotherapy. All trials demonstrated the ability o f [F-18] FDG PET to detect response to chemotherapy, and many showed that [F-18] FDG 
PET can predict response after only one 1 cycle o f treatment. Evidence is also emerging that response to chemotherapy on [F-18] FDG PET 
may predict survival. Unfortunately there is no standardised protocol for scan times, method o f analysis and outcome measures. Also the 
number o f patients in each trial is small, with the maximum number o f patients being 40.
Abbreviations: SUV-standardised uptake value; TUR -  tumour uptake ratio; T:L ratio- tumour to liver ratio
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1.7 Thesis overview and hypotheses
Three major hypotheses will be tested in this thesis.
(a) That a mechanistic approach to clinical trial improves the understanding and
development o f ADEPT
This hypothesis will be examined in chapters 2-4 with the presentation of two 
successive Phase I/II clinical trials of ADEPT. The clinical trials were hypothesis 
led, with a mechanistic design employed in order that the hypotheses proposed at 
the initiation of the clinical trials could be answered by the data collected during 
the trial. This represents a change from the traditional phase I/II dose escalation 
and toxicity assessment trial protocols, which do not primarily assess the 
mechanism of action of therapeutic agents. It is proposed that by measuring 
mechanism a greater understanding of ADEPT may be attained and that the 
development process may thereby be rationally modified.
(b) That a quantitative method of metabolic response assessment in ADEPT may 
augment the assessment o f response in a phase I clinical trial setting, and in 
particular it may aid in the interpretation o f radiological stable disease.
The assessment of response in Phase I/II clinical trials has conventionally been 
by anatomical imaging, such as CT scans. The emergence of [F-18] FDG PET as 
a means of assessing both anatomic and metabolic change in a tumour after 
therapy may lead to improvements in the assessment of efficacy in phase I 
clinical trials. This may ensure that a non-optimised treatment is not pre­
emptively discarded from further development. Chapter 5 discusses the 
development and validation of a method of quantitatively measuring change in 
tumour [F-18] FDG uptake after therapy using gamma camera [F-18] FDG PET. 
This method takes into account changes that occur in tumour size and intensity, 
and employs an automatic program to improve reproducibility and efficiency. 
Chapter 6 outlines the application of this methodology to the phase I/II ADEPT 
clinical trials, and the interpretation of the results obtained.
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(c) That the organisation of the data collected in the ADEPT clinical trials into 
an Ontology and Conceptual Model o f ADEPT can direct mechanistic clinical 
trial design and identify areas for improvement in ADEPT
Chapter 7 discusses the development of an Ontology and Conceptual Model of 
ADEPT designed to provide a framework for the collection of data relating to 
ADEPT. It is argued that with a complex therapy combined with the large 
quantity of data generated from mechanistic clinical trials, that organisation of 
this data is required in order to enhance understanding of ADEPT. It is 
hypothesised that the organisation of the data may lead to the identification of 
areas in which a mechanistic trial design may be augmented and the proposal of 
rational strategies for improving ADEPT. The Ontology and Model will be 
discussed with particular focus on those areas examined in most detail in 
chapters 2-6 of this thesis. In addition, those areas identified as potentially being 
important in order to improve ADEPT will be discussed and priorities for further 
work established.
This thesis will demonstrate that complexity should not be a hindrance to 
therapy, as long as the system can be successfully studied in vivo, in order that 
improvements to the system can be logically made. In fact, as the process that 
leads to the development of cancer is complex, it in increasingly likely that it will 
take a complex strategy to counteract it. The principle of trying to measure 
mechanism and from that deriving data that can be organised into an 
understanding of a therapy is the pervading theme of this thesis. ADEPT is used 
as the therapeutic example here, but many of the principles of mechanistic 
clinical trial design and data organisation are widely applicable to phase I/II 
clinical trial design and rational therapeutic development.
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2 ADEPT clinical trial - A5CP and ZD2767P
2.1 Background
ADEPT is a two-step targeted therapy designed to generate large quantities of 
cytotoxic agent specifically in tumour sites, therefore potentially overcoming 
resistance mechanisms and reducing systemic toxicities associated with 
conventional chemotherapy. The principles of ADEPT and the evolution of its 
development are outlined in chapter 1.
As outlined in chapter 1, two clinical trials have been undertaken with ADEPT 
using CEA as the target, A5CP as the antibody-enzyme and CMDA benzoic acid 
mustard as the prodrug (Bagshawe et al, 1995; Napier et al, 2000). A5CP 
consists of the F(ab')2 fragment of the murine anti-CEA antibody, A5B7, 
chemically conjugated to the bacterial enzyme, carboxypeptidase G2 (CPG2). 
These trials also utilised a galactosylated second antibody directed against CPG2 
(SB43-gal) to clear active CPG2 enzyme from the peripheral circulation before 
prodrug could be administered.
Studies performed during these clinical trials confirmed adequate tumour 
targeting of A5CP with tumour to blood ratios of CPG2 enzyme of >10 0000:1, 
and tumour CPG2 enzyme levels of 0.47 U/g in tumour biopsies, which was 
sufficient for activation of CMDA prodrug. Evidence of activation of CMDA 
into its active drug was attained, as active drug was measured in the systemic 
circulation. The active drug formed from CMDA however, had a long biological 
half-life of 36 minutes (Martin et al, 1997). It was likely that this long half-life 
resulted in leak-back of the drug into the peripheral circulation from the tumour 
and caused the dose-limiting myelosuppression seen (Napier et al, 2000). In 
addition, the low potency of the drug formed from the activation of CMDA 
meant that high tumour enzyme levels were required for generation of 
tumouricidal concentrations of drug. This was achieved by using the second 
antibody clearance system, in order to allow administration of prodrug at 48 
hours when tumour CPG2 enzyme levels were high. The second antibody system
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was, however, undesirable as it was immunogenic and added further complexity 
to ADEPT.
The experience gained in these clinical trials lead to three new hypotheses 
designed to improve ADEPT:
1) The utilisation of a prodrug that forms an active drug with a short half- 
life may prevent ‘leak-back’ and subsequent toxicity seen with CMDA. 
This may improve tumour selectivity and consequently allow more drug 
to be administered with improved efficacy.
2) A high potency active drug may lead to tumouricidal effects at lower drug 
concentrations than were required for efficacy from CMDA. Less CPG2 
may therefore be required in tumour at the time of prodrug administration 
for generation of tumouricidal concentrations of active drug. Thus, it may 
be possible to achieve adequate tumour enzyme targeting using A5CP 
without a clearing antibody system. This would reduce the complexity of 
ADEPT.
3) The design of a phase I/II clinical trial should be mechanistic, and 
therefore allow a maximum of understanding about ADEPT. This will 
rationally direct modifications of ADEPT for the future.
2.1.1 ZD2767P
A new candidate prodrug was required for ADEPT to attain the desired 
characteristics of short half-life and high potency of the active drug. Phenol and 
aniline-mustard prodrugs were considered as it was demonstrated that 
oxycarbonyl and carbamic linkages were also substrates for CPG2 (Niculescu- 
Duvaz and Springer, 1995). These prodrugs, when activated, produce potent 
phenol and aniline mustards.
ZD2767P (4[AyV-bis (2-iodoethyl) amino] phenoxycarbonyl L-glutamic acid) is 
a bis-iodo phenol mustard which is converted by the cleavage of glutamate by 
CPG2 to its active mustard drug, ZD2767D (4[A/^V-bis(2-iodoethyl) amino] 
phenol) (figu re 8). It was designed specifically for ADEPT by Dr CJ Springer 
(ICR) and Mr RI Dowell (AstraZeneca Ltd).
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Figure 8: Chemical structure of ZD2767P and ZD2767D
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Chemical structure ofZD2767P and ZD2767D. The bacterial enzyme, CPG2, 
cleaves a glutamate to generate ZD2767D from ZD2767P.
Preclinical in vitro characteristics
In preclinical experiments the active drug formed from the cleavage of ZD2767P 
by CPG2, ZD2767D, has a chemical half-life of approximately two minutes in 
plasma ('Blakey et al, 1995). This short half-life has been designed to allow 
diffusion within the tumour, without significant escape into the peripheral 
circulation.
The potency of ZD2767P and its active drug, ZD2767D, were tested in vitro 
against LoVo, a CEA positive, colorectal tumour cell line. The concentration of 
drug required to inhibit cell growth by 50% is referred to as IC50. The IC50 for 
ZD2767D exposed to proliferating LoVo cells for a one hour incubation in vitro 
is 0.34 pM (Blakey et al, 1996). The IC50 for the parent prodrug, ZD2767P, is 
over 100 fold more (table 7). The addition of CPG2 enzyme to ZD2767P results 
in an IC50 of the same level as ZD2767D. The drug released from ZD2767P by 
CPG2 enzyme is therefore over 300 fold more potent than the drug released from 
CMDA, which has an IC50 of lOOpM (Bagshawe et al, 1988; Springer et al,
1991; Niculescu-Duvaz and Springer, 1995).
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ZD2767D was also shown to have activity against quiescent LoVo cells, with an 
IC50 of 1.9|jM (Blakey et al, 1996). Even after only 1-minute incubation with 
proliferating LoVo cells the active drug, ZD2767D, had an IC50 of 1.57pM 
(Blakey et al, 1996). This indicates that ZD2767D, which is very lipophilic, is 
rapidly taken up into cells.
Table 7: Potency of ZD2767P and its active drug, ZD2767D
Drug IC50
ZD2767D 0.34 ±0.11 nM
ZD2767P 47 ±31 nM
ZD2767P + CPG2 0.32 ± 0.28 HM
ZD2767D (quiescent cells) 1.9 ± 1.2pM
ZD2767D (1 minute exposure) 1.57 ± 0.41 jliM
The potency ofZD2767P and its active drug, ZD2767D were tested in vitro 
against LoVo colorectal tumour cell line. The IC50 is the concentration o f drug 
required to inhibit cell growth by 50%. Drugs were incubated with proliferating 
LoVo cells for 1 hour (unless otherwise stated). (Blakey et al, 1996)
The Kn, for ZD2767P as a substrate for CPG2 is <3|xM (Springer et al, 1995; 
Senter and Springer, 2001). The Ab* is 30s'1 (*Blakey et al, 1995; Springer et al, 
1995; Senter and Springer, 2001). The turnover of ZD2767P (Acat/Km) is therefore 
approximately 10 fold less than for CMDA. This lower rate of conversion to 
active drug is counteracted by the increased drug potency; consequently overall 
less CPG2 enzyme is required at the tumour site than CMDA to achieve anti­
tumour activity.
The molecular weight of ZD2767P is 720 kDa as a hydroiodide salt, and 590 
kDa as a free base.
Preclinical in vivo experiments
Preclinical toxicities studies were performed in mice and rats with ZD2767P 
alone. The maximum tolerated dose/lethal dose to 10% animals (MTD/LD10) 
occurred in mice at a dose of <315-405mg/m2 x 3 administrations and in rats at 
240-300mg/m2 x 3 administrations. All of the toxicities observed were reversible 
by Day 28. Evidence of toxicity included myelosuppression, cardiac damage 
(myocardial necrosis, mineralisation and haemorrhage), hepatotoxicity (necrosis
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with haemorrhage and inflammatory cell infiltrate), nephrotoxicity (cortical 
tubular necrosis and dilatation, elevations in plasma urea and/or creatinine and 
salivary gland acinar atrophy (D.Blakey, personal communication). In a venous 
irritation study in dogs, a 5mg/ml solution of ZD2767P did not damage the 
vascular wall at the site of injection. 25mg/ml and 50mg/ml led to local 
endothelial loss, thrombus formation, mural necrosis and extravasation 
(D.Blakey, personal communication). ZD2767P must therefore be administered 
via a central line (preferably a Hickman line) to avoid vascular damage.
Single bolus dosing of ZD2767P was compared with 3 doses of ZD2767P over 
2hr (dose at 0,1 and 2hr) in 6 separate studies. In all six studies, giving three 
split doses of ZD2767P following A5CP gave increased median growth delays, 
compared to the single bolus dose of ZD2767P (D.Blakey, personal 
communication). The data indicate that the split dosing regime is likely to be 
more effective than using a single bolus dose. Splitting the dose has the 
additional advantage that lower concentrations of ZD2767P can be administered, 
which may be important in view of the toxicity to blood vessels seen at ZD2767P 
concentrations> 10 mg/ml.
ZD2767P, in summary, is a bis-iodo phenol mustard prodrug, whose active drug 
is over 300 times more potent than CMDA and has a very short biological half- 
life of less than 2 minutes ^Blakey et al, 1995; Springer et al, 1995; Blakey et al, 
1996). This short half-life should allow drug to diffuse locally in the tumour to 
cause cytotoxic effects, but should limit its ability to leak into the peripheral 
circulation. These characteristics are hypothesized to improve efficacy in 
ADEPT systems. ZD2767P requires characterisation in the clinical setting, in 
order to assess and define dose, toxicity, pharmacokinetics and efficacy.
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2.1.2 A5CP without a clearing antibody
It is proposed that with the improved characteristics of ZD2767P, a clearing 
antibody system might not be required for ADEPT. This would be an advantage, 
as it would reduce the complexity of ADEPT. It would also obviate the need for 
a second immunogenic clearing antibody.
Preclinical in vivo experiments
Efficacy
The efficacy of ADEPT using A5CP in combination with ZD2767P, without a 
clearing antibody system, was assessed in a nude mouse model (2Blakey et al, 
1995; Blakey et al, 1996). A5CP antibody/enzyme conjugate (3000U/m2) was 
administered intravenously to nude mice bearing human xenografts of colorectal 
carcinoma (LoVo). Localisation to the tumour of approximately 1% of injected 
dose of A5CP occurred after 72 hours (Blakey et al, 1996). The ratio of tumour 
to normal tissue was 10-50:1 at 72 horns (Blakey et al, 1996). ZD2767P was then 
administered intraperitoneally (ip) as 3 bolus injections, 1 hour apart, and 
resulted in tumour regressions and tumour growth delays of over 30 days with 
very little toxicity as assessed by weight loss (Blakey et al, 1996). The ZD2767P 
dose used was 70mg/kg x 3 administrations (human equivalent 210mg/m2) 
(Blakey et al, 1996). These preclinical experiments suggested that sufficient 
antibody-enzyme could be delivered to tumours without a clearing antibody 
system, and that efficacy could be achieved with the new prodrug, ZD2767P, 
without significant toxicity.
Toxicity
Preclinical studies toxicity studies were performed in mice, rats and marmosets 
using A5CP in combination with ZD2767P. The dose of A5CP used in these 
studies was 3000U/m2. This A5CP dose produces plasma enzyme activity level 
of 0.5U/mL (mice), 0.4U/mL (rats) and 0.2U/ml (marmoset), at 72 hours. The 
MTD/LD10 for mice of ZD2767P occurred at 30mg/m2 x 3 administrations, for 
rats it was 90-180mg/m2 x 3 administrations and for marmosets it was 600mg/m2
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x 3 administrations. All of the toxicities observed were reversible by Day 32. 
Evidence of toxicity was the same as was found with for ZD2767P alone, 
however at lower doses of ZD2767P than with ZD2767P alone.
A5CP without a clearing antibody system, in combination with ZD2767P, has 
therefore shown efficacy in preclinical models, and has potential for clinical use 
(Blakey et al, 1996). This current study is therefore designed to study both the 
new prodrug, ZD2767P, and whether adequate targeting can be achieved using 
A5CP alone, without a second clearing antibody.
2.1.3 Mechanistic clinical trial design
ADEPT is a complex 2-step therapy, in which there are many components that 
could potentially be modified. Designing a clinical trial in which each 
component, where possible, can be quantified, should rationally direct pre­
clinical development. Potentially this will accelerate development of ADEPT as 
the effect of modifications to the system can be measured and later predicted, 
based on mathematical models.
The basic design of this current ADEPT trial was to administer A5CP as a fixed 
dose, and to escalate ZD2767P to define dose limiting toxicity (DLT) and 
maximum tolerated dose (MTD). Once MTD was defined a phase II efficacy 
assessment phase was to be undertaken. The trial incorporates conventional 
phase I clinical trial measures, including toxicity and pharmacokinetics, with 
mechanistic studies in order to achieve a better understanding of ADEPT, and to 
direct modifications in ADEPT for the future.
Rationale for start dose of A5CP and ZD2767P and dose escalation of 
ZD2767P
The dose of A5CP chosen for the clinical trial is a fixed dose of 3000U/m2. This 
is less than was used in previous ADEPT clinical trial (10 000U/m2), as a second 
antibody clearance system would not be used to accelerate the clearance of CPG2 
enzyme from the blood. Preclinical studies in a mouse xenograft model of human 
colorectal cancer, demonstrated that it was feasible to administer ZD2767P 72
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hours after A5CP at this dose level, with a resultant mean growth delay 37 days 
in the tumour, and minimal toxicity as assessed by weight loss (Blakey et al, 
1996).
In pre-clinical toxicity studies the LDio in mice for ZD2767P, 72 hours after 
3000U/m2 of A5CP, was 24.9 mg/m2 x 3. This was administered at a plasma 
CPG2 enzyme level of 0.5 U/ml. In this clinical study the enzyme level at the 
time of prodrug administration was planned to be < 0.2 U/ml and therefore the 
starting dose was calculated to be double the 1/10th of the LDio in mice, i.e. 4.9 
mg/m2 ZD2767P x 3.
The protocol determined three patients would be treated at the starting dose level 
and a minimum of one patient would be treated at each subsequent level. At each 
dose escalation the ZD2767P dose would be doubled, until drug-related toxicity 
was seen in any patient, when a further two patients would be treated at that same 
dose level. Escalations would then follow a “modified Fibonacci” scheme until 
the DLT was reached, with at least three patients treated at each dose level before 
further dose escalating. If any drug-related Grade 3 or Grade 4 haematological 
toxicity, or any drug-related Grade 2, Grade 3 or Grade 4 non-haematological 
toxicity (other than nausea, vomiting and alopecia) was seen in one or more 
patients at a given dose level, then a further three patients would be treated at that 
dose level.
Mechanistic studies
The aims of the mechanistic studies that have been incorporated into this ADEPT 
trial protocol were to quantitatively measure each possible component of ADEPT 
in the clinical setting. They should also provide the data to answer the hypotheses 
that lead to this trial.
The measurements used in this ADEPT trial are listed in table 8:
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Table 8: Measurements in ADEPT trial
Toxicity of A5CP +ZD2767P Method of assessment
Toxicity, MTD and DLT NCI-CTC criteria
Characteristics of A5CP Method of assessment
Serum CPG2 en2yme clearance Methotrexate reduction assay
Tumour CPG2 enzyme levels Methotrexate reduction assay (biopsy)
Blood 1-131 radiolabelled A5CP 
clearance
Gamma counter
Localisation of 1-131 radiolabelled 
A5CP
SPECT analysis of gamma camera 
data
Immunogenicity of A5CP HAMA and HACPG2A by ELISA
Characteristics of ZD2767P Method of assessment
ZD2767P pharmacokinetics HPLC analysis
ZD2767D formation Comet assay (for DNA cross-links)
Efficacy of A5CP + ZD2767P Method of assessment
Anatomical CT scans (WHO response criteria)
Functional [F-18] FDG PET analysis
Serological Serum CEA and CA19-9 levels
Survival Kaplan-Meier survival analysis
Abbreviations: MTD -  maximum tolerated dose; DLT-  dose limiting toxicity; 
NCI-CTC -  National Cancer Institute Common Toxicity Criteria; CPG2 -
carboxypeptidase G2; SPECT -  single photon emission computerised 
tomography; HAMA -  human anti-mouse antibody; HACPG2A -  human anti- 
CPG2 antibody; ELISA -enzyme linked immunosorbance assay; WHO -  World 
Health Organisation; [F-18] FDG PET -  [F-18] fluorodeoxyglucose positron 
emission tomography
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The hypothesis that ZD2767P as the new prodrag for ADEPT may achieve less 
toxicity and greater efficacy than CMDA as a result of the short half-life and 
greater potency of its active drag, ZD2767D, should be addressed by the 
assessment of toxicity, by measuring the pharmacokinetic parameters of 
ZD2767P and by looking for evidence of ZD2767D formation, using comet 
assay, and the assessment of efficacy in combination with A5CP. The hypothesis 
that adequate tumour targeting for activation of ZD2767P, can be achieved using 
A5CP without a clearing antibody system should be addressed by the 
measurement of CPG2 enzyme levels in serum and tumour, in combination with 
the assessment of biodistribution of radiolabelled A5CP, and toxicity and 
efficacy assessments.
2.2 Trial outline
2.2.1 Patient Selection:
The trial had Local Research Ethics Committee (LREC), Department of Health 
United Kingdom, and Administration of Radioactive Substances Committee 
(ARSAC) approval. It was performed according to Good Clinical Practice, under 
the auspices of the Cancer Research Campaign Phase I/II Clinical Trials Group. 
The Cancer Research Campaign’s Drag Development Office monitored the 
clinical data.
All patients gave written informed consent for the study. The eligibility criteria 
were unresectable, locally recurrent or metastatic colorectal carcinoma or other 
CEA expressing tumour; no anti-tumour treatment in the previous 4 weeks; 
bidimensionally measurable disease by plain X-ray, CT or ultrasound scan; age > 
18 years; life expectancy> 4 months; WHO performance status 0,1 or 2; and 
normal haematological, biochemical, renal and hepatic function unless abnormal 
due to tumour. Pre-treatment serum CEA levels were required to be between 
lOpg/L and lOOOpg/L: if the serum CEA was not raised, then CEA had to be 
demonstrated by immunohistochemistry on tumour biopsy (Boxer et al, 1994). 
Patients were excluded if they had pre-existing HAMA to A5B7 or HACPG2A;
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the presence of active brain metastasis; if they were a poor medical risk; HIV,
Hep B or C positive; or pregnant or lactating.
All patients had an intradermal skin test to the A5CP conjugate performed and 
would have been excluded if they formed a positive reaction to it. All patients 
had received previous conventional chemotherapy or radiotherapy, and had either 
relapsed or showed no response. Preclinical studies indicated the need for 
ZD2767P to be injected into a large bore vein, so all patients had a double lumen 
Hickman catheter inserted; in most cases this was into the subclavian vein. All 
patients who received 1-131 radiolabelled conjugate also received thyroid 
blocking with potassium iodide 50mg qds for 10 days commencing one day prior 
to the administration of the radiolabelled product. Patients could receive 
metoclopramide 20 mg tds as an antiemetic if required after the administration of 
prodrug.
2.2.2 Materials
A5CP was manufactured by Lonza Biologies, and supplied by AstraZeneca 
Pharmaceuticals. A5CP was formulated as 50,159 or 150 units/ml sterile 
aqueous solution packed in neutral (Type 1) glass vials with a nominal volume of 
5 ml. A5CP was diluted in 0.9% sodium chloride and administered over two 
hours as a 500 ml intravenous (iv) infusion.
Radiolabelling of A5CP was performed using 370MBq of 1-131 by the N-bromo- 
succinamide/L-tyrosine technique (Adam, 1989). Thin layer chromatography 
(TLC) was performed to assess iodine incorporation and antigen binding was 
assessed using a CEA column.
ZD2767P was manufactured and supplied by AstraZeneca as a non-sterile 
product containing 610 mg of crystalline ZD2767P Hydroiodide per vial (which 
was equivalent to 500 mg of ZD2767P free base). 10 ml of sodium bicarbonate 
solution was added to this and ZD2767P Hydroiodide salt was converted to 
ZD2767P di-sodium salt. The final solution contained 53.7 mg/ml of ZD2767P 
di-sodium salt, which was equivalent to 50 mg/ml of free base. ZD2767P was
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administered as three doses an hour apart, via a fast running iv infusion of 
Dextrose 5%, through a central (Hickman) line.
2.2.3 Treatment Schedule
3000U per m2 of A5CP in 500mL of 0.9% sodium chloride was given over 2 
hours on day 0. 250U of A5CP was radiolabelled with 370MBq 1-131 and 
administered as a slow iv bolus over 2 minutes at the end of the infusion. Daily 
serum CPG2 measurements were performed until the serum CPG2 enzyme levels 
fell below a pre-determined value. This level was initially 0.20U/mL (patients 1, 
3- 9); however because of early toxicity it was lowered to O.lOU/mL (patients 2, 
10-22) then 0.05U/mL for all subsequent patients. At this time ZD2767P was 
administered as 3 bolus injections, 1 hour apart, each over 5 minutes into a fast 
running 5% dextrose drip. Patients were then followed up for a period of at least 
8 weeks from the time of conjugate administration.
2.3 Methods and Results:
2.3.1 Patient demographics
28 patients were recruited, of which, 27 patients (21 males and 6 females) were 
treated in between November 1997 and November 1999. One patient (patient #
8) became ineligible due to deterioration in liver function tests after recruitment 
and prior to treatment. This patient did not receive A5CP or ZD2767P and was 
excluded from further analysis.
The median age of patient’s was 56 years (range 32-74 years). 15 patients (55%) 
had a WHO performance status of 0,11 (41%) had a performance status of 1 and 
1 patient (4%) had a performance status of 2 at the time of entry into the study 
(table 9).
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Table 9: Patient demographics
Male Female All Patients
Patients 21 (78%) 6 (22%) 27 (100%)
Age (years)
Median 57 54.5 56
Minimum 32 32 32
Maximum 69 74 74
WHO
Performance
0
i
12 3 15 (55%)
8 3 11 (41%)
2 1 0 1 (4%)
25 patients had advanced colorectal cancer, 1 patient had a CEA expressing 
carcinoma of the pancreas, and one patient had CEA expressing non-small cell 
lung cancer. All patients had received prior chemotherapy or radiotherapy. The 
median number of prior chemotherapy regimens before entering the study was 2 
(range 0-7) (table 10).
Table 10: Previous chemotherapy regimens in ADEPT patients
ZD2767P dose 
level (mg/m2)
Number of 
patients
Time between last 
chemotherapy and 
ADEPT (days)
Number of 
chemotherapy 
regimens
Median Range Median Range
4.9 5 105 48-710 2 1-3
6.0 1 95 95 1 1
6.37 4 111 41-299 3 2 -4
8.28 3 72 39 -105 2 1-3
12.42 2 88 46-130 2.5 2 -3
15.50 7 87 84-91 1 0-1
18.63 5 137 130 -143 3 2 - 7
All dose levels 27 95 39-710 2 0 - 7
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2.3.2 Toxicity/MTD/DLT
The dose of A5CP remained fixed throughout the study, with the dose of 
ZD2767P being escalated until the MTD was established. The starting dose of 
ZD2767P was 4.9mg/m2 x three doses. At 18.63mg/m2 x three doses, drug- 
related dose limiting toxicity stopped further dose escalation. This consisted of 
Grade 4 thrombocytopaenia in 2 out of 5 patients. One patient at a dose of 
18.63mg/m2 also had a prolonged period of neutropaenia. The ZD2767P dose 
was subsequently reduced to 15.5mg/m2x three doses in order to establish the 
MTD (table 11).
Table 11: Dose escalation schedule of ZD2767P
Dose level 
(mg/m2)
Percentage increase/decrease 
above preceding dose level
4.9 Starting dose
6.37 30%
8.28 30%
12.42 50%
18.63 50%
15.5 25% increase from 12.42 mg/m2
From dose level 4.9 mg/m2 to 15.5 mg/m2 treatment was well tolerated with 
mainly Grade I-II haematological drug-related adverse events (AEs) (table 12).
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Table 12: Highest NCI-CTC grade of haematological toxicity
(ADEPT related) attained for each patient according to ZD2767P 
dose
NCI-CTlC toxic 
(WBC)
ity grade NCI-CTC toxicity grade 
(Platelets)
0 I II III IV 0 I II III IV
4.9mg/m2 4 1 4 1
6.0mg/m2 1 1
6.37mg/m2 4 3 1
8.28mg/m2 3 2 1
12.42mg/m2 2 1 1
15.5mg/m2 4 2 1 4 2 1
18.63 mg/m2 2 2 1 1 1 1 2
Abbreviations: WBC -  white blood cells; NCI-CTC -  National Cancer Institute 
Common Toxicity Criteria
Overall 12 patients experienced Grade I-IV drug related thrombocytopaenia, with 
a median nadir of 4 weeks (27.5 days), and 8 patients experienced Grade I-IV 
drug related leucopaenia, with a median nadir of 6 weeks (41.5 days) (table 13, 
14). Figure 9 shows myelosuppression graphs for the MTD (15.5mg/m2) and 
DLT (18.63mg/m2) ZD2767P dose level.
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Table 13: Platelet nadirs for patients with ADEPT related
thrombocytopaenia
Pt No. Prodrug dose level 
(mg/m2)
Time to nadir 
(days)*
Platelet nadir 
(xl09/L)
NCI-CTC
Grade
#3 4.9 28 26 3
#6 6.0 27 66 2
#10 6.37 42 65 2
#11 8.28 31 97 1
#16 12.42 11 112 1
#17 18.63 27 21 4
#19 18.63 28 58 2
#20 18.63 27 120 1
#21 18.63 20 11 4
#24 15.5 24 68 2
#25 15.5 32 107 1
#28 15.5 35 128 1
(*time to nadir calculated from day ofA5CP (day 0))
Table 14: WBC nadirs for patients with ADEPT related
leucopaenia
PtNo. Prodrug dose level 
(mg/m2)
Time to nadir 
(days)*
WBC nadir 
(x 109/L)
NCI-
CTCCTC
Grade
#3 4.9 35 0.9 4
#6 6 49 3.8 1
#19 18.63 43 2.2 2
#20 18.63 35 2.8 2
#21 18.63 40 0.5 4
#24 15.5 50 1.4 3
#25 15.5 43 3.2 1
#27 15.5 38 3.3 1
(*time to nadir calculated from day o f A5CP (day 0))
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Figure 9: Myelosuppression graphs at MTD and DLT for
patients receiving ADEPT
a) Prodrug dose 15.5mg/m'
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b) Prodrug dose 15.5mg/m2
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c) Prodrug dose 18.63 mg/m2
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d) Prodrug dose 18.63 mg/m2
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Graphical representation o f white cell count and platelet count ofpatients in 
ADEPT trial. Figure 9a) white blood cell count at MTD (ZD2767P dose 
15.5mg/m2) b) platelet count at MTD (ZD2767P dose 15.5mg/m2) c) white blood 
cell count at DLT (ZD2767P dose 18.63mg/m2)  d) platelet count at DLT 
(ZD2767P dose 18.63mg/m2). At the DLT dose o f prodrug(18.63 mg/m2)  almost 
all patients had a fall in WBC and platelets with a nadir o f  WBC at day 42 and 
platelets at day 28. This was not so problematic at the MTD (prodrug dose 
15.5mg/m2).
Abbreviations: MTD -  maximum tolerated dose; DLT -  dose limiting toxicity
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Other side-effects from ADEPT were mild. 16 (59%) patients had grade I drug 
related nausea and 1 (4%) patient had grade II nausea. 11 (41%) patients had 
grade I or II malaise, which was considered at least possibly drug related. 2 (7%) 
patients had grade III malaise, again considered possibly related to the ADEPT 
treatment. 6 (22%) patients developed a fever in the absence of infection which 
may have been related to the ADEPT treatment. Fever in the first 24-48 hours 
following antibody-enzyme administration was regarded as a possible association 
due to immunological effects of receiving a murine protein.
Patients who had grade II or greater drug related toxicity with ADEPT were 
invited to participate in receiving ZD2767P alone, in order to assess its toxicity. 
Three patients agreed to have ZD2767P alone, and these patients were followed 
for a further 6-8 weeks. These patients were patient #3 (ZD2767P dose 
4.9mg/m2), patient #19 (ZD2767P dose 18.63mg/m2) and patient #24 (ZD2767P 
dose 15.5mg/m2). Patient #3 developed Grade 1 nausea after ZD2767P 
administration. Patient #19 had no drug-related toxicities. Patient #24 had a 
transient Grade 1 leucopaenia and neutropaenia, which were considered possibly 
related to ZD2767P. Figure 10 shows myelosuppression graphs for the three 
patients who received prodrug alone.
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Figure 10: Myelosuppression graphs for patients who received
ZD2767P alone
Prodrug alone - WBC
10 n
Patient 03 
(4.9mg/m2)
Patient 19 
(18.63mg/m2)
Patient 24 
(15.5mg/m2)
WBC
(x109/L)
Days where 0 = start prodrug
Prodrug alone - Platelets
250
200
Platelets 150 • 
(x109/L) 100.
50
■7 0 7 14 21 28 35 42 49 56
Days where 0 = start prodrug
Patient 03 (4.9mg/m2) 
—■— Patient 19 (18.63mg/m2) 
Patient 24 (15.5mg/m2)
Graphical representation o f white blood cells (WBC) and platelets in three 
patients who received the prodrug alone toxicity assessment part o f  ADEPT. 
There does not appear to be any drug related myelosuppression in these three 
patients.
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2.3.3 Mechanistic studies
A5CP Pharmacokinetics -  serum CPG2 enzyme levels and clearance of I- 
131 radiolabelled A5CP
Method
Blood samples were taken at 15mins, lhr, 2hrs, 4hrs, 6hrs and then daily after 
A5CP administration to assess clearance of A5CP from blood. The catalytic 
activity of CPG2 in serum was used to prospectively measure clearance of 
A5CP. This was performed initially by spectrophotometric methotrexate 
reduction assay (McCulloch et al, 1971; Hughes et al, 1982), and later the semi­
automated Cobas Fara II centrifugal analyser (Cobas assay) was adopted. CPG2 
enzyme levels below 0.05U/mL were confirmed by a methotrexate reduction 
assay on HPLC (Blakey et al, 1996).
The clearance of 1-131 radiolabelled A5CP was assessed retrospectively by 
gamma counting of plasma samples taken at the same time points.
The clearance of A5CP by both CPG2 enzyme levels and 1-131 radioactivity was 
then graphed and a biexponential model fitted to calculate alpha and beta half- 
lives.
SK Sharma performed measurements of CPG2 enzyme levels and 1-131 
radioactivity.
Results
Three batches of A5CP were used in the trial (Campaign 1, 2 and 4). The p half- 
life of A5CP by clearance of CPG2 enzyme levels from serum was Campaign 1 
= 8.95 hrs (spec assay), Campaign 2 =11.8 hrs (cobas) and Campaign 4 = 15.49 
hrs (cobas).
The P half-life of A5CP by clearance of 1-131 radiolabelled A5CP was 
Campaign 1 = 5.77 hrs, Campaign 2 = 5.08 hrs and Campaign 4 = 11.77 hrs.
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Serum CPG2 enzyme levels on prodrug dav
Method
A blood sample was taken immediately prior to prodrug administration and was 
analysed by methotrexate reduction assay on HPLC to confirm the CPG2 
enzyme level in serum. Enzyme level measurements were performed by SK 
Sharma.
Results
The median serum CPG2 enzyme level on prodrug day was 0.033 U/ml (range 
0.013-0.152 U/ml) by Spec/Cobas and 0.037 U/ml (range 0.011-0.18 U/ml) by 
HPLC. The number of days until prodrug administration was a median of 3 days 
(range 2-9 days). Table 15 shows the serum CPG2 enzyme levels at the time of 
ZD2767P administration by both Spec/Cobas and by HPLC.
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Table 15: Serum CPG2 enzyme levels immediately prior to
ZD2767P administration
Pt No. Conjugate
Campaign
Days until 
prodrug 
administration
Prodrug dose 
(mg/m2)
Enzyme level a 
prodrug (I
t  time of 
f/ml)
Spec/Cobas HPLC
#1 1 2 4.9 0.045 0.0284
#2 1 2 6.37 0.033 0.041
#3 1 3 4.9 0.152 0.0964
#4 1 4 4.9 0.0285 0.037
#5 1 2 4.9 0.013 0.011
#6 1 2 6.0 0.023 0.0196
#7 1 2 4.9 0.035 0.0392
#9 1 2 6.37 0.093 0.063
#10 2 3 6.37 0.0175 0.0405
#11 2 3 8.28 0.03 0.0362
#12 2 3 6.37 <0.1 0.0365
#13 2 3 8.28 0.0265 0.0217
#14 2 3 8.28 0.036 0.0318
#15 2 3 12.42 0.036 0.025
#16 2 2 12.42 0.022 0.03
#17 2 3 18.63 0.018 0.012
#18 2 7 18.63 0.035 0.012
#19 2 3 18.63 0.0465 0.0775
#20 2 3 18.63 0.0145 0.0355
#21 2 3 18.63 0.046 0.104
#22 4 6 15.5 0.026 0.05
#23 4 4 15.5 0.028 0.0972
#24 4 4 15.5 0.037 0.0997
#25 4 4 15.5 0.038 0.18
#26 4 9 15.5 undetectable 0.041
#27 4 3 15.5 0.0321 0.033
#28 4 7 15.5 0.04 0.04275
Spec/cobas enzyme measurements were from blood samples taken on the 
morning o f prodrug administration.
HPLC enzyme measurements were from blood samples taken immediately prior 
to prodrug administration.
Note: Patients #7 to #14 - samples were frozen to -85 °C and thawed twice prior 
to HPLC analysis; Patients #15 and #16 - samples were frozen to -85°C and 
thawed once prior to HPLC analysis. Patients #17 to #28 - samples were stored 
at 4°Cprior to HPLC analysis.
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CPG2 enzvme levels in tumour and normal tissue
Method
In patients who gave their consent, tumour or bone marrow biopsies were taken 
on prodrug day to assess A5CP conjugate localisation. These samples were 
assessed histologically to confirm whether tumour was present in the sample and 
then analysed for CPG2 enzyme levels by HPLC using a methotrexate reduction 
assay (Blakey et al, 1996). CPG2 enzyme measurement was performed by SK 
Sharma. Where appropriate samples were also placed on a phosphor plate and 
imaged overnight to assess for the presence of radioactivity in the biopsy 
specimen, which would indicate localisation of 1-131 radiolabelled A5CP. 
Phosphor plate analysis was performed by G Boxer.
Results
The median CPG2 enzyme level in tumour biopsies was 0.010 U/g (range 0- 
0.208U/g) on prodrug day (n=7) (table 16a). The median CPG2 enzyme level in 
normal tissue was 0.005U/g (range 0-0.062 U/g) (n=5) (table 16b). The median 
ratio of CPG2 enzyme in tumour: blood on prodrug day was 0.4:1 (range 0- 
10.4:1) (table 16c).
I l l
Table 16: CPG2 enzyme levels in tumour and normal tissue
a)
Pt No. Site Histology
CPG2 Enzyme level 
(HPLC) Tumour/serum
ratio
Phosphor
ImagerTumour
(U/g)
Serum
(U/ml)
#1 colon tumour 0.014 0.028 0.5:1 negative
#2 colostomy tumour/ necrosis 0.061 0.041 1.5:1 negative
#5 liver metastases tumour 0.000 0.011 0 negative
#6 liver metastases not done 0.208 0.020 10.4:1 negative
#15 liver metastases tumour 0.010 0.025 0.4:1 positive
#23 liver metastases tumour islands 0.000 0.097 0 negative
#25 liver metastases normal 
liver/necrotic 
tumour debris
0.000 0.180 0 not
performed
b)
PtNo. Site Histology
CPG2 Enzyme level 
(HPLC) Normaltissue/
serum
ratio
Phosphor
ImagerNormal
tissue
(U/g)
Serum
(U/ml)
#11 bone marrow not available 0.005 0.036 0.1 notapplicable
#13 subcutaneousnode
subcutaneous
tissue 0.062 0.022 2.8 negative
#18 bone marrow not available 0.001 0.012 0.1 notapplicable
#19 liver metastases normal liver 0.049 0.077 0.6 negative
#22 bone marrow not available 0.000 0.050 0 notapplicable
c) Median CPG2 
enzyme level Range
Median 
ratio to 
serum
Range
serum (n=27) 0.037 U/mL 0.011-0.180 U/mL
tumour biopsy (n=9) 0.010 U/g 0-0.208 U/g 0.4: 1 0 -10.4 : 1
normal tissue (n=5) 0.005 U/g 0-0.062 U/g 0.1:1 0-2.8: 1
Results o f CPG2 enzyme levels (by HPLC) in biopsies performed on day o f 
administration ofZD2767P in patients in ADEPT study. Where performed, the 
phosphor imager data on 1-131 labelled A5CP is also shown, 
a) Tumour biopsies b) Normal tissue biopsies c) Summary o f median CPG2 
enzyme levels.
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One patient (#12) had ascitic fluid analysed for CPG2 enzyme levels. The CPG2 
enzyme level in the ascites was 0.00975 U/g (serum 0.0365 U/ml) with the 
enzyme level in ascites: serum ratio of 0.27:1.
Figure 11 shows the positive phosphor imager result obtained from a liver 
biopsy from ADEPT patient #15, showing heterogeneous distribution of 
radioactivity throughout the tumour core. Histology from the same liver biopsy is 
also shown.
Figure 11: Phosphor imager showing localisation of 1-131
radiolabelled A5CP
Strom a Tum our
Tumour biopsy from ADEPT Patient HI 5 (liver metastasis from colorectal 
tumour) taken on prodrug day. a) phosphor imager, demonstrating 
heterogeneous radioactivity, indicating localisation and distribution o f  the 1-131 
radiolabelled conjugate b) is an haematoxylin and eosin section o f the core o f  
tissue. It shows areas o f tumour heterogeneously distributed throughout normal 
liver stroma
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Gamma camera imaging
Method
3 ml of A5CP radiolabelled with up to 370 MBq 1-131 was administered to 
patients immediately after the A5CP infusion. The CEA binding and iodine 
incorporation of the radiolabelled A5CP were measured by a CEA column and 
TLC respectively. TLC and CEA binding were performed by SK Sharma.
Patients who received 1-131 radiolabelled A5CP had gamma camera imaging 
performed at 4,24,48, 72 hours (and 96 hours if appropriate) on an AD AC 
Vertex Plus dual headed gamma camera. The imaging consisted of both planar 
and SPECT acquisitions. SPECT images were reconstructed using AD AC 
filtered-back projection software and were corrected for decay, attenuation and 
Compton scatter.
I performed the gamma camera analysis. The method involved drawing regions 
of interests, of at least nine voxels, placed in triplicate in areas of tumour and 
normal tissue (heart, lung, liver), as described by Green et al, 1990. CT and [F- 
18] FDG PET images were used to guide placement of ROIs. Mean counts per 
voxel were recorded. A calibration factor, obtained from scanning a phantom 
containing known amounts of 1-131 under clinical conditions, was used to 
convert from counts per voxel to radioactivity per kg. This value was decay 
corrected and divided by the administered radioactivity dose to calculate the % 
injected radioactivity dose/ kg in tumour and normal tissues (see Appendix 1 for 
example spreadsheets). The enzyme level (U/g) was estimated in the tumour for 
prodrug day, by modelling the % injected radioactivity dose/ kg data as a mono­
exponential clearance and extrapolating to prodrug day. The fraction of 
radioactivity estimated to have localised in tumour at the time of prodrug was 
multiplied by the total administered enzyme units to attain an estimate of enzyme 
level per gram of tumour.
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Results
The results for the antigen binding (CEA column) and iodine incorporation 
(TLC) for 1-131 radiolabelled A5CP are shown in table 17. The enzyme and 
protein concentration of each A5CP conjugate campaign was different, 
consequently the amount radiolabelled also differed. For Campaign 1 ,150U 
(1.35mg) was radiolabelled and the protein concentration was 50U/mL 
(0.45mg/mL). For Campaign 2 477U (4.83mg) was radiolabelled and the protein 
concentration was 159U/mL (1.61mg/mL) and for Campaign 4 450U (*4.5mg) 
was radiolabelled and the protein concentration was 150U/mL (*1.5mg/mL).
Campaign 1 had a median CEA binding of 1-131 conjugate of 6.56% (with a 
range o f2.2 -  24.83%) whilst Campaign 2 had a median CEA binding of 35.9% 
(with a range of 16.7- 68.3%) and Campaign 4 had a median CEA binding of 
21.7% (with a range of 16.5 -  56%). The median iodine incorporation of 1-131 
conjugate was 60.75% for Campaign 1 (with a range of 13.37 -  90%), 88.36% 
for Campaign 2 (with a range of 59.7 -  95%) and for Campaign 4 it was 86.6% 
(with a range of 77 -  97%).
(Note: * - the protein concentration for Campaign 4 is an estimated value based on the specific 
gravity o f the conjugate o f approximately lOOU/mg. The actual value could not be obtained at the 
time o f printing the thesis)
Table 17: CEA binding and 1-131 incorporation of 1-131
radiolabelled A5CP
PtNo. Conjugate Campaign CEA binding of 1-131 A5CP (%)
Iodine incorporation of 
1-131 A5CP (%)
#1 1 4.37 38.0
#2 1 2.2 13.37
#3 1 8.32 90
#4 1 4.8 40.0
#5 1 24.83 88.0
#6 1 11.0 81.5
#7 1 ND* ND*
#9 1 ND* ND*
#10 2 33.5 95
#11 2 68.3 93.6
#12 2 44.6 95.0
#13 2 38.3 95.0
#14 2 39 74.0
#15 2 21.3 86.6
#16 2 40.8 84.64
#17 2 16.7 85.4
#18 2 26.3 94.9
#19 2 39.5 90.12
#20 2 - 27.6 80.75
#21 2 18.39 59.7
#22 4 20 93.43
#23 4 23.4 79.8
#24 4 NDf NDf
#25 4 NDf NDf
#26 4 56 97.0
#27 4 NDf NDf
#28 4 16.5 77.0
The % o f CEA binding represents the % o f the total label which bound to CEA on 
a CEA column. The % iodine incorporation is derived from the % o f iodine that 
remains protein bound after being run on a TLC strip.
* There was no analysis performed on Patients #7 and #9 due to technical 
problems.
f  Patients #24, #25 and #27 did not receive 1-131A5CP 
Abbreviations: ND = not done
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Twenty-four patients had gamma camera scans performed. Three patients (#24, 
#25, #27) had no gamma camera scans performed due to technical problems with 
the camera (radiolabelled conjugate was not administered to these patients). In 
six patients (#1, #3, #4, #5, #6, #7) data was not collected using scatter windows, 
so scatter correction could not be applied to the scans and quantitative SPECT 
analysis could not be performed. Visual examination of the planar images from 
these six patients was not able to demonstrate clear evidence of localisation. 
Overall eighteen patients had SPECT scans performed that were suitable for 
quantitative analysis.
The overall median % injected dose/kg o f radiolabelled conjugate in the tumour 
on prodrug day was 0.185 %/kg, range 0.0006 - 1.05 %/kg (figure 12). The 
median uptake of radiolabelled conjugate in heart (estimate for bloodpool) 
remained higher than in tumour for the 5hr, 24hrs and 46 hrs time-points, and for 
normal liver it remained higher than tumour at all measured time-points. These 
results are consistent with the low median tumour to blood ratio of enzyme 
activity of 0.4:1 attained by HPLC assay.
Figure 12: SPECT analysis of biodistribution of 1-131
radiolabelled A5CP
10 -
□  lung
■  liver
□  heart
■  tumour
5 24 46 69
Median scanning time after I-131A5CP injection [h]
Distribution o f 1-131 radiolabelled A5CP in tumour and normal tissue over time 
by quantitative SPECT imaging. Each time-point is the median o f 18 patients. 
The error bars include 70% o f the data points.
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Figure 13 demonstrates localisation of 1-131 to a presacral tumour in patient 
#18.
Figure 13: SPECT scan at 96 hours showing localisation of 1-131
to a presacral tumour
Bl a d d e i
B la dd e i
/
I untom
1 u niour
Pre-treatment CT scan o f ADEPT Patient #18 (rectal carcinoma) demonstrating 
a presacral tumour mass behind the bladder. SPECT study in same patient at 96 
hours after administration o f1-131 radiolabelled conjugate. This study 
demonstrates uptake o f radioactive tracer into the tumour area.
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Table 18 displays the estimated enzyme units in tumour at the time of prodrug 
administration, based on extrapolation of a mono-exponential model. The median 
number of estimated enzyme units in the tumour at the time of prodrug 
administration was 0.010 U/g, range 0.000037 - 0.054 U/g.
Table 18: SPECT analysis of 1-131 A5CP tumour localisation
with extrapolated estimated tumour enzyme levels
Pt No. Conjugate
Campaign
Days until 
prodrug 
administration
% injected dose 
per kg
Enzyme Level 
extrapolation 
[U/g]
#2 1 2 0.13 0.006471
#9 1 2 0.24 0.013752
#10 2 3 0.12 0.00879
#11 2 3 0.19 0.011571
#12 2 3 0.65 0.035827
#13 2 3 0.6 0.027501
#14 2 3 0.04 0.002169
#15 2 3 0.02 0.001296
#16 2 2 0.19 0.010885
#17 2 3 0.18 0.009828
#18 2 7 1.05 0.054276
#19 2 3 0.06 0.004023
#20 2 3 0.47 0.022163
#21 2 3 0.49 0.028535
#26 4 9 0.0006 0.000037
#28 4 7 0.002 0.000108
median 0.185 0.010357
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Immunogenicitv
Method
Blood was taken from patients pre-study and at weekly intervals post A5CP 
administration for 8 weeks. HAMA and HACPG2A response was measured by 
ELISA and compared with known positive and negative controls (Sharma et al, 
1992). Data has been obtained from SK Sharma.
Results
26 out of 27 patients who received A5CP had sufficient blood samples taken for 
analysis of immunogenicity. All of these patients developed a positive HAMA 
response following the single administration of A5CP. The median number of 
days until developing a positive HAMA was 14 days (range 7-36 days). All 
patients except one (patient #13) developed a positive HACPG2A response. The 
overall median number of days until developing a positive HACPG2 A was 15 
days (range 7-50 days). Table 19 shows the time to developing a positive 
HAMA or HACPG2A for each batch of A5CP conjugate.
Table 19: Immunogenicity of A5CP
Antibody Campaign Time from A5CP 
administration to a positive 
result (days)
Number of 
patients
Median Range
HAMA 1 14 7-22 8
2 14 7 -36 11
4 22 7 -36 7
All Campaigns 14 7-36 26
HACPG2A 1 14 7-22 8
2 14.5 7 -30 10
4 28 21-50 7
All Campaigns 15 7-50 25
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ZD2767P (pro drug) pharmacokinetics
Method
ZD2767P concentrations in plasma were measured by HPLC. Plasma samples 
were taken for prodrug level estimations 2 minutes (mins) after the first and 
second prodrug injection, and at 2, 5,10,15, 30 and 60 mins after the third 
prodrug injection. A complete pharmacokinetic profile including concentration 
of ZD2767P extrapolated back to time 0 minutes (CO), volume of distribution in 
the body at steady state (Vss), area under the curve (AUC) and elimination half- 
life of prodrug (T*/2) was determined for each evaluable patient using a non- 
compartmental model and WinNonlin® (Pharsight Corporation) software. 
Pharmacokinetic data has been obtained from C Springer and J Martin.
Results
All 27 patients had blood samples taken for pharmacokinetic analysis, however 
in some patients a full pharmacokinetic profile could not be obtained due to 
technical problems, in particular haemolysis of blood samples resulting in 
inaccurate and incomplete data.
Table 20 is a summary of the non-compartmental pharmacokinetic values 
calculated at each dose level for all patients in which reliable analysis could be 
performed. Average AUC values increased with increasing doses. The mean 
measured half-life of ZD2767P in plasma at the MTD was 14.5 minutes. The 
values for volume of distribution did not appear dose dependent.
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Table 20: Pharmacokinetic parameters for ZD2767P by dose
level
ZD2767P
(mg/m2)
PtNo. T*
(mins)
AUC
(pg.ml.min)
Clearance
(ml/min)
Cmax
(pg/ml
)
Vss
(L)
4.9 #1, #3, Mean 6.4 8.0 1253 1.1 9.4
#4 SD 1.3 2.1 495 0.4 5.2
Range 3.6-6.2 5.7-9.8 915-1822 0.6-1.3 4.8-15
6.4 #2, #9, Mean 5.4 10.6 1142 1.4 8.4
#10 SD 1.1 1.8 162 0.3 2.3
Range 4.1-6.2 8.6-11.9 1026-1327 1.1-1.7 6.0-10.5
12.42 #16 4.7 33 734 3.7 5.0
15.5 #22-28 Mean 14.5 41 842 3.4 13.4
SD 8.1 17 408 0.8 5.5
Range 7.4-30.0 19-69 409-1547 2.5-4.8 6.2-22.6
18.63 #17-21 Mean 11.8 61 592 5.2 7.8
SD 4.4 26 207 1.9 1.9
Range 7.8-19 36-105 365-989 2.5-7.5 5.9-10.8
Summary o f the non-compartmental pharmacokinetic parameters ofZD2767P 
calculated for all suitable patients. Patients #5, #6, # 7, #11, #12, #13, #14 and 
#15 are omitted due to technical problems preventing accurate analysis to be 
performed. Data for patient #21 (18.63 mg/m2) were generated starting from 5 
minutes, as the 2 minute time point was invalid.
Abbreviations: Ty2 - half-life; AU C-area under curve; Cmax -  maximum 
concentration; Vss -  volume o f distribution at steady state
The maximum concentration (Cmax) of ZD2767P at an administered dose of 
18.63mg/m may be converted from 5.2 pg/ml to pM equivalent by using the 
molecular weight of ZD2767P (as a free base) of 590. This results in a molar 
concentration o f0.0085pM, which is significantly less than would be expected to 
result in cytotoxicity based on the cell cytotoxicity experiments from table 7.
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Figure 14 shows the mean plasma prodrug elimination profiles following the 
third administration of prodrug, for each dose group of patients. This figure 
confirms that the prodrug is essentially cleared for all dose levels within 60 
minutes of administration.
Figure 14: Mean plasma elimination profile for each dose level of
ZD2767P
ZD2767P dose 
(m g/m *)
12.42 (single patient)
15.5
18.63
Time after prodrug dose 3 (min)
Mean plasma prodrug elimination profile following the third administration o f  
ZD2767P for each dose group. Patients with incomplete pharmacokinetic 
analyses are excluded. The profile for the 12.42mg/m2 group is that o f  a single 
patient.
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Figure 15 shows the variation of ZD2767P levels after each of the three 
administrations of prodrug, at each different prodrug dose. There is no obvious 
accumulation of prodrug in the 1 hour interval between doses.
Figure 15: Plasma levels of ZD2767P measured 2 minutes after 
each ZD2767P administration
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Plasma levels ofZD2767P measured 2 minutes after doses 1, 2 and 3. All valid 
values are included. Individual patients are not identified. Only 4 values are 
shown for the dose group 18.63 mg/m2 after dose 3 as the pharmacokinetic 
calculations for one patient were made starting from the 5 minute time point.
Three patients who experienced toxicity with full ADEPT were given prodrug 
alone, and had pharmacokinetic studies performed. Patients #3 (4.9mg/m2) and 
#19 (18.63mg/m ) had pharmacokinetic parameters that were broadly similar to 
those when each was given ADEPT (although data for patient #3 were limited).
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Comet assay
Method
The short half-life of the active drug of ZD2767P prevented it being directly 
measured in the clinical trial. However, as it is an alkylating agent, its lethality to 
cells is via the formation of DNA interstrand cross-links. The presence of DNA 
interstrand crosslinks was measured in the trial by a single cell comet assay. This 
was performed on tumour biopsy specimens and bone marrow aspirates. 
Peripheral blood lymphocytes taken at the same time as the biopsy were used as 
controls. All tumour or bone marrow biopsies were performed on the day of 
receiving prodrug, 1-2 hours after receiving the last prodrug injection (Webley et 
al, 2001). The results of the comet assay were expressed as a %reduction in tail 
moment (RTM). The comet assay was performed by S Webley.
Results
Nine patients had comet assays performed on tumour biopsy specimens (n=5) 
and normal tissue (n=4). 8 of the patients had no significant reduction in tail 
moment seen in the tissues or in the circulating blood lymphocytes measured as 
controls (table 21). However, the tumour biopsy of one patient (#15), had an 
80% RTM in the comet assay thereby indicating the presence of significant DNA 
interstrand cross-links (figure 16). The circulating lymphocytes in the same 
patient did not have DNA interstrand cross-links.
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Table 21: Comet assay
PtNo. Site Histology
Comet assay
Biopsy Lymphocytes
#2 colostomy tumour/necrosis negative no sample
#11 bone marrow not available negative (53% RTM)
negative 
(29% RTM)
#13 subcutaneousnode subcutaneous tissue no analysis
negative 
(24% RTM)
#15 liver metastases tumour positive (80% RTM)
negative 
(24% RTM)
#18 bone marrow not available negative (10% RTM)
negative 
(0% RTM)
#19 liver metastases normal liver negative (0% RTM)
negative 
(0% RTM)
#20 liver metastases not analysed negative (0% RTM)
negative 
(0% RTM)
#23 liver metastasis tumour islands negative (8% RTM)
negative 
(8% RTM)
#25 liver metastasis
normal liver 
necrotic tumour 
debris
negative 
(17% RTM)
negative 
(6% RTM)
Comet assay results in all patients who had tumour or normal tissue biopsies 
performed. Patients #2, #75, #20, #23 and #25 were regarded as having tumour 
biopsies and patients #11, #13, #18 and #19 as having normal tissue biopsies. 
Comet assay o f circulating peripheral blood lymphocytes was used as a control. 
Abbreviation: RTM-reduction in tail moment
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Figure 16: Comet assay
a) b)
W h o l e  B l o o d  L y m p h o c y t e s
CONT RO L  ADEPT 11 ADEPT 15
c)
B i o p s i e s
CO N T RO L  ADEPT 11 A DEP T 15
a) Comet assay on peripheral blood lymphocytes from ADEPT Patient #15, 
showing a normal comet tail
b) Comet assay on cells from a tumour biopsy (liver metastasis from colorectal 
ca) from ADEPT Patient #15, showing a loss o f comet tail, indicating the 
presence o f DNA interstrand cross-links.
c) Graphical representation o f comet assay o f  lymphocytes and biopsies from 
ADEPT Patient #15 (biopsy o f liver metastasis) and ADEPT patient #11 (bone 
marrow biopsy). The DNA from the tumour biopsy from patient #15 has a 
reduction in the comet tail, however the peripheral blood lymphocytes have not 
been affected. This indicates the selective formation o f DNA crosslinks in the 
biopsied tumour cells. In patient #11 there has been a small, but not significant 
reduction in comet tail from bone marrow cell, and no reduction in comet tail in 
peripheral blood lymphocytes. Patient #11 did not have significant 
myelosuppression.
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2.3.4 Efficacy
Radiological assessment 
Method
Radiological assessment of response to ADEPT was performed within 3 weeks 
prior to commencing treatment, and then at 28 and 56 days after ADEPT. 
Response was assessed using standard WHO response criteria, based on change 
in bidimensional diameters of lesions (WHO, 1979). I performed the CT 
measurements under the guidance of a radiologist.
Results
Of the 27 patients, 26 were evaluated for response on day 28, and 22 were 
evaluated for response on day 56 (table 22). Two patients died on study, both 
due to progression of disease (patient #12 died on Day 15 of follow-up, patient 
#17 died on Day 31 of follow-up).
There were no objective responses in this study. Three patients (#15, #18 and 
#22) had stable disease at Day 56. Patients #15 and #18 were the only two 
patients with confirmed positive tumour localisation by either tumour biopsy or 
gamma camera imaging. In addition, patient #15 had a positive comet assay from 
a tumour biopsy indicating prodrug activation. A tumour biopsy could not be 
obtained from Patient #22, and no areas of tumour could be identified on gamma 
camera imaging and a tumour biopsy was not feasible due to the small size of the 
patient’s metastasis.
Interestingly, the CT scans from Patient #24, showed that one of two mediastinal 
lesions had progressed by Day 28; however, by Day 56 the dimensions of this 
lesion had decreased in size and showed no change when compared to baseline. 
According to the response criteria used in this study, the response assigned was 
progressive disease because of the initial progression recorded. The [F-18] FDG 
PET results (see below) indicate at least stable disease on metabolic imaging.
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Table 22: CT scan response and tumour marker levels for all
ADEPT patients
Pt No.
CT
response CEA (jxg/l) CA19-9 (U/ml)
Day
28
Day
56
Pre-
study
Day
28 Day 56
Pre­
study Day 28 Day 56
#1 PD PD 325 376 523 169 270 443
#2 PD PD 264 359 527 124 197 629
#3 PD PD 140 234 512 67 119 505
#4 PD PD 13 36 96 9 61 111
#5 PD PD 846 1218 1496 2465 3008 4148
#6 PD PD 901 1135 1446 43 50 41
#7 PD PD 125 162 175 10839 12140 11754
#9 PD PD 153 279 384 708 953 1336
#10 PD PD 1067 1321 1266 41.8 65 88
#11 PD PD 42 86 97 1108 1244 1244
#12 NE NE 31 34 ND 96050 32570 ND
#13 PD PD 3 4 10 18 20 62
#14 PD NE 30 44 ND 10 14 ND
#15 SD SD 874 1141 1180 7427 7637 9373
#16 PD NE 826 ND >500* 5140 3744 ND
#17 PD NE 145 2156 ND 52 350 ND
#18 SD SD 20 14 18 27 18 21
#19 SD PD 236 298 348 223 305 391
#20 PD PD 862 1700 1456 325 571 590
#21 PD PD 541 513 513 18 19 26
#22 SD SD 19 34 42 31 88 48
#23 PD PD 22 26 29 89 120 145
#24 PD PD 88 85 92 37 45 45
#25 PD PD 347 436 1064 6 6 6
#26 PD PD 3 3 3 10 14 18
#27 PD NE 201 246 285 882 1017 ND
#28 PD PD 3 3 3 6 11 8
analysis performed at a local hospital
Abbreviations: NE- not evaluable; ND- not done; SD -  stable disease; PD -  
progressive disease
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Serum tumour markers
Method
Serum tumour markers (CEA and CA19-9) were measured pre-study, at 
approximately day 28 and day 56.
Results
Table 22 shows the serum tumour marker levels in the patients on the ADEPT 
study. Almost all patients had an increase in serum tumour markers on study, 
which would be consistent with the lack of objective responses in this study. As 
A5CP is an anti-CEA antibody this may make interpretation of serum CEA 
levels difficult. Also the formation of HAMA may interfere with the serum 
marker laboratory assay.
FF-181FDGPET scans
Chapter 6 contains comprehensive details on the analysis of the [F-18] FDG 
PET scans performed as part of this clinical trial. An overview of the 
methodology and results are presented here.
Method
[F-18] FDG PET scans were performed within 2 weeks prior to commencing 
ADEPT, at 4 weeks and then at 8 weeks after ADEPT. Scanning was performed 
on an AD AC Vertex Plus dual headed gamma camera. Patients received 150- 
185MBq of [F-18] FDG and scanning was performed at approximately 60 
minutes post injection.
Reconstruction was performed using standard AD AC iterative reconstruction 
protocols. A correction for attenuation was performed using Chang attenuation 
correction of uniform ellipses (Chang, 1978). A rescaling factor was applied to 
the images prior to analysis, correcting for injected activity of [F-18] FDG and 
time to scanning. A formal correction for blood glucose levels was not made,
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however data with blood glucose levels outside the range 4-7mmol/L were 
deemed unreliable.
Analysis was performed, where data was deemed reliable, using quantitative 
volume of interest (VOI) analysis as described in detail in chapter 5. This 
method uses a mathematically derived automated region growing program to 
objectively define tumour volumes. The total counts within these tumour 
volumes are then compared to assess response. I performed the quantitative 
analysis of all of the [F-18] FDG PET scans.
Results
Of the twenty seven patients who received ADEPT, fifteen patients completed 
three [F-18] FDG PET scans in accordance with the trial protocol. Six patients 
completed two of the three intended scans. Four patients had only their baseline 
[F-18] FDG PET scan performed. Two patients had no [F-18] FDG PET scans 
performed. The details of these scans are outlined in chapter 6.
Eleven patients (#2-#10, #12, #13) received 185MBq of [F-18] FDG and were 
scanned at 45-60 minutes. It was subsequently found that in these patients the 
count rate capability of the camera was exceeded and these scans were deemed 
non-quantitative.
Therefore there were nine patients in whom quantitative analysis would be valid. 
In two of these patients (patient #18 and #23) automated region drawing could 
not be performed. This was due to tumour being adjacent to bladder in one 
patient (patient #18), and poor resolution between tumour and surrounding 
normal tissue in another (Patient #23).
Table 23 outlines the change in total counts in the tumour VOI derived from the 
automated region growing program in the remaining seven patients.
131
Table 23: [F-18] FDG PET quantitative analysis
PtNo. CT scan [F-18] FDG PET 
(% change compared with 
baseline)
4 weeks 8 weeks 4 weeks 8 weeks
#15 SD SD 539% 758%
#19 SD PD 138% 161%
#11 PD PD 146% 114%
#14 PD NA 381% NA
#20 PD PD 111% 162%
#24 PD PD 59% 102%
#26 PD PD 184% 182%
Results o f quantitative [F-18] FDG PET analysis using the percentage change in 
tumour [F-18] FDG uptake compared with baseline, Analysis was performed 
using VOI, with the total count statistic used to calculate the percentage change. 
Comparison is made with CT scan results, measured using WHO criteria. 
Abbreviations: SD -  stable disease; PD -  progressive disease; NA- not 
applicable
The total tumour [F-18] FDG uptake at 4 and 8 weeks increased in almost all 
patients compared to baseline. This was consistent with the CT scan findings, 
tumour marker measurements and clinical picture. The exception to this was 
patient #24, in whom the [F-18] FDG tumour uptake appeared to fall at 4 weeks, 
and remain stable at 8 weeks. This patient had a CEA expressing non small cell 
lung cancer with mediastinal lymphadenopathy, previously treated with 
radiotherapy. This patient remained well on follow-up after ADEPT for 10 
months before relapsing with brain metastasis requiring radiotherapy. It appears 
that the metabolic activity of the tumour may have remained stable with ADEPT 
in this one patient.
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Overall survival
Method
Survival times were calculated from the start of treatment. Overall survival was 
calculated at the time of the ADEPT Final Report (July 2000 is the date of last 
contact) and is plotted using Kaplan-Meier.
Results
At the time of issuing the Final Report on ADEPT, there were 22 confirmed 
deaths and 5 patients were known to still be alive. The median survival o f the 
patients on the ADEPT study was 40 weeks (95% confidence interval 1 0 - 7 0  
weeks) (figure 17). As survival was not an end-point in this study, no major 
conclusions can be drawn from this survival. A median survival of 40 weeks 
would, however, be not unexpected given the patient group’s disease profile and 
demographics.
Figure 17: Kaplan-Meier Survival of patients on ADEPT study
Survival of patients in phase I ADEPT trial 
(Kaplan-Meier)
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2.4 Discussion
The purpose of this ADEPT trial was to investigate a new prodrug (bis-iodo 
phenol mustard, ZD2767P) whose activated form is highly potent and has a short 
half-life, and to study tumour targeting of the antibody-enzyme conjugate, A5CP, 
without a clearance system. The trial was designed in a mechanistic fashion to 
allow the determination of whether conditions for effective therapy with ADEPT 
were met. This included the measurement of CPG2 enzyme levels in serum, 
tumour and normal tissues, 1-131 labelled A5CP biodistribution studies, 
immunogenicity assessment, prodrug pharmacokinetic analysis and comet assay 
for DNA interstrand cross-links.
2.4.1 Toxicity
The toxicity of ADEPT consisted predominantly of myelosuppression, which 
proved dose limiting. DLT was established at a ZD2767P dose of 18.63mg/m2 x 
3 and MTD at 15.5mg/m2 x 3. Myelosuppression occurred with a 
thrombocytopaenia nadir at 4 weeks and neutropaenia at 6 weeks. One patient 
developed Grade 3 thrombocytopaenia'and Grade 4 neutropaenia at the first dose 
level (4.9 mg/m2 - Patient #3), however reducing the serum enzyme level at 
which prodrug was given from 0.20U/ml to O.lOU/mL then 0.05U/ml meant 
further dose escalation was possible. This suggests that activation of ZD2767P 
may have been occurring in the peripheral circulation, leading to systemically 
available active drug that resulted in myelosuppression. The MTD of ZD2767P 
of 15.5mg/m is much lower than was predicted by preclinical mouse models, 
and is approximately 10-15 times lower than the dose of ZD2767P that was 
efficacious in preclinical human xenograft models (70mg/kg in mice =human 
equivalent 210mg/m2) (Blakey et al, 1996). It was impractical to lower the serum 
CPG2 enzyme level at which ZD2767P was given to below 0.05U/mL, as it was 
taking up to nine days for the serum CPG2 enzyme levels to fall to this level.
Other toxicities from ADEPT were mild and consisted predominantly of fever in 
the absence of infection, which is likely to be related to administration of the 
antibody-enzyme, grade I/II nausea, thought to be related to the prodrug and
134
grade I/II malaise. As ADEPT is designed to have very few systemic toxicities, 
this toxicity profile was as predicted.
Three patients with grade II or higher drug related toxicity from full ADEPT had 
ZD2767P alone administered. This was well tolerated with only a few transient 
Grade I ‘possibly’ drug related toxicities experienced. As the prodrug itself was 
shown in vitro to have cytotoxic activity at a level ten fold less than for the active 
drug (Blakey et al, 1996) it was important to demonstrate the safety of ZD2767P 
alone in the clinical setting. Patient #3 had grade 3 thrombocytopaenia and grade 
4 leucopaenia with ADEPT, and had no myelotoxicity with ZD2767P alone. This 
patient did however have grade I nausea with the administration of ZD2767P 
alone. Patient #19 had grade 3 thrombocytopaenia and leucopaenia with ADEPT 
and again no myelotoxicity with ZD2767P alone. Patient #24 had grade 2 
thrombocytopaenia and grade 3 leucopaenia with ADEPT, and a grade I transient 
’possibly’ leucopaenia with ZD2767P alone. ZD2767P alone therefore appears, 
as expected, to be less toxic than full ADEPT in the small number of patients in 
which it was studied.
2.4.2 Mechanistic studies
Studying the individual components in terms of their distribution and function 
facilitates developments of such a complex therapy system. It was also possible 
to monitor the different components of ADEPT through the course of therapy.
A5CP
Pharmacokinetics
The clearance of A5CP from the blood was calculated by two methods. An assay 
of CPG2 enzyme activity was performed using methotrexate reduction assay by 
spectrophotometry, Cobas or HPLC, and the clearance of 1-131 radiolabelled 
A5CP was by measured by recording radioactivity in a sample of blood by 
gamma counter. There were three batches of A5CP produced for this clinical 
study. They varied significantly in enzyme activities (50U/mL -  159U/mL), and 
in their pharmacokinetic profiles. The p half-life of A5CP by clearance of CPG2
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enzyme levels from serum was Campaign 1 = 8.95 hrs (spec assay), Campaign 2 
=11.8 hrs (cobas) and Campaign 4 = 15.49 hrs (cobas). The (3 half-life of A5CP 
by clearance of 1-131 radiolabelled A5CP was Campaign 1 = 5.77 hrs, Campaign 
2 = 5.08 hrs and Campaign 4=11.77 hrs.
The CPG2 assays are functional measures of antibody-enzyme conjugate, which 
depend on the presence of intact CPG2. They are clinically relevant as they 
determine whether prodrug can be safely administered to avoid activation in the 
peripheral circulation. Measurement of radioactivity clearance may reflect not 
only intact antibody-enzyme, but also, fragments of antibody-enzyme with 
radioactivity attached. Radiolabelled material with low or absent enzyme activity 
may have been potentially metabolised in vivo, or damaged by the radiolabelling 
process, artificially shortening the circulating half-life. The shorter half-life of 
A5CP obtained by measuring clearance of radioactivity as opposed to functional 
CPG2 enzyme in this trial is therefore likely to be due to clearance of iodinated 
breakdown products of 1-131 radiolabelled A5CP.
Localisation
The ability to selectively deliver antibody-enzyme to tumour is a critical 
component of ADEPT. It is therefore important to be able to measure both the 
amount of antibody-enzyme that reaches the tumour and its distribution in 
normal tissues. Localisation to tumours is required for efficacy, and uptake in 
non-tumour tissues may result in toxicity.
Radiolabelling antibodies with gamma emitting radioisotopes, followed by single 
photon computerised tomography (SPECT) scanning allows their biodistribution 
to be assessed non-invasively in the clinical situation. Gamma camera imaging 
provides both a visual representation of the distribution of radioactivity, and, if 
the camera is appropriately calibrated, a quantitative estimation of antibody 
localisation. The estimates of antibody localisation obtained using quantitative 
SPECT imaging can then be confirmed in a small number of patients in whom a 
tumour biopsy can be performed and CPG2 enzyme levels directly measured.
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In order for the radiolabelled antibody to provide an adequate representation of 
the biodistribution of actual antibody-enzyme, it needs to remain with 
characteristics as similar as possible to the ‘cold’ unlabelled antibody-enzyme. In 
particular it must retain CEA binding, and have a comparable molecular size, 
conformity and charge. The radioisotope must have a suitable path length for 
quantitative gamma camera scanning, and a half-life that is compatible with the 
biological half-life of the antibody-enzyme. The radiolabel must also remain 
bound in a stable manner to the protein in order to represent its biodistribution. In 
addition, radioprotection issues for staff members should also be considered.
Two imaging methods on a gamma camera have been used to quantify 
localisation of radiolabelled antibodies. These are either planar scanning or 
SPECT scanning. Planar images provide anterior and posterior 2 dimensional 
data. Organs overlying tumour areas may lead to an over or underestimation of 
tumour uptake, due to either addition of radioactivity by overlying organs, or 
masking of the underlying tumour (Green et al, 1990). This is an inherent 
problem with the representation of three-dimensional data in two dimensions. 
Despite these limitations, quantitation has been used on planar imaging to 
estimate radiolabelled antibody localisation for clinical studies (Thomas et al, 
1976; Press et al, 1993; Wiseman et al, 2003). Scanning times are much shorter 
with planar imaging, and data manipulation prior to analysis is minimal.
SPECT scans are acquired by rotating the gamma camera detectors around the 
body, thereby acquiring three-dimensional data. The accuracy of the estimation 
of radioactivity in tissues is reduced, however, by the presence of Compton 
scatter, which leads to blurring of the image. Region delineation without 
correction for this is problematic. Applying scatter correction has been 
demonstrated to overcome this problem and has lead to accurate quantitation in 
both phantom studies and in patients (Green et al, 1990). This method involves 
collecting two sets of data; one in the photopeak and one in the scatter window.
A correction is then applied for Compton scatter, based on a method initially 
described for Tc-99m (Jaszczak et al, 1984). Attenuation correction using 
uniform ellipses can be applied to correct for attenuation of the photon through 
overlying tissues (Chang, 1978). More recently methods that measure actual
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attenuation, rather than applying a linear correction, have been developed and are 
being applied.
Scanning times for SPECT acquisitions are usually longer than for planar 
imaging, in order to achieve adequate count rates for analysis. The detectors go 
through 32 frames around the patient, and usually separate acquisitions are 
required for the thorax and the abdomen (dependent on detector size). The time 
per frame can be altered dependent on the radioactivity levels in the patient, in 
order to achieve a suitable count rate for quantitation. Most SPECT scans are 
performed in 40-60 minutes (for 2 rotations).
SPECT analysis using a correction for both Compton scatter and for uniform 
attenuation, has been applied to estimate the localisation of radiolabelled 
antibody-enzyme in a previous ADEPT study (Napier et al, 2000). In this study 
the estimates of tumour enzyme activity by SPECT analysis of 1-131 
radiolabelled A5CP, were confirmed in 5 out of 10 patients by tumour biopsies. 
The CPG2 enzyme levels in tumour biopsies were measured by a methotrexate 
reduction assay on HPLC (Blakey et al, 1996; Martin et al, 1997). The median 
enzyme concentration in tumours by direct measurement from tumour biopsies 
was 0.47U/g (range 0.32-0.62 U/g) (Napier et al, 2000). The estimated enzyme 
units in the tumour based on the biodistribution of 1-131 radiolabelled A5CP and 
SPECT analysis was 0.34 U/g (range 0.19-0.63 U/g) (Napier et al, 2000). It was 
therefore concluded that gamma camera estimates of enzyme concentrations in 
the tumour were valid. Gamma camera scanning has the advantage of being 
much less invasive than a tumour biopsy and should be suitable for a large 
number of patients, some of which may not have lesions suitable for biopsy.
The radioisotope chosen for radiolabelling of A5CP in this clinical trial was I- 
131.1-131 has a half-life of 8 days. This is appropriate use with for A5CP, which 
has a half-life of 8.95-15.49 hours (by clearance of CPG2 activity from blood). It 
was estimated that 370MBq of radiolabelled 1-131 A5 CP should be sufficient to 
allow quantitative scanning, with reasonable scan times.
Radiolabelling of A5CP with 1-131 was performed using N-bromo- 
succinamide/L-tyrosine technique (Adam, 1989). Thin layer chromatography
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was performed to assess iodine incorporation and antigen binding was assessed 
using a CEA column. There was variation in the CEA binding and iodine 
incorporation between the different batches of A5CP. Campaign 1 had a median 
CEA binding of 6.56%, Campaign 2 had a median CEA binding of 35.9%, and 
Campaign 4 had a median CEA binding of 21.7%. The median iodine 
incorporation of 1-131 conjugate was 60.75% for Campaign 1, 88.36% for 
Campaign 2 and for Campaign 4 it was 86.6%. Campaign 1 had the lowest 
protein concentration, and this may have contributed to its particular poor 
labelling. All three campaigns had fairly low values for CEA binding post 
radiolabelling, indicating that the radiolabelling process may have damaged the 
antibody. Iodine radiolabelling is directed against tyrosine residues on a protein, 
and these may fall within the antigen binding site of an antibody, thereby 
disrupting antigen-antibody binding.
The radiolabelled antibody was administered as slow intravenous injections at 
the end of the cold antibody infusion. SPECT scans were performed at 4,24,48, 
and 72 hours (and 96 hours if appropriate) post administration of radiolabelled 
antibody.
By visual interpretation and quantitative analysis it was apparent that the 1-131 
radiolabelled A5CP did not successfully localise to tumour areas. The median 
uptake of radiolabelled A5CP in heart (estimate for bloodpool) remained higher 
than in tumour for the 5hr, 24hrs and 46 hrs time-points, and for normal liver it 
remained higher than tumour at all measured time-points. The overall median % 
injected dose/kg of radiolabelled conjugate in the tumour on prodrug day was 
0.185 %/kg, range 0.0006 -1.05 %/kg. This translates to an estimated enzyme 
concentration in the tumour at the time of prodrug administration of 0.01 U/g. 
This is much lower than has been seen in mouse tumour model systems, and in 
previous clinical trials.
The tumour biopsy data from 7 patients also showed a median CPG2 enzyme
level of 0.01 U/g in tumour at the time of prodrug administration, indicating a
good correlation between SPECT analysis and direct measurement of enzyme
activity by biopsy. An enzyme level of 0.01 U/g in tumour is, however, much
lower than the value of 0.47U/g of enzyme activity, that was attained in the
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previous clinical study in which a galactosylated clearing antibody was used to 
accelerate clearance of conjugate from the blood (Napier et al, 2000). This 
previous study did, however, use higher amounts of antibody-enzyme conjugate 
(10 000U/m2) and the prodrug was given at an earlier time-point (48 hours), so 
the difference in enzyme levels must be at least partially attributable to these 
factors. However, the fact remains that the amount of enzyme measured in 
tumour in this study is very unlikely to be adequate for therapy. In addition the 
tumour to blood ratios of CPG2 enzyme activity based on methotrexate reduction 
assay were 0.4:1 at the time of prodrug administration, which is also in 
agreement with the lack of localisation seen with the SPECT scans. In the 
previous ADEPT trial tumour to blood ratios of > 10 000:1 were seen (Napier et 
al, 2000). The very low tumour to blood and tumour to normal tissue ratios in 
this trial greatly reduce the therapeutic window of ADEPT, and increase the 
likelihood of serious systemic toxicity due to activation of prodrug in non­
tumour sites. It is likely that the myelosuppression seen at such an unexpectedly 
low ZD2767P dose is likely to have been due to activation of prodrug in the 
systemic circulation and non-tumour tissues. There was no gain to be achieved in 
waiting until further systemic clearance of active CPG2 enzyme had occurred, as 
tumour enzyme levels were already very low, and in some patients it was already 
taking up to 9 days for CPG2 serum enzyme levels of < 0.05 U/mL to be 
attained.
Immunogenictiy
The formation of HAMA and HACPG2A occurred in all patients except one 
(Patient #13 - no HACPG2A formation). The median time to formation of 
antibodies was 14 days. CPG2 is of bacterial origin, and is used in ADEPT 
systems because it has no human equivalent that may lead to endogenous enzyme 
activation. The A5B7 F(ab')2 antibody is murine. The immunogenicity of A5CP 
limits potential for repeated therapy although immunosuppressive therapy has 
been used to permit up to three therapies in the same patient in the past 
(Ledermann et al, 1991; Bagshawe et al, 1995; Bagshawe et al, 1996; Napier et 
al, 2000).
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ZD2767P
ZD2767P pharmacokinetics
The pharmacokinetic profile of ZD2767P was measured in blood by HPLC. 
Average AUC values increased with increasing doses. The mean measured half- 
life of ZD2767P in plasma at the MTD (15.5mg/m2) was 14.5 minutes. The 
prodrug was essentially cleared by 60 minutes in all dose levels, and there was 
no evidence of accumulation of prodrug with the 1 hour intervals between doses.
The maximum concentration of ZD2767P at an administered dose of 
18.63mg/m2 results in a molar concentration of 0.0085jiM, which is significantly 
less than would be expected to result in cytotoxicity based on the cell 
cytotoxicity experiments from Blakey et al, 1996.
ZD2767P is very unstable and required administration within 20 minutes of 
reconstitution. Although this was possible within a clinical trial setting, this 
instability may limit the widespread use of ZD2767P outside a clinical trial 
environment
ZD2767P activation
The active drug formed from ZD2767P has such a short biological half-life that it 
could not be measured in this study. An indirect measurement instead used a 
comet assay on cells retrieved from tumour biopsies in order to ascertain the 
presence of DNA interstrand crosslinks. ZD2767D is an alkylating agent, and 
produces cell kill by DNA interstrand crosslink formation, so the presence of 
crosslinks in the tumour biopsy specimen would indicate that an alkylating agent 
had been active at the tumour site (Webley et al, 2001). Within 30 minutes of the 
tumour biopsy specimen being taken, peripheral blood was also taken to look for 
DNA crosslinks in circulating lymphocytes. Patient #15 had a biopsy of a liver 
metastasis of colorectal cancer. An 80% reduction in comet tail, indicating the 
presence of DNA interstrand crosslinks was demonstrated. The circulating 
peripheral lymphocytes were unaffected, showing no evidence of DNA crosslink 
formation. In this patient, the tumour biopsy specimen also showed evidence of
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1-131 conjugate localisation on phosphor imager (table 16a, figure 11). This 
suggests that in this one patient effective antibody localisation and selective 
prodrug activation may have occurred. This patient had radiological stable 
disease at 56 days.
2.4.3 Efficacy
There were no convincing tumour responses seen in this study by CT scanning 
and only one patient’s tumour appeared not to progress by quantitative metabolic 
imaging using [F-18] FDG PET. The mechanistic studies performed during this 
study indicated that there was inadequate targeting of enzyme to tumour and it 
was thought that even at the MTD responses would be unlikely. Consequently 
the phase II component of the trial was not undertaken.
2.5 Conclusion
This ADEPT trial was designed to study a new prodrug, ZD2767P, and to assess 
the targeting of A5CP without a clearing antibody. It was designed in a 
mechanistic fashion to allow an understanding of ADEPT and to direct changes 
to this system for the future.
With regard to the new candidate prodrug for ADEPT, ZD2767P, 
pharmacokinetic information was attained, and evidence of ZD2767P activation 
was obtained in the tumour of one patient by comet assay, and in the blood, 
indirectly, by the finding of myelosuppression when prodrug was given after 
antibody-enzyme and by lack of myelosuppression when prodrug was given 
alone. The dose achieved of ZD2767P was much less than predicted and this was 
almost certainly as a result of the slow clearance of A5CP from the circulation, 
with residual CPG2 in serum likely to have been causing systemic ZD2767P 
activation. The dose of ZD2767P administered is likely to have been too low to 
be efficacious.
Targeting of A5CP without a clearing antibody was found to be inadequate, with 
tumour to serum enzyme ratios of less than one, which is insufficient for 
selective prodrug activation in tumour. The slow blood clearance of A5CP made
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it impractical to lower the level for serum CPG2 enzyme any lower than 
0.05U/mL. Tumour biopsy and gamma camera data indicated that there would be 
insufficient enzyme in tumour at these late time points for adequate prodrug 
activation to occur. As was found previously the universal production of human 
antibody to A5CP prevented repeated therapy.
This trial demonstrates, however, that it was possible to measure serum CPG2 
enzyme levels and to make a decision on the timing of administration of 
ZD2767P based on these. The toxicities experienced appeared dependent on the 
serum CPG2 enzyme level at the time of administration of ZD2767P. This 
suggests that if adequate tumour targeting of CPG2 can be attained, with 
corresponding low serum and normal tissue CPG2 enzyme levels, adequate dose 
escalation of ZD2767P may be achieved.
In conclusion this trial has demonstrated the potential of ZD2767P for use in 
further ADEPT studies, in which better tumour localisation of antibody-enzyme 
can be achieved. It has shown also that a clearance system should be used with 
the A5CP chemical conjugate, or a better antibody-enzyme targeting system 
needs to be developed. The mechanistic studies performed in this trial assisted 
with the interpretation of the trial outcomes and influenced decisions taken 
during the trial period, such as the lowering of serum CPG2 levels at the time of 
ZD2767P administration in order to allow further dose escalation. They also 
served to prevent the further treatment of up to 14 patients at MTD to assess 
response to ADEPT, as they indicated that the likelihood of response would be 
very low. Mechanistic studies should continue to be incorporated into the design 
of clinical trials of ADEPT for the future, as they have assisted in the 
understanding of ADEPT and the directing of preclinical development for the 
future.
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3 Radiolabelling of glycosylated MFE-23::CPG2 fusion protein
(MFECP1) with Technetium-99m, for quantitation of 
antibody-enzyme biodistribution in ADEPT
3.1 Background
The experience gained with ADEPT in the clinical setting using A5CP in 
combination with ZD2767P prodrug concluded that in the absence of a clearing 
antibody system, inadequate targeting of A5CP to tumour was attained (chapter 
2). In addition, the chemical conjugation process required to form A5CP resulted 
in heterogeneous batches of A5CP, which all differed in enzyme activity, 
pharmacokinetic profile and radiolabelling profile. These findings directed the 
development of a novel genetically engineered fusion protein for ADEPT, 
consisting of a high affinity anti-CEA scFv, MFE-23, in combination with the 
bacterial enzyme CPG2 (Michael et al, 1996; Bhatia et al, 2000; Chester et al, 
2000). Genetic fusion proteins have the advantages of improved homogeneity 
and stability of their protein product, as they do not require further manipulation 
after expression. Also, as the genetic code is known, there are improved 
opportunities for modification of desired properties such as affinity, size, charge 
and immunogenicity (2Chester et al, 2000). The process leading to the 
development of this fusion protein is outlined in detail in chapter 4.
3.1.1 MFECP1 -  preclinical characteristics
MFE-23 was selected using phage display technology for its affinity to CEA 
(Chester et al, 1994). MFE-23 has been studied in both pre-clinical models and 
in clinical trials of radioimmunoscintigraphy and radioimmunoguided surgery, 
and has been shown to effectively localise to CEA expressing tumours (Begent et 
al, 1996; Mayer et al, 2000). In addition, MFE-23 has been shown to be of low 
immunogenicity with none of fourteen patients developing HAMA after one 
administration (Begent et al, 1996).
The fusion protein of MFE-23 in combination with CPG2 was initially developed 
in an Escherichia coli expression system, and was shown to have many of the
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properties desirable for use in ADEPT systems (Michael et al, 1996; Bhatia et al, 
2000) (see chapter 4). The production of the fusion protein in Escherichia coli 
resulted, however, in yields that were too low to support a clinical trial. 
Production in Pichia pastoris was subsequently developed and resulted in a 100- 
fold increase in protein yields and a glycosylated product. In preclinical 
biodistribution experiments the glycosylated MFE-23::CPG2 fusion protein 
(termed MFECP1) resulted in excellent tumour targeting as early as 4-6 hours 
after administration. The tumour to plasma ratios of active CPG2 enzyme were 
250:1 at 6 hours, with an enzyme activity in tumour of 1.3 U/g (±0.2U/g) 
(Sharma et al, 2000). This allowed ZD2767P to be administered at 4-6 hours 
after administration of MFECP1, resulting in tumour growth delays in xenograft 
models, with no resultant toxicity as assessed by weight loss in mice (Sharma et 
al, 2000). This product was therefore chosen as the antibody-enzyme component 
for the next ADEPT clinical trial.
3.1.2 Monitoring distribution of MFECP1 in clinical trials
The ability to quantify the biodistribution of antibody-enzyme in ADEPT in the 
setting of a clinical trial is important for the understanding and subsequent 
development of such a complex therapy. A non-invasive measure of the amount 
of antibody-enzyme in the tumour at the time of prodrug administration is 
desirable to be able to validate whether adequate tumour targeting of enzyme is 
occurring in order to activate prodrug. Secondly, it is important to ascertain 
whether any retention is occurring in non-tumour areas, which may lead to non­
specific activation of prodrug, and consequent toxicity.
Radiolabelling a protein with a suitable y emitting radionuclide and 
administering this to a patient allows gamma camera imaging to be performed, 
and a visual and quantitative assessment of biodistribution of that protein can be 
made. This technique has been shown to result in a valid assessment of tumour 
enzyme level in the last two ADEPT trials (Napier et al, 2000; Francis et al, 
2002). The estimate of tumour enzyme activity attained by gamma camera 
imaging can be confirmed in a subset of consenting patients with a tumour 
biopsy.
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As previously discussed, in order for the radiolabelled product to represent the 
biodistribution of the actual antibody-enzyme, it needs to remain as unaltered as 
possible by the radiolabelling process. In particular it must retain CEA binding, 
and have a comparable molecular size, conformity and charge. The radioisotope 
used must have a suitable path length for quantitative gamma camera imaging, 
and a half-life that is compatible with the biological half-life of the antibody- 
enzyme. The radiolabel should remain bound in a stable manner to the protein.
The rapid clearance of MFECP1 allows prodrug to be administered at 4-6 hours 
after fusion protein administration. Therefore imaging should be performed at 
this time. Technetium-99m (Tc-99m) is used extensively for both visual and 
quantitative gamma camera imaging due to its ready availability, ease and 
inexpensiveness of production, suitable imaging properties (140keV yray with 
89% abundance) and a half-life of 6 hours (Mease and Lambert, 2001). It was 
therefore proposed to be a candidate radioisotope for radiolabelling MFECP1 for 
the new ADEPT clinical trial.
Several methods have been described for radiolabelling scFv with technetium. 
Since many scFv do not contain disulfide bridges, those methods which are 
dependent on free sulfhydryl groups could only be made available by either using 
a thiol containing chelator or by genetically engineering in a cysteine into the 
scFv. Chelation methods have been associated with instability of the labelled 
proteins, and attempts to genetically engineer in cysteine groups into proteins 
may lead to problems with protein expression, folding or stability (Verhaar et al, 
1996). Transfer of technetium in vivo to other sulfur-containing ligands may also 
be a source of radiopharmaceutical instability (Stalteri et al, 1999).
Recently a new method has been developed for technetium radiolabelling of
proteins in which a stable Tc-99m -carbonyl [99mTc(H20)3(C0)3]+ (TcCO)
intermediate is formed directly from pertechnetate ["“TcOJ'by reduction with
sodium borohydride (NaBHU), in a carbon monoxide (CO) atmosphere (Alberto
et al, 1998). Formation of the TcCO intermediate can, using this method, be
achieved using technetium in a sodium chloride solution (sodium pertechnetate),
which is the commonest way technetium is eluted from a commercial
molybdenum-99 ("Mo)/"mTc generator. Once the TcCO intermediate is formed
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it can readily exchange its three labile water ligands with a variety of donor 
ligands to form a stable complex. A possible donor ligand is histidine (!Waibel et 
ah 1999).
Hexahistidine tags (His tags) are commonly engineered onto recombinant 
proteins in order to facilitate purification using immobilised metal ion-affinity 
chromatography (IMAC) (Casey et al, 1995). IMAC purification was used in the 
production of MFECP1, so a His tag was readily available for site-specific 
labelling. The His tag of MFECP1 is located on the C terminal end of CPG2, 
away from the antigen binding site. This is an advantage as the label should not 
interfere with antigen binding and, as it is associated with the CPG2 end of the 
molecule, it should reflect the distribution of CPG2 enzyme, which is the 
component of MFECP1 ultimately responsible for prodrug activation in the 
ADEPT system. Technetium radiolabelling of MFE-23, has been successfully 
performed by this method, also using the His tag, and has been shown to be an 
effective and robust method in this setting (2Waibel et al, 1999).
The aims of these experiments therefore are to radiolabel MFECP1 with TcCO 
via site-specific radiolabelling to the His tag on the C terminus end of the 
protein. Once the conditions for radiolabelling have been defined, a preclinical 
biodistribution experiment will be performed to ascertain whether the 
localisation of TcCO radiolabelled MFECP1 accurately reflects distribution of 
active CPG2 enzyme in a human xenograft model. These results will be used to 
ascertain whether this method could be used to radiolabel MFECP1 in order to 
assess biodistribution of antibody-enzyme for the next ADEPT clinical trial.
3.2 Method
3.2.1 Formation of Tc-99m- carbonyl (TcCO)
Sodium carbonate (Na2C0 3 ) 4mg, sodium potassium tartrate (NaK-Tartrate) 
20mg, and sodium borohydride (NaBfLj) 5mg were added to an 8mL glass vial. 
This was then sealed and flushed with carbon monoxide for 10 minutes. To 
prepare the intermediate, 0.5mL of Tc-99m in saline solution was added to the 
vial, which was heated in a water bath at 75°C for 15 minutes. The mixture was
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cooled to room temperature and neutralised with 0.1 mL of 1M phosphate- 
buffered saline (PBS) and 0.12 mL of 1M hydrochloric acid (final pH=7.0).
F reeze d ried  k its
Freeze dried kits were prepared by dissolving sodium carbonate (Na2CC>3) 4mg, 
sodium tartrate (Na2Tartrate) 20mg, and sodium borohydride (NaBFL) 5mg with 
lOOpL of water added in 8mL glass vials and then lyophilised for 1 hour. The 
sealed vials were then purged with carbon monoxide for 10 minutes, before 
being stored for later use at -40°C. The TcCO complex was then made by adding 
0.5mL of Tc-99m in saline solution to the vial, and heating in a water bath to 
75°C for 15 minutes. The mixture was cooled to room temperature, neutralised 
with O.lmL of 1M PBS and 0.12 mL of 1M hydrochloric acid (final pH=7.0).
The formation of TcCO was confirmed by reverse phase high performance liquid 
chromatography (RP-HPLC) using a Galaxy Jupiter column.
3.2.2 TcCO - MFECP1 complex
The TcCO - MFECP1 complex was made by simply mixing the MFECP1 
solution and the TcCO solution together. The formation of TcCO - MFECP1 was 
monitored over time with size exclusion HPLC on a Biosep 3000 column eluted 
at 0.5ml/min with 0.1M phosphate buffer, pH 7, or by instant thin layer 
chromatography (ITLC) developed in 0.9% sodium chloride. The influence of 
temperature and protein concentration on the rate of formation of the TcCO 
MFECP1 complex was studied.
3.2.3 PD10 purification
A PD10 sepharose column (Amersham Life Sciences, Amersham, UK) was 
primed by washing through 20mL of PBS. The amount of activity of the 
radiolabelled antibody (lmL) was recorded and the radiolabelled antibody was 
then added to the column. 2mL PBS was added and collected into vial 1. lmL 
PBS was then added and collected into vial 2. This process was repeated three 
times (vials 3,4 and 5). The radioactivity was recorded for each vial and in the
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column. Vial 2 contained the purified product. The purified product was 
confirmed by using size exclusion HPLC as outlined above.
3.2.4 CEA binding
CEA column
The CEA column was prepared by washing with 5mL of 3M ammonium 
thiocyanate. The column was regenerated by adding 20mL PBS. 5pL of 
radiolabelled antibody was diluted by adding 295pL of PBS. The activity was 
recorded with the gamma counter. The radiolabelled antibody in PBS (300pL) 
was added to the column. The non-bound fraction was washed out with 3mL 
PBS and collected for counting. The first lmL was kept separate for 
reapplication to column. The bound antibody was eluted off the column using 
3mL 50mM diethylamine (DEA). The bound fraction was collected for counting. 
The column was then regenerated with PBS. The first unbound fraction was 
reapplied (lmL) to column and the run repeated (in case of column saturation 
with the first run).
Cell binding assay
2 confluent flasks of MKN45 CEA expressing cells were trypsinased and 
resuspended in 5mL of cold 1% bovine serum albumin (BSA)/PBS in a 
universal. This was then centrifuged at 1000 rpm for 5mins. The supematent was 
discarded and cells resuspended in 3mL cold 1% BSA/PBS. All cell clumps were 
broken by repeated syringing through a 23G (blue) needle.
2 rows of 5 eppendorf tubes were prepared. 0.5mL of cold 1% BS A/PBS was 
pipetted into tubes 2-5 of each row. 0.5mL of the cell suspension was pipetted 
into tubes 1 and 2 of each row. Tube 2 was briefly vortexed and 0.5mL of the 
contents were transferred to tube 3. Tube 3 was briefly vortexed and 0.5mL of 
the contents were transferred to tube 4. Tube 4 was briefly vortexed and 0.5mL 
of the contents were transferred to tube 5. Tube 5 was briefly vortexed and 
0.5mL of the contents were discarded. The rows of tubes were labelled 1-5 and 
6- 10.
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0.5mL of cell suspension was added to 2 further eppendorf tubes. These tubes 
were labelled NSB (non-specific binding). 50pL of unlabelled antibody was 
added to each of these tubes and they were vortexed briefly.
The radiolabelled antibody was diluted to a final concentration of 50ng/mL with 
cold 1% BS A/PBS and made to a final volume of 4mL. 250|iL of the diluted 
radiolabelled antibody was pipetted into tubes 1-10, both NSB tubes and 2 
further empty eppendorf tubes. The last 2 tubes were labelled T (total activity).
Tubes 1-10 and NSB were briefly vortexed and then inserted into sterilin 
universal containers. They were then incubated for 2 hours while rotating on the 
spiramix.
Tubes 1-10 and NSB were then placed in a microfuge for 2 mins at 1300rpm. 
The supernatant was discarded taking care not to disturb the pellet. 0.5mL of 1% 
BSA/PBS was then pipetted into each tube and vortexed to resuspend the pellet. 
Again the tubes were placed in the microfuge for 2 mins at 1300rpm and the 
supernatant was carefully removed and discarded the taking care not to disturb 
the pellet.
All eppendorf tubes were counted in the gamma counter (tubes 1-10, NSB and 
T).
The immunoreactive fraction was calculated by plotting the total/bound fraction 
against the dilution factor used, with the reciprocal of the y intercept giving the 
value for immunoreactive fraction.
3.2.5 Stability studies
Size exclusion fast perfusion liquid chromatography (FPLC) was performed to 
assess for stability of TcCO-MFECPl. TcCO labelled MFECP1 diluted in PBS 
was applied to a Superose-12 column (XK 16/60) run at a flow rate of 
0.5mL/min (in PBS) using a Millipore-Waters 650E system. 2mL fractions were 
collected after they had passed through the column. Radiactivity in each fraction 
were counted in a Minaxi Auto-Gamma 5000 Series Gamma Counter (Packard
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Instruments). Counts were plotted against fraction number to give a radioactivity 
profile.
Overnight incubation of TcCO radiolabelled MFECP1 in human serum (1:20) at 
37°C was then performed, and the FPLC process repeated. A 1:9 dilution with 
PBS was made before applying the sample to the FPLC column.
3.2.6 Histidine challenge
A 10 000 fold excess of histidine was incubated with TcCO radiolabelled 
MFECP1.
The histidine solution was made by adding 70mg histidine to 0.5mL PBS 
(pH=4). The pH was normalised to 7 by adding 0.15mL sodium hydroxide 
(NaOH) and 0.35mL PBS.
TcCO radiolabelling of MFECP1 and PD10 purification was performed (size 
exclusion HPLC was used to confirm a pure product). 50pL of histidine solution 
was added to 500pL of radiolabelled MFECP1. 250pL of this solution was kept 
at 25°C and 250pL at 37°C. Of the remaining 500pL of TcCO-MFECPl, 250jllL 
was kept as a control at 25°C, and 250pL as a control at 37°C.
Size exclusion HPLC, as described above, was performed on both histidine 
containing and control samples kept as 25°C and 37°C at 1 hour and 24 hours.
3.2.7 Biodistribution studies
The biodistribution of TcCO radiolabelled MFECP1 was assessed in LS174T 
nude mice xenografts. LS174T is a CEA expressing human colon 
adenocarcinoma cell line which, when implanted in nude mice, results in 
tumours that express CEA on their cell surface, but no measurable CEA in the 
circulation. Small tumour pieces (1mm3) were implanted into the flanks of the 
mice and were allowed to grow until the tumours were 0.1-0.2cm3 in size.
Radiolabelling was performed using freeze dried kits in which 300MBq of 
pertechnetate was labelled to 9.6mg/600U of MFECP1. The final labelled
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volume was 2mL. 0.3mL was removed for analysis (TLC, CEA binding and 
FPLC), leaving a final volume of 1.7mL (170MBq, 8.16mg, 510U). This was 
then diluted with 0.9% sodium chloride to allow a volume of 0.2mL of to be 
administered via the tail vein of 3 groups of 5 mice as a single injection of 
lOMBq/ 0.48mg/30U TcCO MFECP1.
Tissues (blood, liver, kidney, lung, spleen, colon, muscle and tumour) were taken 
at 1 hour, 4 hours and 6 hours to assess distribution of radioactivity and for 
measurement of enzyme activity. The tissues taken for counting of radioactivity 
were weighed then dissolved overnight in 7M potassium hydroxide. The 
following day they were homogenised then counted in the Minaxi Auto-Gamma 
5000 Series Gamma Counter (Packard Instruments). The tissues taken for 
assessment of enzyme activity were weighed then frozen at -70°C. Analysis of 
enzyme activity was performed by SK Sharma using a methotrexate reduction 
assay on HPLC as previously described (Blakey et al, 1996; Martin et al, 1997).
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3.3 Results
3.3.1 Assessment of Formation of TcCO
The formation of the TcCO intermediate was assessed by reverse phase HPLC. 
>99% of activity was in the TcCO peak on the RP-HPLC trace, and <1% of 
activity was in the form of pertechnetate (figure 18).
Figure 18: Reverse phase HPLC trace of TcCO
TcCO
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Freeze dried kits
Formation of TcCO was monitored by RP HPLC after storing the kits at -40°C. It 
was found that the kits remained viable for at least 6 months. Yield was >99%.
3.3.2 Assessment of Formation of TcCO-MFECPl complex
The incorporation of TcCO onto MFECP1 was assessed by HPLC and ITLC.
The TcCO-MFECPl complex was found to be a heterogeneous product, 
consistent with known glycosylations causing variations in molecular weight of 
the product and produced several peaks on the HPLC trace (figure 19).
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Figure 19: Size exclusion HPLC displaying formation of TcCO -
MFECP1 complex
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HPLC trace (size exclusion column) showing gradual incorporation o f TcCO 
onto MFECP1 over time. Figure 19 a) is after 30 mins incubation o f TcCO with 
MFECP1. Figure 19 b) is after 12Omins incubation with TcCO and MFECP1. 
The TcCO MFECP1 peak increases with time and the TcCO peak decreases. The 
presence o f several TcCO MFECP1 peaks is consistent with the heterogeneity o f  
the protein due to its glycosylations.
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Effect of Temperature on labelling:
The rate of formation of the TcCO - MFECP1 complex was found to be 
temperature dependent, with a higher proportion of MFECP1 labelled at 30 
minutes when incubated at 37°C than at room temperature (25°C). However, 
incubating at 37°C resulted in the formation of high molecular weight aggregates, 
seen on HPLC. At 4°C the rate of formation of the TcCO - MFECP1 complex 
was found to be slower than at room temperature. There were no aggregates 
formed either at room temperature or at 4°C after three hours incubation (figure 
20).
Figure 20: Effect of temperature on radiolabelling
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Effect of Concentration of MFECP1 on labelling
The %incorporation of TcCO to the MFECP1 varied with the concentration of 
MFECP1 used. At concentrations of protein >lmg/mL in the TcCO - MFECP1 
solution, the rate o f incorporation of TcCO to MFECP1 occurred slightly faster 
than at lower protein concentrations (figure 21).
Figure 21: The effect of varying protein concentrations on the rate 
of radiolabelling of MFECP1
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3.3.3 PD10 purification
PD10 purification was performed and shown by HPLC and ITLC to successfully 
be able to isolate the TcCO - MFECP1 complexes, with post purification traces 
showing efficient separation of the free TcCO and the TcCO MFECP1 
complexes (figure 22).
Figure 22: PD10 purification
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3.3.4 CEA binding
CEA binding of the TcCO radiolabelled MFECP1 using the CEA affinity column 
resulted in a median CEA binding o f 75% (range 61-77%). As a control, binding 
to a sepharose column was used -  this resulted in non-specific binding to the 
column of a median of 12% (range 6-16%).
The immunoreactive fraction o f the tracer was also using a cell based assay. This 
resulted in CEA binding of 54% (4 dilutions) (figure 23).
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Figure 23: Cell binding assay
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3.3.5 Stability studies
The FPLC trace obtained on the TcCO -MFECP1 diluted in PBS resulted in a 
single broad peak, which corresponded with the molecular weight of the protein 
(figure 24).
Figure 24: FPLC trace of TcCO-MFECPl in PBS
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After overnight incubation in human serum at 37°C an addition high molecular 
weight appeared which would be consistent with some degree of aggregation of
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the protein (figure 25). The majority of the activity stayed, however, within the 
peak corresponding to TcCO-MFECPl.
Figure 25: FPLC trace of TcCO-MFECPl after overnight 
incubation in serum at 37°C
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3.3.6 Histidine challenge
The retention time for a TcCO -histidine peak was identified by radiolabelling 
histidine with TcCO and running on size exclusion HPLC. Size exclusion HPLC 
analyses were then performed at approximately 1 hour and 24 hours on both 
histidine containing and control TcCO-MFECPl samples and the % of total 
activity in the TcCO -histidine peak was measured. In the control samples after 1 
and 24 hrs at both 25°C and 37°C, <4% of total radioactivity was in the TcCO- 
histidine peak while in the samples with 10 000 fold excess of histidine up to 
25% of the total radioactivity occurred in the TcCO-histidine peak. This indicates 
that at high concentrations of histidine, displacement of technetium from the His 
tag onto free histidine can occur. A 10 000 fold excess of histidine is however 
not likely to arise in a physiological situation. These results are summarised in 
table 25 and figure 26.
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Table 25: Percentage activity in TcCO-histidine peak on HPLC
25°C 37°C
1 hr 24 hrs 1 hr 24 hrs
control 1.1% 3.9% 2.5% 2.3%
His x 10 000 5.2% 15.9% 7.8% 24.6%
Figure 26: Histidine challenge
□  control 
■  His x 10 000
3.3.7 Biodistribution study
ITLC on radiolabelled TcCO-MFECPl used for the biodistribution study 
confirmed >99% TcCO incorporation onto MFECP1. CEA binding was 75% on 
the CEA column.
The results of distribution of radioactivity in the tissues studied at 1 hour, 4 hours 
and 6 hours are shown in figure 27.
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Figure 27: Biodistribution of TcCO-MFECPl in mice bearing
human colorectal cancer xenografts
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The median % injected radioactivity/ g for each tissue at each time point is 
shown in figure 28:
Figure 28: Median %injected dose/g tissue
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The % injected dose/gram ofTc-99m radiolabelled MFECP1 present in each 
tissue at 1 hour, 4 hours and 6 hours is displayed. The data represented is the 
median results from 5 mice at each time-point, with the error bar representing 
the range.
These results show high uptake and retention of radioactivity in the liver, spleen 
and kidneys while the radioactivity rapidly clears from blood, colon, lung and 
muscle. There is some retention o f activity in the tumour.
Liver, kidney, lung spleen and tumour were analysed for enzyme activity, as 
there were insufficient amounts of tissue in the other organs for analysis. The 
following analysis was performed by and data obtained from SK Sharma (figure
29).
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Figure 29: CPG2 enzyme activity after administration of TcCO-
MFECPl
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The median enzyme activity in each organ at 1, 4 and 6 hours is shown in figure 
30.
Figure 30: Median CPG2 enzyme activity at 1,4 and 6 hours
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Median CPG2 enzyme activity at 1 hour, 4 hours and 6 hours after 
administration o f  30U ofTc-99m radiolabelled MFECP1. The data set 
represents the median o f 4 mice, with the error bars representing the range o f  
data points.
The enzyme biodistribution results show retention of enzyme activity in the 
tumour, but not in the other organs studies. These results are consistent with 
previous enzyme distribution experiments of unlabelled MFECP1 (Sharma et al, 
2000).
The level of radioactivity in each organ was then used to calculate an estimated 
CPG2 enzyme activity in tumour and normal tissues (% injected dose/g 
multiplied by injected enzyme units), and compared with the actual enzyme 
activity present as measured by methotrexate reduction assay by HPLC. Figure 
31 and table 26 display the estimated enzyme units/g by radioactivity in each 
organ, compared with the actual measured enzyme units by HPLC at each 
timepoint.
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In the tumour the TcCO radiolabelled MFECP1 provides an excellent estimate of 
actual enzyme activity, however it does not appear to provide a good estimate of 
enzyme distribution in most normal tissues.
Figure 31: CPG2 enzyme activity in various tissues after
administration of TcCO-MFECPl
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Graphical representation o f the comparison between actual CPG2 enzyme 
activity (by HPLC) in various tissues at 1, 4 and 6 hours after administration o f  
SOU ofTc-99m radiolabelled MFECP1, compared to estimated enzyme 
concentration in these tissues by the presence o f  radioactivity. The error bars 
represent the range o f the data points.
Table 26: CPG2 enzyme activity in tumour and normal tissues
1 hour (U/g) 4 hours (U/g) 6 hours (U/g)
actual estimate actual estimate actual estimate
liver 1.52 11.20 0.00 8.66 0.00 7.16
kidney 0.09 2.71 0.00 2.42 0.00 2.08
lung 0.01 0.28 0.00 0.21 0.00 0.17
spleen 0.22 3.91 0.01 3.17 0.00 2.47
tumour 0.73 0.69 0.38 0.47 1.26 0.77
Table o f the actual CPG2 enzyme activity in a variety o f organs at 1, 4 and 6 
hours, compared with the estimated CPG2 activity based on the localisation o f  
TcCO MFECP1. The values shown are the median values o f  4-5 mice at each 
timepoint.
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3.4 Discussion
Technetium carbonyl site-specific radiolabelling to the hexahistidine tag of 
MFECP1 appeared a promising technique for use in the phase I ADEPT clinical 
trial, in order to non-invasively follow the biodistribution of MFECP1. Its 
advantages were that the label would be directed to a site not involved in antigen 
binding and that the label itself should therefore not disrupt antigen -  antibody 
interactions. Also, as the His tag was on the CPG2 part of the molecule, in the 
event of proteolytic cleavage of the fusion protein, the enzyme itself could be 
followed, which is important as it is this which activated prodrug in the ADEPT 
system. Since IMAC purification was used in the production of MFECP1, a His 
tag was readily available for site-specific labelling. Technetium-99m was an 
attractive isotope to use as part of a clinical trial due to its ready availability, 
short half-life, suitable pathlength for quantitative imaging and low cost.
The experiments performed showed that technetium carbonyl labelling was 
reproducible and relatively robust. The production of freeze-dried kits was 
successful, and further simplified the labelling procedure. Technetium carbonyl 
labelling of MFECP1 resulted in preservation of CEA binding (61-77% by CEA 
column, 54% by cell binding assay), and after PD10 purification resulted in a 
sufficiently pure product (>99% by ITLC).). Stability studies indicated that the 
complex was quite stable in saline (3-4% loss in 24 hours) but that incubation 
with histidine in 10 000 fold excess could displace up to 25% of the technetium 
carbonyl. Incubation in serum indicated that the little or no proteolytic 
degradation occurs although some aggregation of the protein was seen.
The animal biodistribution experiments demonstrated that the amount of 
radioactivity reaching the tumour was a good estimate of actual measured 
enzyme activity. In addition, the measured enzyme activity by HPLC in tumour 
and other sites were comparable to previous biodistribution experiments using 
unlabelled MFECP1 (Sharma et al, 2000). This supports the idea that this form 
of radiolabelling did not appear to damage the antibody-antigen binding or the 
CPG2 enzyme activity of MFECP1. It may therefore provide a good estimate of 
antibody-enzyme localisation in the tumour for ADEPT therapy.
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However, these experiments also revealed high uptake of technetium in the liver, 
spleen and kidneys, which did not correlate with enzyme activity. It seems likely 
that following non receptor-mediated uptake and cellular internalisation by these 
tissues (due in part to the glycosylations of MFECP1) the labelled fusion protein 
is rapidly catabolised resulting in loss of enzyme activity. However the 
technetium radiolabel, as a metal ion, is subsequently retained within the cells. In 
the tumour, internalisation of the labelled fusion protein is not expected to occur 
since CEA is not internalised to any great extent. Thus the enzyme activity 
remains intact and can be suitably estimated by the levels of radioactivity. This 
technique could therefore not be used to predict the levels of enzyme activity 
remaining in normal organs during ADEPT therapy and any uptake into tumour 
masses present in or adjacent to these organs may well be obscured by the high 
non-antigen mediated uptake.
Radiolabelling MFE-23 with technetium has been performed by Verhaar et al by 
genetically engineering in a cysteine in the C-terminal tail (MFE-23-cys) 
(Verhaar et al, 1996). This resulted in some dimerisation MFE-23-cys (12.5% of 
total protein was dimerised) due to the addition of the cysteine group (Verhaar et 
al, 1996). The labelling efficiency of technetium onto the MFE-23-cys protein 
was low (5-10%), however there was retention of CEA binding (55% bound to 
CEA by CEA column) (Verhaar et al, 1996). Biodistribution studies reported 
better tumour uptake of technetium radiolabelled MFE-23 than for iodine 
radiolabelled MFE-23 at 24 and 48 hours, however the tumour to blood ratios 
were not as high as with iodine, due to retention of technetium in normal organs 
for longer than iodine (Verhaar et al, 1996). The renal uptake of technetium was 
very high at both 24 and 48 hours.
Radiolabelling of MFE-23 with technetium has also been performed by 
genetically engineering MFE-23 with a metallothionein peptide attached to the C 
-terminal end for direct radiometal binding without the need for a chelator 
(Pietersz et al, 1998). Preclinical studies showed good tumour localisation from 4 
hours post administration (5.37% injected dose/gram tumour) however, there was 
also high uptake in kidneys, spleen, liver and stomach (9.96%, 5.11%, 4.09% 
and3.61% injected dose/g respectively) resulting in poor ratios with these organs
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at 4 hours (Pietersz et al, 1998). The ratios improved by 24 hours. The 24 hour 
time-point was not measured in the TcCO MFECP1 biodistribution experiments 
because the timepoint that was of interest was at 4-6 hours, when it was 
important to know what the biodistribution of MFECP1 was prior to 
administration of prodrug in ADEPT.
Radiolabelling with 1-131 has been performed in previous ADEPT studies in 
order to quantify the biodistribution of the antibody-enzyme conjugate. 1-131 has 
a half-life of 8 days, which is suitable for radiolabelling A5CP, which has a 
longer systemic circulating time of 9-16 hours, but is not ideal for MFECP1, 
which has a very short systemic half-life. 1-123 may be used as an alternative, as 
it is a y emitter with a half-life of 13.27 hours. It has a 159keV y emission, which 
is suitable for imaging purposes, however 1-123 is expensive and not readily 
available. Iodine radiolabels to the tyrosine residues of a molecule and can lead 
to iodination in multiple sites on the protein, including the antigen binding site. 
This has the disadvantage of potentially damaging the ability of the antibody to 
interact with its antigen.
Radiolabelling MFECP1 with 1-123 using the chloramine T method was used as 
an alternative to TcCO ^Sharma et al, 2001). This resulted in CEA binding of 
53.6%, measured on a CEA column. Iodine incorporation was 93.6%. The 
biodistribution of 1-123 radiolabelled MFECP1 in the LS174T tumour model is 
shown in figure 32. (Experiments performed by and data obtained from SK 
Sharma).
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Figure 32: Biodistribution of 1-123 radiolabelled MFECP1 in
LS174T xenograft model
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Biodistribution o f1-123 radiolabelled MFECP1 in LSI 74T xenograft mouse 
model. The data shown are the median values with the error bars indicating the 
range. (Experiments performed by and data obtained with permission from SK 
Sharma).
The distribution o f 1-123 radioactivity is fairly similar in all measured organs. As 
1-123 may be present on multiple sites o f MFECP1, catabolism of MFECP1 in 
non-target tissues may lead to the formation on non-functioning fragments, 
which retain some 1-123 activity. This may account for background 1-123 
radioactivity in organs in which there would not be expected to be functional 
CPG2 enzyme at 4 and 6 hours. During catabolism of MFECP1 in non-target 
tissues it is also likely that dehalogenation of 1-123 occurs leading to release o f I- 
123 back into the blood and subsequent excretion through the kidneys.
At the 6 hour timepoint there is a median of 1.9% injected dose/g o f radioactivity 
in the tumour. 25U of MFECP1 were administered in this experiment, so this 
equates to an estimated CPG2 enzyme level o f approximately 0.5U/g (actual 
CPG2 enzyme levels were not measured in this experiment). This is less than is 
found in the tumour with unlabelled MFECP1 (median 1.3U/g at the 6 hour time­
point) (Sharma et al, 2000). This would be in keeping with the reduced CEA
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binding that occurs after radiolabelling with iodine, and suggests a reduction in 
antibody-antigen interaction. The TcCO method of radiolabelling appears in 
comparison, to have a much greater retention of CEA binding (median 75% 
range 61-77%), which would be consistent with the His-tagged labelling 
approach, distant to the antigen binding site.
3.5 Conclusion
Radiolabelling of MFECP1 with technetium carbonyl was successfully 
performed and shown to produce a stable product with retained antigen-binding 
and enzyme activities. Biodistribution experiments showed that the amount of 
radioactivity retained by the tumour provided a good estimation of actual 
measured enzyme activity, indicating that this radiolabelling method can predict 
the distribution of antibody-antigen binding and enzyme activity of MFECP1 in 
vivo. However, high retention of radioactivity in normal tissues would make 
imaging studies difficult, as surrounding high normal tissue uptake may impair 
tumour visualisation. The technetium carbonyl method remains, however, a 
promising technique for radiolabelling His tagged proteins for the future.
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4 ADEPT with MFECP1 and ZD2767P
4.1 Background
The clinical trial of ADEPT using A5CP, in combination with ZD2767P, 
reported in chapter 2, identified several areas where modifications could be 
directed in order to improve the likelihood of efficacy in ADEPT. In particular, 
the antibody-enzyme targeting system was found to be unsatisfactory, with 
tumour to normal tissue ratios of less than one attained and low quantities of 
CPG2 enzyme delivered to the tumour (0.01 U/g). Tumour specificity was not 
achieved, and toxicity was thought to have arisen as a result of slow clearance of 
antibody-enzyme from normal tissues leading to systemic activation of prodrug. 
Reducing the CPG2 enzyme level at which a decision was made to proceed with 
prodrug administration from 0.2U/mL to 0.05U/mL allowed limited dose 
escalation of ZD2767P to occur. However, the maximum tolerated dose was 
defined at a lower dose of ZD2767P than was expected based on preclinical 
experience. Attempts to delay administration of prodrug until blood CPG2 levels 
fell further were futile, as in some patients up to nine days were required before 
prodrug could be administered, and by this time it was estimated that tumour 
CPG2 enzyme levels would be inadequate for efficacy.
As previously discussed, the slow clearance of A5CP was overcome in previous 
clinical trials of ADEPT by using a galactosylated second clearing antibody 
system directed against the active site of CPG2 (Bagshawe et al, 1995; Napier et 
al, 2000). This second antibody cleared residual A5CP from the peripheral 
circulation, and allowed prodrug to be administered at 48 hours after A5CP 
administration, at which time it was demonstrated that the tumour to blood ratio 
of CPG2 enzyme was >10 000:1 and the amount of CPG2 enzyme in tumour was 
0.47 U/g (Napier et al, 2000). Tumour selectivity was thereby achieved. The 
drawbacks of re-introducing the second antibody clearance system for ADEPT 
however include the added immunogenicity of the second antibody and the 
further complexity of the system.
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An additional limitation of A5CP is that a chemical conjugation process is 
required to link A5B7 F(ab')2 antibody to CPG2 (Melton et al, 1993) This 
process is not ideal as it may damage the protein, resulting in reduced enzymatic 
activity and potentially impairing its targeting ability. It is also a complex, 
expensive procedure, which is associated with difficulties in obtaining a 
homogeneous product. The three batches of A5CP used in the clinical trial 
reported in chapter 2 varied significantly in their enzyme concentrations, 
pharmacokinetics and radiolabelling profiles.
In view of these limitations with A5CP new candidate antibody-enzyme 
complexes were explored. Genetic fusion proteins were investigated for ADEPT 
as they have several advantages over antibody-enzyme conjugates (Neuberger et 
al, 1984; Bosslet et al, 1992; Bosslet et al, 1994; Michael et al, 1996; Bhatia et 
al, 2000; Chester et al, 2000). They are much easier to manipulate and modify, as 
the genetic code is known. In addition it is possible to attain much greater 
product homogeneity as the entire antibody-enzyme is encoded from one 
construct. The production of large quantities of homogenous product is therefore 
much more feasible and there is a greater potential for modification to attain 
desired characteristics such as high affinity or low immunogenicity. They can 
also be produced in bacteria or yeast, which can be fairly rapid and reduces the 
risk of contamination with mammalian or viral DNA (2Chester et al, 2000).
4.1.1 Antibody-enzyme for ADEPT
The experience attained in the previous ADEPT clinical trials in combination 
with preclinical studies suggested that the following characteristics of antibody- 
enzyme are desirable to improve the efficacy of ADEPT:
- Ability to delivery high levels of enzyme to tumour
- Ability to attain a high tumour to normal tissue ratio (specificity)
- High viable to necrotic tissue ratio of enzyme
- Stability in production and in vivo
- Rapid localisation to allow same or next day therapy
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- Low immunogenicity to allow repeated therapy without the need for 
immunosuppressive therapy
It is a core component of ADEPT that enough enzyme is delivered to the tumour 
to be able to activate prodrug. The intratumoural site of delivery is also 
important, as enzyme present in the viable tumour areas at the time of prodrug 
administration will ensure that active drug is being generated in these areas and 
not just in the necrotic centre of the tumour. In addition this may be of 
importance for accessibility of prodrug to enzyme. It has been shown by 
radioluminography on human colorectal tumour xenografts, that in the first 24 
hours after administration, tumour specific antibodies are distributed 
predominantly in the viable areas of tumour, whereas non-specific antibodies 
pass into the necrotic centre of tumours, where they are unlikely to have any 
effect (Flynn et al, 1999; Flynn et al, 2002).
Tumour selectivity depends upon active enzyme being delivered to tumour and 
not being present in normal tissues at the time of prodrug administration. If 
enzyme is present in normal tissues when prodrug is administered activation will 
occur in non-tumour areas, and toxicity is likely to result. The timing of 
administration of prodrug is therefore very important, as if given too early, 
before systemic clearance has occurred, will result in toxicity, and if given too 
late there may be inadequate amounts of enzyme in the tumour, or the antibody- 
enzyme which is present may have passed through the viable tumour areas into 
the necrotic centre of the tumour, as is seen with antibodies alone (Flynn et al,
2001).
An antibody-enzyme that is stable in production is a practical requirement for a 
clinical product. It is also important that the antibody-enzyme complex remains 
intact in vivo, to allow tumour targeting of functional enzyme. This is dependent 
not only on the inherent stability of the product, but also on its susceptibility to 
proteolytic cleavage or metabolism. This may not be a problem in ‘normal 
tissues’, as functional enzyme is not required there, but it is a problem if it occurs 
in tumour, as it will result in inadequate amount of enzyme in the tumour to 
activate prodrug.
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The immunogenicity of A5CP used in previous ADEPT clinical trials has limited 
the ability to administer repeated therapy. Although ADEPT is a tumour specific 
treatment with the potential for much larger amounts of cytotoxic agent to be 
generated in tumour than could be administered systemically, it is unlikely that a 
single treatment will result in cure. It would therefore be advantageous to be able 
to administered repeated treatments, without the need for immunosuppressive 
therapy. Currently the antibodies used for ADEPT are murine, although there is 
the potential to humanise the antibodies to reduce immunogenicity for the future. 
The enzyme currently used to activate prodrug, CPG2, is bacterial. It is now 
potentially possible with genetic engineering techniques to try and modify the 
immunogenicity of CPG2, whilst retaining its enzyme activity, and this is 
currently being explored (Spencer et al, 2002).
If ADEPT can be administered as a same or next day therapy it becomes not only 
more clinically feasible, but also it may allow several cycles of ADEPT to be 
administered before immunogenicity develops. This may be a further method if 
avoiding the use of immunosuppressive treatments.
4.1.2 MFECP1 (Glycosylated MFE-23::CPG2 fusion protein)
A genetically engineered fusion protein of the murine scFv, MFE-23, with the 
bacterial enzyme, CPG2 emerged as the lead candidate antibody-enzyme 
complex for ADEPT. ScFv antibodies consist of a Vh and Vl chain connected by 
a flexible peptide linker. They retain full antigen specificity, however are 
approximately one fifth the molecular weight of whole IgG. Their small 
molecular weight leads to rapid tumour penetration, however because they clear 
rapidly from the circulation overall less antibody may be delivered to tumour 
(Milenic et al, 1991; Flynn et al, 2002). Positive tumour to normal tissue ratios 
may be achieved as early as 4 hours after administration compared to 3-7 days 
for whole antibody (Colcher et al, 1990; Savage et al, 1993; Begent et al, 1996). 
ScFv derived from phage libraries are ideal for use as fusion proteins due to their 
small molecular size and because their genetic code is known, making the 
formation of genetic fusion proteins a relatively straightforward process. In 
addition, the removal of a large part of the antibody molecules appears to lead to
reduced immunogenicity in scFv compared to whole IgG (Begent et al, 1996).
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MFE-23
MFE-23 is a scFv of molecular weight 27kDa. It was derived from a filamentous 
phage display library and selected for its affinity for CEA from a library of 107 
clones made from the spleen cells of a mouse immunized with CEA (Chester et 
al, 1994; Begent et al, 1996). MFE-23 has an affinity 10 times greater than A5B7 
for CEA (Chester et al, 1994). The dissociation constant (kD) of MFE for CEA is 
2.5nmol/L.
MFE-23 was produced in E.coli and purified using immobilised metal affinity 
chromatography (IMAC). IMAC purification exploits the binding of 
polyhistidines to metal chelates, such as copper, and allows purification for 
proteins that have a C-terminal hexahistidine tag engineered into their design 
(Casey et al, 1995). An imaging study was performed in 10 patients with CEA- 
expressing tumours using 1-123 radiolabelled MFE-23 and a radioimmunoguided 
surgery (RIGS) study was performed in 35 patients using 1-123 radiolabelled 
MFE-23 (Begent et al, 1996; Mayer et al, 2000). In both studies radiolabelled 
MFE-23 was shown to be safe and to localise effectively to CEA positive 
tumours (Begent et al, 1996; Mayer et al, 2000). Relatively high renal uptake of 
radiolabelled MFE-23 was found, which would be consistent with filtration of 
MFE-23 by the kidney, due to its small molecular weight (Begent et al, 1996). 
Intact MFE-23 was found in the urine, which would suggest very little 
proteolytic digestion was occurring in vivo (Begent et al, 1996). No unexpected 
areas of uptake were found. MFE-23 appeared to have low immunogenicity as no 
HAMA could be detected against MFE-23 after administration in all patients 
participating in the studies (Begent et al, 1996; Mayer et al, 2000).
The crystal structure of MFE-23 has been determined and a model for its 
interaction with CEA proposed (Boehm et al, 2000; Boehm and Perkins, 2000). 
This information suggests that a humanisation strategy may be feasible and 
provides some insight into the high affinity between CEA and MFE-23. All six 
antigen-binding loops of MFE-23 have been shown to be involved in the 
interaction with CEA in a proposed docking model (Boehm and Perkins, 2000). 
This detailed knowledge about MFE-23 may direct developments for the fixture.
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MFE-23 ::CPG2 expressed in E.coli
A genetic fusion protein was developed consisting of MFE-23 and CPG2 (MFE- 
23 ::CPG2). This was initially expressed in Escherichia coli and purified using 
CEA affinity chromatography and size exclusion gel filtration (Michael et al, 
1996). MFE-23 ::CPG2 delivery to tumours in vivo was assessed after 
intravenous injection of purified MFE-23 ::CPG2 into nude mice bearing CEA- 
expressing LS174T human colon adenocarcinoma xenografts. MFE-23 ::CPG2 
cleared rapidly from circulation and CPG2 catalytic activity in extracted tissues 
showed tumour to plasma ratios of 1.5:1 (6 h), 10:1 (24 h), 19:1 (48 h) and 12:1 
(72 h) (Bhatia et al, 2000). MFE-23 ::CPG2 catalytic activity was not retained in 
normal tissues resulting in excellent tumour to normal tissue enzyme ratios 48 h 
after injection. These were 371:1 (tumour to liver), 450:1 (tumour to lung), 562:1 
(tumour to kidney), 1,477:1 (tumour to colon) and 1,618:1 (tumour to spleen) 
(Bhatia et al, 2000). The favourable tumour: normal tissue ratios occurred at 
early time points when there was still 21% (24 h) and 9.5% (48 h) of the injected 
activity present/g tumour tissue (Bhatia et al, 2000). These results showed that 
MFE-23 ::CPG2 delivered satisfactory quantities and high tumour to normal 
tissue ratios of CPG2 activity after a single injection without the need for a 
secondary clearance system.
The high tumour concentrations and selective tumour retention of active enzyme 
establish that MFE-23::CPG2 fusion protein expressed in E.coli had potential to 
give improved clinical efficiency for ADEPT. However, expression of the MFE- 
23::CPG2 fusion protein in E.Coli resulted in a relatively low yield (0.5-1.0 
mg/L) which limited its suitability for clinical use. To obtain greater yields and 
improve the ease of purification, MFE-23 ::CPG2 with a hexahistidine tag (His 
tag) was expressed in yeast Pichia pastoris.
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MFECP1 expressed in Pichia pastoris
Expressing MFE-23 ::CPG2 fusion protein in Pichia pastoris and purifying it 
with IMAC via the His tag resulted in a hundred-fold increase in yield and a 
glycosylated product ^Chester et al, 2000). This product is referred to as 
MFECP1 (figure 33).
Figure 33: Schematic diagram of MFECP1
A O X  p r o m o t e r
Pgene —--------------
Branched mannose
Schematic representation o f  the genetic construct o f MFECP1 and the protein 
product. The genetic construct consists o f MFE-23, CPG2 enzyme and a 
hexahistidine tag, with an AOX promoter, and a cleavage site. After production 
in Pichia pastoris, the protein is expressed as a dimer, with two MFE-23 scFv 
molecules, and 1 functional CPG2 moiety. MFECP1 is glycosylated by Pichia 
pastoris, with 2 short chain branch mannose chains. (Figure obtained with 
permission from K  Chester).
CPG2 forms a dimer in its natural state, and it is required to be in this form for 
enzymatic function. Therefore for each moiety of MFECP1 there is one 
functionally active CPG2 molecule and two MFE-23 molecules. This should 
serve to improve the functional affinity o f MFE-23. The glycosylations o f 
MFECP1 have been characterised by Tandem Mass Spectroscopy, and have been 
found to be short-branched mannose, which are present on 2 of a possible 3 N- 
glycosylation sites on the molecule. The molecular weight of dimeric MFECP1 is
MFE-23
a-factor Antibody (MFE-23) Enzyme (CPG2)
His
Production in yeast
His tag
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142.56 kDa -147.10 kDa (heterogeneity due to glycosylations from production in 
Pichia pastoris). There are 644 amino acids per monomer.
Preclinical biodistribution studies
Biodistribution studies of enzyme activity measurements in nude mice bearing 
human colon adenocarcinoma xenograft, LS174T, given intravenous injection of 
MFECP1 (lOOOU/kg = 3000U/m2) showed localisation in tumours at earlier time 
points than observed with the A5CP conjugate and the non glycosylated fusion 
protein. MFECP1 cleared rapidly from plasma within 6 hours after injection but 
enzyme activity persisted in tumours (1.34U/g at 4 hours, 1.14U/g at 6 hours) 
resulting in tumour to plasma ratio of 19:1 at 4 hours and 163:1 at 6 hours 
(Sharma et al, 2000). Tumour to liver, kidney, lung and spleen ratios at 6 hours 
were 175:1, 221:1, 235:1 and 193:1 respectively (Sharma et al, 2000). This 
allows the administration of prodrug as early as 6 hours after fusion protein 
injection. The CPG2 enzyme levels in tumours that were achieved should be 
adequate to activate prodrug.
Studies using radiolabelled MFECP1 indicate that the mechanism of rapid 
systemic clearance of CPG2 enzyme is likely to be due to hepatic metabolism. 
Hepatic receptors for the glycosylations of MFECP1 clear the antibody-enzyme 
from the systemic circulation, and lead to protein degradation, resulting in loss of 
enzyme activity. Measurements of radioactivity demonstrate very high levels in 
the liver as early as 1 hour after administration, however this is without the 
presence of active enzyme (chapter 3). This would indicate that the radiolabel 
remains present on protein fragments, but there is no intact CPG2 present. 
Tumour radioactivity levels are, however, more consistent with measured CPG2 
enzyme activity, suggesting that active enzyme is preserved in tumour sites.
When the in vivo stability of MFECP1 was assessed in LS174T xenografts (using 
SDS polyacrylamide gel electrophoresis and autoradioluminography), 1-125 
radiolabelled fusion protein was shown to remain intact after 4 hours in the 
tumours (K. Chester personal communication).
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Preclinical efficacy studies ofMFECPl in combination with ZD2767P
In LSI74T xenograft models the average tumour growth delay achieved with a 
single cycle of ADEPT using MFECP1 (lOOOU/kg) and ZD2767P (70mg/kg x 3) 
was 9 days, and with the SW1222 xenograft model, which is a more sensitive 
tumour, average tumour growth delays of 15 days were achieved. Repeated cycle 
ADEPT, in which up to 3 cycles of ADEPT were administered 5-7 days apart, 
average tumour growth delays of 21 days were achieved in LS174T xenografts, 
with no increase in toxicity as assessed by weight loss (<10% weight loss). 
Repeated cycle ADEPT with MFECP1 in combination with ZD2767P therefore 
appears well tolerated and associated with improved efficacy as compared to 
single cycle treatment (SK Sharma, personal communication).
Advantages ofMFECPl compared to A5CP
MFECP1 was designed specifically for use in ADEPT systems. It is a robust, 
stable molecule that is produced in a homogeneous and pure form in a single 
process suitable for scaling up in an industrial setting. High tumour specificity 
and high affinity were obtained by selecting the antibody for affinity from an 
immunised phage library (Chester et al, 1994). Further functional affinity was 
obtained by designing the fusion protein to have two single chain Fv antibodies. 
High purity was achieved by engineering a hexahistidine tag onto the C-terminus 
of the molecule permitting purification by immobilised metal affinity.
Previous clinical trials of ADEPT demonstrated that rapid blood clearance was 
necessary to achieve low blood levels of enzyme at a time when there was still 
sufficient enzyme in the tumour for prodrug activation there. Rapid blood 
clearance is achieved by expressing the fusion protein in the yeast Pichia 
pastoris, which adds glycosylation with branched mannose to the fusion protein 
as a post-translational modification. Preclinical studies confirm rapid systemic 
clearance and high tumour to normal tissue ratios, which provides an advantage 
over A5CP (SK Sharma, personal communication). Same or next day therapy 
should be achievable. The rapid clearance should also result in lower circulating 
CPG2 levels and reduce the likelihood of systemic activation of prodrug, which 
may have contributed to the myelosuppression in the previous ADEPT study.
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Repeated therapy has been demonstrated in preclinical models to be associated 
with improved efficacy and may be possible in the clinical setting before HAMA 
and HACPG2A responses develop.
These design features ofMFECPl required testing in a clinical setting.
4.1.3 Clinical Trial Design
The clinical trial of ADEPT with MFECP1 in combination with ZD2767P was 
designed to include conventional phase I/II endpoints of toxicity, 
pharmacokinetics and efficacy, in combination with mechanistic studies to 
examine whether the components of ADEPT were functioning as predicted in a 
clinical setting.
The hypotheses being tested in the clinical trial were
a) That MFECP1, a glycosylated fusion produced in Pichia pastoris, would 
be safe to administer to humans
b) That MFECP 1 would provide superior tumour targeting when compared 
to A5CP
c) That the improved tumour targeting attained with MFECP 1 would allow 
escalation of ZD2767P to doses comparable to those which produced 
efficacy in the preclinical setting
d) That repeated therapy with ADEPT may be possible without the 
requirement for immunosuppressive drugs
e) That the mechanistic studies included within the trial protocol would 
provide information on whether each component of ADEPT was 
functioning as designed in the clinical setting, and could be used to direct 
treatment decisions within the clinical trial, and aid identification of areas 
of ADEPT requiring refinement for the future.
MFECP1 safety
MFECP 1 for the clinical trial was produced in a new Good Manufacturing 
Practice (GMP)-like production facility (Copley May Production Unit) in the 
CRUK Targeting and Imaging Group, Department of Oncology, Royal Free
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Hospital. Non-glycosylated Pichia produced recombinant endostatin (Sim et al, 
1999) has been used safely in humans (Herbst et al, 2002), however MFECP 1 
was, to our knowledge, the first glycosylated Pichia product to be administered 
to humans. Consequently its safety had to be established.
Administration was performed under controlled conditions, with full 
resuscitation facilities available. Toxicity was recorded according to The 
National Cancer Institute Common Toxicity Criteria (NCI CTC) Version 2.0.
The starting dose ofMFECPl was 5000U/m2. Preclinical studies had been 
performed with a dose equivalent to 3000U/m2, however to try to ensure 
adequate enzyme delivery to tumours, the higher dose of 5000U/m2 was 
proposed. Up to 20000U/m2 of CPG2 enzyme had previously been safely 
administered as A5CP in a previous ADEPT clinical trial (Bagshawe et al, 1994), 
and the trial protocol was designed to allow the escalation ofMFECPl 
administered dose up to 20000U/m2 if inadequate tumour enzyme levels were 
attained by tumour biopsy or quantitative SPECT imaging.
Tumour targeting ofMFECPl
The features ofMFECPl that were designed to provide superior tumour targeting 
when compared with A5CP included rapid tumour localisation, good tumour to 
normal tissue ratios and the delivery of active CPG2 enzyme to tumour in 
quantities that should be sufficient for prodrug activation.
Measurements of CPG2 enzyme activity in serum by methotrexate reduction 
assay on HPLC was used to assess the half-life and systemic clearance of intact 
functional MFECP 1 (Blakey et al, 1996). Where possible, tumour biopsies were 
performed, to measure tumour CPG2 levels by methotrexate reduction assay on 
HPLC (Blakey et al, 1996). A non-quantitative immunohistochemistry assay was 
also adopted using an anti-CEA antibody, and an anti-CPG2 antibody, to 
ascertain the presence ofMFECPl in tumour biopsies, and its microscopic 
distribution within the tumour areas.
MFECP 1 was radiolabelled with 1-123 in order to assess the biodistribution of 
radiolabelled MFECP 1 by quantitative SPECT analysis, and clearance of 1-123
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radiolabelled MFECP 1 from blood by gamma counting. Preclinical 
biodistribution experiments using iodine radiolabelled MFECP 1 suggested that 
the distribution of radioactivity in sites other than tumour was not representative 
of intact MFECP 1, due to the rapid hepatic metabolism ofMFECPl, which was 
likely to have lead to iodinated breakdown products and dehalogenation 
^Sharma et al, 2001) (chapter 3). Therefore the quantitative gamma camera 
analysis was used to estimate tumour CPG2 enzyme levels, which were 
confirmed in a small number of patients with tumour biopsies. In addition it was 
used to ascertain whether there was uptake of radiolabelled MFECP 1 into 
unexpected areas, which may have lead to toxicity.
Dose escalation of ZD2767P
The previous clinical trial of A5CP in combination with ZD2767P established a 
MTD of ZD2767P of 15.5mg/m2 x 3 administrations, with a serum CPG2 
enzyme level of <0.05U/mL (Francis et al, 2002)(chapter 2). This dose of 
ZD2767P was much lower than was predicted by preclinical studies, and was 
proposed to be too low for efficacy. The dose of ZD2767P that resulted in 
growth delay of xenografts of human CEA expressing colorectal cancers in mice 
was 70mg/kg (scaled for surface area = 210mg/m2). It was proposed therefore 
that the dose of ZD2767P would need to be escalated to 10-20x the MTD of the 
previous trial in order to attain efficacy.
The more rapid systemic clearance ofMFECPl compared to A5CP should result 
in much lower levels of CPG2 enzyme in normal tissues at the time of ZD2767P 
administration and therefore less systemic activation of ZD2767P should occur. 
It was likely therefore that further dose escalation may be achieved beyond the 
MTD in the previous ADEPT trial.
The proposed starting dose of ZD2767P was 12.42mg/m2 (one dose level below 
MTD attained in the previous ADEPT study), with a serum CPG2 enzyme level 
of <0.05U/mL. Once safety was established at the first dose level, dose doubling 
was scheduled to be undertaken until grade II or higher drug related toxicity was 
experienced, at which time the cohort of patients was to be expanded to three, 
and dose increases to occur at 30% increments. At least 4 weeks was to elapse
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before a new patient was treated at the next dose level, to ensure safety at the 
previous dose level. This scheme of dose escalation was designed to allow the 
attainment of potentially therapeutic dose of ZD2767P in 4-5 dose doublings, 
providing drug related toxicity did not ensue.
The toxicity of ZD2767P was assessed and recorded using the National Cancer 
Institute Common Toxicity Criteria (NCI CTC) Version 2.0.
Pharmacokinetic analysis of ZD2767P was performed, in the same manner as for 
the previous ADEPT trial. Comet assay was again used to indirectly assess for 
prodrug activation, by identifying the presence of DNA cross-links. There 
remains no suitable direct method of assessing drug formation, as the half-life of 
the active drug is too short for direct measurement. Blood samples were taken in 
all patients prior to and 60-120 minutes after administration of ADEPT to assess 
for DNA crosslinking in peripheral lymphocytes. In addition, comet assay were 
performed on cells obtained from tumour biopsies or bone-marrow biopsies.
Repeated therapy
The immunogenicity (HAMA and HACPG2A) ofMFECPl was assessed weekly 
by ELISA. This was used to help determine whether MFECP 1 had reduced 
immunogenicity compared to A5CP, and whether repeat therapy in the second 
phase of the trial may be possible without immunosuppressive therapy,
Mechanistic studies
The mechanistic studies undertaken to ascertain whether the components of 
ADEPT were functioning as proposed, have been outlined above as they relate to 
each hypothesis being tested and are summarised in table 27.
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Table 27: Mechanistic studies in ADEPT MFECP1 and ZD2767P
clinical trial
Toxicity ofMFECPl +ZD2767P Method of assessment
Toxicity, MTD and DLT NCI-CTC criteria
Biodistribution ofMFECPl Method of assessment
Serum CPG2 enzyme clearance Methotrexate reduction assay
Tumour CPG2 enzyme levels Methotrexate reduction assay (tumour 
biopsy)
Tumour MFECP 1 localisation Immunohistochemistry (tumour biopsy)
Blood 1-123 radiolabelled MFECP1 
clearance
Gamma counter
Tumour localisation of 1-123 
radiolabelled MFECP 1
SPECT analysis of gamma camera data
Immunogenicity Method of assessment
Immunogenicity MFECP 1 HAMA and HACPG2A by ELISA
Characteristics of ZD2767P Method of assessment
ZD2767P pharmacokinetics HPLC analysis
ZD2767D formation Comet assay (for DNA cross-links)
Efficacy ofMFECPl + ZD2767P Method of assessment
Anatomical CT scans (RECIST)
Functional [F-18] FDG PET analysis
Serological Serum CEA and CA19-9 levels
Survival Kaplan-Meier survival analysis
Efficacy of ADEPT with MFECP 1 and ZD2767P was a secondary endpoint in 
this study and was assessed by conventional radiological assessment, with the 
newly adopted Response Evaluation Criteria in Solid Tumours (RECIST) 
criteria, which utilises the maximal unidimensional diameter of target lesions 
(Therasse et al, 2000). [F-18] FDG PET was used to assess functional changes in 
glucose metabolism in tumours with therapy.
Mechanistic studies were also incorporated into the protocol to guide decisions 
regarding timing of administration of prodrug, dose escalation decisions for 
MFECP 1, and whether a repeated therapy component of the trial should be 
undertaken.
A new rapid (5 minute incubation) methotrexate reduction assay by HPLC was 
validated and adopted for this trial, in addition to the previously used 30 minute
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incubation assay. The 5 minute assay was designed to be able to rapidly identify 
when serum CPG2 enzyme levels had fallen sufficiently to allow the safe 
administration of ZD2767P. Its limit of sensitivity for CPG2 enzyme activity was 
0.005 U/mL. The 30 minute incubation assay was also modified, re-validated and 
streamlined, to allow a more rapid result to be made available. The 30 minute 
incubation assay was validated to a CPG2 enzyme activity o f0.002 U/mL. 
Decisions on whether to administer prodrug were made were based on the result 
of these assays.
The protocol had integrated in it the option to increase the administered dose of 
MFECP 1 if inadequate tumour CPG2 enzyme levels were achieved, as measured 
on tumour biopsy and by quantitative SPECT analysis. In addition, prior to 
undertaking a repeated therapy part of the trial, the protocol was written to 
incorporate a ‘data review’, in which the mechanistic, toxicity and efficacy data 
were to be assessed and a decision to proceed based upon this data. This was 
designed to allow the transition between single dose and repeated dose ADEPT 
to occur without having to design an entirely new trial, as long as the mechanistic 
data collected suggested that the components of ADEPT were functioning as 
designed in the clinical setting.
The mechanistic studies incorporated within this clinical trial were therefore not 
only important for attaining a better understanding of ADEPT, and for directing 
its further development, they were also integral to the decisions made within the 
trial itself.
4.2 Trial outline
4.2.1 Patient Selection
The trial was conducted under a Doctors’ and Dentists’ Exemption (DDX) and 
had Cancer Research UK Institutional Review Board (CIRB), Local Research 
Ethics Committee (LREC) and Administration of Radioactive Substances 
Committee (ARSAC) approval. It was conducted according to the principles of 
the International Conference on Harmonisation of Good Clinical Practice (ICH
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GCP). Cancer Research UK Drug Development Office monitored the clinical 
data.
All patients gave written informed consent for the study. The eligibility criteria 
were unresectable, locally recurrent or metastatic colorectal carcinoma; 
measurable disease according to the RECIST criteria; age >18 years; life 
expectancy> 4 months; WHO performance status 0,1 or 2; and normal 
haematological, biochemical, renal and hepatic function unless abnormal due to 
tumour. Pre-treatment serum CEA levels were required to be between lOpg/L 
and lOOOpg/L: if the serum CEA was not raised, then CEA had to be 
demonstrated by immunohistochemistry on tumour biopsy. Patients were 
excluded if they had pre-existing HAMA to A5B7, or HACPG2A; the presence 
of active brain metastasis; if they were a poor medical risk; HIV, Hep B or C 
positive; or pregnant or lactating.
Patients were required to have been offered standard chemotherapy or 
radiotherapy, and had either relapsed or showed no response. All patients who 
received 1-123 radiolabelled MFECP 1 also received thyroid blocking with 
potassium iodide 50-60mg three times a day for five days commencing two days 
prior to the administration of the radiolabelled product. ZD2767P must be 
administered into a large bore vein, and so most patients had a Hickman line 
inserted.
4.2.2 Materials
MFECP 1 was produced in the Copley May Production Unit in the Department of 
Oncology, Royal Free Hospital, under the supervision of Dr Kerry Chester. 
MFECP 1 was produced in Pichia pastoris by a process of fermentation, followed 
by IMAC purification. It was expressed as a glycosylated product, and secreted 
as a functional dimer. It was aliquoted into vials and stored in sterile pyrogen- 
free PBS at -80°C. Reconstitution involved thawing MFECP 1 gently at room 
temperature to form a solution and then made up to 500mL with 0.9% sodium 
chloride for administration. Administration was intravenously over 90-120 
minutes, with a test dose being given prior to the infusion commencing.
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Radiolabelling ofMFECPl was performed with 1-123 using the chloramine T 
method. TLC was performed to assess iodine incorporation and antigen binding 
was assessed using a CEA column. 1-123 radiolabelled MFECP 1 was initially 
administered at the end of the MFECP 1 infusion, however after patient #8 it was 
administered during the MFECP 1 infusion. Administration was intravenously 
over 2 minutes.
ZD2767P was manufactured and supplied by CRUK Formulation Unit, 
Strathclyde. It was supplied as a non-sterile product containing 610 mg of 
crystalline ZD2767P Hydroiodide per vial (which was equivalent to 500 mg of 
ZD2767P free base). 10 ml of sodium bicarbonate solution was added to this to 
form a solution containing 50 mg/ml of free base, which is the form used for 
dosing. ZD2767P was administered as three doses an hour apart, via a fast 
running iv infusion of Dextrose 5%, through a central (preferably Hickman) line.
4.2.3 Treatment Schedule
5000U per m2 ofMFECPl in 500mL of 0.9% sodium chloride was given over 
90-120 hours on day 1. lmL ofMFECPl was radiolabelled with up to 500MBq 
of 1-123 and administered as an intravenous bolus over 2 minutes either during or 
at the end of the infusion. Serum CPG2 measurements were performed until the 
serum CPG2 enzyme levels fell below a pre-determined value. This level was 
initially 0.05U/mL (patients #1-4), however because of early toxicity it was 
lowered to 0.005U/mL (patients #4-13). At this time ZD2767P prodrug was 
administered as 3 bolus injections, 1 hour apart, each over 5 minutes into a fast 
running 5% dextrose drip. Patients were then followed up for a period of at least 
8 weeks from the time ofMFECPl administration.
The trial also has a second phase of repeated therapy with ADEPT, at a dose of 
ZD2767P below MTD, once MTD has been established. Immunosuppressive 
therapy may be required in this second phase to prevent the development of 
HAMA or HACPG2A.
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4.3 Methods and Results
This clinical trial is ongoing. The first thirteen patients treated with ADEPT with 
MFECP 1 in combination with ZD2767P will be discussed in detail below.
4.3.1 Patient Demographics
Table 28 shows the demographics of the thirteen patients treated with ADEPT. 
There have been six males and seven females treated, with a median age of 58 
years. All patients had CEA expressing tumours, with the majority having 
colorectal cancer (nine patients). The median number of prior chemotherapy 
regimens is three.
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Table 28: Patient Demographics
Pt
No.
ZD2767P 
dose level 
(mg/m2)
Gender Age
(yrs)
WHO
PS
CEA
Gig/L)
Primary
Tumour
Disease
sites
Prior
chemoRx
regimens
#1 12.42 Female 53 1 549.5 Colon Lung and 
liver
5
#2 12.42 Male 41 0 177.5 Gastro-
oesophage
al
Liver 4
#3 12.42 Female 45 0 471.8 Unknown
primary
adenoca
Lung and 
liver
2
#4 16.15 Male 61 1 369.9 Colon Lung.
Regional
and
metastatic
nodes
5
#5 12.42 Male 75 1 213 Colon Liver 2 (both same 
regimen)
#6 12.42 Female 62 1 501.3 Colorectal Liver 3
#7 12.42 Male 64 0 499.9 Colon Lung and 
liver
3
#8 16.15 Male 69 1 18.9 Colon Lung, 
liver and 
pelvic 
metastases
3
#9 16.15 Female 54 1 598 Breast Liver and 
bone
4
#10 21.0 Female 35 1 123.3 Breast Lung, 
bone and 
brain
5
#11 21.0 Female 65 0 55.8 Gastric
and
ColonJ
Lung and 
liver
3
#12 33.6 Male 58 0 36.3 Colon Liver 1
#13 33.6 Female 41 0 201.8 Colon Lung, 
liver and 
pelvic 
metastases
2
Abbreviations: WHO PS - World Health Organisation Performance Status; 
chemoRx -  chemotherapy; adenoca - adenocarcinoma
f  Patient #11 had two primary tumours. Both tumours were expressing CEA and 
the patient was allowed into the study.
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4.3.2 Toxicity/MTD/DLT
Method
The toxicity ofMFECPl and ZD2767P was assessed and recorded using the 
NCI-CTC Version 2.0.
Results
The tolerability of ADEPT was assessed with regard to both MFECP 1 and 
ZD2767P prodrug. MFECP 1 had not previously been administered to humans, so 
to minimise risk, the infusion was started very slowly and completed over 2 
hours. The only toxicity directly attributable to MFECP 1 fusion protein was 
Grade I rigors/chills, Grade I allergy/immunology-other and Grade I fever seen 
in a total of two of thirteen patients. No other significant toxicity attributable to 
MFECP 1 has been recorded at the fixed dose of 5000U/m2 used.
The dose of ZD2767P has been escalated in this study and has been examined at 
four dose levels: 12.42 mg/m2, 16.15 mg/m2, 21.0 mg/m2 and 33.6 mg/m2. All 
drug-related adverse events (AEs) of ADEPT with MFECP 1 in combination with 
ZD2767P are listed in Table 29. There have been very few drug-related 
toxicities seen and even fewer Grade 3 or 4 drug-related AEs reported.
A DLT (Grade 3 thrombocytopenia) was seen in Patient #3, at the first dose level 
of 12.42 mg/m2. The Grade 3 thrombocytopenia was first experienced at Day 14, 
and this patient required platelet support. Additionally this patient experienced 
Grade 3 leucopaenia and Grade 3 neutropaenia, also thought to possibly be drug- 
related. The serum CPG2 enzyme level in this patient prior to ZD2767P prodrug 
administration was the highest of all patients’ treated to date (0.0167 U/ml). 
Unfortunately this patient also had rapidly progressive malignant disease, with 
the new development of brain metastasis whilst on follow-up for ADEPT. This 
patient’s Day 29 CT scan confirmed progression of systemic disease, and she 
was too unwell for her Day 57 CT assessment. The possibility remains that this 
patient’s bone-marrow failure may at least, in part, have been as a result of the
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involvement of bone marrow by tumour for which there was evidence on MRI 
and bone scan.
In view of the DLT experience at a ZD2767P dose of 12.42 mg/m2, this dose 
level was expanded to six patients. A protocol amendment was also instituted so 
that ZD2767P prodrug would be given at CPG2 enzyme levels of <0.005 U/ml 
rather than <0.05 U/ml (which was in place at the first dose level). This 
amendment was initiated as a result of the toxicity experience by Patient #3, and 
the possibility that this toxicity may have been as a result of activation of 
ZD2767P prodrug in the peripheral circulation by circulating CPG2 enzyme. 
Since this change has been instituted there have been no reported drug-related 
haematological toxicities. In view of the perceived added safety of this 10-fold 
reduction in CPG2 enzyme activity, an amendment was approved to allow the 
dose escalation schedule to return to the original planned scheme, and dose- 
doubling was recommenced.
There have been no drug-related serious adverse events.
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Table 29: Summary of adverse events related to ADEPT (worse
grade per patient)
Adverse Event 
(CTC Version 2.0)
Dose level 
(mg/m2)
Maximum Grade Number of Patients
1 2 3 4 Total % % with 
Grade 3/4
Allergy/Immunology-other 12.42 1 0 0 0 1 7.7% 0%
16.15 0 0 0 0 0 0% 0%
21.0 0 0 0 0 0 0% 0%
33.6 0 0 0 0 0 0% 0%
All dose levels 1 0 0 0 1 7.7% 0%
Leucopaenia 12.42 0 0 1 0 1 7.7% 7.7%
16.15 0 0 0 0 0 0% 0%
21.0 0 0 0 0 0 0% 0%
33.6 0 0 0 0 0 0% 0%
All dose levels 0 0 1 0 1 7.7% 7.7%
Neutropaenia 12.42 0 0 1 0 1 7.7% 7.7%
16.15 0 0 0 0 0 0% 0%
21.0 0 0 0 0 0 0% 0%
33.6 0 0 0 0 0 0% 0%
All dose levels 0 0 1 0 1 7.7% 7.7%
Thrombocytopaenia 12.42 1 1 1 0 3 23.1% 7.7%
16.15 1 0 0 0 1 7.7% 0%
21.0 0 0 0 0 0 0% 0%
33.6 0 0 0 0 0 0% 0%
All dose levels 2 1 1 0 4 30.8% 7.7%
Fatigue 12.42 2 2 0 0 4 30.8% 0%
16.15 0 1 0 0 1 7.7% 0%
21.0 0 0 0 0 0 0% 0%
33.6 _0__ 0 0 0 0 0% 0%
All dose levels ~2 3 0 0 5 38.5% 0%
Rigors, chills 12.42 1 0 0 NA 1 7.7% 0%
16.15 0 0 _0__ NA 0 0% 0%
21.0 0 0 _0__ NA 0 0% 0%
33.6 0 0 0 NA 0 0% 0%
All dose levels 1 0 0 NA 1 7.7% 0%
Fever 12.42 0 0 . 0 0 0% 0%
16.15 0 0 0 0 0 0% 0%
21.0 0 0 0 0 0 0% 0%
33.6 1 0 0 0 1 7.7% 0%
All dose levels 1 0 0 0 1 7.7% 0%
GASTROINTESTINAL
Nausea 12.42 2 0 0 NA 2 15.4% 0%
16.15 1 0 0 NA 1 7.7% 0%
21.0 0 0 0 NA 0 0% 0%
33.6 1 0 0 ' NA 1 7.7% 0%
All dose levels 4 0 0 NA 4 30.8% 0%
Vomiting 12.42 2 0 0 0 2 15.4% 0%
16.15 1 0 _0__ 0 1 7.7% 0%
21.0 0 o ' 0 0 0 0% 0%
33.6 0 0 J i 0 0 0% 0%
All dose levels 3 0 ± J 0 3 23.1% 0%
NA = not applicable
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4.3.3 Mechanistic studies
A5CP Pharmacokinetics -  serum CPG2 enzyme levels and clearance of I- 
123 radiolabelled A5CP
Method
A 2.5 ml blood sample was taken into a plain tube for CPG2 levels and 1 ml of 
blood was taken into an EDTA tube for 1-123 levels at 5 min, lh, 2h, 3h, 4h, 5h 
and 6h after the MFECP 1 fusion protein. If the patient’s serum CPG2 enzyme 
level was above 0.05 U/ml (later amended to 0.005 U/ml) further blood samples 
were taken on Day 2. In addition, a blood sample for CPG2 activity was taken 
immediately before the first ZP2767P administration and at the time of tumour or 
bone marrow biopsy (if this was performed).
The catalytic activity of CPG2 was measured by HPLC using methotrexate as a 
substrate. A 5 min incubation assay was used for Patients #1 to #10 (pre-prodrug 
samples for Patients #6 to #10 were incubated for 30 min) and a 30 min 
incubation assay was adopted for Patients #11 to #13. The limit of quantitation 
for the 5 min incubation assay was 0.005 U/ml and for 30 min incubation assay 
was 0.002 U/ml.
Blood samples were measured for 1-123 radioactivity by a Packard Cobra 11th 
Series Auto gamma counter, and were decay corrected to time of injection. They 
were expressed as %injected dose/kg blood.
HPLC and gamma counter analysis was performed by SK Sharma.
Results
Figure 34 displays the pooled serum CPG2 enzyme levels from HPLC analysis 
for all data points for which there was an absolute value recorded for Patients #1 
to #13. Values of below the sensitivity of the assay (recorded as ‘<0.005U/mL’ 
or ‘<0.002U/mL’) could not be plotted. The data was modelled based on 
biexponential clearance, and an a  and a p half-life has been calculated (model 
applied by AJ Green). The a  half-life was 0.35 h and the p half-life was 6.0 h.
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Figure 34: CPG2 enzyme levels by HPLC with biexponential
clearance model
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Table 30 displays the serum CPG2 enzyme level prior to ZD2767P prodrug 
administration (and the time at which the blood sample was taken) for Patients 
#1 to #13.
Table 30: CPG2 enzyme levels at the time of ZD2767P
administration
Pt No. Time of first ZD2767P 
(hrs after start of 
MFE-CP1)
Time of Serum Sample 
(hrs after start of 
MFE-CP1)
CPG2
activity
(U/ml)
#1 7.57 7.32 0.00516
#2 7.13 5.38 0.0111
#3 7.52 7.48 0.0167
#4 6.85 6.53 <0.005
#5 8.42 6.37 <0.005
#6 23.47 22.90 <0.002
#7 21.28 18.57 <0.002
#8 20.70 20.58 <0.002
#9 25.82 25.10 0.00232
#10 21.75 21.57 <0.002
#11 20.45 17.50 <0.002
#12 21.85 18.48 <0.002
#13 21.45 21.20 <0.002
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Figure 35 displays the pooled blood radioactivity data for patients who had 
radiolabelled MFECP1 administered (Patients #1 to #6 and #8 to #13). A 
biexponential model has been applied to the data and an a  and p half-life has 
been calculated (model applied by AJ Green). The a  half-life was 0.7 h and the P 
half-life was 11.8 h. Patients #3 and #11 had very high %injected dose/kg 
radioactivity in their blood at the 5 min time point (51.43% and 41.35% 
respectively). These results cannot be correct and so measurements earlier than 
30 min in all patients have been excluded from this current analysis until this 
problem can be resolved.
The faster clearance of functional enzyme activity in the blood than radioactivity 
is attributed to deactivation o f enzyme in the radiolabelled fusion protein, whilst 
its breakdown products, which may still have 1-123 attached, continue to 
circulate. This is consistent with findings in animal models (see chapter 3).
Figure 35: Blood clearance of 1-123 radiolabelled MFECP1
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CPG2 enzyme levels in tumour and normal tissues
Method
Tumour biopsies were obtained from patients who consented to this additional 
procedure. Biopsies were performed under radiological guidance on the day of 
administration of ZD2767P and, where possible, within 30-120 min post final 
ZD2767P administration. The tissue was then divided and distributed where 
appropriate for histological assessment and immunohistochemistry.
Biopsy tissue was snap frozen in iso-pentane (cooled in liquid nitrogen) and 5pm 
cryostat sections cut. Sections were acetone-fixed and stained by haematoxylin 
and eosin (H+E) to reveal morphology. CEA and MFECP1 distribution was 
demonstrated by immunohistochemistry using monoclonal anti-CEA antibody 
(A5B7) and anti-CPG2 antibodies (SB43 mouse monoclonal and CAMR 
polyclonal), respectively. Appropriate controls were included to confirm 
specificity of immunohistochemistry. Distribution of target antigen and antibody 
fusion protein were demonstrated by brown peroxidase reaction product in the 
sections and digital images were produced using a Zeiss Axiocam colour camera. 
Histological assessment and immunohistochemistry were performed by G Boxer.
Results
Tumour biopsies have been taken from two patients (#6 and #12) in this study. 
The results are summarised in Table 31. In addition the biopsy from Patient #6 is 
shown in Figure 36.
The biopsy of liver metastasis from Patient #6 was shown to contain metastatic 
adenocarcinoma surrounded by fibromyxoid stroma. Immunohistochemistry with 
anti-CEA antibody confirmed that these tumour areas expressed CEA. Further 
immunohistochemistry with anti-CPG2 antibody confirmed the presence of 
CPG2 in the CEA expressing tumour areas, consistent with tumour localisation 
of MFECP1 in this patient (Figure 36). The sensitivity of immunohistochemistry 
with anti-CPG2 and anti-CEA antibodies is not known and although positive data
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demonstrate the principal of localisation the significance of a negative result is 
uncertain.
The CPG2 enzyme levels could not be measured because the biopsies were too 
small (approximately 1 mg). There was not sufficient tumour tissue for comet 
assay.
Table 31: Tumour biopsy results
Pt
no.
Biopsy
site
Time of 
biopsy (hrs 
after start 
MFECP1)
Histopathology
Immunohistochemistry
CEA CPG2
#6 liver 6.13 1) necrotic tumour notinterpretable
not
interpretable
2) adenocarcinoma positive positive
#12 liver *25.33 1) adenocarcinoma positive negative
2) normal liver negative negative
3) normal liver negative negative
*exact time not recorded -  this is an estimate
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Figure 36: Digital image of a liver biopsy from ADEPT pt #6
H&E
High Power
Anti-CEA
Consecutive histopathological slices from a tumour biopsy o f liver metastasis 
from a patient with colorectal cancer. The H+E stain shows tumour 
heterogeneity with small clumps o f  tumour areas. Immunohistochemistry has 
been performed with the positive areas showing as brown. 
Immunohistochemistry with an anti-CEA antibody shows a positive reaction in 
areas consistent with tumour clumps. The anti-CPG2 antibody shows a positive 
reaction in the same areas. The high power view o f the anti-CP G 2 antibody 
reaction shows a tumour area in more detail.
These results indicate the presence o f  both CEA and CPG2 enzyme in these 
tumour areas. This provides evidence, in this one patient, o f  localisation o f  
enzyme to CEA positive tumour areas.
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Gamma camera imaging
Method
1 ml of MFECP1 radiolabelled with up to 500 MBq 1-123 was administered to 
patients during or immediately after the MFECP1 infusion. The iodine 
incorporation and CEA binding of the radiolabelled MFECP1 were measured by 
TLC and a CEA column respectively. (TLC and CEA binding were performed 
by and results obtained from SK Sharma).
Gamma camera imaging was performed at 30 min, 4 h, 6 h and 24 h post 
administration of 1-123 radiolabelled MFECP1. This imaging consists of total 
body scanning or planar images, with at least one quantitative SPECT scan 
performed at 4-6 h, and a further SPECT scan again at 24 h, if there was 
sufficient radioactivity remaining.
The SPECT scans were reconstructed and corrected for Compton scatter and 
attenuation. I performed the gamma camera analysis. This consisted of placing 
regions of interest (ROI) on tumour areas and normal tissues, including liver, 
lung, heart and kidney, as outlined in chapter 2. Where available, [F-18] FDG 
PET scans were used to visually correlate tumour areas. The % injected dose/kg 
of radioactivity was calculated for each tumour site and normal tissues, using a 
calibration factor derived from a phantom with a known amount of radioactivity 
scanned under clinical conditions. The amount of enzyme units could only be 
estimated in tumour, due to the known problems with rapid breakdown of 
MFECP1 leading to misrepresentation of radioactivity for active enzyme in non­
tumour tissues. The enzyme activity in tumour was calculated by multiplying the 
% injected dose/kg of radioactivity in tumour by total injected enzyme units and 
dividing by 1000 to convert to units per gram (Green et al, 1990; Francis et al,
2002).
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Results
Table 32 displays the CEA binding arid the TLC results for the 1-123 
radiolabelled MFECP1. This was performed on the radiolabelled sample prior to 
administration to the patient. The median CEA binding was 56.19% (range 48.1- 
65.2%) and the median % iodine incorporation by TLC was 97.86% (range 
92.75-99.152%).
Table 32: 1-123 radiolabelling of MFECP1
Pt no. CEA binding 
(%)
TLC (% 
incorporation)
#1 51.6 96.9
#2 48.1 97.68
#3 55.57 95.198
#4 57.99 95.6
#5 62.84 95.0
#6 58 92.75
#7 not radiolabelled not radiolabelled
#8 50.6 98.75
#9 56.3 98.5
#10 65.2 99.11
#11 58.4 99.152
#12 56.07 99.03
#13 54.02 98.03
Abbreviation: TLC -  thin layer chromatography
Total body scans visually confirmed the rapid hepatic clearance of MFECP1, 
with 30 min scans showing high levels of radioactivity in the liver (see Figure 
37). The 4-6 h time point shows less hepatic uptake, with more evidence of free 
1-123 as a result of metabolism of the MFECP1 by the liver. This was seen as I- 
123 uptake in the stomach and excretion in the urinary system. There were no 
unexpected areas of uptake.
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Figure 37: Total body gamma camera scans showing uptake of I-
123 radiolabelled MFECP1
HU
Total body gamma camera images, anterior and posterior at 30 min, 2, 4 and 22 
h after injection o f 1-123 radiolabelled MFE-CP1 in Patient #2. The 30 min 
time-point shows high hepatic uptake o f radioactivity, which has reduced at the 
later time-points. At 2, 4 and 22 h free 1-123 can be seen in the stomach (seen in 
the thorax o f this patient who had a partial oesophagectomy with gastric-pullup 
performed), renal pelvis and bladder. This patient had hepatic metastasis from 
gastro-oesophageal cancer.
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The patients who had quantitative SPECT scans performed are displayed in 
Table 33. Due to camera faults four patients had SPECT scans for which 
quantitative analysis could not be performed (one had corrupt data, one 
transmission scan failed, two had camera failure and so the patients were scanned 
in the Department of Nuclear Medicine on a non-calibrated camera). One patient 
received insufficient radioactivity for SPECT scans to be performed (Patient #1).
Table 33: SPECT scans in ADEPT patients
PtNo. Activity 1-123 
(MBq)
Time of 
SPECT scan 
(hrs after 
radiolabel)
Comments
#1 7 not done 7 MBq injected dose - no SPECT 
performed
#2 100 4.77 Exact injected activity uncertain due to 
residual activity in syringe post injection 
not being measured
5.22
#3 137.4 4.45
#4 138.2 4.58
5.12
#5 213.7 4.73 SPECT data corrupt
#6 134.8 3.67
#7 not done not done no radiolabel administered
#8 264.6 4.22 bilateral ureteric obstruction
20.35
#9 231.7 2.92 AD AC camera fault -  patient scanned in 
Nuclear Medicine (non-quantitative data)
#10 300.7 3.97 transmission scan failed so no attenuation 
correction applied (non-quantitative data)
#11 171.2 3.87
#12 275.7 2.13 AD AC camera fault -  patient scanned in 
Nuclear Medicine (non-quantitative data)18.17
#13 227.2 4.35
21.18
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Figure 38 shows the %injected dose/kg of radioactivity in each organ and 
tumour area for all patients for whom quantitative SPECT analysis was possible.
Figure 38: SPECT analysis at 4-6 hours in individual patients
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Figure 39 displays the median %injected dose/kg o f radioactivity for each organ 
at both 4-6 h and 24 h.
Figure 39: Median %injected dose/kg of 1-123 radiolabelled
MFECP1 at 4-6 hours and 24 hours
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(The error bars represent the entire range o f the data set)
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As already discussed, radioactivity in the liver, heart and kidneys were unlikely 
to reflect intact MFECP1. Consequently only tumour CPG2 activity was 
estimated (Table 34), and not normal tissue enzyme levels. The estimated 
median CPG2 enzyme activity in tumour sites at a median of 5.47 h after the 
commencement of MFECP1 was 0.20 U/g (range 0.13-0.37 U/g) and at a median 
of 21.63 h was 0.11 U/g (range 0.10-0.12 U/g).
Table 34: Estimation of tumour CPG2 enzyme level at 4-6 hours 
and 24 hours based on SPECT analysis of localisation of 1-123 
radiolabelled MFECP1
4-6 hours
Estimated CPG2 enzyme 
activity in tumour from SPECT
PtNo. Time of scan (hrs 
after radiolabel)
Time of scan (hrs after 
start of MFECP1)
tumour 1
(U/g)
tumour 2
(U/g)
tumour 3
(U/g)
#2 4.77 7.48 0.24 0.25 ND
#3 4.45 7.72 *0.23 0.37 0.35
#4 5.12 7.20 **0.20 **0.18 ND
#6 3.67 5.47 0.21 0.17 ND
#8 4.22 4.95 0.13 ND ND
#11 3.87 4.42 0.17 0.16 ND
#13 4.35 5.35 ***0 19 ND ND
median 4.35 5.47 0.20
24 hours
Estimated CPG2 enzyme 
activity in tumour from SPECT
PtNo. Time of scan (hrs 
after radiolabel)
Time of scan (hrs after 
start of MFECP1)
tumour 1
(U/g)
tumour 2
(U/g)
tumour 3
(U/g)
#8 20.35 21.08 0.12 ND ND
#13 21.18 22.18 ***0.10 ND ND
median 20.76 21.63 0.11
All tumours represent liver metastasis except where marked: 
*pleural mass; **inguinal lymph nodes; ***presacral mass 
ND = not done
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Figure 40 and figure 41 are examples o f transverse slices of SPECT scans, with 
the equivalent [F-18] FDG PET scans, showing tumour areas. It can be seen that, 
despite reasonably high levels of background radioactivity, that areas of 
increased radioactive tracer occurred in regions that would be in keeping with the 
tumour areas, based on the [F-18] FDG PET functional images.
Figure 40: [F-18] FDG PET and SPECT images on patient #2
Visually equivalent transverse slices (2 consecutive slices) o f the pre-treatment 
[F-18] FDG PET scan and the 6 hour SPECT scan on patient #2. The liver is 
shown, with metastatic tumour regions clearly visible on the [F-18] FDG PET 
scan. The SPECT scan shows increased radiolabel uptake in the area o f the liver 
that corresponds to the tumour lesions on [F-18] FDG PET. There is a high 
background level o f radioactivity in the liver on the SPECT scan.
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Figure 41: [F-18] FDG PET and SPECT images on patient #4
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Visually equivalent transverse slices (2 consecutive slices) o f  the pre-treatment 
[F-18] FDG PET scan and the 6 hour SPECT scan on patient #4. This patient 
has inguinal lymph node metastasis from colorectal cancer, shown on the [F-18] 
FDG PET scan as a ‘hot spot The SPECT scan also shows increased uptake in 
this region, indicating tumour localisation.
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Immunogenicitv
Method
A 10 ml blood sample was taken into a plain blood tube for HAMA/HACPG2A 
levels at the following times: pre-study and at weekly intervals while on study, 
for example on Days 8,15,22,29,36,43, 50 and 57.
Immunogenicity was assessed by ELISA against A5B7 (HAMA assay) and 
CPG2 (HACPG2A assay). Results are presented as Positive or Negative for 
HAMA and HACPG2 A at each time point tested. Levels below an optical 
density (OD) of 0.2 (see Figure 42) are defined as negative (>3 standard 
deviations above the mean for pre-treatment values for 20 patients before 
treatment with ADEPT). Analysis was performed by and data obtained from SK 
Sharma.
Results
Pre-treatment samples showed all 13 patients (100%) were negative for HAMA 
and HACPG2A.
The post treatment samples showed all 13 patients (100%) were negative for 
HAMA and 10 patients (76.9%) were negative for HACPG2A at all time-points. 
The three patients who were positive for HACPG2A were Patients #2, #3 and 
#12. Patient #2 was positive from 21 days after treatment but was negative at 
Day 56. Patient #3 was positive at 43 days after treatment and Patient #12 was 
positive from Day 18 after treatment (see Figure 42).
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Figure 42: Human anti-CPG2A (HACPG2A) response in patients
who have received MFECP1
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HACPG2A. The line represents 3 standard deviations above mean pre-treatment 
values (O.D. o f 0.2)
Abbreviations: O.D. -  optical density
ZD2767P (prodrug) pharmacokinetics 
Method
A 2.5 ml blood sample was taken into a heparinised tube containing rat serum 
albumin (RSA) at 2 min following each of the first two doses of ZD2767P 
prodrug given at hourly intervals. Similar samples were taken after 2, 5, 10, 15, 
30 and 60 min following the third dose o f ZD2767P, given at a further 1 h 
interval. Each sample was analysed by HPLC and a full pharmacokinetic profile 
was generated for each patient with WinNonLin software. Means (+/- standard 
deviation [SD]) were calculated from input of all patient data in each group, 
regardless of reliability (including groups with two patients). Analysis was 
performed by and data obtained from C Springer and J Martin.
Results
Figure 43 represents the ZD2767P prodrug plasma elimination profiles in all 13 
patients. There appears to be no build-up of ZD2767P prodrug in the plasma
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during the course of the three doses, and prodrug is essentially eliminated from 
the plasma within 1 hour of the third dose for all the dose levels.
There was variation in the range of values for measured PK parameters within 
most dose groups. Means (±SD) have been calculated by the pharmacokinetic 
software for all patients in each dose level, including the groups with only two 
patients, with all values in Table 35. The unreliable results are indicated in 
italics.
The mean value for the extrapolated concentration at time = 0 (C o) rises with 
increasing ZD2767P dose level. As the mean area under the curve at infinity 
(A U C m f) rises with the increased dose levels 12.42,16.15 and 21.0 mg/m2, the 
mean clearance rate was seen to fall. The individual and the mean dose group 
values for volume of distribution at steady state (Vss) indicate likely containment 
in the blood. The overall mean elimination half-life (T1/2 ) of all patients with 
reliable results was 8.54 minutes (±SD 3.17minutes with a median of 7.9 
minutes.
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Figure 43: Plasma elimination profiles after third dose of
ZD2767P
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Table 35: Summary of ZD2767P phamacokinetic values
Elimination 
T m (min)
C0 0lg/ml) AUCin,
(Ug.ml.min)
CL (ml/min) VM (ml)
Dose level: 12.42 mi5/m2
Patient #1 7.5 5.9 48 408 4065
Patient #2 3.5 3.4 17 1391 6879
Patient #3 14.3 4.8 58 344 6131
Patient #5* 9.1 2.3 19 1236 14352
Patient #6**
Patient #7 8.0 4.8 31 740 6416
Mean
(12.42 mg/m2)
8.5 4.2 34 824 7568
(+/- SD) 3.9 1.4 18 475 3943
Dose level: 16.15 mig/m2
Patient #4 6.4 4.5 28 1136 9085
Patient #8 6.4 6.0 61 468 4447
Patient #9*** 8.3 7.0 75 378 4135
Mean
(16.15 mg/m2)
7.0 5.8 55 671 5889
(+/-SD) 1.1 13 24 433 2773
Dose level: 21.0 mg/m2
Patient #10 12.8 6.8 86 544 9240
Patient #11 10.1 11.0 108 303 3557
Mean
(21.0 mg/m2)
11.5 8.9 97 424 6398
(+/- SD) 1.9 3.0 16 170 4019
Dose level: 33.6 mg/mz
Patient #12 7.8 14.0 96 743 6878
Patient #13 8.6 14.7 98 582 5379
Mean
(33.6 mg/m2)
8.2 143 97 663 6128
(+/-SD) 0.60 0.49 1.2 114 1060
* Time point 6 min omitted from input PK data as possible saline
contamination.
** No results as single lumen Hickman line allowed prodrug contamination 
o f plasma samples.
*** Time points 10, 15, 29 and 60 min unreliable as only 2/3 o f LOW quality 
control samples acceptable due to technical difficulties with normal plasma used 
to construct LOW calibration range, but usedfor pharmacokinetic analysis.
Abbreviations: Tm - half-life; Co- concentration at time = 0; AUCi»/- area under 
the curve at infinity; Cl -  clearance; Vss.- volume o f distribution at steady state; 
SD -standard deviation
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Comet assay
Method
Comet assays were performed to indirectly assess activation of ZD2767P into an 
active cytotoxic alkylating agent, ZD2767D. ZD2767D has too short a half-life 
for direct measurement of drug levels, and therefore the presence of DNA 
interstrand crosslinks, as assessed on a comet assay, may provide indirect 
evidence of ZD2767D formation and effect. Comet assays were performed on 10 
ml blood samples (taken into heparinised tubes), at 60-120 min after the last 
ZD2767P was administered, and where applicable, on tumour or bone marrow 
biopsy specimens. If a tumour or bone marrow biopsy was performed the blood 
sample was taken within 10 min of the biopsy.
The result was recorded as a percentage reduction in tail moment (%RTM) and 
was calculated as the change in comet tail compared to control. A negative value 
for %RTM indicates crosslinking. Analysis was performed by and data obtained 
from J Hartley.
Results
No tumour or bone marrow biopsy specimens had comet assay performed (one 
tumour biopsy was performed prior to prodrug administration -  patient #6, and 
so the comet assay was not performed, the other had insufficient tissue for comet 
to be performed -  patient #12). The comet assay was therefore only performed 
on peripheral blood lymphocytes. The results are shown in Table 36. No patients 
have had substantial crosslinking seen in their circulating lymphocytes. These 
results are consistent with the low levels of haematological toxicity experienced 
in this ADEPT study to date. Patient #11 has the most crosslinking (23.75% 
reduction in tail moment) however this patient did not experience haematological 
toxicity.
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Table 36: Comet assay (lymphocytes)
PtNo. %RTM
#1 -6.4
#2 -8.9
#3 1.9
#4 9.4
#5 2.48
#6 13.2
#7 3.2
#8 0
#9 8.2
#10 10.8
#11 -23.75
#12 -4.0
#13 4.5
Abbreviations: %RTM-  percentage reduction in tail moment
4.3.4 Efficacy 
Radiological Assessment 
Method
A minimum of one course of ADEPT (defined as MFECP1 followed by 
ZD2676P) was required for a patient to be considered evaluable for response. 
The response criteria used in this study were RECIST (Therasse et al, 2000). 
Tumour assessments were performed pre-study and then every 28 days or more 
frequently, if clinically indicated. All patients had CT scans for response 
assessment.
Results
Thirteen patients (100%) were evaluable for tumour response to at least Day 29 
(see Table 37). Six patients (46.2%) had stable disease at Day 29, which was 
reduced to four patients (30.8%) at Day 57 (Patient # 6 withdrew from the study; 
Patient #13 progressive disease at Day 57). Seven patients (53.8%) had 
progressive disease at Day 29 and Day 57. There were two patients (15.4%) who 
did not have a Day 57 disease assessment performed as they came off study
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before Day 57 (Patient #3 was too unwell for Day 57 assessment and Patient #6 
voluntarily withdrew from the study).
Table 37: Radiological response to ADEPT
Assessment
Day
Response Number of 
patients (%) 
n = 13
PtNo.
Day 29 Stable Disease 6 (46.2%) #1, #6, #7, #10, #11, #13
Progressive Disease 7 (53.8%) #2, #3, #4, #5, #8, #9, #12
Not Evaluable 0 (0%) -
Day 57 Stable Disease 4 (30.8%) #1, #7, #10, #11
Progressive Disease 7 (53.8%) #2, #4, #5, #8, #9, #12, #13
Not Evaluable 2 (15.4%) #3, #6
Serum tumour markers 
Method
Serum tumour markers (CEA, CA19-9 and where, appropriate, CA15-3) were 
taken pre treatment and at day 29 and 57 after ADEPT.
Results
The serum tumour marker results on all patients are shown in Table 38. As 
MFECP1 is an anti-CEA antibody this may make interpretation of serum CEA 
levels difficult. The serum CA19-9 or CA15-3 tumour marker levels on all 
patients increased after ADEPT except patient #10, who had a small fall in serum 
CA15-3 tumour marker from a level of 344.4 U/mL pre-treatment to 289 U/mL 
at 46 days after treatment with ADEPT. This patient also had a small fall in 
serum CEA from 123.3 pg/L to 115.9 pg/L at 46 days after ADEPT. This fall in 
tumour markers was accompanied by stable disease on CT scan at day 29 and 57 
after ADEPT.
Patient #1 had a fall in serum CEA tumour marker levels (from 549.5 pg/L pre 
ADEPT to 468.6 pg/L at day 56), however this was not reflected in this patient’s 
CA19-9 tumour marker levels, which rose from 348 U/mL pre ADEPT to 766
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U/mL at day 56. Patient #1 also attained stable disease on CT scan at day 29 and 
57.
Table 38: Serum tumour marker levels in patients who received
ADEPT
Pt
No.
CEA(|ig/L) CA19-9 (U/mL) CA15-3 (U/mL)
pre Day29 Day57 pre Day29 Day57 pre Day29 Day57
#1 549.5 439.8 468.6 348 642 766 ND ND ND
#2 177.5 466.8 799.2 11 11 15 ND ND ND
#3 471.8 802.8 860.7 ND ND ND ND ND ND
#4 396.9 397.4 404.7 956 1046 880 ND ND ND
#5 214.8 516.6 773 295 463 678 ND ND ND
#6 501.3 973.4 950.7 ND ND ND ND ND ND
#7 499.9 562 773 508 878 1539 ND ND ND
#8 18.9 38.9 67.1 43 50 76 ND ND ND
#9 587 977 1551 ND ND ND >300 1549 2145
#10 123.3 116 115.9 ND ND ND 344.4 349 289
#11 57.8 84.9 129.4 NR NR NR ND ND ND
#12 23.9 48.7 133.1 28 61 116 ND ND ND
#13 190 202.6 415.6 42 42 55 ND ND ND
ND -  not done
NR- not raised- tumour marker levels were taken, but did not fall outside the 
normal range.
F-18 FDG PET scans 
Method
[F-18] FDG-PET scans were performed on consenting patients to assess changes 
in tumour glucose metabolism with therapy. Scans were performed pre study and 
at approximately 2-4 weeks and then 8 weeks post ADEPT therapy. Patients 
fasted for 5 hours prior to injection of 130 MBq of F-18 FDG. Scans were 
performed at 90 min on an AD AC Vertex Plus Co-Incidence camera. Acquired 
data was reconstructed using standard iterative protocols, with attenuation 
correction (attenuation maps were acquired using Caesium-137 sources).
Analysis of [F-18] FDG PET scans were performed after correction for injected 
dose and time to scanning. I performed the analysis using the volume of interest 
quantitative technique (VOI) as discussed in chapter 5. The total counts obtained
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from tumour volumes were used to quantify change as a percentage of the pre­
study tumour total counts. Mathematically derived volumes of interest were also 
defined on normal background tissues (usually liver, lung and chestwall) in order 
to validate changes in tumour FDG uptake.
Results
Nine of thirteen patients participated in the [F-18] FDG PET component of the 
ADEPT study. Quantitative analysis was performed in seven of these patients’ 
scans (the baseline [F-l 8] FDG PET scan for Patient #6 was corrupt and no 
analysis could be performed, and problems with the injection of FDG for the 
second scan for Patient #2 meant that the exact injected dose was uncertain). All 
patients show an increase in tumour FDG uptake after ADEPT (table 39). In two 
patients (#8 and #11) quantitative tumour volumes could not be defined on the 
baseline [F-18] FDG PET scan, however they could be defined on the post 
treatment scan. This is consistent with disease progression. Quantitative analysis 
of Patient #9 revealed an abnormal degree of change in FDG uptake in 
background normal tissues (lung and chestwall) between the pre-study and 6 
week scan, which would suggest that the quantitation of tumour FDG uptake 
may not be reliable.
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Table 39: [F-18] FDG PET analysis
Quantitative-VOI
PtNo. CT Response 
(4weeks)
CT Response 
(8 weeks)
Early PET 
Response 
(2-4 weeks)
Late PET 
Response 
(8 weeks)
#3 PD ND 240% ND
#4 PD PD 129% ND
#5 PD PD 144% 379%
#7 SD SD 109% 126%
#8 PD PD PD PD
#9 PD PD ND *601%
#11 SD SD PD ND
% in table represent a % change compared to baseline -  no change from 
baseline would be recorded as 100%, a reduction from baseline has a value 
<100% and an increase from baseline has a value >100%
* background ‘normal 7 tissues in this patient varied greatly between scans, 
indicating that data may not be accurate.
Reasons for ND (not done): Patient #3 too unwell for 8 weeks scan; Patients #4 
and #11 AD AC camera fault for 8 weeks scan; Patient #9 scan performed at 6 
weeks due to fault in AD AC camera prior to this.
Abbreviations: PD = progressive disease; SD = stable disease; VOI- volume o f 
interest
220
4.4 Discussion
The results from the first 13 patients treated with ADEPT will be discussed in 
terms of the hypotheses proposed at the commencement of this trial (section 
4.1.3).
MFECP1 safety
There has been little precedent for the administration of a protein such as 
MFECP1 in humans. The combination of a murine antibody for tumour 
targeting, a bacterial enzyme for prodrug activation, a hexahistidine tag for 
simplified purification and short-branched mannose glycosylations added by the 
production process in Pichia pastoris is, to our knowledge, unique to this 
molecule. Despite the potential risks of administration of such a molecule to 
humans, MFECP1 was found to be safe and well tolerated. It was associated with 
Grade I ‘possible’ drug-related toxicities of low grade fever and chills, in two of 
the thirteen patients. Fever and chills would not be unexpected after the 
administration of a foreign protein; and for it to have occurred only in two 
patients was reassuring for the safety of this molecule.
Tumour targeting of MFECP1
The tumour targeting of MFECP1 will be discussed in terms of systemic 
clearance, tumour localisation, and the possible impact of administered dose.
Systemic clearance o f antibody-enzyme
Systemic clearance of antibody-enzyme was studied by measuring serum CPG2 
enzyme levels and distribution of radiolabelled MFECP1. The two give different 
information; the serum CPG2 enzyme levels being a reflection of intact 
circulating MFECP1 and the radiolabel tracking the distribution of the protein 
and its breakdown products.
Measurement of serum CPG2 enzyme levels showed that functioning CPG2 
enzyme was rapidly cleared from the blood. The (3 half-life for enzyme activity in 
serum was 6.0 hours. Radiolabelled MFECP1 was also shown to clear rapidly
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from the blood, however not as rapidly as the active enzyme. The p half-life was 
11.8 hours for clearance of radioactivity from the blood. The reason for the 
slower elimination of radioactivity was apparent from the gamma camera 
imaging. This showed radioactivity rapidly accumulating in the liver as early as 
30 minutes after administration of radiolabelled MFECP1, indicating uptake of 
MFECP1. This was followed at 2 hours by diminishing radioactivity in the liver, 
but increasing uptake in the kidneys and in the stomach wall (f ig u re  37). The 
liver contains receptors for the glycosylations of MFECP1, which appear to 
mediate the rapid uptake of MFECP1. This is followed by catabolism of the 
protein, leading to loss of enzyme activity. Radiolabelled peptide fragments and 
free iodine are then released back into the circulation and cleared through the 
kidneys, or excreted by the stomach and other parts of the gastrointestinal tract. 
This process accounts for the slower clearance of radioactivity than of enzyme 
activity in normal tissues.
Anecdotally it was noted that patients with extensive hepatic involvement of 
tumour tended to clear MFECP1 from the blood much slower than those with no, 
or minimal hepatic involvement by tumour. Patients who were noted to have 
particularly extensive infiltration of their liver with tumour were patients #3, #6 
and #9. Patients #6 and #9 had the slowest clearance of CPG2 enzyme from their 
blood, and patient #3 had dose limiting toxicity. This supports the concept that 
the rapid clearance of CPG2 from the systemic circulation is likely to be from 
hepatic metabolism.
In the previous ADEPT trial clearance of CPG2 enzyme from the systemic 
circulation was slow, with a p half-life for A5CP of over 15 hours (Campaign 4) 
(chap ter  2). The more rapid clearance of MFECP1 was a design feature in order 
to allow administration of prodrug at a much earlier time-point than was possible 
with A5CP. It was hypothesised that this would increase the likelihood of their 
being sufficient CPG2 in tumours at this time, and that the CPG2 enzyme that 
was present would be likely to be located in viable tumour areas, rather than in 
the necrotic centre of the tumour where its effectiveness would be limited.
The rapid systemic clearance of MFECP1 resulted in serum CPG2 enzyme levels
considered safe for administration of prodrug at 24 hours after MFECP1
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administration, compared to a median of 3 days for A5CP. This was despite an 
increase in administered dose of CPG2 enzyme from 3000U/m2 in the A5CP 
ADEPT trial to 5000U/m2 for this trial.
Tumour Localisation ofMFECPl
The total amount of CPG2 that is delivered to tumour is likely to influence the 
effectiveness of activation of prodrug, and subsequently the potential efficacy of 
ADEPT. It was therefore desirable to ascertain the amount of functional enzyme 
in tumour at the time of prodrug administration. The information was attained by 
the measurement of functional enzyme in tumour on tumour biopsy specimens 
and by estimation of tumour antibody-enzyme localisation by gamma camera 
imaging of radiolabelled MFECP1.
Two tumour biopsies have been obtained in the 13 patients reported here. It was 
impractical to perform tumour biopsies on the earlier patients in the study, as the 
timing of the biopsies were such that they would have been performed in the 
evening, outside routine working hours. As liver biopsies may be associated with 
potential morbidity and complications, this was avoided.
One tumour biopsy of liver metastasis from colorectal cancer taken at 
approximately 6 hrs after the commencement ofMFECPl showed 
immunohistochemical evidence of CPG2 enzyme localisation in tumour at sites 
containing CEA (Figure 36). Enzyme appeared to have localised in all the 
tumour areas of this biopsy and in none of the non-tumour areas. However, 
another tumour biopsy of liver metastasis from colorectal cancer taken at 
approximately 24 hrs after commencement ofMFECPl failed to demonstrate the 
presence of CPG2. Immunohistochemistry is non-quantitative and the levels of 
detection are not known -  it is possible that the assay was too insensitive to 
detect the presence of CPG2, or that there was indeed no significant amount of 
CPG2 present in the tumour of this patient at 24 hours.
The tumour biopsy specimens were too small for an accurate measurement of the 
amount of active CPG2 to be made by methotrexate reduction assay on HPLC.
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Quantitative gamma camera imaging of 1-123 labelled MFECP1 was also used to 
ascertain whether adequate localisation ofMFECPl was occurring. It was 
estimated that the median tumour enzyme level at approximately 6 hours after 
commencement ofMFECPl was 0.2 U/g, and at approximately 22 hours, 0.11 
U/g. These levels of CPG2 activity are expected to be sufficient to activate 
prodrug (ZD2767P). Although gamma camera imaging is an indirect method of 
determining enzyme levels, it has correlated well with direct enzyme levels 
measured in tumour biopsies in two previous clinical trials (Napier et al, 2000; 
Francis et al, 2002).
As discussed above, radioactivity was also found to be distributed in non-tumour 
areas (liver, kidneys, stomach, blood). Preclinical models have supported the 
concept explained above, that radioactivity in blood and normal tissues is not 
representative of functioning enzyme, and is instead a reflection of fragments of 
radiolabelled protein, or free iodine. However in tumour areas measurements of 
radioactivity do seem to provide a reasonable estimation of actual enzyme 
activity. Importantly, radioactivity was not found to be distributed in any sites 
other than those expected from preclinical experience. In particular there was no 
evidence of specific bone marrow uptake of radioactivity.
Unfortunately only 2 of the 13 patients had SPECT scans at 24 hours that were 
suitable for quantitative analysis. Although it was hoped that patients would 
receive 500MBq of 1-131 radiolabelled MFECP1, problems with the 
radiolabelling lead to only a median of 192MBq was administered (range 7-300 
MBq). This meant that with the short half-life of 1-123 of 13 hours, and the rapid 
metabolism and dehalogenation of 1-123 radiolabelled MFECP1, very little 
radioactivity was present at 24 hours. Even with prolonged SPECT scan times 
image quality was poor, and count rates very low. Recalibration of the camera 
had to be performed at these very low count rates in order to validate the scans 
quantitatively. This problem may be overcome by using 1-131 instead of 1-123.1- 
131 has a half-life of 8 days, and radioactive decay over 24 hours will therefore 
be less problematic. 1-131 also appears to have a better labelling efficiency than 
1-123, which should lead to a more satisfactory amount of radiolabel applied to 
MFECP1.
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In summary, there is preliminary evidence to suggest that MFECP1 localises to 
tumour, with one tumour biopsy at approximately 6 hours showing 
immunohistochemical evidence of the presence of CPG2, and gamma camera 
imaging estimating tumour CPG2 enzyme levels to be 0.20U/g at approximately 
6 hours and 0.1 lU/g at approximately 22 hours after commencement of 
MFECP1. These enzyme levels are likely to be capable of activating prodrug. 
Additionally there is a tumour to blood ratio of at least 50:1 at the time of 
prodrug administration, which should provide tumour selectivity.
Administered dose o f MFECP1
In the current clinical study, ZD2767P is administered at approximately 24 hours 
after MFECP1. This time-point ensures that active CPG2 enzyme has cleared 
from systemic tissues, and this is reflected in serum CPG2 levels, which have 
been <0.002U/mL in the majority of patients. However, in some patients this 
enzyme level is attained in serum even as early as 6-8 hours after the 
commencement ofMFECPl. Although quantitative SPECT analysis indicates 
that sufficient CPG2 enzyme for activation of prodrug should be present in 
tumour areas even at 24 hours, this has not yet been confirmed by tumour biopsy.
In preclinical models ZD2767P was administered at 6, 7 and 8 hours post 
MFECP1, whereas currently in the clinical trial ZD2767P is administered at 22- 
24 hours after MFECP1. It may be that at 24 hours there is not sufficient CPG2 
enzyme in the tumour to activate prodrug. Administering ZD2767P at a time- 
point between 6 and 24 hours post administration ofMFECPl is challenging in 
the clinical setting, due to the constraints of medical and nursing staff 
availability, the instability of ZD2767P, which must be administered within 20 
minutes of reconstitution, radiolabelling and gamma camera requirements, and 
the feasibility of tumour biopsies which should be performed within normal 
working hours. The reduction in time between 24 to 6 hours will also have to be 
performed in a careful step-wise fashion, as severe and potentially life- 
threatening myelotoxicity has resulted with much lower ZD2767P doses than are 
currently being used, when activation has occurred through residual enzyme in 
normal tissues.
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An alternative strategy would be to reduce the administered dose ofMFECPl, 
which should result in serum CPG2 levels of <0.002 U/mL at earlier time-points. 
A dose scheduling study has been performed in preclinical models, in which the 
most favourable tumour to normal tissue ratios achieved at 6 hours post 
administration ofMFECPl were for human dose equivalents ofMFECPl of 
2400-3600U/m2 (Table 40) (Data obtained with permission from SK Sharma).
Table 40: Dose scheduling of MFECP1 in preclinical model
MFECP1 dose
MFECP1 dose in mice 15U 20U 30U 60U
‘Human equivalent’ 
MFECP1 dose
1800U/m2 2400U/m2 3600U/m2 7200U/m2
Plasma CPG2 enzyme level 
at 6 hours by HPLC (U/mL)
<0.002 <0.002 <0.002 0.032
Tumour CPG2 enzyme level 
at 6 hours by HPLC (U/g)
0.31 0.95 1.6 2.54
Tumour to plasma CPG2 
ratio
>155:1 >475:1 >800:1 79:1
MFECP1 was administered to nude mice bearing LS174T human colorectal 
cancer xenografts. Plasma and tumour CPG2 enzyme levels were measured by 
methotrexate reduction assay on HPLC at 6 hours after administration, and 
tumour to plasma ratios were calculated. (Data obtained with permission from 
SK Sharma)
Reducing the administered dose ofMFECPl may allow the administration of 
ZD2767P 6-8 hours after commencement ofMFECPl. However, the reduction in 
total administered dose ofMFECPl may be associated with an overall reduction 
in the amount of CPG2 enzyme that is delivered to tumour. Increasing the 
administered MFECP1 dose to 10000U/m2 or even 20000U/m2 should deliver 
more antibody-enzyme to tumour, however it may take longer for serum CPG2 
enzyme levels to fall below 0.002U/mL, and administration of prodrug will 
probably be at 24 hours. This may also be a reasonable strategy, providing there 
is evidence that active CPG2 remains in viable tumour areas at this time-point. 
This would require biopsy confirmation of active CPG2 enzyme in tumour areas 
at 24 hours, with the addition of immunohistochemistry to confirm its location.
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More tumour biopsies in this clinical trial are therefore required to provide 
invaluable information regarding the amount of functional CPG2 enzyme at 24 
hours in the tumour, and will help guide the decision on whether the amount of 
MFECP1 being administered is appropriate for the time of prodrug 
administration.
Dose escalation of ZP2767P
In the previous ADEPT study, the MTD of ZD2767P was attained at 15.5mg/m2, 
which was much lower than predicted based on preclinical models, and likely to 
be too low for efficacy. It was theorised that the slow systemic clearance of 
A5CP lead to circulating CPG2 being present at the time of prodrug 
administrations, and consequently peripheral activation of ZD2767P occurred, 
with resultant toxicity in the form of myelosuppression. The more rapid systemic 
clearance ofMFECPl should obviate this problem, and allow greater dose 
escalation of ZD2767P to occur. Two factors therefore appear to influence the 
amount of active drug generated from ZD2767P; CPG2 enzyme levels and the 
administered dose of ZD2767P.
CPG2 enzyme level
The protocol was designed to have a fixed dose ofMFECPl administered, and 
the dose of ZD2767P prodrug escalated to establish MTD. One incidence of DLT 
(Grade 3 myelosuppression) was experienced at the first dose level of ZD2767P 
(12.42 mg/m2). The serum CPG2 enzyme level prior to ZD2767P administration 
in this patient was 0.0167 U/ml. It is possible that ZD2767P was activated in 
blood at this enzyme concentration, which may have caused this patient’s 
myelosuppression. This patient also had very aggressive malignant disease, with 
bone marrow involvement, which may have contributed to the development of 
myelosuppression.
In the initial phase of this study prodrug was given when the serum enzyme 
concentration was below 0.05 U/ml and subsequently, because of this episode of 
dose limiting myelosuppression, the serum enzyme level at which prodrug could 
be administered was reduced to 0.005 U/ml. This modification was made
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possible by the improvements attained in the HPLC methotrexate reduction assay 
for functional CPG2 activity. The previous ADEPT trial used the Cobas analyser 
for a rapid (within 1 hour) measurement of serum CPG2 enzyme levels however 
it was only sensitive to a CPG2 level of >0.05U/mL. HPLC was required to 
define CPG2 enzyme levels below this however, in the last ADEPT study, the 
HPLC assay took 2-3 hours to attain a result. This would not have been practical 
for this trial as MFECP1 cleared rapidly, and the CPG2 enzyme level had to be 
known within an hour, in order that the decision to proceed with prodrug 
administration could be instigated. Improvements in the efficiency of this assay, 
and extensive validation testing, meant that a 5 minute incubation assay was 
developed, validated to a minimum CPG2 enzyme level o f0.005 U/mL and a 30 
minute incubation assay valid to 0.002 U/mL.
Dose escalation of prodrug was resumed and for Patients #5 to #13 no further 
myelosuppression attributable to ADEPT was observed. To attain this level of 
CPG2 enzyme in the blood, prodrug administration was delayed until the 
following day. There has been no evidence of myelosuppression in these 
patients, and the comet assays performed on peripheral blood lymphocytes 
confirm no convincing evidence of cross-links in the peripheral blood samples, 
which is in keeping with the low levels of myelotoxicity seen.
It appears therefore that at a serum CPG2 enzyme level of < 0.002U/mL no 
significant activation of ZD2767P in the peripheral circulation occurs. This is in 
keeping with in vitro data looking at the level of CPG2 enzyme activity required 
in the serum/plasma of a variety of species to activate an otherwise non-toxic 
dose of ZD2767P to kill 50% of LoVo tumour cells (Table 41).
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Table 41: CPG2 concentration required to activate a non-toxic
ZD2767P concentration and inhibit cell growth by 50%
Media CPG2 concentration (U/ml)
No serum 0.0129 ±0.0037
Foetal calf serum (10%) 0.0129 ± 0.0037
Human plasma (10%) 0.0193 ± 0.0093
Mouse plasma (10%) 0.023 ± 0.0087
Monkey plasma (10%) 0.034 ± 0.0127
The CPG2 concentration required to activate a non-toxic dose o f ZD2767P 
sufficiently to inhibit cell growth o f 50% ofLoVo cells. Each result is the median 
o f 3 experiments. The CPG2 concentration required differs with each different 
species'plasma/serum. The lower the value, the less CPG2 is requiredfor 
activation. (Data obtained, with permission, from D. Blakey and H. Newell).
In 10% human plasma a CPG2 level of 0.0193 U/mL in combination with 
ZD2767P will cause 50% inhibition of growth of LoVo cells. In mouse and 
monkey plasma the CPG2 enzyme levels required are higher than this. It has 
been recognised that ZD2767P in combination with CPG2 is more unstable 
human plasma than with some other species. To counteract continued conversion 
from prodrug to active drug occurring for the pharmacokinetic analysis of 
ZD2767P, rat serum albumin is added to heparinised blood tubes, as ZD2767P in 
combination with CPG2 is more stable in rat serum than in human plasma. As 
ZD2767P activation occurred in 10% human plasma at 0.0193U/ml, it is likely 
that the critical level for significant activation of prodrug in the systemic 
circulation for the purposes of this trial, will occur somewhere between 0.02 and 
0.002U/ml. This is consistent with the clinical data acquired in this trial so far.
The enzyme level in the systemic circulation or in normal tissues is therefore an 
important determinant of toxicity from ADEPT, however, the enzyme level in 
the tumour is a determinant of efficacy. Selective tumour targeting of antibody- 
enzyme is designed to create a differential between functional enzyme levels in 
tumour and normal tissues. This forms a therapeutic window when CPG2 
enzyme levels in the systemic circulation or other normal tissues are below the 
threshold required to activate ZD2767P, whilst sufficient CPG2 enzyme is 
present in tumour to result in prodrug activation. It is likely that the current
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administration schedule of administering ZD2767P, 24 hours after MFECP1 
when serum CPG2 enzyme levels are <0.005 U/ml will avoid systemic prodrug 
activation, however it is not yet clear that sufficient CPG2 enzyme is in tumour 
at this time for activation of prodrug. Based on the data collected in the trial to 
date, a tumour CPG2 enzyme level of 0.11 U/g at 24 hours (SPECT data) should 
be adequate for activation of prodrug, however, as discussed already, tumour 
biopsy data would be desirable to confirm this levels of CPG2 enzyme activity.
A > 50:1 tumour to normal tissue gradient of CPG2 enzyme activity, as appears 
to be the current situation from the data acquired to date, should create a 
sufficient therapeutic window for selective tumour targeting, and allow safe dose 
escalation of ZD2767P prodrug, and potentially efficacy once an adequate 
ZD2767P dose is reached.
ZD2767P dose
The dose levels of ZD2767P prodrug attained in the clinical trial results 
presented here were 12.42 mg/m2 to 33.6 mg/m2. Dose escalation is continuing in 
the clinical trial with doubling of the dose after every two patients. The dose of 
ZD2767P prodrug used in preclinical mouse models was 70mg/kg (210 mg/m2) 
and the aim of the dose escalation scheme is to reach this level in this study. Two 
further patients have been safely treated at 66.2 mg/m2, and one patient at 
132.4mg/m2 without evidence of myelosuppression, at the time of writing of this 
thesis. Dose limiting toxicity for ZD2767P prodrug has not been reached when 
prodrug is administered at the current protocol serum enzyme level (< 0.005 
U/ml). There is therefore a prospect of reaching a prodrug level equivalent to that 
which was necessary for effective therapy of human colon cancer in an animal 
model system.
The ZD2767P pharmacokinetic data can be used to assist in understanding
whether doses of ZD2767P are being achieved that are equivalent to those which
resulted in efficacy in the preclinical studies. As discussed previously the active
drug formed from ZD2767P has too short a half-life to be measured as part of a
clinical trial. The concentration of ZD2767P (in combination with CPG2)
required to be cytotoxic to 50% of LoVo cells in vitro was 0.32pM (Blakey et al,
1996) (table 7, chapter 2). The concentration extrapolated to the time of
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administration (Co) of ZD2767P in plasma from the clinical samples taken at a 
ZD2767P dose of 33.6mg/m2 was 14.3 pg/mL (mean value). Using the molecular 
weight of ZD2767P (as a free base) of 590, this gives a molar concentration of 
0.024pM, which is significantly less than would be expected to result in 
cytotoxicity. A more recent publication by Monks et al has tested the in vitro 
sensitivity of a range of colorectal cancer cell lines and non small cell lung 
cancer cell lines to the combination of ZD2767P + CPG2 (Monks et al, 2002). It 
was found that there was a differential sensitivity between the cell lines ranging 
from a ZD2767P dose (in combination with CPG2) required to inhibit 50% of the 
cells (IC50) of 0.04pM to 2.2 pM (Monks et al, 2002). The most sensitive cell 
line was LS174T. They also looked at the proportion of cells developing DNA 
cross-linking by comet assay, and found that significant levels of cross-linking 
were usually only attained at ZD2767P concentrations (+CPG2) 10-100 times 
higher than the IC50 concentrations (Monks et al, 2002).
This in vitro data would indicate that the concentration of ZD2767P required to 
result in potential tumour efficacy is at least 10-20 times higher than is currently 
being attained with the present administered dose of ZD2767P. It may be 
expected therefore that another 3-4 dose-doublings of ZD2767P may be required 
to reach potentially therapeutic ZD2767P concentrations.
ZD2767P alone has cytotoxicity, although the dose required to attain this is 
approximately 100 fold higher than its active drug (Blakey et al, 1996; Monks et 
al, 2002). If dose escalation continues with only minimal conversion to active 
drug, due to very low CPG2 enzyme levels both systemically and in tumour 
areas, then theoretically a dose may eventually be reached in which the prodrug 
itself has cytotoxicity. This could be tested by administering prodrug alone to 
patients who have toxicity with full ADEPT, as was done in the previous ADEPT 
trial.
In view of the pharmacokinetic data, it is clearly too early in this study to make a
meaningful assessment of efficacy because an optimal prodrug dose has not yet
been achieved, and there has been no attempt at repeated therapy. Stable disease
has been observed in four of 13 assessable patients, and in one patient, with
breast cancer known to be responsive to alkylating agents, this was accompanied
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by stabilisation of tumour markers. [F-18] FDG PET analysis indicated that the 
patients with radiological stable disease, appeared to have metabolic tumour 
progression, further supporting the need to further escalate ZD2767P dose to 
attain therapeutic levels. No tumour biopsies have had sufficient tissue for comet 
analysis, and so evidence of the development of DNA cross-linking indicating 
prodrug activation, has not been attained yet for this trial. The opportunity for 
assessing this should arise as the trial continues, and more tumour biopsies are 
obtained.
In summary, the conditions appear now to have been established to support the 
continued dose doubling of ZD2767P, with the aim of attaining a dose likely to 
result in tumour cytotoxicity.
Repeated therapy
Three of 13 patients made measurable levels of HACPG2A during the period of 
the study (56 days). This contrasts with 26 of 27 patients developing antibody to 
CPG2 at a median of 15 days in the previous study using A5CP (Francis et al, 
2002). The presence of the hexahistidine tag on the C terminus of CPG2 is a 
possible reason for this reduced immunogenicity because this may interfere with 
the immunogenicity of the major B cell epitope of CPG2, CM79, which involves 
the C terminus (2Sharma et al, 2001; Spencer et al, 2002).
There is also no evidence that HAMA has formed with the administration of 
MFECP1. The ELISA used to assess for the presence of HAMA is against A5B7 
as there is no positive control for MFE-23, as no human antibodies have yet been 
produced against MFE-23 in the two clinical trials in which it was used (Begent 
et al, 1996; Mayer et al, 2001). A5B7 is also a murine antibody, and it is possible 
that antibodies to MFE-23 if formed would be cross reactive with A5B7. This is 
not entirely satisfactory, as antibodies directed specifically against epitopes 
unique to MFE-23 may be missed. In order to try and minimise this problem 
ELIS As were also performed against MFE-23, using the pre treatment serum and 
post -treatment serum of the same patient, in the same ELISA plate. No clear 
evidence of increasing optical density after treatment with MFECP1 was found 
in any of the 13 patients, thereby providing some reassurance that immune
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complex formation between MFE-23 and antibodies in human serum was 
unlikely to have occurred (SK Sharma, personal communication).
The low immunogenicity of MFE23 may be due to its small molecular size, 
resulting in a minimal amount of murine protein exposure. The protein folding of 
MFECP1 may also protect MFE-23 from immune exposure. In addition the 
presence of glycosylations may be assisting in its escape from immune activation 
by initiating rapid hepatic clearance and catabolism ofMFECPl or by shielding 
potentially immunogenic sites.
MFECP1 therefore presents a potentially unique opportunity to be able to 
administer repeated therapy with ADEPT without the need for 
immunosuppressive treatment. This is very encouraging as preclinical studies 
confirm that repeated therapy with ADEPT results in improved efficacy, with no 
significant additional toxicity, as assessed by weight loss. The average tumour 
growth delays in LS174T xenograft model with single cycle of ADEPT was 9 
days and with repeated cycle ADEPT, in which 3 cycles were administered 5-7 
days apart, average tumour growth delays of 21 days were achieved. The 
important advantage of the MFECP1 ADEPT system pre-clinically is its greatly 
reduced toxicity compared to A5CP. ADEPT with A5CP causes significant 
weight loss, which prevents administration of repeated therapy for a 14-day 
period. However, ADEPT with MFECP1 does not cause this weight loss, and 
allows 3 cycles of therapy to be administered within 14 days without toxicity.
The scheduling ofMFECPl would need to be considered if repeated therapy was
to be undertaken. Myelosuppression with ADEPT has, in the clinical trials
performed to date, occurred with a nadir at 4-6 weeks, which is later than with
conventional chemotherapy. It may be therefore argued that ADEPT cycles
should be 4-6 weeks apart, to ensure additive toxicity does not result. However
this may limit the number of cycles that could be administered before
immunogenicity results. The alternative would be to administer a dose that does
not cause myelosuppression (ie: a dose below MTD) and administer ADEPT
cycles more frequently, such as two or three times a week. This may allow the
administration of six or more cycles before immunogenicity develops. This
disadvantage of this approach may be that less prodrug is administered on each
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occasion, so efficacy may be compromised, and bone marrow toxicity may 
accumulate and potentially be more severe. As the trial progresses and more data 
is collected on the tolerability of ADEPT at higher ZD2767P doses, it may 
become more apparent as to which strategy should be undertaken. The preclinical 
evidence suggests, however, that repeated therapy may be required for significant 
therapeutic efficacy to result from ADEPT.
Mechanistic studies
The mechanistic studies incorporated into this trial protocol have provided data 
necessary to make informed decisions during the trial, and will help the 
interpretation of the clinical data in order to rationally modify ADEPT for the 
future.
In particular the decisions regarded optimal timing of administration of prodrug 
could not have been made without the serum CPG2 enzyme measurements, or 
the gamma camera data. The serum CPG2 enzyme measurements were required 
to define a limit for when ZD2767P could be administered to avoid activation in 
the systemic circulation, and the gamma camera imaging was used to quantify 
tumour enzyme levels, and to confirm that there were no unexpected areas of 
uptake ofMFECPl. The ZD2767P pharmacokinetic data provided guidance on 
how close the dose levels reached in the trial were to attaining similar 
pharmacokinetic profile to those associated with efficacy in preclinical models. 
The comet assay, as an indirect indicator of prodrug activation, has confirmed no 
significant DNA cross-linking in circulation lymphocytes, in agreement with the 
low levels of toxicity attained so far, and will be used to assess whether any 
evidence of prodrug activation can be seen in tumours from biopsy specimens. 
Immunogenicity data is a requirement for assessing the feasibility of 
administering ADEPT repeatedly. [F-18] FDG PET data confirms that there is 
not yet any evidence of metabolic response to ADEPT, further supporting the 
need for further dose escalation of ZD2767P.
Without the mechanistic data, dose escalation of ZD2767P would have been 
slowed to 30% at the first dose level. However, by being able to measure the 
serum CPG2 enzyme levels, and make decisions on the timing of administration
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of ZD2767P based on these, dose escalation has been able to safely continue at a 
dose -  doubling rate. This is an important concept, as without this mechanistic 
data, the clinical trial may have been halted due to the development of early 
toxicity. The ZD2767P dose level required for efficacy appears to be 
significantly higher than 12.42 mg/m2, and stopping the trial at a dose around 
12.42 mg/m2 would have been premature.
A two year interval between completion of the previous ADEPT clinical trial and 
commencement of this one is rapid given the requirement of having to develop a 
new targeting system. This is an advantage of mechanistic trial design, as by 
allowing the identification of factors which are likely to improve the efficiency 
and efficacy of a system, these factors can be focussed on and modified, rather 
than blindly having to alter the system. This should ultimately speed up drug 
development times.
The mechanistic data collected in this trial has therefore provided the means to 
allow examination and interpretation of the hypotheses proposed at the inception 
of this clinical trial. The mechanistic studies have defined the conditions required 
to allow safe escalation of ZD2767P to dose levels beyond those attained in the 
previous ADEPT trial. By defining these conditions, dose escalation has been re­
initiated at a dose-doubling rate, which should accelerate the speed at which 
potentially efficacious dose levels of ZD2767P are reached. The mechanistic 
studies will also be used to obtain data for directing modifications to ADEPT for 
the future.
4.5 Conclusion
Data is presented on thirteen patients treated with ADEPT with MFECP1 in
combination with ZD2767P prodrug. MFECP1 has fulfilled its design potential
of low toxicity, rapid blood clearance and low immunogenicity. There is some
preliminary evidence to suggest that adequate tumour localisation is occurring,
however further tumour biopsies and gamma camera data are required to define
this further. Administration of ZD2767P prodrug is possible at higher doses than
were achieved previously, provided that serum enzyme levels are below 0.005
U/ml. Dose escalation of ZD2767P prodrug is currently continuing with the
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potential, in three more dose levels, to reach the levels of prodrug that were 
effective in human colon carcinoma xenografts in mice. The low 
immunogenicity ofMFECPl allows the possibility of repeated therapy, without 
the requirement for immunosuppressive therapy. These data provide the basis for 
continuing dose escalation of ZD2767P to define MTD, and for then proceeding 
as proposed to a repeated therapy component of this clinical trial, in which 
efficacy may be more meaningfully assessed.
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5 [F-18] FDG PET for response assessment
5.1 Background
The assessment o f efficacy is an essential component in the development of new 
cancer therapeutics. The current accepted method of response assessment is by 
dimensional change in tumour size on conventional radiological imaging. This is 
discussed in detail in Chapter 1. This method of assessing efficacy has several 
limitations including not being able to define viable tumour from necrotic tissue 
or fibrosis, difficulty with measuring lesions that are poorly delineated, problems 
with representing three dimensional tumour volumes in two dimensions, 
insensitivity to the biological anti-tumour effect of treatments and measurement 
inconsistencies.
[F-18] FDG PET scans in contrast, by representing glucose metabolism, provide 
both a metabolic and a morphological assessment o f tumours (see Chapter 1). 
Tumours are extremely heterogeneous, and this heterogeneity is well represented 
on [F-18] FDG PET scans, as they reflect the viable tumour mass. Necrotic 
centres can be seen as ‘cold’ areas surrounded by a ‘hot’ viable ring (Figure 44). 
Even within the viable tumour mass there are variations in the degree of 
metabolic activity.
Figure 44: [F-18] FDG PET image
Gamma camera [F-18] FDG PET image showing a transverse slice through the 
liver o f a patient with a large liver metastasis from colorectal cancer. The 
heterogeneity o f [F-18] FDG uptake throughout the metastasis is apparent. 
There is an outer rim o f increased [F-18] FDG activity and a ‘cold’ necrotic 
core.
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[F-18] FDG PET scans are quantitative 3 dimensional images and therefore 
tumours may be assessed in terms of shape, volume and intensity. This is of 
particular value in the assessment of change with therapy in a heterogeneous 
tumour mass. In addition, as [F-18] FDG uptake represents viable tumour, a 
reduction in uptake may be an earlier and more sensitive method of assessing the 
efficacy of a treatment than radiological imaging.
5.1.1 Methods of assessing response using [F-18] FDG PET
One of the current limitations to the more widespread use of [F-18] FDG PET for 
response assessment is the lack of consensus on how change in tumour [F-18] 
FDG uptake after therapy should be measured. The current methods of 
assessment of response to chemotherapy with [F-18] FDG PET are visual 
analysis, semi-quantitative techniques and kinetic modelling.
Visual analysis
Visual analysis is a process of visually comparing the tumours seen on an [F-18] 
FDG PET performed pre-treatment with one performed post treatment in the 
same patient. Visual analysis depends on the change in tumour compared to 
background tissue (Hoekstra et al, 2000). It is a subjective method, and therefore 
may have problems with reproducibility, reliability, and operator experience and 
fatigue. It is difficult to quantify visual changes, and therefore visual analysis 
may be of limited use in clinical trials of efficacy.
Semi-auantitative techniques
The standardised uptake value (SUV) (also called dose uptake ratio -  DUR) is a 
semi-quantitative technique that has been widely adopted for quantitation of 
intensity of [F-18] FDG uptake in tumours. It is a value derived from the mean 
tumour radiotracer concentration (MBq/L), which is then corrected for injected 
activity (MBq) and body weight (kg) (Figure 45).
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Figure 45: SUV equation
8  x rQini
Abbreviations:
S U V b w - standardised uptake value correctedfor body weight 
Q- radiotracer concentration in tissue (MBq/L)
W - body weight o f patient (kg)
Qinj -  injected activity o f  [F-18] FDG (MBq)
SUV measurements are performed on scans obtained from dedicated PET 
scanners, and are only suitable for images that have had measured attenuation 
correction applied. A region of interest (ROI) is placed within an area of tumour 
and an SUV obtained pre and post treatment. A reduction in SUV indicates a 
response to treatment and an increase in SUV indicates tumour progression. SUV 
analysis is performed on static PET images, which are acquired after [F-18] FDG 
uptake into cells is complete (‘plateau phase’). This is usually assumed to be at 
60 minutes after injection.
SUV is a simple method that is suitable for widespread use, however, it has 
several limitations. A correction is applied for body weight or body surface area; 
however this is not particularly relevant when serial scans are performed in the 
same patient, as there body weight does not usually change greatly between 
scans (Kim et al, 1994; Kim and Gupta 1996). There is no correction for blood 
glucose level, or time to scanning, both of which may significantly affect SUV 
measurements (Langen et al, 1993; Keyes, 1995). There is no agreement on the 
size or placement of ROI, or whether mean or maximum counts/voxel should be 
recorded. Also there is no correction for partial volume effects, which occur 
particularly in lesions less than twice the resolution of the PET scanner (Young 
et al, 1999). In addition, SUV values account for tumour intensity alone, and do 
not represent any change that may occur in tumour volume or mass with therapy. 
Despite these limitations SUV is currently the most frequently used method of 
reporting response on [F-18] FDG PET scans.
Tumour to background ratios are based on a similar technique to SUV, however
ROI are placed on tumour areas and on background ‘normal’ tissues. These are
then compared between pre and post treatment scans. Attenuation correction is
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not necessarily required for this type of analysis (Imran et al, 1998). This 
technique is limited by the arbitrary placement of ROI (as with SUV) and the 
possibility that normal tissues may change with chemotherapy, thereby 
influencing the tumour to background measurement (Hoekstra et al, 2000).
Kinetic analysis
Kinetic analysis is performed on dynamically acquired [F-18] FDG PET scans. 
This involves measuring the metabolic rate of glucose within tumours over time. 
It has been most widely used for cerebral PET, but has also been used for whole 
body PET (]Wahl et al, 1993; Romer et al, 1998; Smith et al, 2000; Choi et al, 
2002; Spence et al, 2002). Kinetic analysis is complex and time-consuming, and 
is unlikely in its current form to be suitable for routine use. It also has several 
areas of potential inaccuracies, including not accounting for tumour 
heterogeneity, the assumption that intracellular dephosphorylation of [F-18] FDG 
is negligible and the assumption that the cellular transport and phosphorylation 
of [F-18] FDG is equivalent to glucose (lumped constant =1) (Hoekstra et a/,
2000). Also it requires arterial blood sampling, which is laborious and not 
practical out of the research environment.
5.1.2 Gamma camera [F-18] FDG PET
Most studies of response assessment to chemotherapy have been performed with 
dedicated PET systems. Gamma camera PET is a versatile and affordable 
alternative to dedicated PET, particularly for centres without an on-site 
cyclotron. Its reduced sensitivity may limit its clinical applicability; in terms of 
staging or lesion detection, however, it should not limit its capability to reflect 
change in a visible tumour mass after therapy. The potential widespread 
availability and multifunctionality of gamma camera PET means it could feasibly 
be accessible on a much greater scale than dedicated PET, and thereby applicable 
to both research and clinical settings.
Studies have shown that the differences in lesion detection between gamma 
camera PET and dedicated PET are more apparent for lesions < 1.5cm (Ak et al,
2001). This is particularly problematic for small lung lesions when gamma
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camera PET is performed without attenuation correction. Therefore the 
utilisation of gamma camera [F-18] FDG PET for response assessment should be 
feasible, providing the lesions followed are of a size that is appropriate for the 
resolution of the camera.
At the time this work was undertaken there were no published studies using 
gamma camera [F-18] FDG PET to assess response to chemotherapy. One study 
has since been published using visual analysis to assess response to 
chemotherapy and predict prognosis in patients with aggressive non-Hodgkin’s 
and Hodgkin’s lymphoma using gamma camera [F-18] FDG PET (Kostakoglu et 
al, 2002). There remains no published quantitative method of assessing response 
to chemotherapy using gamma camera [F-18] FDG PET.
5.1.3 Quantitative gamma camera [F-18] FDG PET analysis to assess 
response to chemotherapy
It was proposed that a new method of defining tumour regions and of analysing 
change in these tumour regions was required to assess response to chemotherapy 
using gamma camera [F-18] FDG PET. It was desirable for the tumour regions 
obtained to represent both tumour morphology and intensity of metabolic 
activity, and the analysis of change to also reflect change in both of these 
parameters. It was hypothesised that this may represent an improvement over 
methods of analysis that only take into account changes in tumour [F-18] FDG 
intensity.
Once the methodology was developed it was proposed that it would be validated 
in a series of patients receiving conventional chemotherapy, and compared with 
other measurements of assessment of response including CT scans, tumour 
markers and patient outcome measures such as survival. It was also proposed to 
ascertain if response to chemotherapy could be predicted using this methodology 
after 2-4 weeks of treatment, and to ascertain if gamma camera [F-18] FDG PET 
scans were of value in the interpretation radiological stable disease.
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5.2 Development of a novel method of assessing change in tumour [F-18]
FDG uptake with therapy
5.2.1 Method
The two components required to assess response to therapy using [F-18] FDG 
PET were:
a) a method of delineating tumour regions which was reproducible, 
objective and representative of both tumour morphology and metabolic 
activity
b) a means of quantitating change in tumour regions between scans that 
takes into account changes in tumour size and changes in intensity of [F- 
18] FDG uptake
Automated programs were developed for both these components by Dr Alan 
Green, using a programming interface installed on the AD AC workstations 
called Provision, which provides an interface between the nuclear medicine 
imaging system and the C++ programming language. The development process 
for the region defining program was conjoint work between myself and Dr Alan 
Green, in consultation with Professor Richard Begent. The concept of a 
histogram method of analysis was initially derived from Dr Peter Amlot, and 
then implemented by Dr Alan Green.
5.2.2 Results 
Delineation of tumour volumes
An automated iterative adaptive threshold based region program was developed 
to delineate tumour volumes in an objective and reproducible way. This is a 
mathematically derived methodology which requires an operator to identify the 
tumour and then place a seed-point anywhere within the tumour area. The 
operator then defines a threshold value (a percentage). The tumour region will 
grow contiguously from the seed-point to including any voxels with counts/voxel 
above the current threshold. The mean is recalculated after each iteration and the
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threshold percentage value reapplied. This process continues until no further 
voxels can be drawn. To ensure reproducibility, once the final volume is defined, 
the region is re-grown from the maximum count/voxel, outwards. This ensures 
that wherever the seed-point is placed within the tumour the same region will 
always be grown.
The principles of the automated region growing program are represented 
diagrammatically in Figure 46. Figure 47 displays a tumour volume drawn by 
the program. The tumour regions drawn by this method are termed volumes of 
interest (VOI).
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Figure 46: A utom ated region growing program
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Diagrammatic representation o f  the automated region-growing program. Each 
square represents a voxel with the counts in that voxel represented numerically. 
The seed point is chosen within a tumour area, which is seen as a 'hotspot ’ on 
the scan. The program then generates regions by assessing contiguous voxels to 
ascertain if  their value is above the current nominated threshold. This threshold 
is adaptive -  it changes with each new region formed, to remain constantly 85% 
of the current mean o f  the region.
Green squares are those which are included in the tumour VOI, blue squares 
represent the contiguous voxels with counts above the current threshold (will be 
included in VOI), orange squares represent contiguous voxels with counts below 
the current threshold (will not be included in tumour VOI). The tan squares 
represent the remainder o f  the voxels.
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Figure 47: VOI region generation
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Figure 47 a) displays consecutive cross-sections o f a patient with liver 
metastases from colorectal cancer with the VOI generated from the automated 
region growing program. Figure 47 b) displays a projected view from the 3- 
dimensional data set o f  the PET scan in the same patient, with the tumour VOI 
created from the automated region growing program.
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Quantitating change in tumour uptake of [F-181 FDG
Once the tumour areas have been delineated a method is required to assess if 
change has occurred between scans. This should take into account changes that 
may occur in tumour intensity and size.
Lesion statistics can be generated from the tumour volumes derived from the 
automated region-growing program. The statistics generated and how they 
represent the tumour is shown in table 43.
Table 43: Lesion statistics
Lesion statistic Represents in tumour
Number of voxels Size (volume) of tumour
Mean counts/voxel Intensity of metabolic activity
Maximum counts/voxel Maximal intensity of metabolic activity
Total counts Total tumour [F-18] FDG uptake
An alternative method of representing change in the tumour regions after therapy 
is to plot histograms of the tumours, with the x axis representing counts/voxel 
and the y axis the number of voxels (figure 48). This gives a representation of 
the distribution of counts within the tumour and how the counts change with 
therapy. Changes in the ‘count density histogram’ are more difficult to quantity 
than simple lesion statistics, but they do provide an overall view of the change in 
count distribution in a tumour with therapy.
Both the lesion statistics and the count density histograms will be used in the [F- 
18] FDG PET response assessment study.
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Figure 48: Count density histogram
F're treatment 
Post 1 
Post 2
Count density histograms displaying the change in [F-18] FDG uptake in a 
tumour after chemotherapy. The x axis is the number o f counts per voxel, and the 
y  axis is the number o f voxels with that number o f counts per voxel The red line 
represents the tumour histogram prior to receiving chemotherapy, the green 
histogram is after 3 weeks o f chemotherapy, and the yellow histogram is after 12 
weeks o f chemotherapy. The area under the curve (AUC) represents tumour 
volume.
There has been a shift o f  the peak to the left over the 12 weeks, indicating a 
reduction in intensity o f  the tumour. There us also a reduction in the AUC o f the 
histograms, representing a reduction in volume o f the tumour after therapy.
These histograms would therefore be indicative o f a tumour response to 
chemotherapy.
5.3 [F-18] FDG PET response assessment study
5.3.1 Trial outline 
Trial aims
The trial was designed to assess the measurement of response to chemotherapy 
using gamma camera PET, in a broad range of tumour types and over a variety of 
expected tumour responses, in order to validate the automated region growing 
program, the VOI lesion statistics and histogram methods of analysis. In addition 
the trial aimed to determine whether changes in tumour [F-18] FDG uptake 
predict response to chemotherapy after only 2-4 weeks of treatment, and to 
ascertain whether gamma camera [F-18] FDG PET can assist in the interpretation
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of radiological ‘stable disease’. The assessment of response to chemotherapy on 
[F-18] FDG PET was compared to conventional response criteria including 
radiological imaging, WHO performance status, tumour markers and patient 
outcome.
Patient selection
Thirty-one patients with advanced or metastatic solid tumours, who were to 
receive chemotherapy with standard first or second line regimens, were recruited 
into the study. The study had Administration of Radioactive Substances 
Advisory Committee (ARSAC) approval and Local Research Ethics Committee 
(LREC) approval. The eligibility criteria included age >18 years, WHO 
performance status 0, 1 or 2, life expectancy of >9-12 weeks and serum 
creatinine <150 mmol/L. Patients were also required to have measurable disease 
by conventional radiological imaging according to the RECIST criteria. Patients 
were excluded if they were pregnant, had uncontrolled diabetes or any other 
significant co-morbidity which may prevent them from completing the study. 
Patients were required to sign a consent form for the study, and were made aware 
that the [F-18] FDG PET scan results could not be used to influence their 
clinician’s management decisions regarding efficacy of therapy.
Treatment schedule
Patients had conventional imaging and serum tumour marker measurements 
performed within 2 weeks prior to commencing chemotherapy and again after 9- 
12 weeks of treatment (after 6 cycles of chemotherapy for 2 weekly regimens, 
and 3 cycles of chemotherapy for 3 or 4 weekly regimens). [F-18] FDG PET 
scans were performed within 2 weeks prior to commencing chemotherapy, at 2-4 
weeks after the commencement of treatment (after 2 cycles of chemotherapy for 
2 weekly regimens, and after 1 cycle of chemotherapy for 3 or 4 weekly 
regimens) and again at 9-12 weeks (after 6 cycles of chemotherapy for 2 weekly 
regimens, and 3 cycles of chemotherapy for 3 or 4 weekly regimens). Patients 
were followed until the completion of their chemotherapy. Additional 
radiological imaging and tumour marker measurements were recorded every 9- 
12 weeks for patients who proceeded with chemotherapy, until chemotherapy
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was completed. The trial protocol stipulated that the [F-18] FDG PET scan 
results would not be used to influence management decisions.
1F-181 FDG PET scans
Patient preparation
Patients were asked to fast for 5 hours prior to injection of [F-18] FDG. [F-l 8] 
FDG was acquired from a commercial offsite cyclotron. 130MBq of [F-18] FDG 
was administered, and scans were commenced at 90 minutes post injection. 
Patients were rested after injection. Patients with pelvic tumours had 20mg 
intravenous frusemide administered at the time of [F-18] FDG injection. Blood 
sugar levels were recorded by dextrostix and by a laboratory blood sugar 
measurement taken from the time of [F-18] FDG injection. Patients had their 
height and weight measured on each visit.
Once chemotherapy had commenced, [F-18] FDG PET scans were scheduled to 
be performed at least 1 week after the administration of chemotherapy in order to 
try and prevent false positive results due to a ‘tumour flare’ reaction to 
chemotherapy.
[F-18] FDG PET Scan protocol
[F-18] FDG PET scans were performed on an AD AC Vertex Plus dual headed 
gamma camera 90 minutes after injection of [F-18] FDG. Transmission and 
emission scans were acquired. The full width half maximum (FWHM) for the 
camera was 4.8mm (manufacturer’s specifications). Emission scans had a 
50.8cm field of view and were acquired according to the manufacturers 
recommendations. Correction for decay was applied on the fly. Transmission 
scans were performed with Caesium-137 point sources. Most patients had 2 
rotations performed; however some patients required 3 rotations. The set-up 
position of the patient was recorded and each subsequent scan utilised the same 
set-up procedure. Scan protocols were kept consistent in the same individual 
patient on subsequent scans.
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Reconstruction was performed using standard AD AC iterative reconstruction 
protocols, with correction for attenuation and scatter. A rescaling factor was 
applied to the images prior to analysis. The rescaling was for injected dose of [F- 
18] FDG, time to scanning and frame time of the scans. The frame time was 
always kept constant, and so the only variables were injected dose of [F-18] FDG 
and time to scanning. The correction for time to scanning was for radioactive 
decay that occurs due to the short half life of [F-18] radioisotope. The formula 
for the correction factor is shown in figure 49.
Figure 49: Correction factor applied to [F-18] FDG PET scans
prior to analysis 
cf= A*B*C
where
A = activity[MBq]To / activity[MBq]Tx
B = EXP {(At (mins)To -  At (mins) T, )*(LN(0.5))/tV2FDG}
C = frame (secs)To/ frame (secs)Tx
Abbreviations: c f -  correction factor; activity -  injected activity; To -  baseline 
scan; Tx - subsequent scan; EXP -  exponential; At -  time between injection and 
commencement o f scan; mins -  minutes; L N - log; ttt [F-18] FDG -  half-life o f 
FDG (factor used was 109.2 minutes); frame -  time per frame during scan; secs 
- seconds
A  formal correction for blood glucose levels was not made, however data with 
blood glucose levels outside the range 4-7mmol/L were deemed unreliable. 
Patient weights were recorded for each scan; however no formal correction for 
weight was applied.
Previous validation studies of the camera demonstrated a non-linear relationship 
between activity (MBq) and measured counts/voxel at high singles count rates 
due to dead-time effect due to detector flooding (Green et al, 1999). All patients 
were therefore scanned within the quantitative range, aiming for a singles count 
rate of approximately 700kcps.
Scanning at 90 minutes post injection was adopted to try and ensure scanning at a 
time when glucose uptake in to tumours was complete (plateau phase). Scanning
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at later time points than this was impractical, as [F-18] FDG was obtained from 
an off-site supplier, and was not received until the afternoon.
Patient’s [F-18] FDG PET scan conditions including the injected activity, time to 
scanning, patient set-up position, scan protocols and image reconstruction 
methods were all kept as consistent as possible in serial scans, in order that these 
factors would not influence tumour [F-18] FDG uptake results.
5.3.2 Methods
Radiological assessment
Radiological response assessment was performed according to the RECIST 
criteria (Therasse et al, 2000). A Radiologist, who was unaware of the patient’s 
clinical course, performed the analysis.
Tumour markers
Relevant tumour markers (CEA, CA19-9, CA15-3 or AFP) were measured prior 
to the commencement of chemotherapy, and repeated every 9-12 weeks whilst 
chemotherapy continued.
1F-181 FDG PET analysis
Automated region generation /  VOI generation
Tumour volumes were defined on the corrected images, using the automated 
region-growing program discussed above. The threshold used was 85% at all 
times. Each individual tumour site had a seed point placed in it, to draw each 
individual tumour volume. The tumour volumes (at all sites) were then all added 
together to obtain final VOI.
A modification of this method, termed ‘VOI subtraction’, was also used. This 
involved defining the initial VOI as described above, and then subtracting this 
tumour volume from the scan, followed by reapplying the automated region 
growing program to the new image. Subtraction was applied until all tumour 
areas were defined. The final region obtained was termed ‘VOI subtraction’.
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Normal tissue volumes were also defined, by placing a seed point in normal 
liver, lung or chest wall, and the automated region growing program generating 
regions based on +/- 20% threshold of the current mean.
Lesion statistics
Lesion statistics were calculated from the final VOI for each time-point. The 
lesion statistics used were tumour volume (total number of voxels), mean 
counts/voxel, maximum counts/voxel and total counts. The change in each lesion 
statistic was then displayed as a percentage change compared to baseline. If a 
tumour’s [F-l 8] FDG uptake reduced the value was <100% and if it increased it 
was >100%.
Histogram analysis
Tumour volumes of interest were defined as above and then displayed as count 
density histograms, with the counts per voxel on the x-axis, and total number of 
voxels on the y-axis. The histograms were displayed before and after 
chemotherapy to assess change.
Normal tissue volumes of interest were also plotted on the count density 
histogram to assess the degree of variation in background tissues between scans.
Overall Survival
The overall survival of patients was recorded, and the survival time in days 
calculated from the first day of commencing chemotherapy. Kaplan Meier 
analysis and log rank analysis were performed on this data using Prism software.
5.3.3 Results
Patient demographics
Thirty-one patients were recruited into the study over a two-year period 
commencing in July 2000. The demographics of the patients are listed in Table 
44.
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Table 44: Patient demographics
Pt
No.
Age
(yrs)
Gender
(M/F)
Primary
tumour
Site of 
metastasis
1st or 2°* 
line chemo
Chemo
type
Schedule
(weekly)
#1 60 M Oesophageal Local recurrence 
Subcut nodules
1st Taxol 3 wkly
#2 57 M Colorectal Liver 1st Irino/ 5FU 2 wkly
#3 55 M Colorectal Liver 1st Irino/5FU 2 wkly
#4 56 F Colorectal Liver 1st Irino/ 5FU 2 wkly
#5 52 M Pancreatic Local recurrence 1st Gem 4 wkly
#6* 69 M Pancreatic Local recurrence 1st Gem 4 wkly
#7 70 M Colorectal Liver, presacral 1st 5FU/ oxali 2 wkly
#8 63 M Colorectal Liver 1st Irino/5FU 2 wkly
#9 62 M HCC Lung, liver 1st Cis/ 5FU 2 wkly
#10 53 F Colorectal Liver 1st Irino/ 5FU 2 wkly
#11 49 M Oesophageal Lung, bone, 
adrenal
2nd ELF 4 wkly
#12 56 M Colorectal Lung, liver 1st 5FU/ oxali 2 wkly
#13 60 M Oesophageal Local recurrence 1st ECF 3 wkly
#14 63 M Colorectal Lung, liver 1st 5FU
(MdG)
2 wkly
#15 73 M Colorectal Liver 1st 5FU
(MdG)
2 wkly
#16 58 F Colorectal Liver 1st 5FU/ oxali 2 wkly
#17 37 F Breast Liver 2nd Taxotere 3 wkly
#18 45 M HCC Lung 1st 5FU/ cis 2 wkly
#19 46 F HCC Liver 1st 5FU/ cis 2 wkly
#20 68 M Colorectal Lung 1st 5FU
(MdG)
2 wkly
#21 60 M Colorectal Lung, liver 2nd Irino/ 5FU 2 wkly
#22 58 F Colorectal Liver 1st 5FU
(MdG)
2 wkly
#23 67 F Breast Liver, bone 1st ECF 3 wkly
#24 45 F Unknown Lung, liver, 
bone, paraortic 
LN
2nd Irino/ 5FU 2 wkly
#25* 34 F Breast Lung, bone, 
brain
2nd CMF 3 wkly
#26 43 F Lung Lung,
mediastinal LN
1st Gem/carb
0
3 wkly
#27 77 F Colorectal Liver 1st capecitabi
ne
3 wkly
#28 71 F Colorectal Liver, lung 2nd Irino/ 5FU 2 wkly
#29* 52 M Pancreatic Liver 1st Gem 4 wkly
#30 74 M Colorectal Liver, lung 2nd Oxali/
5FU
2 wkly
#31 65 F Breast Lung, liver, 
ovary, ascites, 
paraumbiliacal
2nd Paclitaxel 3 wkly
Abbreviations: M-male, F-female; chemo -  chemotherapy; HCC -  
hepatocellular carcinoma; L N -  lymph node; irino -  imotecan; 5FU- 5 
fluorouracil; MdG -  modified de Gramont; gem -  gemcitabine; oxali -  
oxaliplatin; CM F- cyclophosphamide, methotrexate andfluorouracil; carbo -  
carboplatin; cis -  cisplatin; ECF -  epirubicin, cisplatin and fluorouracil; ELF-  
epirubicin, leucovorin andfluorouracil 
* diabetic
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There were eighteen males and thirteen females. The median age was 58 years 
(range 34-77 years). Three patients were diabetic. The patient group was derived 
from a range of primary solid tumour types; sixteen patients had colorectal 
carcinoma, three patients had oesophageal carcinoma, four patents had breast 
cancer, three patients had pancreatic carcinoma, three patients had hepatocellular 
carcinoma, one patient had non-small cell lung cancer and 1 patient had an 
unknown primary (suspected oesophageal).
Twenty-eight patients had metastatic disease, and three patients had advanced 
local disease or local recurrence, unsuitable for curative resection. Twenty-three 
patients were having first-line chemotherapy, and eight patients were having 
second-line chemotherapy. Multiple chemotherapy regimens were used, with 
nineteen patients having 2 weekly treatment and twelve patients having 3 or 4 
weekly cycles.
Radiological assessment
The response to chemotherapy according to radiological assessment by RECIST 
criteria is listed in Table 45.
Table 45: Radiological response to chemotherapy (RECIST)
RECIST
response
9-12 week assessment 18-24 week assessment
Total Pt No. Total Pt No.
CR 0 0
PR 7 #8, #15, #16, #17, #21, 
#22,#26
6 #4, #8, #16, #17, #21, 
#31
SD 15 #2, #3, #4, #5f, #6, #9, 
#10, #12, #14, #19, #20, 
#23, #25, #27, #31
4 #6, #14, #25, #27
PD 5 #11, #24, #28, #29*, 
#30*
0
NA 4 #1, #7, #13, #18 21 #1-3, #5, #7, #9-13, 
#15, #18-20, #22-24, 
#26, #28-30
Abbreviations: CR -  complete response; PR -partial response; SD- stable 
disease; PD- progressive disease; NA -  not assessable 
f  measured by ultrasound 
* progression due to appearance o f new lesions
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Twenty-seven patients had a radiological response assessment performed at 9-12 
weeks. In all patients this was performed using spiral CT, except for patient #5, 
who was assessed by ultrasound. There were no complete responses seen, seven 
patients attained a partial response, fifteen patients had stable disease, and five 
patients fulfilled the RECIST criteria for disease progression. Two of the patients 
who had disease progression by RECIST criteria developed new lesions on CT, 
without significant increase in dimensional size of lesions. Four patients did not 
have a 9-12 week response assessment performed; patients #1 and #18 died prior 
to having a response assessment performed, patient #13 had radiotherapy 
performed and was taken off study and patient #7 was found to have non- 
measurable disease on MRI of pelvis and no formal response assessment by 
radiological criteria could be performed.
Ten patients went on to have an 18-24 week radiological response assessment. 
Six patients attained a partial response and four patients had stable disease.
Tumour markers
Table 46 displays the tumour marker results for all patients, and compares them 
to the RECIST radiological assessment.
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Table 46: Tumour markers
Pt RECIST RECIST CEA (mmol/L) CA19-9 (Units/L)
ID (9-12 wks) (18-24 wks) Pre 9-12 wks (% of pre) 18-24 wks (% of pre) Pre 9-12 wks (% of pre) 18-24 wks (% of pre)
#1 NA NA No assessable tumour markers
#2 SD NA 242 130 (54%) 86 (36%) 1152 613 (53%) 294 (26%)
#3 SD NA No assessable tumour markers
#4 SD PR 18006 8864 (49%) 9385 (52%) 1572 937 (60%) 1194 (76%)
#5 SD NA No assessable tumour markers
#6 SD SD No assessable tumour markers
#7 NM NM NA NA NA 45 4 (9%) NA
#8 PR PR 651 12 (2%) 16 (2%) 5624 i 127 (2%) 106 (2%)
#9 SD NA No assessable tumour markers
#10 SD NA 846 2223 (263%) NA 2578 4789 (186%) NA
#11 PD NA 252 834 (331%) NA NA NA NA
#12 SD NA 81 320 (395%) NA NA NA NA
#13 NA NA No assessable tumour markers
#14 SD SD 745 422 (57%) 504 (68%) 379 372 (98%) 620 (164%)
#15 PR NA 463 16.3 (4%) NA NA NA NA
#16 PR PR 293 28 (10%) 11 (4%) 272 123 (45%) 85 (31%)
#17 PR PR No assessable tumour markers
#18 NA NA No assessable tumour markers
#19 SD NA NA NA NA 729 332 (46%) NA
#20 SD NA No assessable tumour markers
#21 PR PR No assessable tumour markers
#22 PR NA 277 128 (46%) NA NA NA NA
#23 SD NA No assessable tumour markers
#24 PD NA 63 360.9 (573%) NA NA NA NA
#25 SD SD No assessable tumour markers
#26 PR NA No assessable tumour markers
#27 SD SD 302 167.4 (55%) 61 (20%) NA NA NA
#28 PD NA 30.4 146.1 (481%) NA NA NA NA
#29 PD NA No assessable tumour markers
#30 PD NA 773 974 (126%) NA 678 933 (138%) NA
#31 SD PR No assessable tumour markers
Abbreviations: CR -  complete response; PR -partial response; SD- stable disease; PD- progressive disease; NA -  not applicable
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Fourteen patients had raised CEA tumour markers, which were appropriate for 
repeated assessment at 9-12 weeks. Of these, nine patients had a fall in CEA 
tumour marker (median 46% of pre-treatment value; range 2%-57%). Five 
patients had an increase in CEA tumour markers at 9-12 weeks (median 331% of 
pre treatment value; range 126%-481%).
Nine patients had raised CA19-9 tumour markers suitable for repeat assessment 
at 9-12 weeks. Of these, seven patients had a reduction in CA19-9 (median 46% 
of pre treatment value; range 2%-98%), and two patients had an increase in 
CA19-9 (median 162% of pre treatment value; range 138%-186%).
IF-181 FDG PET analysis
[F-18] FDG PET scans were performed on all patients, however for a variety of 
reasons, not all patients completed the trial protocol. Table 47 summarises the 
number of scans performed on each patient.
Table 47: [F-18] FDG PET scans
Number of [F- 
18] FDG PET 
scans completed
Total
number
patients
Pt No.
1 6 #1, #13, #18, #20, #29, #31
2 3 #5, #6, #30
3 22 #2, #3, #4, #7, #8, #9, #10, #11,
#12,#14,#15, #16, #17, #19, #21, #22, #23, 
#24, #25, #26, #27, #28
Twenty-two patients completed all three [F-18] FDG PET scans as per the trial 
protocol. Three patients completed two of three scans. In two of these patients 
the tumour could not be seen on [F-18] FDG PET scans, and so the third scan 
was not performed (#5, #6). In one patient the camera failed for the third PET 
scan (#30). In six patients only one [F-18] FDG PET scan was performed. Two 
of these patients deteriorated and died prior to completing the study (#1, #18). 
The camera failed for one patient (#29), the [F-18] FDG injection was injected 
into the subcutaneous tissues for one patient, leading to significant artefacts 
(#20), and one patient did not fast for the PET scan, and the scan was not reliable 
(#13). One patient could not tolerate the scan, and the scan was aborted (#31).
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Four patients had [F-18] FDG PET scans performed, in which no tumour areas 
could be seen. These were patients #3, #5, #6 and #9. Patient #3 had a body 
weight of 130-138kg, and due to his body habitus the scan quality was extremely 
poor. Tumour areas could not be clearly defined. Patients #5 and #6 had 
pancreatic cancer, with locally advanced disease. Patient #9 had hepatocellular 
carcinoma with very small volume liver metastasis. It is likely that the gamma 
camera PET was of insufficient sensitivity to detect the lesions in these three 
patients.
Table 48 summarises the patient group according to tumour type, completion of 
a pre-treatment PET scan and at least one follow-up scans and subsequent 
tumour detection on [F-18] FDG PET.
Table 48: [F-18] FDG PET scans according to tumour type
Tumour type Number of 
patients
Number of patients 
with pre and post 
PET scans performed
Number of 
patients with 
tumour visible 
on PET scan
Colorectal 16 15 14
Oesophageal 3 1 1
Pancreatic 3 2 0
HCC 3 2 1
Lung 1 1 1
Breast 4 3 3
Unknown primary 1 1 1
Total 31 25 21
Abbreviations: HCC -  hepatocellular carcinoma
In total, therefore, twenty-one of the thirty-one patients had [F-18] FDG PET 
scans that were suitable for analysis to compare different forms of response 
assessment. Patient #7 however, was found not to have measurable disease by 
conventional response criteria, and therefore could not be included in the 
comparative analysis. Analysis is therefore reported on twenty patients who had 
[F-18] FDG PET scans at 2-4 weeks, nineteen of whom had [F-18] FDG PET 
scans also at 9-12 weeks.
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Automated region growing program/ VOI generation
It was possible to generate tumour volumes for analysis from eighteen of the 
twenty patients (90%) with a baseline and at least one follow-up [F-18] FDG 
PET scan. For two patients (#15 and #25) the differentiation between tumour and 
surrounding normal tissue was not large enough to allow the mathematical 
generation of a tumour area using the automated region growing program. 
Therefore these patients could not be analysed by this method.
There were two patients in whom the VOI subtraction program generated tumour 
volumes which were visually much more representative of actual tumour load 
than without subtraction. These were patients #4 and #23. In particular it was 
apparent that without the subtraction technique large volumes of tumour had 
been missed on either the baseline or follow-up scan (figure 50).
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Figure 50: Example of the VOI subtraction method compared to
VOI
Figure 50 displays the three PET scans on a) patient #4 and b) patient #23 with 
the tumour regions generated by both the VOI program and the VOI subtraction 
program. For both patients the VOI subtraction program provides a better 
representation o f actual tumour mass than with the VC I program.
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Lesion statistics
Table 49 and 50 outlines the results of the analysis of [F-18] FDG PET scans 
pre-treatment and at 2-4 weeks and 9-12 weeks post chemotherapy, using the 
lesion statistics from the tumour VOI. The results have been expressed as a 
percentage change compared to baseline. The changes in [F-18] FDG uptake 
have been compared to current standard response assessment of radiological 
imaging, RECIST criteria, and relevant tumour markers, both taken at 9-12 
weeks after commencement of chemotherapy.
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Table 49: [F-18] FDG PET analysis (2-4 weeks)
*1
9-12 weeks [F-18] FDG PET (2-4 weeks)
Pt
No.
RECIST (%) Tumour
markers
VOI VOI subtraction
Total
cts
Mean Vol Max Total
cts
Mean Vol Max
#8 PR 29% 2% 11% 97% 11% 84% 19% 74% 26% 84%
#15 PR 58% 4% X X X X X X X X
#16 PR 47% 10% 36% 58% 62% 51% 25% 63% 40% 51%
#17 PR 60% NA 76% 73% 104% 68% 50% 95% 53% 68%
#21 PR 49% NA 0% 0% 0% 0% 0% 0% 0% 0%
#22 i PR 65% 46% 83% 81% 102% 76% 78% 82% 96% 76%
#26 PR 7% NA 14% 46% 30% 35% 14% 46% 30% 35%
median 49% 7% 25% 66% 46% 60% 22% 69% 35% 60%
9-12 weeks |F-18] FDG PET (2-4 weeks)
Pt
No.
RECIST (%) Tumour
markers
VOI VOI subtraction
Total
cts
Mean Vol Max Total
cts
Mean Vol Max
#11 PD 214% 331% 229% 96% 240% 123% 167% 105% 160% 123%
#24 PD 123% 573% 114% 73% 155% 92% 74% 76% 104% 92%
#28 PD 141% 481% 144% 73% 196% 60% 80% 80% 99% 60%
#30 PD 106% 126% 79% 78% 101% 80% 81% 79% 103% 80%
median 132% 406% 129% 76% 176% 86% 81% 80% 104% 86%
cl
9-12 weeks [F-181 FDG PET (2-4 weeks)
Pt
No.
RECIST (%) Tumour
markers
VOI VOI subtraction
Total
cts
Mean Vol Max Total
cts
Mean Vol Max
#2 SD 76% 54% 67% 97% 69% 96% 30% 119% 25% 96%
#4 SD 76% 49% 48% 81% 60% 101% 81% 79% 102% 101%
#10 SD 103% 263% 104% 102% 102% 71% 110% 94% 117% 71%
#12 SD 116% 395% 97% 77% 127% 82% 93% 79% 119% 82%
#14 SD 100% 57% 97% 108% 90% 110% 57% 122% 46% 110%
#19 SD 88% 46% 0% 0% 0% 0% 0% 0% 0% 0%
#23 SD 90% NA 169% 89% 190% 92% 114% 90% 126% 92%
#25 SD 96% NA X X X X X X X X
#27 SD 94% 55% 69% 64% 107% 68% 54% 74% 72% 68%
median 94% 55% 83% 85% 96% 87% 69% 85% 87% 87%
[F-18] FDG PET scans at 2-4 weeks after commencement o f  chemotherapy
analysed by VOI analysis and compared to standard radiological imaging 
(RECIST) and tumour markers. All values are expressed a % compared to 
baseline - s o  a reduction in size/ volume or ratio is expressed as a value < 100% 
and in increase as > 100%.
Abbreviations: PR -  partial response; PD -progressive disease; SD -  stable 
disease; Pt No -  patient number; V O I- volume o f interest; Total cts -  total 
counts; Vol -  volume; NA -  not applicable; X -  not able to be analysed by this 
technique
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Table 50: [F-18] FDG PET analysis (9-12 weeks)
*1
9-12 weeks [F-18] FDG PET (9-12 weeks)
Pt
No.
RECIST (%) Tumour
markers
VOI VOI subtraction
Total
cts
Mean Vol Max Total
cts
Mean Vol Max
#8 PR 29% 2% 2% 47% 4% 42% 1% 57% 1% 42%
#15 PR 58% 4% X X X X X X X X
#16 PR 47% 10% 0% 0% 0% 0% 0% 0% 0% 0%
#17 PR 60% NA 8% 75% 11% 56% 9% 74% 12% 56%
#21 PR 49% NA 0% 0% 0% 0% 0% 0% 0% 0%
#22 PR 65% 46% 38% 60% 64% 58% 23% 69% 33% 58%
#26 PR 7% NA 17% 42% 41% 32% 17% 42% 41% 32%
median 49% 7% 5% 45% 8% 37% 5% 50% 7% 37%
M
9-12 weeks [F-18] FDG PET (9-12 weeks)
Pt
No.
RECIST (%) Tumour
markers
VOI VOI subtraction
Total
cts
Mean Vol Max Total
cts
Mean Vol Max
#11 PD 214% 331% 360% 120% 301% 147% 321% 139% 230% 147%
#24 PD 123% 573% 407% 107% 380% 117% 1189% 80% 1478% 117%
#28 PD 141% 481% 330% 168% 197% 151% 283% 162% 174% 151%
#30 PD 106% 126% ND ND ND ND ND ND ND ND
median 132% 406% 360% 120% 301% 147% 321% 139% 230% 147%
cl
9-12 weeks [F-18] FDG PET (9-12 weeks)
Pt
No.
RECIST (%) Tumour
markers
VOI VOI subtraction
Total
cts
Mean Vol Max Total
cts
Mean Vol Max
#2 SD 76% 54% 43% 85% 50% 81% 19% 105% 18% 81%
#4 SD 76% 49% 150% 136% 110% 128% 90% 110% 82% 128%
#10 SD 103% 263% 83% 89% 94% 56% 167% 69% 243% 56%
#12 SD 116% 395% 124% 84% 147% 94% 138% 83% 166% 94%
#14 SD 100% 57% 64% 99% 64% 98% 65% 97% 67% 98%
#19 SD 88% 46% 0% 0% 0% 0% 0% 0% 0% 0%
#23 SD 90% NA 258% 79% 326% 76% 73% 97% 75% 76%
#25 SD 96% NA X X X X X X X X
#27 SD 94% 55% 0% 0% 0% 0% 0% 0% 0% 0%
median 94% 55% 74% 85% 79% 79% 69% 90% 71% 69%
[F-18] FDG PET scans at 9-12 weeks after commencement o f chemotherapy 
analysed by semi-quantitative methods and compared to standard radiological 
imaging (RECIST) and tumour markers. All values are expressed a % compared
to baseline - s o  a reduction in size/ volume or ratio is expressed as a value < 
100% and in increase as > 100%.
Abbreviations: PR -  partial response; PD -progressive disease; SD -  stable 
disease; Pt No -  patient number; V O I- volume o f interest; Total cts -  total 
counts; Vol -  volume; NA -  not applicable; ND -  not done; X -  not able to be 
analysed by this technique
264
Comparison of lesion statistics
Table 51 displays the Pearson correlation coefficients comparing % change in 
VOI statistics, and VOI subtraction statistics to the % change in tumour lesion 
size on CT scans according to RECIST criteria.
Table 51: Correlation of semi-quantitative analysis methods with
CT scan dimensional measurements
Pearson correlation coefficient
2-4 week PET scan 9-12 week PET scan
VOI total counts 0.83 0.75
VOI mean 0.32 0.57
VOI volume 0.80 0.67
VOI max 0.49 0.67
VOIsub total counts 0.78 0.47
VOIsub mean 0.37 0.59
VOIsub volume 0.72 0.36
VOIsub max 0.49 0.67
Abbreviations VOI- volume o f interest; VOIsub -  VOI subtraction
At both the 2-4 week and the 3 month [F-l 8] FDG PET scan the semi- 
quantitative method with the best correlation with CT scans was the total counts 
statistic of the VOI method.
‘Total counts’ is a value that takes into account the total metabolic activity of the 
tumour region generated by the automated region growing program. At 2-4 
weeks the six patients who had a partial response to chemotherapy by 
conventional assessment all had at least a 15% reduction in total counts of their 
tumour VOI. The median value was 25% of baseline and the smallest reduction 
was to 83% of baseline (range 0-83%). At the 9-12 weeks the reduction in total 
counts was to a median of 5% compared to baseline (range 0-38%).
There were four patients who had progressive disease on their 9-12 week CT 
scan. Three of these patients had a corresponding increase in tumour [F-18] FDG 
uptake at 2-4 weeks, as assessed by total counts (pt #30 did not have an increase 
in [F-18] FDG uptake, however this patient was deemed to have progressive 
disease on CT scans by the appearance of new lesions). The median increase was 
to 129% of baseline (range 79-229%). At the 9-12 week PET scan the total
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counts increased in the 3 patients who had disease progression on CT scan (pt 
#30 did not have a 9-12 week [F-18] FDG PET scan). The median value at 9-12 
weeks was 360% (range 330-407%).
In contrast, at 2-4 weeks in the six patients who obtained a partial response on 
CT scan, all had a fall in mean counts/voxel and maximum counts/voxel, 
however the tumour volume fell in four patients and increased slightly in two 
patients (102% and 104%). By the 9-12 week [F-18] FDG PET scan all lesion 
statistics had reduced in the six responding patients. In the four patients with 
progressive disease on CT scan, the lesion statistics on the 2-4 weeks [F-18]
FDG PET showed that the tumour volumes increased in all 4 patients (although 
in pt #30 this was only to 101%) but the mean counts/ voxel fell in all 4 patients 
and the maximum counts per pixel fell in 3 patients. This would be converse to 
that which would be expected for a progression of disease, and indicates that 
disease progression may not necessarily be associated with an increase in 
intensity of tumour [F-18] FDG uptake. By 9-12 weeks again all of the lesion 
statistics reflected disease progression in the three assessable patients.
VOI or VOI subtraction
The % change in total counts for VOI subtraction compared to VOI were in most 
cases similar, however at 2-4 weeks in the four patients who had progressive 
disease on CT scans, the value was only raised in one patient (pt # 11 167%), and 
was reduced in the other 3 patients (pt # 24 74%, pt #28 80% and pt #30 81%).
Of the two patients in whom the VOI subtraction method produced more 
representative tumour volumes than VOI alone, the values obtained for change in 
total counts between baseline and the 2-4 week and 3 month [F-18] FDG PET 
scan were altered by using the VOI subtraction method. For patient #4 at 2-4 
weeks the % change in total counts compared to baseline was 48% using VOI 
and 81% using VOI subtraction. At 9-12 weeks it was 150% using VOI and 90% 
using VOI subtraction. Patient #23 had a % change in total counts compared to 
baseline of 168% at 2-4 weeks with VOI and 114% with VOIsub. At 9-12 weeks 
this was 258% with VOI and 73% with VOIsub. As both patients had 
radiological stable disease at 9-12 weeks it is appears that the VOI sub values
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were more representative than the VOI values, when compared to the CT 
findings.
Histogram analysis
Histogram analysis was applied to all the tumour volumes and representative 
normal regions including chest wall, liver and lung, derived by the VOI and VOI 
subtraction methods. No satisfactory method of exporting the histograms into a 
program that could analyse and interpret quantitatively the change in histograms 
with chemotherapy was developed. Consequently the histograms were just used 
as a visual representation of change in tumour with therapy, and as a method of 
confirming that the background tissues had not changed significantly after 
chemotherapy. Figure 51 shows the count density histogram of the tumour of a 
patient who appeared to have a response to chemotherapy on [F-l 8] FDG PET. 
Figure 52 shows the count density histogram of a patient who appeared to 
progress on chemotherapy. Also displayed are the corresponding histograms of 
normal tissues on both patients.
The normal tissues were found to overlap on histogram analysis between 
corrected scans on all patients used in the VOI analysis indicating that, within the 
relatively crude limits of this method, normal tissues remain stable in individual 
patients after chemotherapy. This is important as if the normal tissues were found 
not to be consistent the changes detected in tumour may be unreliable.
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Figure 51: Histogram analysis -  responding patient
Pre treatment 
Post 1 
Pos t 2
Figure 51 a) is the count density histogram o f the tumour from patient #22, who 
attained a partial response on CT scan at 9-12 weeks. The tumour VOI 
represented was generated by the automated region growing program. The red  
line represents the histogram o f the tumour pre treatment, the green line is at 2-4 
weeks, and the yellow line is at 9-12 weeks. There has been a shift o f  the curves 
to the left, indicating a shift to lower intensity, and there has been a reduction in 
area o f  the curves, indicating a reduction in size o f  the tumour. These finding 
would be consistent with a response to therapy.
Figure 51 b) is the count density histogram o f areas o f  normal liver in the same 
patient. The histograms overlap, indicating that the normal tissues have 
remained largely unchanged with treatment.
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Figure 52: Histogram analysis -  progressing patient
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Figure 52 a) is the count density histogram o f the tumour from patient #71, who 
developed progressive disease on CT scan at 9-12 weeks. The tumour VOI 
represented was generated by the automated region growing program. The red 
line represents the histogram o f the tumour pre treatment, the green line is at 2-4 
weeks, and the yellow line is at 9-12 weeks. There has been an increase in area 
o f the curves and a small shift o f  the curves to the right. These finding would 
support the finding o f progressive disease after therapy.
Figure 52 b) is the count density histogram o f areas o f normal liver in the same 
patient. The histograms overlap, indicating that the normal tissues have 
remained largely unchanged with treatment
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Overall survival
The overall survival of patients was plotted according to their response on [F-18] 
FDG PET scan or CT scan. This was performed using Kaplan Meier survival 
curves and log rank analysis. The results are shown in Figure 53. A partial 
response on [F-18] FDG PET was defined as <85% of baseline using the total 
counts statistic of the VOI method, 85-110% was stable disease and >110% was 
progressive disease. The significance of any observed difference between the 
curves is expressed on the graphs.
There was a statistically significant improvement in survival for patients who 
responded to chemotherapy by [F-18] FDG PET (2-4 weeks and 9-12 weeks) and 
by CT scan (9-12 weeks).
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Figure 53: Survival of patients in [F-18] FDG PET study
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5.4 Discussion
The hypothesis tested in this chapter was that a method of analysis of tumour [F- 
18] FDG uptake which took into account changes in both tumour size and 
metabolic activity could be developed, and when applied in the clinical setting 
may represent an improvement over methods of analysis that take into account 
tumour [F-18] FDG intensity alone.
An automated region growing program was developed, and a method of analysis 
proposed. A clinical trial was undertaken to validate the both the automated 
region growing program and the method of analysis in a series of patients 
receiving conventional chemotherapy. The analysis compared measurements of 
tumour [F-18] FDG intensity with those of intensity and volume combined. The 
clinical trial was also designed to determine whether the response to 
chemotherapy could be predicted using gamma camera [F-18] FDG PET after 
only 2-4 weeks of treatment and to assess whether gamma camera [F-18] FDG 
PET could assist in the interpretation of radiological stable disease.
These objectives will be discussed individually below along with a general 
discussion of the use of gamma camera PET to assess response to chemotherapy.
5.4.1 Automated region growing program, lesion statistics and count 
density histogram -  application and validation.
Delineation of tumour volumes
The VOI automated region growing program was designed because the current 
methods of defining regions of interest on tumour areas on [F-18] FDG PET 
scans were thought to be unsatisfactory, particularly for use with gamma camera 
PET. Methods such as SUV, which depend upon drawing ‘by hand’ 
representative regions of interest, are subjective and arbitrary in the size, shape, 
number and placement of the regions. In addition they are limited to only 
measuring the intensity of tumour [F-18] FDG uptake, and do not take into 
account any change in size or shape of the tumour. Figure 54 displays an 
example of regions of interest drawn on three sequential [F-18] FDG PET scans.
272
Figure 54: ROI placement on serial scans
b) * c)
t f  1
Gamma camera [F-18] FDG PET scans displaying cross-sectional slices 
through the liver o f a patient with liver metastasis from colorectal cancer. The 
scans have been taken on three separate occasions, prior to (a) and after 
chemotherapy (b and c). A region o f interest has been drawn in a representative 
tumour area on all three scans in the visually hottest part o f  the tumour.
Phantom studies using equivalent spheres filled with [F-18] FDG have shown 
that the differentiation between tumour and background is less for gamma 
camera PET than dedicated PET (Zimny et al, 2001). It is therefore more 
difficult to define by hand the outer border o f tumours, and changes with therapy 
may be smaller in magnitude than with full ring scanners.
Co-registration of [F-18] FDG PET images with CT or MRI scans have been 
used with the anatomical information obtained from the CT or MRI scans used to 
draw tumour areas on the [F-18] FDG PET scans. This method works well for 
brain PET and MRI, however, there are inherent difficulties with co-registering 
whole-body scans. [F-18] FDG PET scans are acquired over an hour, and 
patients are therefore breathing regularly. CT scans are taken over only a few 
minutes and usually are performed with patients in maximum inspiration. There 
can be significant alterations in position o f the lungs, diaphragm and abdominal 
organs between normal respiration and maximum inspiration, which creates 
inaccuracies with co-registration. In addition, the setup position differs between 
CT and PET. CT requires the arms to be raised, above the head, in order to avoid 
artefacts, and the [F-18] FDG PET scan (with attenuation correction) does not 
require this. Patients could raise their arms above their heads for the [F-18] FDG 
PET scan, however, as the scan is for an hour this can become uncomfortable,
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and may result in movement artefacts. Also, if patients are slightly rotated when 
lying for their scan, the CT and [F-18] FDG PET scans will not be properly 
aligned.
Many co-registration software algorithms are now available, and these will align 
CT or MRI scans and [F-18] FDG PET scans based on internal reference points 
or mutual information algorithms (Studholme et al, 1997). This often requires 
complex computing, and the anatomical information obtained from the PET scan 
may not be sufficient for good registration. The registration of CT scans with the 
transmission component of the PET scan, and then reorientating the scans 
accordingly, may improve the registration process. Another option is to use 
external fiducial markers, however it was found that changes in skin surface 
anatomy did not always reflect changes in deep anatomy (2Wahl et al, 1993). The 
advent of PET/CT, in which the PET scanner and the CT scanner are mounted on 
the same gantry, has greatly improved the ability to accurately co-register 
images, as the patient is in the same position for both scans. The registration 
process is then much more straightforward, as the co-ordinates of both scans are 
used for the registration process (Israel et al, 2001). This has not overcome the 
problem of respiration artefacts, but it has greatly simplified the co-registration 
process, and increased its utility especially for the accurate anatomical 
localisation of lesions.
Once the PET image is co-registered with the CT image, tumour regions are 
obtained by drawing by hand around the CT defined tumour areas. This could be 
extremely laborious as, from the experience from our study, the volume of 
disease in some patients was very large. Also, there were patients in whom, 
particularly for liver metastasis, the CT showed a diffuse, poorly defined change, 
and the [F-18] FDG PET image showed clearly abnormal hypermetabolic 
regions. In addition, if a patient required a CT scan to accompany every PET 
scan for assessment of response to therapy, the radiation dose to the patient must 
become a factor to consider.
Another alternative would be to register the [F-18] FDG PET scans to each other,
and regions drawn on the first scan may be reapplied to subsequent scans.
Reproducible setup positions would need to be used, and there will be
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unavoidable differences in internal organ position. Again, difficulties were 
envisaged with this technique. Large changes in a tumour mass with time will 
alter the anatomy of the underlyingorgan. Particularly this is a problem for the 
liver, as a responding tumour decreases in bulk and the overall liver size may 
reduce, and conversely, a growing liver metastasis may increase the mass of the 
liver. When temporally related scans are registered, the tumour areas may no 
longer correspond anatomically. In addition, if a tumour responds in time, the 
region drawn on the baseline scan would encompass the tumour, and on 
subsequent scans, the tumour and some normal tissue. If a tumour progresses the 
baseline region encompasses the tumour, but the subsequent larger tumour will 
fall outside the baseline region of interest. The region of interest may even fall 
into necrotic areas, resulting in a misleading impression of reduced [F-18] FDG 
uptake.
It is for all these reasons that co-registration techniques were not pursued beyond 
initial investigation. The initial co-registrations that were performed were very 
laborious and the abovementioned drawbacks became readily obvious. A method 
that allowed tumours to be defined based on their morphology and intensity at 
each timepoint was thought to be more useful than defining the baseline tumour 
and comparing the [F-18] FDG uptake in the same area on subsequent scans. 
These concepts lead to the development of the automated region growing 
program.
The advantages of the automated region growing program include that it is 
mathematically defined, and therefore is an objective, rather than subjective 
process. As the process is automated it is considerably less time-consuming than 
drawing individual regions on each slice by hand. The regions are reproducible, 
different operators will all define the same regions, therefore it is much more 
consistent than other methods of region growing. The program draws tumour 
volumes that are representative of both tumour morphology and metabolic 
activity. In the clinical trial, 90% of patients in whom tumour regions could be 
seen on the [F-18] FDG PET scan had their tumour volumes defined by the 
automated region growing program. In sixteen out of eighteen (89%) of these 
patients the automated region growing program defined tumour volumes that
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visually appeared representative of the tumour regions (two patients required the 
subtraction method outlined below). The disadvantage is that it was not 
applicable to all patients -  10% of patients in this group could not be analysed by 
this method because the differentiation between tumour and normal tissue was 
not sufficient to allow region generation.
The VOI region growing program is also applicable to dedicated PET images, 
where it actually should be more effective as the higher count rate and detector 
efficiency allows better discrimination between tumour and normal tissue areas.
It could also be applied to gamma camera PET performed without attenuation 
correction, although the image quality and differentiation between tumour and 
normal tissues may not be as sharp, and this may reduce its utility.
The VOI subtraction (VOIsub) method was adopted when volumes drawn from 
the automated region growing program (VOI) were not representative of the 
entire tumour area. In particular, if two tumours were adjacent to one another 
only the more metabolically active tumour was drawn. If the seed point was 
placed on the less metabolically active lesion the region spread to the more active 
lesion and did not draw the adjacent lesion. This limitation was overcome by 
subtracting out of the total image the VOI of the more metabolically active 
tumour, and then reapplying the automated region growing program. The 
adjacent lesion can then be drawn; however there is usually also a ‘rim’ which is 
drawn around the initial lesion (figure 55). This process may be repeated as 
many times as necessary in order to obtain representative tumour volumes.
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Figure 55: VOI subtraction
cr
Figure 55 a) displays a transverse section through the liver o f  a patient with liver 
metastasis from colorectal cancer. Figure 55 b) is the region drawn on the same 
slice using the automated region drawing program. Figure 55 c) is the additional 
region drawn using the VOI subtraction technique -  it can be seen that the small 
tumour region adjacent to the very hot central tumour area has now been 
included. The rim around the original tumour is also shown Figure 55 d) shows 
this final region subtracted from the original image, in order to demonstrate that 
the entire tumour has now been drawn.
The VOI subtraction method has its own limitations. It is very laborious, 
although this could be improved with updated programming. It is much more 
subjective than the simple VOI method, as the user must decide how many 
rounds of lesion subtraction and reapplication of the program to do. Also it 
always leads to a reduction in mean counts/ voxel o f the final tumour volume 
compared to the one-step VOI method, as lesions are included with lower counts/ 
voxel than would have been included in the VOI program with no subtraction.
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In this study there were two patients (patients #4 and #23) in whom this 
technique appeared to produce more representative tumour volumes than by the 
VOI method alone. This also affected their lesion statistics. There may, therefore, 
be a small number of scans in which the VOI subtraction method may be more 
representative of tumour mass than the VOI method. It would not seem practical 
to employ the subtraction technique in all situations as it is time-consuming, and 
adds a level of subjectivity in defining when lesion subtraction should stop.
The VOI region growing program was also used to define regions of normal 
tissues (lung, liver, chest wall). These were used to assess variation in 
background tissues between scans, and thereby to validate that changes that 
occurred in tumour [F-18] FDG uptake were independent of the background 
tissues. The program was defined to grow if the adjacent voxels were +/-20% of 
the current mean. It became apparent, however, that a tighter range was required, 
as there was some spread from one normal tissue to the next. For example, 
seeding the lung region in the periphery of the lungs would allow ‘spread’ to the 
chest wall, and if the seed-point was too medial in the lungs the region spread to 
the heart. The program could be improved by restricting this count variation to 
+/-10% of the current mean. In addition the normal tissue volumes were large 
(approximately 500 voxels), and this was problematic particularly in the liver of 
patients with large volume liver metastasis in whom it was difficult to find 
suitably large areas of normal liver to place a seed-point. This could be corrected 
by reducing the number of iterations performed before the program stops.
The VOI region growing program was developed on AD AC Provision software, 
with minimal software support from the company. It therefore became very 
difficult to instigate even minor program changes. It would be desirable to 
transfer the program to a more widely used and flexible software system so it 
could be applied to different PET systems, and tested on these. This would also 
allow modifications to be made more easily.
The method used of an automated iterative adaptive threshold technique was one
of many possible means of objectively defining the difference between tumour
and non-tumour areas. It is relatively simple and has served to illustrate the
principle that the differences between tumour and non-tumour areas can be
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mathematically defined. There have been several published alternative methods 
of defining tumour volumes for quantitative analysis with [F-18] FDG PET on 
dedicated systems. One of these is termed spherical 3D blob analysis (Salman et 
al, 2000). This is also based on a threshold technique, and allows the automated 
extraction of tumour blobs in a similar manner to the VOI analysis used here.
The threshold value is, however, fixed. The VOI generated is then used to 
calculate SUV values, and to compare to CT tumour volumes. When used in 
eight patients this method appeared encouraging for the assessment of response 
to chemotherapy. Another method used is a CT guided adaptive thresholding 
method, whereby the volume of a tumour is calculated from the CT scan, and 
based on the lesion to background ratio of the lesion on the PET scan, a threshold 
value is calculated and applied (Erdi et al, 1997). This work showed that a fixed 
threshold of 40% may be used to define tumour regions, provided the lesion is 
larger than 4mL and has a lesion to background ratio > 5:1. Unfortunately, the 
low count rate capability of the gamma camera PET system means that most 
tumours actually have a lower tumour to background ratio than this, thereby 
limiting the applicability of any fixed threshold system. This is in concurrence 
with our own experience which found that if a fixed threshold was used the 
resultant volume of interest was not representative of the visible tumour area.
Other techniques could include a method based on a % difference between 
tumour and non-tumour areas, or a ‘contour mapping’ technique, which takes 
into account the gradients of change in [F-18] FDG uptake. Both of these 
techniques, however, depend on background normal tissues, and if the [F-18] 
FDG uptake in normal tissues changed with chemotherapy this may result in 
misleading representation of tumour areas.
In conclusion, the VOI region growing program was found to be a very 
promising method for delineating tumour regions for further analysis. Its 
advantages were that it was rapid, reproducible, automated and in most cases 
provided a good representation of tumour regions. Its main limitations were that 
it was not able to define tumour volumes on all patients and that the program had 
difficulty defining two adjacent lesions separately.
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Quantitating change in tumour uptake of [F-181 FDG
Once the tumour volume was defined, a method of qUantifiying change in [F-l 8] 
FDG uptake was required. The methods used to assess change in tumour [F-18] 
FDG uptake in the tumour regions defined by the VOI region growing program 
were lesion statistics or histogram analysis.
Lesion statistics
The lesion statistics calculated from the tumour VOI can be divided into those 
that measure tumour size (volume), and those that reflect uptake intensity (mean 
counts/voxel, maximum counts per voxel). The total counts statistic combines 
both and measures total tumour [F-18] FDG uptake.
The clinical trial demonstrated that the total counts statistic appeared the most 
useful for assessing change in tumour [F-l 8] FDG uptake with chemotherapy 
when compared to the result of a 3 month CT scan. This may be because it 
reflects both tumour size and metabolic activity. The Pearson correlation 
coefficient obtained from a direct comparison between percentage change in 
dimensional measurements on CT and change in total counts from VOI was 0.83 
at the 2-4 weeks PET scan and 0.75 at the 3 month PET scan.
The main situation in which VOI total counts appeared more representative of 
true response than VOI mean counts was in the prediction of progressive disease. 
Patients who had progressive disease on CT scan at 9-12 weeks did not 
consistently have an increase in VOI mean counts on [F-18] FDG PET at 2-4 
weeks. The VOI volume did however increase. By the 3 month [F-18] FDG PET 
scan the VOI mean counts had increased compared to baseline. As the VOI mean 
counts represent the intensity of metabolic activity within a tumour, it appears, 
from this very limited sample, that early progression on [F-18] FDG PET may be 
associated with an increase in lesion size prior to an increase in metabolic 
intensity. More patients are required to define this relationship clearly, however 
this finding, if substantiated, may hold significant implications for the sensitivity 
of methods of analysis of [F-18] FDG PET that only take into account 
measurements of tumour intensity and not tumour size.
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Count density histogram
The histogram method of analysis appeared very promising, as it was a means to 
represent changes in the distribution of [F-18] FDG activity within the tumour 
VOL Unfortunately no satisfactory method of transferring the data from the 
workstation or analysing this data was identified and therefore it was not possible 
to take this method to its full potential. The shape of the histograms changed with 
chemotherapy, however, interpreting and reporting the significance of this 
change was difficult without a method of quantifying it. There were several 
situations in which the tumour histograms were more difficult to assess.
Examples of these are displayed in figure 56.
The histogram method was useful for identifying whether the background tissues 
varied between baseline and subsequent scans, although, again without a method 
of quantifying or delineating this variation it was difficult to measure or record 
change in [F-18] FDG uptake in normal tissues after chemotherapy.
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Figure 56: Tumour histograms
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Figure 56 a) is a tumour histogram from patient #12 who had radiological stable 
disease at 9-12 weeks. The histogram appears to increase in size but reduce in 
intensity after treatment. Figure 56 b) is the tumour histograms produced using 
the VOI method and c) is the tumour histograms using VOI subtraction from  
patient #23. For this patient the VOI subtraction technique produced much more 
representative tumour volumes than the VOI technique. This patient also had 
radiological stable disease on CT scan at 9-12 weeks. Again the tumours appear 
to reduce in intensity but increase in size. Figure 56 d) is the tumour histogram 
from patient #28 who had progressive disease on CT scan at 9-12 weeks. There 
is clear progression from the baseline scan to the 9-12 week scan (red to yellow  
lines respectively), however, the 2-4 week result appears to be less intense.
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5.4.2 Can gamma camera [F-18] FDG PET be used to predict response to 
chemotherapy after 2-4 weeks of treatment?
The data from this trial supports the emerging evidence that [F-18] FDG PET can 
be used to predict response to chemotherapy as early as 2-4 weeks after 
treatment. If a ‘partial response’ on [F-18] FDG PET was arbitrarily defined as a 
15% or greater reduction in the total counts on tumour VOI compared to 
baseline, then the sensitivity at the 2-4 week [F-18] FDG PET scan for detecting 
a partial response would be 100%, but the specificity would be 58%. This low 
specificity is due to the ‘false positives’ of 1 patient with progressive disease 
(#30) and 4 patients with stable disease (#2, #4, #19, #27) on CT scan at 9-12 
weeks. As previously mentioned pt #30 was deemed a ‘progressive disease’ on 
conventional imaging, due to the development of a new lesion on CT. The 
tumour markers of this patient increased at 9-12 weeks to 126% of baseline, 
confirming the likelihood that this is indeed a false positive. Of the 4 patients 
with stable disease who had a > 15% reduction in [F-18] FDG uptake at 2-4 
weeks, three patients continued chemotherapy beyond 9-12 weeks, with pt #2 
going on to liver resection, pt #4 achieving a partial response at 6 months, and pt 
#27 remaining with stable disease at 6 months on CT scan. The fourth patient (pt 
#19) was recommended to continue chemotherapy, however declined due to 
toxicities. In addition all four patients had considerable improvements in their 
serum tumour markers at 9-12 weeks (54%, 49%, 46% and 55% respectively for 
pts #2, #4, #19, #25). It may therefore be that the [F-18] FDG PET scan and 
tumour markers detected a biological response in the tumours of these four 
patients that was not detected by conventional radiological imaging.
I f ‘progression’ on [F-18] FDG PET was defined as a >10% increase in [F-18] 
FDG uptake, then the sensitivity at 2-4 weeks using total counts on tumour VOI 
analysis would be 75% and the specificity 93%. Pt #30 would not have been 
detected as progressive disease, and pt #23 would have been deemed disease 
progression, whereas the radiological measurements indicated stable disease. 
Chemotherapy was stopped on pt #23 at 9-12 weeks due to cardiac toxicity, and 
this patient did not have any tumour markers for evaluation.
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Table 52 demonstrates the relationship between VOI total counts at 2-4 weeks 
and the outcomes of patients with respect to whether they continued with the 
same chemotherapy regimen beyond 9-12 weeks or stopped chemotherapy at 9- 
12 weeks.
Table 52: VOI total counts at 2-4 weeks and patient outcome
Chemotherapy continued at 9-12 
weeks
Chemotherapy stopped at 9-12 
weeks
PtNo. RECIST
Response
2-4 week 
VOI total 
counts (%)
Pt no. RECIST
Response
2-4 week 
VOI total 
counts (%)
#8 PR 11% #11 PD 229%
#16 PR 36% #24 PD 114%
#17 PR 76% #28 PD 144%
#21 PR 0% #30 PD 79%
#22 PR 83% #10 SD 104%
#26 PR 14% #12 SD 97%
#2 SD 67% #19 SD 0%*
#4 SD 48% #23 SD 168%*
#14 SD 97%
#27 SD 69%
median 58% median 109%
This table divides the patients into those who continued with the same 
chemotherapy regimen after their 3 month CT scan and those who stopped. The 
[F-18] FDG PET values are those from the VOI total count statistic on the 2-4 
week [F-18] FDG PET scan, and are expressed as a % o f baseline value.
* indicates patients who stopped chemotherapy due to toxicity 
Abbreviations: PR -  partial response; SD -  stable disease; PD-progressive 
disease
If a decision had been taken at the time of the 2-4 week [F-18] FDG PET scan to 
stop chemotherapy for patients who had an increase in [F-18] FDG uptake 
(>110% by total counts of VOI), chemotherapy would have been stopped on four 
patients. None of these patients actually continued chemotherapy beyond 9-12 
weeks. Three had progressive disease on CT scan at 9-12 weeks, and one had 
stable disease with cardiotoxicity at 9-12 weeks. Importantly, no responding 
patients would have been missed by this method.
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If a decision had been made to only continue chemotherapy on patients who had 
a reduction in [F-18] FDG uptake to <85% of baseline, chemotherapy would 
have been continued on 11 patients. 9 of these 11 patients (82%) attained a 
partial response or stable disease on the 9-12 weeks CT scan, and went on to 
continue chemotherapy beyond 9-12 weeks. 2 of the 11 patients stopped 
chemotherapy at 9-12 weeks (1 due to progressive disease on CT and 1 due to 
toxicities). Of the seven patients who did not have a fall in tumour [F-18] FDG 
uptake to <85% of baseline at 2-4 weeks, six (86%) actually stopped 
chemotherapy at 9-12 weeks, and one (14%) continued. This patient (pt#14) had 
stable disease on the 3 month CT scan and went on to complete 6 months of 
chemotherapy, and again attained stable disease on the 6 month CT scan. If this 
rule had been applied this patient may have had their chemotherapy stopped 
early, and although this patient never attained a partial response on CT scan, they 
did complete 6 months of chemotherapy with radiological stable disease. Again 
no responding patients would have been missed by applying this rule; however, 
one patient with stable disease would have been missed.
The ability to predict patients who respond to chemotherapy at an earlier time- 
point than is currently possible with radiological imaging is important for several 
reasons. Chemotherapy carries with it a physical and psychological burden, and 
the ability to inform a patient after only one treatment that they are responding 
would relieve considerable anxiety, and would improve patient tolerability of 
side-effects. If a patient is not responding they may be able to stop treatment 
early, and limit unnecessary toxicities. In addition, it appears that from the 
survival data collected in this study, patients who respond to chemotherapy with 
a reduction in [F-18] FDG tumour uptake at 2-4 weeks, have a statistically 
significantly improved survival than those who do not. This is very encouraging 
for responding patients, and may help identify the subset of non-responders who 
could benefit from earlier intervention to try and obtain a better outcome for this 
group of patients. Finally, there are cost-benefit implications. New 
chemotherapies are expensive to develop, and once licensed the cost may limit 
their availability as Health Authorities are unable to afford them within their 
budgets. This cost may be significantly reduced by the ability to detect 
responding patients after only one cycle of treatment, therefore reducing the
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number of cycles of chemotherapy required to be given to non-responders, and 
any associated costs in terms of morbidity and hospitalisation to manage side- 
effects.
If the aim is to identify non-responders earlier, it appears from the limited 
number of patients available in this study, that if the VOI total counts at 2-4 
weeks is >110% of the baseline value, patients are very unlikely to have a 
response to chemotherapy (0% subsequently responded at 9-12 weeks). In 
addition, these patients have a significantly worse prognosis in terms of overall 
survival as shown in figure 53 (p=0.04). This is the group of patients in whom 
stopping chemotherapy early may be advantageous in terms of toxicities, cost 
and in trying to improve their prognosis by intervening earlier to try a different 
treatment regimen.
Conversely if a patient has a VOI total counts of <85% at 2-4 weeks they may be 
reassured from this study that they have >90% chance of having some benefit 
from chemotherapy, as only 1 of the 11 patients in this study with VOI total 
counts <85% at 2-4 weeks went onto have progressive disease at 9-12 weeks. 
This may be advantageous to patients who are struggling with the psychological 
or physical burden of chemotherapy. Also, reassuringly, they appear to have a 
survival advantage over those who did not obtain a reduction in tumour [F-18] 
FDG uptake after one cycle of chemotherapy.
5.4.3 Does gamma camera [F-18] FDG PET aid the interpretation of 
radiological stable disease?
The management of patients who obtain radiological stable disease after 
chemotherapy remains an undefined area. ‘Stable disease’ is poorly understood -  
it may represent a minor response to chemotherapy or no response to 
chemotherapy. Consequently the decision of whether to continue with the same 
chemotherapy regimen or whether to stop is also very difficult. It is often taken 
after patient -  physician discussion and with the degree of toxicities experienced 
factored in. With the emergence of novel biological therapies for cancer with low 
toxicity, stable disease if sustained, may become a more acceptable outcome.
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One reason for patients attaining stable disease may be that the detection of 
response to therapy by radiological imaging only measures dimensional changes 
in tumours. [F-18] FDG PET imaging, by reflecting a metabolic process, should 
improve the ability to ascertain the biological effect of therapies, and could help 
guide decision making in clinical practice.
In this study of 31 patients, overall 15 patients (48%) had stable disease by 
RECIST criteria on their 9-12 week assessment. This is a large proportion of 
patients in which it is uncertain whether they have had any benefit from their 
chemotherapy. Eight of these patients had [F-18] FDG PET scans that were 
suitable for analysis with the VOI total counts technique. Table 53 summarises 
the VOI total counts values on the 2-4 week and 9-12 week [F-18] FDG PET 
scans, in combination with the tumour marker response and clinical outcome. 
The 18-24 week CT response is indicated in patients who continued 
chemotherapy beyond 9-12 weeks, and had a subsequent assessment performed
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Table §3: Patients with CT defined stable disease
Pt
No.
CT scan 
(9-12 wks)
Tumour
Markers
VOI
(2-4 wks)
VOI
(9-12 wks)
Clinical outcome 
at 9-12 wks
CT scan 
(18-24 wks)
#2 SD 54% 67% 43% Continued 
chemotherapy 
(liver resection)
ND
#4 SD 49% *48%
(81%)
*150%
(90%)
Continued
chemotherapy
PR
#14 SD 57% 97% 64% Continued
chemotherapy
SD
#27 SD 55% 69% 0% Continued
chemotherapy
SD
#10 SD 263% 104% 83% Stopped
chemotherapy
NA
#12 SD 395% 97% 124% Stopped
chemotherapy
NA
#19 SD 46% 0% 0% Stopped
chemotherapy due 
to toxicities
NA
#23 SD ND *168%
(114%)
*258%
(73%)
Stopped
chemotherapy due 
to toxicities
NA
The outcome and clinical decision whether to continue chemotherapy on eight 
patients who attained stable disease on CT scan after 9-12 weeks o f 
chemotherapy compared to the change in tumour markers at 9-12 weeks, and the 
change in VOI total counts at 2-4 weeks and 9-12 weeks.
* VOI total counts used, however VOIsub tumour regions were more 
representative in these patients The VOIsub total counts value is given in 
brackets.
Abbreviations: VOI -volume o f interest; SD -  stable disease, PR -partial 
response, ND -  not done, NA -  not applicable
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Four of the eight patients proceeded with chemotherapy after the 9-12 week 
assessment CTscan. All four patients had a fall in their serum tumour markers at 
9-12 weeks (median 52% range 49-57%). Three patients had a fall in tumour [F- 
18] FDG uptake to <85% of baseline at the 2-4 week [F-18] FDG PET scan. One 
of these patients attained a partial response on CT scan at 18-24 weeks, one had a 
sustained stable disease and one went onto have a liver resection and was not 
further assessed. In these three patients there is the indication that the 
chemotherapy may have been producing a positive effect that was not detected 
on CT scan. The fourth patient had stable tumour [F-18] FDG uptake at 2-4 
weeks (97%), which had reduced further at 9-12 weeks to 64% of baseline.
These values indicate a response to chemotherapy, which is supported by the 
tumour marker values and the attainment of sustained stable disease on CT scan 
at 18-24 weeks.
Of the four patients who stopped chemotherapy at 9-12 weeks, two stopped due 
to toxicities. The two patients who stopped due to lack of evidence of response to 
the chemotherapy both had substantial increases in their tumour marker values at 
9-12 weeks (263% and 395%). The VOI total counts at 2-4 weeks were not 
indicative of a response to chemotherapy (97-104%). By 9-12 weeks they had 
increased in one patient (124%) indicating progressive disease. In the other 
patient the tumour [F-18] FDG uptake fell to 83% of baseline. This was not in 
agreement with the tumour marker values or the clinical decision to stop 
chemotherapy.
The [F-18] FDG PET scan results were not used in this study to influence 
physician decisions as to whether to continue chemotherapy, however, the CT 
scan and tumour markers results were. There is a good correlation between 
tumour marker response to chemotherapy and subsequent decision of whether to 
proceed with chemotherapy for these patients with stable disease. This supports 
the utility of serum tumour markers in this situation, but this must be interpreted 
with some caution as it may have been because of the tumour marker result that 
the decision was made to continue or stop chemotherapy.
Overall the [F-18] FDG PET results did appear to be in agreement with the
clinical outcome of patients, particularly for patients who continued
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chemotherapy beyond 9-12 weeks in whom there was a reduction in tumour [F- 
18] FDG uptake at 2-4 weeks. These three patients did appear to be benefiting 
from chemotherapy, and continuing treatment resulted in a favourable outcome 
for all three patients. It appears therefore, from this limited evidence, that 
chemotherapy should be continued on patients who attain a reduction in tumour 
[F-18] FDG uptake at 2-4 weeks, and who are tolerating chemotherapy, as there 
does appear to be some evidence of therapeutic benefit in these patients.
5.4.4 Issues associated with use of [F-18] FDG PET for response 
assessment
There are several issues that were identified to be important in influencing the 
validity of serial [F-18] FDG PET scans. These include the timing and frequency 
of [F-18] FDG PET scans, patient preparation and protocol issues and the 
influence of partial volume effects on small lesions.
Timing and frequency of fF-l 81 FDG PET assessments
The timing of an [F-18] FDG PET assessment after therapy is important, as early 
information is very helpful for directing further management plans, however, it 
must be shown that the assessment is performed at a time when the results are 
reliable. There is a concern that there may be a ‘metabolic flare’ reaction to 
chemotherapy, which will result in a false-positive result on [F-18] FDG PET, if 
the timing of the PET scan is too close to the administration of chemotherapy. 
This has been shown to be problematic when scanning was performed at 24 
hours after chemotherapy in two studies to date (Rozenthal et al, 1989; De Witte 
et al, 1994). However, in one recent study, responses were seen on [F-18] FDG 
PET at 24 hours after administration of the novel tyrosine kinase inhibitor, 
imatinib mesylate (Glivec) (Demetri et al, 2002).
The administration of radiotherapy has also been associated with an increased 
uptake post therapy in patients who were ‘responders’ (Haberkom et al, 1991; 
Hautzel and Muller-Gartner, 1997; Spence et al, 2002). This, again, was thought 
to be metabolic flare, and may be problematic for up to 6 months post 
radiotherapy (Haberkom et al, 1991).
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A review of response assessment using [F-18] FDG PET by the EORTC PET 
Study Group in 1999 recommended that a pre-treatment [F-18] FDG PET 
assessment be performed within 2 weeks of commencement of chemotherapy. 
The timing of follow-up [F-18] FDG PET scans should be dependent on the 
study protocol, however, to avoid possible ‘flare’ reaction, [F-18] FDG PET 
scans should ideally be timed 1-2 weeks after chemotherapy (Young et al, 1999).
The recommended frequency of PET assessments has not yet been established. 
[F-18] FDG PET scans on a dedicated PET system result in an effective radiation 
dose to the patient of 7-9.5mSv (using 370 -  500MBq [F-18] FDG) (Valentin,
1998). The amount of [F-18] FDG administered for a gamma camera [F-18]
FDG PET scan is 20-25% of that required for a dedicated [F-18] FDG PET scan. 
This results in a radiation does of <3mSv (Valentin, 1998). A whole body CT 
scan has an estimated effective radiation dose of 12mSv (Brenner and Elliston, 
2004). These radiation doses should be considered when planning trial protocols.
Patient preparation and PET protocols
Patient preparation is very important if [F-18] FDG PET scans are to be used to 
detect longitudinal change in tumour [F-18] FDG uptake with therapy. Tumour 
[F-18] FDG uptake may be affected by many factors including, the injected [F- 
18] FDG dose, time to scanning, the patient’s blood glucose level, skeletal 
muscle uptake of tracer and the presence of urine in the bladder or renal pelvises.
The absolute amount of [F-l 8] FDG uptake within a tumour will be influenced 
by the injected activity. In addition, the PET camera used to scan the patient may 
have an optimal range of sensitivity, and large changes in injected activity, may 
be not correctable by simple rescaling factors. It is therefore important to try and 
keep the injected activity as constant as possible between the pre treatment and 
post treatment scans.
The time to scanning is also very important. Static [F-18] FDG PET scans are 
taken when the uptake of [F-18] FDG into tumours is presumed to be complete 
(plateau phase). Therefore the tumour uptake of [F-18] FDG should not change 
significantly over the scan period. Usually the plateau phase is assumed to be at
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60 minutes post injection of [F-18] FDG, however, evidence is emerging that 
time-points later than this may be more appropriate as active tumour uptake of 
[F-18] FDG may still be occurring at 60 minutes. In one study the average time 
to attaining plateau for patients with lung cancer was almost 300 minutes 
(Hamberg et al, 1994). The difference in SUV found between taking a 60 minute 
SUV measurement compared to a SUV measurement at the actual plateau 
timepoint was found to be an average of 46% different (Hamberg et al, 1994). 
This can lead to quite significant errors. If the scan is performed before the 
plateau phase is attained, then differences in the time between injection of [F-18] 
FDG and the time to commencing the scan in serial scans may have a significant 
effect on the tumour [F-18] FDG uptake. Again, this may not be a linear effect, 
and therefore will not be correctable by simple rescaling factors.
Patients must be fasted prior to [F-18] FDG injection as [F-18] FDG competes 
with glucose, and high circulating glucose levels will lead to poor tumour 
resolution due to high background [F-18] FDG levels and low tumour uptake 
(Langen et al, 1993; Lindholm et al, 1993; Diederichs et al, 1998). It is 
recommended that patients be fasted for 6 hours prior to injection of [F-18] FDG 
and a patient’s blood sugar level is between 4-7 mmol/L (Young et al, 1999). 
This is particularly important when two consecutive scans in the same person are 
to be compared, as the tumour [F-18] FDG uptake will be reduced as a result of 
high blood sugar levels, rather than therapeutic effect. This makes the scanning 
of patient’s with uncontrolled diabetes difficult, as their blood sugar levels may 
vary considerably between scans.
It is important that patients are well hydrated prior to having a [F-18] FDG PET 
scan, as [F-18] FDG is excreted through the urinary system. Concentrated urine 
has very high radioactivity, and can lead to artefacts on the reconstructed images. 
The use of frusemide 20-40mg is recommended for areas of interest in the pelvis 
or near the kidneys, to avoid the image artefacts associated with concentrated 
urine (Young et al, 1999).
Skeletal muscle when exercised will take up glucose; therefore patients must rest
prior to and after [F-18] FDG injection. Diazepam may be required for muscle
relaxation, especially for patients with head and neck tumours (Young et al,
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1999). Cardiac muscle also utilises glucose, however it is more difficult to 
control cardiac muscle glucose utilisation for [F-18] FDG PET scans. Caffeine 
intake can result in increased cardiac muscle uptake, and it may be useful to ask 
patients to have the same intake of caffeine in the 24 horns prior to their scan on 
each occasion.
The protocol of the [F-18] FDG PET scan must be duplicated for the baseline 
and the subsequent scan to ensure consistency. This includes set-up positions, 
time per frame, presence or absence of attenuation correction and reconstruction 
protocols. The set-up position is particularly important for gamma camera PET, 
as there is a count-rate drop-off effect towards the edges of the detectors. Also 
the scans are performed with a 50% overlap, which is accounted for in the 
reconstruction protocols. Overlaps at different parts of the scans may however, 
influence tumour [F-18] FDG activity due to reconstruction effects, rather than a 
real change.
The standardisation of all of these factors between [F-18] FDG PET scans in the 
same patient will reduce the errors that may occur simply as a result of 
inconsistent patient preparation. This is extremely important when [F-18] FDG 
PET is being used for quantitative response assessment.
Partial volume effects
All of the quantitative methods of analysis used commonly are potentially 
subject to the partial volume effect that occurs for small lesions. This is a 
particular problem if the lesion’s size is less than two times the resolution of the 
camera. The AD AC Vertex Plus Gamma Camera has a FWHM of 4.8 mm when 
with measured attenuation correction was applied (manufacturer’s 
specifications). Therefore for lesions of less than 1cm a significant partial 
volume effect may occur, leading to the lesion appearing much less intense, 
purely due to its size, and the camera’s resolution. Partial volume effects may 
therefore lead to an exaggerated reduction in intensity when a tumour reduces in 
size, or an increase in intensity due to an increase in tumour size, as 
demonstrated in figure 57. This may result in an over estimate of the effect of a 
treatment. This will be problematic for all of the methods of analysis, but can be
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avoided by only analysing lesions that do not fall into this low resolution range 
of the camera.
Figure 57: Partial volume effect
A Jasczak phantom with 5 spheres each filled with [F-18] FDG to a ratio o f  10:1 
to background. The spheres are sized 40mm, 30 mm, 19mm, 10mm and 6 mm 
from left to right. There are also two air filled spheres o f 40mm and 30mm. The 
phantom has been scanned using the clinical protocol, and measured attenuation 
has been applied. The spheres appear to be less intense as they reduce in size -  
this is due to the partial volume effect that occurs due to a loss o f resolution as 
lesion size approaches the FWHM o f the system (data obtained with permission 
from KL Adamson).
In the [F-18] FDG assessment study, all o f the patients with lesions for which the 
VOI region growing program was able to generate tumour volumes had tumours 
of > 2cm, and so the partial volume effects should therefore have been minimal.
Figure 58 demonstrates a patient with a 4cm lung metastasis, which reduced to 
2cm on CT scan at 9-12 weeks. There is almost certainly some partial volume 
effect occurring in the tumour at the 2-4 week, and 9-12 week [F-18] FDG PET 
scan. The automated region growing program was unable to define tumour 
volumes at these time points, and therefore lesion statistics could not be obtained.
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Figure 58: Partial volume effects in clinical setting
Transverse and volume views o f  a patient with a lung metastasis from colorectal 
cancer. The lesion is clearly visible on the baseline study and barely visible at 2- 
4 weeks and 9-12 weeks. The size o f  this lesion may have contributed to its 
reduced intensity due to partial volume effects.
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5.5 Conclusion
A method of objectively, rapidly and reproducibly defining [F-18] FDG PET 
tumour regions has been developed and the analysis of these regions, taking into 
account both tumour [F-18] FDG uptake intensity and volume, applied in a 
clinical setting. This method of assessing response to chemotherapy using 
gamma camera [F-18] FDG PET was shown to correlate with conventional 
response assessment using RECIST criteria. Importantly the [F-18] FDG PET 
response was also found to be a statistically significant indicator of survival in 
this patient group. Therefore within the limitations of this relatively small study, 
it can be concluded that gamma camera [F-18] FDG PET using volume of 
interest analysis is a valid tool for assessing response to chemotherapy.
This trial, although small in numbers, also provides evidence that a patients’ 
response to chemotherapy and their survival may be predicted by gamma camera 
[F-18] FDG PET at 2-4 weeks after the commencement of chemotherapy (1-2 
cycles). This is valuable in determining those who should persevere with 
chemotherapy, and may identify those who are not responding at an earlier stage, 
in order that their treatment plan may be modified appropriately. Gamma camera 
[F-18] FDG PET also appeared to provide useful additional information for the 
interpretation of stable disease.
In conclusion gamma camera [F-18] FDG PET for assessment of response to 
chemotherapy warrants further investigation, and the VOI technique appears a 
useful method of semiquantitative assessment of response in this setting.
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6 [F-18] FDG PET and the assessment of response in phase I/n
ADEPT clinical trials
6.1 Background
[F-18] FDG PET for the assessment of response to therapy has predominantly 
been used to assess the effect of established chemotherapy regimens. However, a 
potentially important role for [F-18] FDG PET exists in the assessment of the 
efficacy of agents being tested in the Phase I and II clinical trial setting (Price et 
al, 1995). Patients who participate in Phase I/II clinical trials are often heavily 
pre-treated and their tumours are likely to be less chemosensitive than patients 
with chemo-naive tumours. Additionally they often have a large tumour burden, 
and may have some alteration in functioning of critical organs or overall 
performance status. Agents tested in phase I/II clinical trials may not be fully 
optimised, with dosage, scheduling or timings being manipulated and modified 
as part of the clinical trial design protocol. These factors all contribute to reduce 
the likelihood of a radiological response to agents tested in the phase I/II setting.
[F-18] FDG PET scans, by representing a metabolic process, have been shown to 
be more sensitive at detecting response to chemotherapy than CT scans (Jansson 
et al, 1995; Findley et al, 1996; Bokemeyer et al, 2002). They can also assess 
response earlier than by CT scans, and evidence is emerging of their use for 
prognosis in terms of survival (Weber et al, 2003). The ability to detect response 
earlier and the improved sensitivity for detection of response over CT 
assessments are important attributes for early studies of cancer therapies.
6.1.1 Application of [F-18] FDG PET imaging to ADEPT clinical trials
Phase I/II clinical trials of ADEPT are subject to all of the factors listed above 
which reduce the likelihood of attaining a clear radiological response after 
treatment. In addition, the immunogenicity of the antibody-enzyme used in 
ADEPT may limit therapy to only one ‘cycle’ of treatment, which further 
reduces the likelihood of attaining a reduction in size of the tumour. By being a 
complex strategy, there are many variables that may be modified in ADEPT, and
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having a more sensitive means of detecting effect of the treatment on the tumour 
may aid in directing these modifications.
Previous clinical trials of ADEPT have been associated with cohorts of patients 
who attain stable disease by radiological imaging (Bagshawe et al, 1995; Napier 
et al, 2000). Understanding the significance of this has been difficult. It may 
indicate that ADEPT has been ineffective, or it may indicate some therapeutic 
benefit, but not of sufficient magnitude to have resulted in a radiological 
response. As ADEPT is designed to be relatively free of toxicities ‘stable 
disease’ may be an acceptable endpoint if it does indeed reflect some degree of 
therapeutic benefit. A greater understanding of the effect of ADEPT on tumours 
that have radiological stable disease is therefore required.
Serum tumour markers have been used to assess response to chemotherapy 
(Rustin, 2003), however ADEPT utilises an anti-CEA antibody, which makes the 
interpretation of subsequent change in CEA levels difficult. A fall in CEA levels 
may occur as a result of clearance of serum CEA by the anti-CEA antibody. 
Additionally the formation of HAMA may interfere with the assay used for 
serum tumour marker estimation, which adds further uncertainty to these 
measurements.
The combination of a non-optimised treatment in a potentially resistant patient 
group, the tendency to attain radiological stable disease in past ADEPT clinical 
trials and the absence of an alternative means of assessing efficacy, such as 
tumour markers, have lead to the need for a better method of assessing the effect 
of ADEPT in phase I/II clinical trial setting. It was hypothesised that [F-18] FDG 
PET, by reflecting changes in tumour glucose metabolism, may provide a more 
sensitive means of detecting response in ADEPT. It was also proposed that [F- 
18] FDG PET could be used to aid the interpretation of radiological stable 
disease in the phase I/II ADEPT clinical trials.
These hypotheses were examined as part of the phase I/II ADEPT clinical trials 
using the methodology developed in chapter 5 to assess change in tumour [F-18] 
FDG uptake with the therapy.
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6.2 [F-18] FDG PET in phase I/II ADEPT trials
The method and analysis for both clinical trials are presented separately as there 
were differences in the timing and protocols used for [F-18] FDG PET scans, and 
in the method of CT response assessment.
6.2.1 ADEPT A5CP and ZD2767P
Method
[F-18] FDG PET scans were performed on patients within 2 weeks prior to 
commencing ADEPT, at 4 weeks and then at 8 weeks after ADEPT. Patients 
were fasted for 4-6 hours prior to injection and scanning was performed on an 
AD AC Vertex Plus dual headed gamma camera. Initially patients were injected 
with 185MBq of [F-18] FDG and scanned at 45-60 minutes post injection. 
Subsequent phantom studies revealed that this exceeded the quantitative range of 
count rate capability of the detectors of the camera, and consequently from 
patient #11 onwards all patients received a maximum of 150MBq of [F-18] FDG 
and were scanned at a minimum of 60 minutes.
Attenuation correction capabilities were not available for the AD AC Vertex Plus 
gamma camera until the end of this ADEPT trial. Therefore the majority of 
patients were scanned with the collection of only emission data. Emission scans 
had a 50.8cm field of view and were acquired according to the manufacturer’s 
specifications. Correction for decay was applied on the fly. Most patients had 2 
rotations performed; however some patients required 3 rotations. Patients were 
scanned with their arms above their head, out of the field of view.
Reconstruction was performed using standard AD AC iterative reconstruction 
protocols. A correction for attenuation was performed using Chang attenuation 
correction of uniform ellipses (Chang, 1978). A rescaling factor was applied to 
the images prior to analysis, correcting for injected activity of [F-18] FDG and 
time to scanning (figure 49, Chapter 5).
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A formal correction for blood glucose levels was not made, however data with 
blood glucose levels outside the range 4-7mmol/L were deemed unreliable.
Analysis was performed, where data was deemed reliable, using the automated 
region growing program as described in Chapter 5, to define tumour volumes. A 
threshold of 85% was applied at all times. VOI subtraction was only applied if 
the tumour region, drawn by the region drawing program, did not appear visually 
representative of the total tumour burden. Lesion statistics were obtained and 
count density histograms drawn as described previously. The lesion statistics 
used were tumour volume (total number of voxels), mean counts/voxel, 
maximum counts/voxel and total counts. The change in each lesion statistic was 
then displayed as a percentage change compared to baseline. The count density 
histograms of tumours were displayed, but not quantified. The count density 
histograms of the normal tissues (liver, lung) were displayed, and used to aid 
interpretation of whether the background tissues of the scan had altered 
compared to baseline.
CT scans were performed on patients prior to the commencement of ADEPT and 
at 4 and 8 weeks after ADEPT as outlined in the trial protocol (chapter 2) 
Response on CT scan was assessed using WHO criteria of bidimensional 
measurements.
Results
Table 54 outlines the details of the [F-18] FDG PET scans performed on the 
patients in the ADEPT study.
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Table 54: [F-18] FDG PET scans in ADEPT A5CP and ZD2767P
clinical trial
PtNo. No. scans Chang/AC Quantitative Comment
#1 0 NA NA camera not functional
#2 3 Chang no
#3 3 Chang no
#4 3 Chang no high blood glucose (diabetic)
#5 3 Chang no
#6 3 Chang no
#7 3 Chang no
#8 1 Chang no pt did not receive ADEPT
#9 2 Chang no camera fault scan 3
#10 3 Chang no
#11 3 Chang yes
#12 1 Chang no pt deceased
#13 2 Chang no pt unwell scan 3
#14 2 Chang yes pt unwell scan 3
#15 3 Chang yes
#16 1 Chang yes pt unwell
#17 1 Chang yes pt unwell
#18 3 Chang yes corrupt data scan 3
#19 3 Chang yes
#20 3 Chang yes
#21 2 Chang NA pt unwell scan 3. 
data corrupt scan 1 and 2
#22 2 Chang yes tumour not seen
#23 2 Chang yes camera fault scan 3
#24 3 Chang yes
#25 0 NA yes camera fault
#26 3 Chang yes
#27 3 AC no no rescaling information
Data was regarded as non-quantitative i f  the singles count rate for the scan was 
outside the quantitative range.
Abbreviations: NA -  not applicable, A C — attenuation correction.
Of the twenty seven patients who received ADEPT, fifteen patients completed 
three PET scans in accordance with the trial protocol. Six patients completed two 
of the three intended scans. Three patients were too unwell for their final PET 
scan, the camera had a fault for the final scan in two patients and no tumour was 
visible for one patient, and so the third scan was not performed. Four patients had 
only their baseline [F-18] FDG PET scan performed. One of these patients did 
not go on to receive ADEPT, due to becoming ineligible just prior to receiving 
treatment. The three remaining patients were too unwell for further [F-18] FDG
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PET scans. Two patients had no [F-18] FDG PET scans performed. This was due 
to the camera not being functional for both patients.
Attenuation correction transmission scans were only performed on all three scans 
of patient #28. All other patients only had emission scans performed, and Chang 
attenuation correction of uniform ellipses applied during reconstruction.
Eleven patients (#2-10, #12, #13) received 185MBq of [F-18] FDG and were 
scanned at 45-60 minutes, and consequently were deemed to not have 
quantitative scans due to this exceeding the count rate capability of the camera. 
For one patient (#28) the scan set-up and rescaling information were not 
recorded, and consequently rescaling could not be applied to the scans.
Therefore there were nine patients in whom quantitative analysis could be 
performed.
Table 55 shows the results of the quantitative [F-18] FDG PET analysis 
performed on the patients who received ADEPT with A5CP and ZD2767.
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Table 55: Quantitative analysis of [F-18] FDG PET scans in 
patients who received ADEPT (A5CP and ZD2767P)
Pt
No.
Assessment
time
CT scan 
response
VOI
total
counts
mean volume max
#15 4 wks SD 539% 73% 738% 77%
8wks SD 758% 82% 924% 88%
#19 4 wks SD 138% 90% 154% 96%
8wks PD 161% 92% 175% 101%
#18 4 wks SD X X X X
8wks SD NA NA NA NA
#11 4 wks PD 146% 106% 138% 109%
8wks PD 114% 120% 135% 128%
#14 4 wks PD 381% 125% 305% 165%
8wks NA NA NA NA NA
#20 4 wks PD 81%
(111%)
94%
(104%)
87%
(107%)
107%
(107%)
8wks PD 114%
(162%)
108%
(121%)
105%
(134%)
109%
(109%)
#24 4 wks PD 59% 79% 75% 79%
8wks *PD 102% 102% 100% 98%
#26 4 wks PD 184% 91% 201% 92%
8wks PD 182% 62% 293% 66%
#23 4 wks PD X X X X
8wks PD NA NA NA NA
The quantitative [F-18] FDG PET analysis results on the nine patients in whom 
analysis was possible participating in the ADEPT A5CP and ZD2767P clinical 
trial Values are expressed as a percentage o f baseline value. Where applicable, 
values obtainedfrom VOI subtraction are identified in parenthesis. It was not 
possible to define tumour regions on patient #18, as the tumour was adjacent to 
the bladder, and could not be differentiated from it, or on patient #23, as there 
was inadequate tumour differentiation from background for regions to be 
generated.
*Patient #24: one o f two mediastinal lesions had progressed by on CT scan at 4 
weeks, but by 8 weeks the dimensions o f this lesion had decreased in size and 
showed no change when compared to baseline. According to the response 
criteria used in this study, the response assigned was progressive disease 
because o f the initial progression recorded
Abbreviations: PD -  progressive disease; SD -  stable disease; VOI -  volume o f  
interest; NA -  not applicable; X -  not able to be analysed by this technique.
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The automated region drawing program was able to define tumour regions on 
seven o f the nine patients (78%). In one patient (patient #18) the tumour was a 
presacral mass and situated immediately adjacent to the bladder. The region 
growing program was unable to draw the lesion, as the region drawn spread to 
the bladder as it was hotter than the tumour. Even with subtraction techniques the 
presacral mass could not be defined. The second patient’s tumours were not 
sufficiently contrasted from the background tissues to allow region generation 
(patient #23). In one patient (patient #20) VOI subtraction was required to define 
visually acceptable tumour regions, and the VOI subtraction values were deemed 
more representative than the VOI values (displayed in Figure 59)
Figure 59: VOI and VOI subtraction in patient #20
[F-18] FDG PET images from patient #20 in ADEPT A5CP and ZD2767P 
clinical trial. The [F-18] FDG PET scans are volume images performed a) pre  
ADEPT, b) 4 weeks after ADEPT and c) 8 weeks after ADEPT. The volumes o f  
interest (VOI) obtained are displayed, along with the volume o f interest obtained 
using subtraction (VOI subtraction). The VOI subtraction images appear more 
representative o f the total tumour mass than the VOI images.
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Three patients had stable disease on CT scan at 4 weeks, two of which continued 
to have stable disease on CT scan at 8 weeks post ADEPT. VOI analysis was 
performed on two of these patients and both showed an increase in VOI total 
counts at 4 and 8 weeks. Therefore the [F-18] FDG PET scans in these patients 
suggest progressive disease.
Of the seven patients who had progressive disease at the 4 and 8 week CT scan, 
five had VOI analysis performed. The median VOI total counts value at 4 weeks 
in these patients was 146% (range 59-381%), and at 8 weeks was 132% (range 
102-182%). Using an increase of total counts on VOI analysis to 110% compared 
to baseline as a PET definition for progressive disease, four of the five patients 
had PET progressive disease at 4 and 8 weeks. The fifth patient was patient #23, 
in whom the CT scan at 4 weeks showed progression of one mediastinal mass, 
which reduced in size by 8 weeks. This patient had a CEA expressing non small 
cell lung cancer with mediastinal lymphadenopathy, previously treated with 
radiotherapy. The mediastinal masses were very difficult to assess and measure 
on CT scan as there was uncertainty as to whether abnormal tissue was active 
tumour, or scarring post radiotherapy. This patient had stable tumour markers 
with treatment (pre-treatment CEA 85jLLg/l, 4 weeks 88pg/l, 8 weeks 92pg/l) and 
remained well on follow-up without the requirement for further chemotherapy or 
radiotherapy for 10 months after completion of ADEPT. The patient then 
relapsed with brain metastasis. The [F-18] FDG PET scans on this patient are 
shown in figure 60. The quantitative analysis shows a VOI total count statistic of 
59% of baseline at 4 weeks and 102% at 8 weeks. There was a large reduction in 
the background normal tissues at 4 weeks (liver mean counts/voxel was 72% of 
baseline), which had returned to acceptable limits by 8 weeks (liver mean 
counts/voxel was 102% of baseline), which will account for some of the 
reduction in tumour [F-18] FDG uptake at 4 weeks. However, even with 
allowance for this, it appears that the metabolic activity of the tumour at least 
remained stable with ADEPT in this patient.
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Figure 60: [F-18] FDG PET scans ADEPT patient #24
ADEPT A5CP pt24
M ediastinal  
, tum our
3lMarl999 06Mayl999 l lJ u n l9 9 9
[F-18] FDG PET scans on ADEPT patient #24 taken pre treatment and at 4 and 
8 weeks after commencement o f  treatment. Visually equivalent transverse slices 
through the mediastinum are displayed, along with volume images.
There were three patients in whom the statistics obtained from the normal tissue 
regions (liver and lung), and the histograms, suggested a large variation in 
background [F-18] FDG uptake. These were patients #14, #24 and #26. These 
results may need, therefore, to be interpreted with caution.
306
6.2.2 ADEPT MFECP1 and ZD2767P
Method
[F-18] FDG PET scans were a voluntary component of the ADEPT MFECP1 and 
ZD2767P clinical trial, and were performed pre study, at 2-4 weeks and then 8 
weeks post ADEPT therapy. Patients were asked to fast for five hours prior to 
injection of 130 MBq of [F-18] FDG. Scans were performed at 90 min on the 
AD AC Vertex Plus Co-Incidence camera. Acquired data was reconstructed using 
standard iterative protocols, with attenuation correction (attenuation maps were 
acquired using Caesium-137 sources).
Emission scans had a 50.8cm field of view and were acquired according to the 
manufacturer’s recommendations. Correction for decay was applied on the fly. 
Most patients had 2 rotations performed; however some patients required 3 
rotations.
Reconstruction was performed using standard AD AC iterative reconstruction 
protocol, with attenuation correction applied based on transmission data.
Analysis of [F-18] FDG PET was performed after correction for injected dose 
and time to scanning. A formal correction for blood glucose levels was not made, 
however data with blood glucose levels outside the range 4-7mmol/L were 
deemed unreliable.
Analysis was performed using lesion statistics derived from the regions obtained 
from the automated region drawing program, as described above. Count density 
histograms were also displayed for tumour and normal tissue (live, lung, chest 
wall) regions.
CT scans were performed on patients prior to the commencement of ADEPT and 
at 4 and 8 weeks after ADEPT as outlined in the trial protocol (chapter 4) 
Response on CT scan was assessed using unidimensional measurements as part 
of the RECIST criteria (Therasse et al, 2000).
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Results
Nine of thirteen patients participated in the [F-18] FDG PET component of the 
ADEPT study (table 56).
Table 56: [F-18] FDG PET scans in ADEPT MFECP1 and
ZD2767P clinical trial
Pt No. Number of 
[F-18] FDG 
PET scans
Comment
#1 0 Camera fault
#2 2 2nd scan -  problems with [F-18] FDG injection
#3 2 3rd scan - patient too unwell
#4 2 3rd scan - camera fault
#5 3
#6 2 scan 1 - corrupt data
#7 3
#8 3
#9 2 2nd scan performed at 6 weeks. No 3rd scan
#10 0 Patient refused
#11 2 3rd scan - camera fault
#12 0 Camera fault
#13 0 Camera fault
Quantitative analysis was performed in seven of these patients’ scans (the data 
acquired for patient #6 was corrupt and no analysis could be performed, and 
problems with the injection of [F-18] FDG for the second scan for Patient #2 
meant that the exact injected dose was uncertain).
All patients show an increase in tumour [F-18] FDG uptake after ADEPT (see 
Table 57) In two patients (#8 and #11) tumour regions could not be defined on 
the baseline [F-18] FDG PET scan, however they could be defined on the post 
treatment scan. This would be consistent with disease progression (PD). 
Quantitative analysis of Patient #9 revealed an abnormal degree of change in [F- 
18] FDG uptake in background normal tissues (lung and chest wall) between the 
pre-study and 6 week scan, which would suggest that the quantitation of tumour 
[F-18] FDG uptake may not be reliable.
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The patient with the smallest increases in tumour [F-18] FDG uptake by VOI 
total counts was patient #7, who attained stable disease on CT scan. This may 
indicate that the degree of tumour progression in this patient was less than for the 
other patients, however, the small sample size makes further interpretation 
difficult.
Table 57: [F-18] FDG PET analysis of patients in ADEPT trial of
MFECP1 and ZD2767P
Pt
No.
Assessment
time
CT scan 
response
VOI
total
counts
mean volume max
#7 4 wks SD 109% 120% 90% 128%
8wks SD 126% 129% 98% 138%
#11 4 wks SD PD PD PD PD
8wks SD ND ND ND ND
#3 4 wks PD 240% 98% 244% 106%
8wks PD ND ND ND ND
#4 4 wks PD 129% 138% 94% 158%
8wks NA ND ND ND ND
#5 4 wks PD 173% 120% 144% 134%
8wks PD 469% 124% 379% 147%
#8 4 wks PD PD PD PD PD
8wks PD PD PD PD PD
#9 4 wks PD ND ND ND ND
8wks PD *601% *224% *268% *227%
The quantitative [F-18] FDG PET analysis results on the seven patients in whom 
analysis was possible participating in the ADEPT MFECP1 and ZD2767P 
clinical trial. Values are expressed as a percentage o f baseline value.
* background ‘normal 7 tissues in this patient varied greatly between scans, 
indicating that data may not be accurate.
Reasons for ND (not done): Patient #3 too unwell for 8 weeks scan; Patients #4 
and #11 AD AC camera fault for 8 weeks scan; Patient #9 scan performed at 6 
weeks due to fault in AD AC camera prior to this.
Abbreviations: PD -  progressive disease; SD -  stable disease; VOI -  volume o f 
interest; NA -  not applicable; ND -  not done; X -  not able to be analysed by this 
technique
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Figure 61 displays the volume of interest drawn by the automated region 
growing program for patient #5. Figure 62 displays the count density histogram 
for the tumour volumes. The count density histogram and the lesion statistics in 
this patient indicate tumour progression, with an increase in tumour [F-l 8] FDG 
uptake after treatment with ADEPT. Figure 63 displays the count density 
histograms of the normal tissues (liver, lung, chestwall) from patient #5, showing 
very little variation in background [F-18] FDG uptake between scans.
Figure 61: VOI derived from automated region growing
program for patient #5
Figure 61 a) displays equivalent transverse slices o f the three [F-18] FDG PET 
scans performed on patient #5. The images show a liver metastasis from 
colorectal cancer. Figure 61 b) displays the tumour region derived using the 
automated region drawing program at the same transverse slice. Figure 61 c) 
displays the tumour region subtracted out o f the image.
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Figure 62: Count density histogram of tumour regions
from patient #5
Count density histograms o f  the tumour regions derived from patient #5 using the 
automated region drawing program. The tumour region derived from the 
pretreatment [F-18] FDG PET scan is red, the 4 week scan is the green line and 
the 8 week scan is the yellow line. There has been a right shift on the x-axis after 
treatment, representing an increase in intensity o f [F-18] FDG uptake. There is 
also an increase in volume o f  the tumour region after treatment, as represented 
by an increase in area under the curve. The increase in both intensity and 
tumour volume are consistent with tumour progression.
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Figure 63: Count density histograms of normal tissue
regions from patient #5
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Normal tissue count density histograms from patient #5 taken pre ADEPT, then 2 
and 8 weeks post ADEPT.
a) Liver
b) Lung
c) Chestwall
There is very little variation in the background tissues, suggesting the 
background tissues did not change significantly between scans, This supports the 
concept that the changes found in the tumour areas were real changes, and not 
as a result o f variations in the overall [F-18] FDG uptake in the scans.
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Figure 64 displays the [F-18] FDG PET images from patient #7 who attained 
stable disease on CT scan at 4 and 8 weeks.
Figure 64: ADEPT MFECP1 and ZD2767P -  patient #7
[F-18] FDG PET scans (transverse slices and volume display) performed on 
patient #7 pre ADEPT and at 2 and 8 weeks after ADEPT. CT scans at 4 and 8 
weeks after ADEPT when compared to baseline fulfilled the RECIST criteria for  
stable disease. [F-18] FDG PET quantitative analysis using lesion statistics 
demonstrated an increase in tumour [F-18] FDG uptake at 2 weeks, which had 
further increased at 8 weeks post treatment. This is consistent with progressive 
disease by [F-18] FDG PET analysis.
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6.3 Discussion
[F-18] FDG PET scans were performed as part of the ADEPT phase I/II clinical 
trials to enhance the assessment of response to ADEPT and to aid in the 
interpretation of radiological stable disease.
The concept of using [F-18] FDG PET to assess dose-responsiveness of a phase I 
drug was proposed in 1995 by Price et al (Price et al, 1995). This concept can be 
adapted for ADEPT phase I/II clinical trials as they are dose-escalation studies. It 
is proposed that at initial prodrug doses there may be an initial increase in tumour 
[F-18] FDG uptake as the prodrug dose is inadequate for therapeutic effect. As 
therapeutic doses are reached the tumour [F-18] FDG uptake reduces. If there is a 
dose-dependent effect on the tumour, tumour [F-18] FDG uptake may reduce 
incrementally with increasing prodrug doses. This could provide evidence for 
efficacy of ADEPT, even if radiological imaging did not result in ‘responses’.
[F-18] FDG PET to assess response to ADEPT will be discussed below in terms 
of the interpretation of the [F-18] FDG PET results in both ADEPT studies and a 
discussion of the technical issues and feasibility of using [F-18] FDG PET for 
response assessment
6.3.1 Response in ADEPT phase I/II clinical trials as assessed by [F-18] 
FDG PET
In the ADEPT clinical trial of A5CP and ZD2767P, all patients, except patient 
#24, had an increase in tumour [F-18] FDG uptake after ADEPT. The two 
patients (#15 and #19) who had radiological stable disease and [F-18] FDG PET 
scans suitable for quantitative VOI analysis, both had increases in tumour [F-18] 
FDG uptake, indicating a lack of response to ADEPT. This would be consistent 
with the trial’s mechanistic study findings, which indicate that there was 
inadequate tumour targeting of A5CP. This would lead to a very low likelihood 
of efficacy.
Anecdotally, patient #24, who was a chemo-naive patient with mediastinal lymph 
node involvement from non small cell lung cancer, had an initial reduction in
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tumour [F-18] FDG uptake and then returned to baseline levels of [F-18] FDG 
uptake. The background normal tissues also showed a drop in [F-18] FDG uptake 
at the 4 week PET scan, which may account for some of the fall in tumour [F-18] 
FDG uptake. At 8 weeks the background [F-18] FDG uptake and tumour [F-18] 
FDG uptake was stable. This patient’s CT scan was difficult to interpret due to 
previous mediastinal radiotherapy leading to some uncertainty as to the size of 
mediastinal lymph nodes. This is an area where CT scans have limitations, as 
differentiation between post radiotherapy fibrosis and tumour recurrence cannot 
be easily identified. The CT scan measurements indicated an increase in tumour 
size at 4 weeks and a reduction to baseline tumour size at 8 weeks. This patient 
did not, however, require any further treatment for her non small cell lung cancer 
for 10 months after ADEPT, and her tumour markers remained stable. This 
patient had many features that would increase the likelihood of her tumour 
responding to ADEPT. Non small lung cancer is known to be responsive to 
alkylating agents, she had not had any previous chemotherapy and the volume of 
her disease was small. It is possible therefore, that in this one patient, tumour [F- 
18] FDG uptake was stable after ADEPT, and metabolically the tumour may 
have therefore been stable with treatment.
In the ADEPT study of MFECP1 and ZD2767P, again all tumours showed an 
increase in tumour [F-18] FDG uptake after ADEPT. This included two patients 
with stable disease on CT scan. This trial remains in the dose escalation phase, 
with dose escalation occurring at dose-doubling rates. The preclinical data 
suggests that a much higher prodrug dose than is currently being used is required 
for efficacy. It is again, therefore, not unexpected that there has been no 
reduction in tumour [F-18] FDG uptake after ADEPT, as the prodrug doses used 
so far in the clinical trial are likely to be subtherapeutic. It is perhaps 
encouraging that the smallest increase in tumour [F-18] FDG uptake occurred in 
patient #7, who attained radiological stable disease after ADEPT. This may 
suggest that there has been some minor effect of ADEPT in this patient, by 
reducing the amount of tumour [F-18] FDG uptake relative to the other patients, 
or it may just be a reflection of a more indolent disease in that patient.
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As none of the patients participating in either ADEPT clinical trial had a 
response to ADEPT on their [F-18] FDG PET scans, it appears unlikely that any 
patients have had a metabolic response to therapy. The reasons for this are 
understood -  for ADEPT with A5CP and ZD2767P, there was inadequate 
localisation of antibody-enzyme, and for ADEPT with MFECP1 and ZD2767P 
dose escalation in continuing. It is difficult therefore to accept or refute the 
hypothesis that [F-18] FDG PET may be more sensitive in detecting a response 
to ADEPT than conventional imaging. [F-18] FDG PET imaging did, however, 
appear useful in the interpretation of radiological stable disease. In the four 
combined patients from both ADEPT trials who had stable disease on CT scan 
and quantifiable [F-18] FDG PET scans, all appeared to have progression of 
disease by metabolic imaging.
6.3.2 Technical issues in using [F-18] FDG PET for assessment of response 
in ADEPT
Attenuation correction
[F-18] FDG PET scans performed on patients in the ADEPT A5CP and
ZD2767P study were performed without attenuation correction. This presents
several potential problems. Firstly the patients must be scanned with their arms
out of the field of view (usually held above their head), as the arms will attenuate
the emissions from the body. This can be very difficult for the patient as the scan
time is usually 60 minutes. Secondly a uniform correction algorithm of ellipses
had to be applied to the scan for attenuation correction (Chang, 1978). This is
based in the principle that the deeper within the body that the photon originated
from, the more the attenuation that occurs prior to it reaching the detectors. This
method does not take into account the different amounts of attenuation that occur
as the photon passes through different substances. Air, water and solid organs all
attenuate the photon differently. Transmission scans identify these different
states in order to apply an appropriate correction for the attenuation that occurs in
the photon as it passes through. However, without this information the correct
attenuation factor cannot be applied. Consequently, the ability to detect small
lesions, particularly in the lung, is reduced without measured attenuation
correction (Ak et al, 2001). In addition, the differentiation between tumour and
316
normal tissues may not be as well defined as with attenuation corrected images. 
This may hinder the ability of the automated region drawing program to depict 
tumour regions.
Despite these limitations, it was possible to define tumour regions using the 
automated region growing program, in seven of nine patients. In two patients the 
automated region growing program could not define the tumour -  in patient #18 
the tumour was a presacral mass and was adjacent to the bladder. Even when 
subtraction techniques were employed, the tumour could not be generated as the 
tracer within the bladder could not be separated from the tumour. In patient #23, 
there was inadequate differentiation between tumour and surrounding liver to 
allow a region to be generated. This patient’s scans are displayed below (Figure 
65). There was one patient (patient #20) in whom the initial tumour region did 
not appear representative of the entire tumour, therefore VOI subtraction was 
employed.
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Figure 65: [F-18] FDG PET scans from Patient #23
ADEPT A5CP and ZD2767P
Chang attenuated [F-18] FDG PET scans (transverse slice and volume display) 
on patient #23 performed a) pre and b) post treatment with ADEPT A 5CP and 
ZD2767P. The differentiation between tumour (liver metastasis from colorectal 
cancer) and normal liver was not adequate for region generation.
Singles count rates and detector flooding
In the ADEPT A5CP and ZD2767P study the data on eleven patients could not 
be used as it was found that the injected dose of [F-l 8] FDG and the time to 
scanning were such that the acquired singles count rate exceeded the quantitative 
range of count rate capability o f the camera. This resulted in ‘flooding’ of the 
detectors. Consequently the relationship between count rate and radioactivity at 
these high levels was non-linear, and therefore was not quantitative.
Scan setup and patient preparation
In the ADEPT A5CP and ZD2767P trial [F-18] FDG PET scans were performed 
at 60 minutes post administration o f [F-18] FDG. As previously discussed 
evidence is emerging that the uptake of [F-18] FDG into tumour cells may not
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have reached a plateau at this time point, and waiting longer between time of 
injection and time of scanning would therefore be more desirable for 
reproducible results. The protocol developed in the [F-18] FDG PET assessment 
study (chapter 5) was followed for the ADEPT MFECP1 and ZD2767P study, 
with the injected dose of [F-18] FDG reduced to 130MBq and the time of 
scanning to 90 minutes. In addition [F-18] FDG PET scans were performed at 2 
weeks rather than 4 weeks after treatment. This, along with the additional 
advantage of having measured attenuation correction available for the ADEPT 
MFECP1 trials means that the data collected from this study is more comparable 
with the results obtained from the [F-18] FDG PET assessment study than the 
ADEPT A5CP trial.
As discussed in chapter 5, it is of critical importance that if serial [F-18] FDG 
PET scans are to be used to assess response to therapy, the patient preparation 
parameters and scan setup parameters must be kept as constant as possible 
between scans. This includes injected [F-18] FDG dose, time to scanning, fasting 
time, number of rotations scanned, patient’s position on the camera, camera start 
and stop points. This allows the possible confounding effects of all of these 
features to be minimised as much as possible. The count density histograms of 
the normal tissues (liver, lung, chest wall) are used as an indication of how much 
the ‘background’ of the scan has varied at serial time points. The majority of 
patients, especially in the ADEPT MFECP1 study, had normal tissue regions that 
remained very consistent in their [F-18] FDG uptake between scans. This 
improves the likelihood that a change in tumour [F-18] FDG uptake is a true 
tumour specific effect related to the therapy given, rather than a global ‘whole 
body’ change in [F-18] FDG uptake.
6.3.3 Feasibility of using [F-18] FDG PET in the assessment of response in 
phase I/II ADEPT clinical trials
The addition of [F-18] FDG PET scans to the trial protocol appeared feasible, 
with the main reason that some patient did not complete the [F-18] FDG PET 
scans being camera faults. The availability of off-site [F-18] FDG was adequate 
in both the clinical trials and did not prove to be a limiting factor.
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The main limitation to the addition of the [F-18] FDG PET scans to the ADEPT 
trial protocols is that it requires patients to have three additional scans. Patients 
who participate in phase I/II clinical trials may undergo a large number of 
invasive or non-invasive tests as a result of being in a clinical trial. The addition 
of three [F-18] FDG PET scans may be too much of a burden for some patients.
It was for this reason that the [F-18] FDG PET component of ADEPT was made 
optional in the ADEPT MFECP1 study.
The region growing program for the delineation of tumour regions and the 
subsequent interpretation of these regions using lesion statistics and histogram 
analysis was successfully applied in the majority of patients. Two of nine 
patients (22%) could not have regions defined in the ADEPT A5CP group. The 
absence of true attenuation correction for these scans may have contributed to the 
difficultly in defining tumour regions in these patients. Two of the seven patients 
in the ADEPT MFECP1 group could not have tumour defined on the baseline 
scan, but they were defined on subsequent scans, indicating a progression of 
disease. Unfortunately however, because the initial tumour regions could not be 
defined, the degree of progression could not be quantified.
6.4 Conclusion
Both ADEPT clinical trials reported in this thesis included [F-18] FDG PET for 
the assessment of response to therapy. This was undertaken in order to ascertain 
if [F-l 8] FDG PET was more sensitive than conventional radiological imaging in 
the detection of response in a phase I/II clinical trial setting, and to assist in the 
interpretation of radiological stable disease. None of the patients in either 
ADEPT clinical trial, including those who attained stable disease on CT scans, 
demonstrated a metabolic response to ADEPT using [F-18] FDG PET. The 
reasons for a lack of response to ADEPT are understood, and the [F-18] FDG 
PET analysis results therefore supported the findings of the mechanistic studies 
performed in both clinical trials.
The inclusion of [F-18] FDG imaging protocols in future ADEPT clinical trials
appears feasible, and the VOI analysis technique developed and validated in
chapter 5 were applicable in the phase I/II clinical trial setting. The collection of
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more data as the ADEPT MFECP1 clinical trial progresses will be valuable to 
the understanding of the role metabolic tumour imaging may have in the 
assessment of response to therapy in phase I/II clinical trials.
321
7 ADEPT Conceptual Model and Ontology
7.1 Background
Mechanistic trials generate large quantities of data, which can be overwhelming. 
Interpreting this data into knowledge is challenging, especially as increasing 
information is attained. The clinical trials reported in this thesis are the third and 
fourth ADEPT clinical trials using this particular ADEPT system, and integrating 
clinical trial data from all four trials would greatly add to knowledge, but 
logistically is difficult. In addition the world-wide knowledge base about 
tumours, targets, genomics, proteomics and novel therapeutics is constantly 
growing and changing rapidly. A system of organising and integrating all of this 
data is therefore required. It is proposed that this process will facilitate clinical 
trial design and further direct the rational development of ADEPT.
7.2 Aim
Informatics aims to organise data in a meaningful way for the purpose of aiding 
interpretation and knowledge of complex data. Bioinformatics is ‘the application 
of tools of computation and analysis to the capture and interpretation of 
biological data* (Bayat, 2002). Bioinformatics has been adopted as the term used 
to describe the organisation of molecular and pathway data, whereas informatics 
refers to the organisation of non-molecular data. Both informatics and 
bioinformatics are rapidly expanding fields. The Human Genome Project and the 
advent of array technology have been some of the driving forces behind it. The 
amount of data that has been generated on genomics and proteomics has been 
astronomical. Organising these data into a form that can be accessed by others, 
and used in a meaningful way has been challenging.
One method of organising data is by using a relational ontology. An ontology has 
been defined as specification of a conceptualisation, or a description of all the 
concepts and relationships of a specified agent (Gruber, 1993). An ontology is 
designed to enhance ‘knowledge sharing’ or re-use of knowledge. A relational 
ontology aims to list concepts and relationships in a hierarchical way. Ontologies
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are now publicly available via the internet for gene and protein structure and 
function. They have been developed with the aim of organising this information 
and making it more accessible.
It is hypothesised therefore that the development of a hierarchical ontology of 
ADEPT may aid in the organisation of the data acquired from ADEPT. The 
ontology is used to define the key terms of ADEPT. A conceptual model may be 
additionally used in order to visually represent the overlap and relationship 
between components. From this identification of terms and relationships a 
database may be developed in which the mechanistic data acquired from ADEPT 
may be stored in an organised manner, which would be accessible for queries. 
The organisation of data may also be useful to direct clinical trial design by 
identifying where more data needs to be collected to develop an understanding of 
the mechanism of ADEPT in the clinical setting. It may also help identify and 
direct the areas of modification required to enhance ADEPT for the future.
The three aims of the ADEPT Ontology and Conceptual Model therefore were to
1) organise the data acquired from ADEPT
2) aid in clinical trial design by identifying areas where the acquisition of 
mechanistic data may provide useful information to improve the 
understanding of ADEPT in the clinical setting.
3) identify areas of ADEPT which may require improvement
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7.3 ADEPT Ontology
7.3.1 Method
The ADEPT ontology was created using Protege-2000, an ontology tool, from 
Stanford University School of Medicine (Protege, 2000). Protege-2000 is an 
open-source java tool for creating the architecture for a hierarchical ontology. It 
consists of ‘classes’, which are the components of the agent being described, and 
‘slots’ which make up the features and attributes of the classes. ‘Instances’ 
consist of data entered into the slots, and can form, in conjunction with the 
Ontology and its classes, a knowledge base.
In practical terms, classes of the Ontology are defined, and then ordered into a 
subclass-superclass hierarchy. Slots are then developed, which are ‘data entry 
points’. Limitations can be made on the type of data entry required. For example 
it is possible to stipulate if a description is required or a yes/no data point. In 
addition, data may be compulsory or optional. The data that is entered is into the 
slots are the ‘instances’.
It was beyond the scope of this current work to fully define all slots and instances 
for the ADEPT Ontology. Instead, the class structure was the main focus, and 
examples of slots and instances have been used throughout.
324
7.3.2 Results
The ADEPT Clinical Trials Ontology has five ‘superclasses’: Patient, Tumour, 
Target, Therapeutic and Therapy (figure 66). Each will be described individually 
below.
Figure 66: ADEPT Ontology -  superclasses
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®" © t u m o u r ”
© ■ © t a r g e t ”
© ■ © t h e r a p e u t ic ”
© ■ © T H E R A P Y
Patient
The patient forms the environment in which any therapy is ultimately tested. 
Being able to access data that describes and defines the patient is therefore 
required. This allows a record to be kept of the features o f the patient group in 
which a therapy has been tested. Clinical trial protocols will outline inclusion and 
exclusion criteria, aimed to define a relatively homogenous physiological 
environment within a patient group. In particular body systems such as renal 
function, liver function and bone marrow function may influence biodistribution, 
metabolism, excretion and toxicity from a therapy. These will usually have limits 
placed on them and values recorded for them in a clinical trial. Additional 
information that may be important to store include patient demographics (age, 
gender, body surface area), a record o f current medications and any co­
morbidities.
In addition the patient has a disease state which, for this ontology, is cancer. This 
also needs describing in terms of tumour type and classification (link to 
TUMOUR superclass), previous treatments, and an assessment of disease burden 
-  which may require re-assessment at a variety o f time points. These assessments 
may consist o f a record o f disease sites, radiological assessment (eg: CT scan), 
functional imaging assessment (eg: [F-18] FDG PET), tumour markers and 
temporal measures such as survival (figure 67).
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Figure 67: Patient subclasses in Ontology
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Tumour
There are a variety of different ways of describing or classifying a tumour 
(figure 68). One method is by a histological classification, which may include 
either Medical Subject Headings (MeSH® classification) or a histological 
description. The MeSH® classification is a controlled vocabulary developed by 
the National Library of Medicine (NLM) to facilitate searching for articles in 
MEDLINE® and other collections. It is useful as it provides a standardised 
language that can be cross-referenced back to MEDLINE® and other search 
tools (http://www.nlm.nih.gov/mesh) (NLM, 2002). It does not however provide 
specific data about the individual tumour.
Conventionally tumours have been described by their histological appearance 
after surgical resection. This may include histological cell type, grade, stage, 
TNM classification, presence or absence of vascular or lymphatic invasion, 
number of lymph nodes involved, degree of differentiation, information on 
proximity of tumour to resection margins and immunohistochemistry findings. 
This information has been used to decide clinical decisions with regard to 
treatments and prognosis (Stangl et al, 1994; 2Compton et al, 2000).
An alterative to the histological approach to classifying and describing tumours, 
there is now a molecular approach, based on the genomic and/or proteomic 
features of the tumour. Molecular data may be useful for identifying targets for 
therapy, or by establishing molecular features which are associated with 
increased or decreased likelihood of responding to a particular treatment (Adlard 
et al, 2002).
A gene ontology termed GO (Gene Ontology) has been developed by the Gene 
Ontology Consortium (The Gene Ontology Consortium, 2001). It may be 
accessed by amiGO, which is an HTML browser for the Gene Ontology, and 
allows navigation through the Ontology via the internet (www.godatabase.org). 
The Gene Ontology is actually three ontologies used to describe attributes of 
gene products. These three ontologies are biological process, cellular component 
and molecular function.
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Ensembl is a genome database that collects and stores all available genomic data 
(www.ensembl.org). DNA sequences or known genomic constructs can be 
located and viewed via the database.
An example of a database o f proteins is InterPro (www.ebi.ac.uk/interpro) 
(Apweiler et al, 2000). It consists o f protein families, domains and functional 
sites in which identifiable features found in known proteins can be applied to 
unknown protein sequences.
These gene and protein ontologies and databases could be linked to by the 
ADEPT clinical trial ontology or database, in order to access molecular 
information relevant to the tumours being studied.
Figure 68: Tumour subclasses
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Potential targets for tumour-directed treatments may be part o f the tumour cell or 
may occur in the surrounding tumour vasculature or stroma (figure 69). 
Genomics and proteomics are having an increasing role in defining specific 
molecular features of tumours, which may represent abnormalities o f ‘normal’ 
biological processes (Saijo et al, 2003; Workman, 2003). These may form 
suitable targets for novel treatments. As part of the Ontology, links could be 
created between the superclass TARGET and known genomic and proteomic 
databases and Ontologies to facilitate target identification and characterisation.
For the purpose of this Ontology, the Proteomic subclass of Tumour Cell has 
been further subdivided into Cell Process, Differentiation Antigen, 
Immunoglobulin Idiotype or Tumour Antigens. The cell processes in tumour 
cells which may be targeted include signal transduction pathways (eg: growth
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factor receptors, tyrosine kinases, RAS signal transduction proteins), cell cycle 
regulators (eg: cyclin-dependent kinases) or apoptotic pathways (eg: p53). 
Differentiation antigens (eg: CD20, CD25, CD33) and immunoglobulin idiotypes 
(B cell lymphomas) are of particular relevance to haematological malignancies. 
Melanomas may however also express differentiation antigens (eg: 
MelanA/MART-1, gplOO/Pmel 17, gp75/TRP-l) (Roitt et al, 2001) Tumour 
antigens are a heterogenous group o f molecules that have been found to be 
associated with tumours, but their molecular role in carcinogenesis is not always 
well understood. These may include the oncofetal proteins (carcinoembryonic 
antigen, alphafetoprotein, human chorionic gonadotrophin), cancer testis antigens 
(eg: MAGE, GAGE, BAGE), or other glycoproteins (eg: CA17-1A, CA19-9, 
CA15-3).
Figure 69: Target subclasses
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The Tumour Antigen subclass has had slots defined for it in the Ontology, as this
is o f particular relevance for the ADEPT system discussed in this thesis. These
slots aim to define the characteristics o f the tumour antigen. They include name,
classification, molecular size, structure, chromosome, function, site (intracellular
or cell surface), normal tissue expression, distribution in tumour, mechanism of
expression, secreted form (yes or no), cancer types which express it, possible
cross-reactivity, prevalence, method of measurement of serum levels and tumour
levels o f expression, and values for serum quantity or tumour quantity of
expression. These slots have been chosen as they both describe the antigen, and
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are of relevance to its usefulness as a target. There are also slots linking the 
instance to known Ontologies and Databases available on the internet. These 
include GO gene consortium (www.godatabase.org), the Ensembl gene database 
(www.ensembl.org), InterPRO (www.ebi.ac.uk/interpro) and Swiss-Prot 
(www.ebi.ac.uk/swissprot).
CEA, as the target for ADEPT in this thesis, has been entered in as an Instance 
(figure 70). The characteristics of CEA have been listed and links to the gene 
and protein databases recorded. These existing databases allow access to detailed 
information such as chromosome location, DNA sequence, amino acid sequence 
and function. An example of some of the information that can be accessed is 
displayed in figure 71.
CEA is just one of many possibilities as a target for a treatment such as ADEPT. 
Listing the attributes of a target may aid in deciding the most appropriate target 
to use for a particular treatment. It will also influence the development process 
for a therapeutic agent. The target itself may have features that will contribute to 
the success or failure of a treatment, and recognising these features should be a 
part of the design of a therapy.
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Figure 70: Tumour Antigen Slots with CEA entered as an
Instance
p  Carcinoembryonic antigen (CEA) (type=TUMOUR ANTIGEN, name=APEPT2_00142)
name
Carcinoembryonic antigen (CEA)
Classification vfcl -
loncofetal antigen
Cancer Types Vtttich Express K vjc] -
Colorectal cancer
Breast cancer
Gastric cancer
Oesophageal cancer
=>ancreatic cancer
NSCLC
Prevalence
m:>
!
Wmost universally expressed in colorectal cancer
Secreted Form
yes ▼I
Site
cell surface ▼
Distribution In Tumour vfct -
liable tumour areas
Normal Tissue Expression
Molecular Weight
I80k0a
Structure
Part of immunoglobulin superfamily 
702 amino acids 
Highly glycosylated 
27-33nm
7 domains (CEA1-7) arranged in linear zig-zag pattern
Function rvr c
Cell adhesion molecule (possibly)
Immune regulation in Gl tract (possibly)
Chromosome
ET"
Mechanism Of Expression vTc]
overexpression
Possible Cross-reactivity vfcf-
Granulocytes 
Monocytes 
Kupffer ceils 
Bile canaliculi 
Pancreastlc acini 
Lymphocytes
Glycocalyx of microvilli on the columnar epithelium of the colon flumlnal side only)
vi c
Measui ed By (serum) V [g -
radioimmunoassay
Value Tumour C Measured By (tumour) C
Immunohistochemistry
radiolimmunoluminography -
GO Gene Consortium Entry ;v c -
00:0005887 Integral to plasma membrane
Ensembl rvfci-
IENSG00000105388
InterPRO IvTcFJ
IPR007110 Immunoglobulin-llke
Swiss Prot V 0  -
P06731 CEA5_Human
Amino Acid Sequence v@  -
MESP8APPHR WCIPWQRLLL TASLLTFWNP 
PTTAKLTIE8 TPFNVAEGKE VLLLVHNLPQ 
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OSLPVSPRLQ LSNDNRTLTL LSVTRNDVGP 
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LPVSPRLQLS NGNRTLTLFN VTRNDARAYV 
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GIPQQHTQVL FIAMTPNNN GTYACFVSNL 
ATGRNNSIVK SITVSA8GTS PGLSAGATVG 
IMIGVLVGVAU
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Figure 71: CEA chromosome location and sequence
information
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Therapeutic
The THERAPEUTIC superclass may be divided into the therapeutic type or may 
be described in terms of the characteristics of the therapeutic. The type of 
therapeutic may include chemotherapeutics, radiation therapy, hormonal 
treatments, small molecules, gene therapies and antibody therapies. Antibodies 
may be used as biomodulators or as targeting agents (see chapter 1). As 
targeting agents they may be used for tumour directed delivery of radiation, 
toxins, chemotherapeutics, or a ‘tag’ which will be recognised by a second 
administered therapeutic as part o f a pretargeted strategy. ADEPT is a 
pretargeted strategy, with the enzyme being the ‘tag’ used to activate prodrug to 
active drug in tumour sites (figure 72).
Figure 72: Therapeutic type subclasses
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Therapeutics may be also described in terms o f their individual characteristics. 
ADEPT consists o f two therapeutic entities, an antibody-enzyme targeting 
molecule and a prodrug activation system. In addition the antibody-enzyme 
moiety may either be described as a whole or in terms of its individual 
components -  antibody and enzyme.
Each therapeutic component may be described in terms of structure, function, 
method of production, manipulation of product, in vitro and in vivo
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characteristics (figure 73). The antibody-enzyme moiety, and the prodrug/drug 
system will be discussed in more detail.
Figure 73: Therapeutic characteristics subclasses
<? ©  THERAPEUTIC M
©- © T Y P E  OF THERAPEUTIC 
<? © C H AR AC TE R ISTIC S  
<? ©ANTIBO DY-ENZYM E 
©■ © A N T IB O D Y  
©■ ©  ENZYME
<? ©ANTIBO DY-ENZYM E MOEITY 
©  STRUCTURE (AB-ENZ)
©  FUNCTION (AB-ENZ)
© P R O D U C T IO N  (AB-ENZ)
©  MANIPULATION OF PRODUCT (AB-ENZ)
©  IN VITRO (AB-ENZ)
<? ©  IN VIVO (AB-ENZ)
© P R E C L IN IC A L  (AB-ENZ)
©  CLINICAL (AB-ENZ)
<? © P R O D R U G -D R U G
© S T R U C T U R E  (P/D)
© F U N C T IO N  (P/D)
© P R O D U C T IO N  (P/D)
©  MANIPULATION OF PRODUCT (P/D)
©  IN VITRO (P/D)
<? © I N  VIVO (P/D)
© P R E C L IN IC A L  (P/D)
© C L IN IC A L  (P/D)
334
Antibody-enzyme Moiety
Figure 74 displays the ‘instance’ of MFECP1 entered into the structure slots. 
Antibody_name and enzyme_name can link to the appropriate instance within 
the antibody class and enzyme class, and more detailed information may be 
recorded about the individual characteristics o f the antibody and enzyme used to 
form the antibody-enzyme moiety. Links can also be made to protein databases 
including InterPRO, Swiss Prot and Oca protein structural database 
(http://oca.ebi.ac.uk). The appropriate identification for each relevant molecule 
for these databases is listed.
Figure 74: Instance (MFECP1) entered into antibody-
enzyme moiety structure slots
Antibody-enzyme Name
MFECP1
Antibody Name 0 □
[MFE23
Enzyme Name |"v c ! “ 1
carboxypeptidase G2
CPG2
Antibody Enzyme Linkage m[cl! -
jgenetic engineered
Species Of Origin fc:R
Mouse (antibody)
Pseudomonas aeriginosa (enzyme)
Molecular Weight
142.56- 147.1 OkDa (dimer)
Conformation
MFE-23 and CEA interaction
Docking model
Reference: (Boehm et al., 2000) (Boehm and Perkins, 2000)
Immunogenic Sites . i y m - j
InterPRO
CPG2: IPR002933 and IPR001261
v c
CM79 may have reduced immunogenicityin MFECP1 (? due to presence of His tag)
Sw iss Prot 0 c ] -
CPG2: P06621
Oca Database vlc|-
MFE-23:1QOK
CPG2:1CG2
Components pyfcir-
Two MFE23 scFv
One functionally active dimeric CPG2 enzyme
Glycosyfations vjcl"
short branch mannose chains on 2 N glycosylation sites
characterised byTandem Mass Spectroscopy
Tags vTcl [-■
hexahistidine tag on C terminal end
Amino Acid Sequence
644 amino acids per monomer
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The antibody-enzyme moiety may also be described in terms of function. This is 
displayed for MFECP1 in figure 75. The function o f the antibody is to bind to 
antigen, and the function of the enzyme is to catalyse a chemical reaction, which 
in the setting of ADEPT, is used to convert prodrug to active drug.
Figure 75: Instance (MFECP1) entered into antibody-
enzyme moiety function slots
Antibody-enzyme Name
MFECP1
Target Antigen
CEA
(LINK TO CEA in TARGET class)
Affinity
MFE-23 is a high affinity scFv 
kD is 2.5nmol/L (MFE-23 for CEA)
c
Avidity
avidity improved by two MFE-23 per functional moeity
V C
Enzymatic Reaction V
Hydrolysis to form active drug and glutamate 
oxycarbonyl (-OCO-) linkage 
carbamoyl (-NHCO-) linkage
Method Of Measurement (enzyme) V c |
methotrexate reduction assay
HPLC or Spec
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The production of the antibody-enzyme moiety may be described in terms of the 
production method, purification process, assessment process (stability, 
solubility), and the final formulation and storage conditions. This information is 
important as the production process may influence characteristics of the 
antibody-enzyme. For example when MFECP1 was produced in an E. Coli 
expression system it had a slower biodistribution in preclinical models than when 
it was produced in a P. pastoris expression system (see Chapter 4). This was 
due to the glycosylations added by P. pastoris. In addition recording the details 
of the production process is important for accountability and cross-referencing 
and also for eventual commercial development. Figure 76 displays MFECP1 as 
an instance in the antibody-enzyme moiety production slots.
Figure 76: Instance (MFECP1) entered into antibody-
enzyme moiety production slots
<$> MFECP1 (type=PROPUCTION (AB-ENZ), name=ADEPT2_0Q253)
Antibody enzyme Name
MFECP1
Method Of Linking Antibody And Enzyme
genetic
Produced In v [ c
Pichia Pastoris
=J
Cell Name
X-33
Cell Type
yeast
Method Of Production : V l_C -
fermentation
Method Of Purification [ V [ c \Z
IMAC purification (using His tag)
Yield
10Omg/L
V c
Solubility VI C
4mg/mL
1-----1
Stability 1  i n  -
stable for >2years a t-80 degrees C.
Stability Assessed By v ' i i  -
SDS-PAGE
western blotting
enzyme activity
ELISA
size exclusion
Purity i 1
>95%
Purity Assessed By
SDS Page
collision induced dissociation mass spectrometry of tryptic digest
Formulation Of Final Product VI C
sterile grade PBS
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The manipulation of product slot may include the radiolabelling of antibody- 
enzyme. This could be described by defining the radiolabel used, the method of 
radiolabelling and any purification process required, the amount of radioactivity 
used, the labelling efficiency, a measurement of the antigen binding of the 
radiolabelled protein, and the stability o f the radiolabelled protein. In addition the 
method of measuring radiolabelled protein in vivo can be described (figure 77).
Figure 77: Instance (MFECP1) entered into antibody-
enzyme moiety manipulation of product slots
<$> MFECP1 (type=MANIPULATIQN OF PRODUCT, name=ADEPT2_Q0277) (I
Antibody-enzyme Name
MFECP1
Radiolabel
1-123
Amount Radioactivity
500MBq
Method Of Purification
PD10 column
LS174T xenograft tumour model 
tum our: 1.9% injected dose/g at 6 hrs
V C
Antigen Binding
56.2% (range 48.1-65.2%) [clinical trial data]
CVAntigen Binding Measured By
CEA column
Radiolabel Method v c " - 1
chloramineT
 Labelling Efficiency
97.9% (range 92.8-99.2%) [clinical trial data]
V  || C |l ~  [ Labelling Efficiency Measured By
Stability V c
stable forxx hours at 25 degrees C
Stability Assessed By V c -
FPLC
HPLC
Preclinical Biodistribution Studies V c
thin layer chromotography
Measured By (serum)
gamma counter on blood samples
Measured By (tumour)
quantitative SPECT analysis
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The in vitro slot o f a therapeutic moiety may be used to record toxicity or 
efficacy. The information recorded may include the cell line name, the protocol 
used and the effect. As the antibody-enzyme in ADEPT is used as a targeting 
vehicle it would not be expected to have either significant efficacy or toxicity to 
cell lines in the in vitro setting, and cell-line experiments have not been 
performed with antibody-enzyme alone.
The in vivo slots o f the antibody-enzyme moiety may include preclinical animal 
model data or clinical trial data. The in vivo data may include scheduling data, 
biodistribution data and toxicity data. This could be linked to the subclasses and 
slots used in the THERAPY superclass which is discussed in more detail below.
Prodrug-Drug
The prodrug/ drug therapeutic may also be described under the headings of 
structure, function, production, manipulation of product, in vitro and in vivo 
characteristics (figure 78). The prodrug activation system used in the ADEPT 
trials in this thesis is ZD2767P, which, when activated by CPG2, is converted to 
ZD2767D. The ZD2767P system will be discussed as the instance for the slots 
described for each subclass below.
Figure 78: Prodrug-drug therapeutic subclasses
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The structure (P/D) subclass with its slots for the prodrug/ drug therapeutic is 
shown in figure 79.
Figure 79: Instance (ZD2767P) entered into prodrug/ drug
structure slots
|> ZP2767P (type=STRUCTURE (P.O), name=APEPT2 _00289) fcF
Name Prodrug Name Drug
ZD2767P ZD2767D
Chemical Name Produg Chemical Name Drug
4[N,N-bis (2-iodoethyi) amino] phenoxycarbonyl L-glutamic acid 4[N,N-bis(2-iodoethyl) amino] phenol
Chemical Structure DrugChemical Structure Prodrug
N O HCOjM
Molecular Weight
|720 kDa as a hydroiodide salt, and 590 kDa as a free base
Chemotherapeutic Class
lenol mustard 
alkyating agents
V C
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The prodrug/ drug therapeutic may also be described in terms of function (figure 
80). In the ADEPT system the function of the prodrug is to be activated by a 
specified enzyme to form an active drug. The function o f the active drug is to 
cause cytotoxicity. The mechanism of cytotoxicity may be described.
Figure 80: Instance (ZD2767P) entered into prodrug/ drug
function slots
<P ZD2767P (type=FUNCTION (PdD), name=APEPT2_00291) lex
Name Prodrug
ZD2767P
Activation Co-efficient n
Km (ZD2767P as a substrate for CPG2) <3microM 
kcat is 30s-1
Mechanism Of Cytotoxicity v  c
alkylating agent 
DNA cross-links
Endogenous Activation
none
V C
Name Drug
ZD2767D
Enzyme Name
CPG2
Cytotoxicity Measured By
comet assay
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The production process may also be described. These slots may include method 
of production, stability, purity, solubility, formulation and reconstitution of the 
final product.
It may be useful to manipulate the prodrug/ drug after production by 
radiolabelling or ‘tagging’ in order to follow its biodistribution. This has not yet 
been done for this ADEPT system.
The slots o f the in vitro subclass are shown in figure 81. For each in vitro 
experiment the cell-line used, protocol and outcome should be recorded. The 
types o f in vitro experiments that may be performed are listed in table 58. These 
may include the chemical half-life of both the prodrug and drug, potency cell -  
line experiments, and enzyme activation assays.
Figure 81: Prodrug/ drug in vitro slots
p ZD2767P (type=IN VITRO (P/D), name=ADEPT2_00293) DDE
Name Prodrug Name Drug
ZD2767P ZD2767D
Chemical Half-life Prodrug I v f c =1- Chemical Half-life Drug | V c “ j
Experiment v fcl -
Cell Line V C
Protocol V C  -
Outcome V Cl -
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Table 58: List of in vitro experiments for Prodrug/ Drug
SLOTS FOR PRODRUG/ DRUG IN VITRO SUBCLASS
Chemical half-life Prodrug____________________________
Chemical half-life Drug_______________________________
Potency Prodrug__________ Cell line___________________
_________________________Protocol__________________
_________________________Outcome (IC50)____________
Potency Drug_____________Cell line___________________
_________________________Protocol__________________
_________________________Outcome (IC50)____________
Enzyme activation assay____ Cell line___________________
_________________________Protocol__________________
_________________________Outcome (CPG2 concentration)
Mechanism of action_______ Cell line___________________
_________________________Protocol__________________
_________________________Outcome (comet assay)______
The in vivo data that may be collected about the prodrug/ drug may include 
preclinical experiments, or data from clinical trials. The information may include 
dose scheduling, pharmacokinetics, mechanism of action and toxicity data. This 
will be discussed further under the THERAPY class headings.
Therapy
For the purpose of this Ontology THERAPY is the term used to describe the 
coming together of PATIENT, TUMOUR, TARGET and THERAPEUTIC.
THERAPY may occur as a preclinical model or as a clinical trial. Each of these 
may then be divided into components that define the protocol and components 
which define the outcome (figure 82).
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Figure 82: THERAPY subclasses
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®- ©  OUTCOME
The subclass preclinical model may be divided into further subclasses as shown 
in figure 83.
Figure 83: Preclinical model subclass of THERAPY
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9 ©  PRECLINICAL_PROTOCOL 
© A N IM A L  
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9 © C E L L L IN E
© D E S C R IP T IO N
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©IMPLANTATION  
©  PRECLINICAL_SCHEDULE 
©■ ©  THERAPEUTIC ”
© ■ © T A R G E T ”
9 ©  PRECLINICALJDUTCOME
©  PRECLINICAL_DELIVERY OF THERAPEUTIC 
©  PRECLINICAL_MECHANISM 
9 ©  PRECLINICAL_EFFECT
©  PRECLINICAL_EFFICACY 
©  PRECLINICAL_TOXICITY
The preclinical protocol should define the animal system in which the therapy 
will be tested, the xenograft used, the schedule o f administration, the therapeutic 
used (link to THERAPEUTIC) and the target (link to TARGET). The xenograft 
can be further divided into the cell-line used, and the protocol for implantation. 
The cell line may be described, and it may be linked to the TUMOUR superclass.
The preclinical outcome may be subdivided into delivery of therapeutic, 
mechanism and effect. Effect may be divided into efficacy and toxicity.
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The Clinical Trial subclass of THERAPY maybe also subdivided into protocol 
and outcome (figure 84).
Figure 84: Clinical trial subclass
9  © T H E R A P Y
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© ■©O U TC O M E
Each clinical trial has a trial protocol, in which the patient group in which the 
therapy is to be performed is defined (link to PATIENT superclass) (figure 85). 
As discussed earlier, the patient can be subdivided into the parameters which 
define the physiological environment, and the disease state (cancer). Within the 
disease state the tumour may be defined (link to TUMOUR superclass), the 
treatments the patient has had may be recorded and the burden of the cancer 
defined.
Also within the clinical trial protocol the therapeutic is defined (link to 
THERAPEUTIC superclass). The target is also defined (link to TARGET 
superclass). The target is considered separately to the tumour as although the 
target should be ideally confined to the tumour, it is often also expressed in non­
tumour sites.
345
Figure 85: Clinical Trial Protocol subclasses
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The schedule o f administration of therapeutics is defined within a trial protocol. 
This may include the following slots (table 59).
Table 59: Slots defined for the Schedule therapeutics subclass of
clinical trial protocol
Slots______________________________________________
Dose______________________Antibody-enzyme____________
___________________________ Radiolabelled antibody-enzyme
___________________________ Prodrug_____________________
Schedule of administration Antibody-enzyme____________
___________________________ Radiolabelled antibody-enzyme
___________________________ Prodrug_____________________
Time of administration______ Antibody-enzyme____________
___________________________ Radiolabelled antibody-enzyme
___________________________ Prodrug_____________________
Protocol defined enzyme level at the time of prodrug 
administration
Also as part of schedule, is the schedule o f investigations performed within a 
clinical trial. These are for the purposes o f measuring the outcomes discussed 
below. They will include clinical assessments, blood tests, radiological imaging, 
gamma camera scans or PET scans.
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Figure 86 displays the outcome measures of a clinical trial, which are 
subdivided into delivery o f therapeutic, action and effect.
Figure 86: Clinical Trial Outcome subclasses
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Delivery o f therapeutic
The delivery o f therapeutic may be divided into pharmacokinetic data, 
biodistribution data and immunogenicity data (figure 87).
Figure 87: Delivery of therapeutic subclasses
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Pharmacokinetic data may be collected for antibody-enzyme or for prodrug 
and/or drug. In the ADEPT clinical trials presented in this thesis, 
pharmacokinetic measurements of antibody-enzyme were made by two methods. 
One involved the measurement of CPG2 enzyme activity in the serum of patients 
at a variety o f timepoints, and the other involved the measurement of 
radioactivity in the blood o f patients who had radiolabelled antibody-enzyme 
administered. The a  and p half-lives were calculated for the patient group as a 
whole using both sets o f results. Different results were obtained by each method, 
which is expected as both methods are measuring different aspects o f the 
antibody-enzyme. The measurement o f enzyme activity is an assessment o f 
function of the antibody-enzyme, and is likely to represent the intact molecule. 
The measurement of radioactivity however, may measures the radioisotope
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which may be either attached to intact antibody-enzyme, antibody-enzyme 
fragments or as free radioactivity in the blood.
Pharmacokinetic data was also obtained in the clinical trials for the prodrug. This 
was measured by HPLC, used to detect prodrug in plasma samples at a variety of 
time points. A range of pharmacokinetic parameters were derived, including 
plasma concentrations, half life, volume of distribution, clearance and area under 
the curve. It would be desirable also to be able to measure pharmacokinetic 
profile of the active drug, however, the active drug generated from ZD2767P had 
too short a chemical half-life for this to be feasible.
Biodistribution data is used to assess the distribution of the therapeutic in the 
normal tissues, and in the tumour of the patient. In the ADEPT trials the 
biodistribution of antibody-enzyme was assessed by radiolabelling, and using 
quantitative gamma camera imaging to measure tumour and normal tissue 
distribution of radioactivity. Tumour estimates of antibody-enzyme 
concentrations obtained by this method were validated in a small number of 
patients with tumour biopsies, and direct measurement of CPG2 enzyme level by 
methotrexate reduction assay (HPLC).
It was not possible to measure tumour or normal tissue biodistribution of active 
drug in these ADEPT clinical trials due to the very short chemical half-life of 
ZD2767D.
Immunogenicity has also been included in the subclass of delivery of therapeutic, 
because the presence of human antibodies against epitopes on the antibody- 
enzyme moiety may influence the delivery of antibody-enzyme. Immunogenicity 
was measured in both ADEPT trials, by ELISA assay. MFECP1 appeared less 
immunogenic than A5CP and may have the potential for repeated administration 
prior to the development of human antimurine or human anti-CPG2 antibodies.
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Action
Figure 88 shows the subclasses of action.
Figure 88: Action subclasses
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The action subclass contains data on the measurements of action o f the 
therapeutic in the therapy setting. For example in ADEPT, the antibody-enzyme 
has two actions; to bind antigen, and to act as an enzyme. Currently the binding 
of antigen is measured indirectly on tumour biopsies by using 
immunohistochemistry to ascertain the presence and distribution of CEA and 
antibody-enzyme. This is performed by using an anti-CEA antibody and an anti- 
CPG2 antibody. The immunohistochemistry cannot be performed on the same 
histological slide so consecutive slides are used. The enzyme activity o f CPG2 is 
assessed in tumour sites directly in tumour biopsies with measurement of CPG2 
activity by methotrexate reduction assay.
The prodrug/drug therapeutics’ action is to cause cytotoxicity. ZD2767D is an 
alkylating agent, and its mechanism of cytotoxicity is by forming DNA cross­
links. This can be measured on single cells from tumour biopsies, bone marrow 
aspirates or peripheral blood lymphocytes, by a comet assay (described in 
chapters 2 and 4).
Tumours are also known to have resistance mechanisms, which may counteract 
the cytotoxicity o f the therapeutic agent being tested. DNA repair mechanism 
may counteract the DNA cross-links formed from the alkylating agents used in 
ADEPT. The presence o f resistance mechanisms will affect the potential efficacy 
of a therapeutic system.
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Effect
Effect may be divided into effect on tumour, termed efficacy, or effect on non­
tumour tissues, termed toxicity (figure 89).
Figure 89: Effect subclasses
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Efficacy can be assessed by anatomical imaging, such as CT scans or MRI. 
Anatomical imaging provides a measure of change in dimensions of a tumour 
with therapy. Alternatively functional imaging may be used, such as [F-18] FDG 
PET, as discussed in chapter 5 and 6. This may provide an assessment o f 
metabolic activity o f the tumour with therapy. Tumour markers may also be used 
to assess response to therapy, although in most tumour types they will be used in 
conjunction with other assessments of response as their role has not yet been 
fully validated. Other measures of response may include changes in ‘overall 
well-being’ of patients such as WHO Performance Status, Quality o f Life 
measures or measures o f exercise capacity. Temporal measures may also provide 
data on the effectiveness o f a treatment. This includes survival measures such as 
overall survival or progression free survival.
For each of these subclasses the slots used could include assessment time (time 
of assessment related to commencement of therapy), the method used (such as 
RECIST criteria for anatomical imaging), and the result.
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Toxicity may be sub-classified into a record of toxicity events in a clinical trial, 
serious adverse events or the dose- defining toxicities. The dose-defining toxicity 
subclass may be divided into maximum tolerated dose and dose limiting 
toxicities.
The standard method for measuring toxicity in clinical trials is by the Common 
Toxicity Criteria (CTC). The toxicity slots should include the time of the event 
(in relation to commencement of therapy), the organ/system involved, the CTC 
description, the CTC grade, whether it was related to the study drug or drugs, the 
dose of study drug used and when/ if the toxicity resolved. This information is 
very useful when deciding doses for future clinical trials using the same agents.
7.4 ADEPT conceptual model 
7.4.1 Method
The ADEPT conceptual model is a diagrammatic means of expressing the 
relationship between the 5 core superclasses identified in the ADEPT Ontology 
(PATIENT, TUMOUR, TARGET, THERAPEUTIC and THERAPY). It serves 
as an adjunct to the Ontology and aims to define some of the interactions 
between the superclasses. Overlap particularly occurs in the THERAPY 
superclass, because it represents a ‘coming together’ of all of the superclasses. A 
Venn diagram system has been used to show the relationships between the five 
superclasses in the conceptual model.
7.4.2 Results
The diagrammatic representation of the basis of the conceptual model is shown 
in figure 90. Four of the superclasses defined in the ADEPT Ontology are 
‘objects’ (PATIENT, TUMOUR, TARGET and THERAPEUTIC), whilst 
THERAPY is the ‘action’ of adding the THERAPEUTIC to PATIENT/ 
TUMOUR/ TARGET.
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Figure 90: ADEPT conceptual model
PATIENT
TUMOUR
TH
THERAPEUTICTARGET
The model may be considered in layers.
The first layer is the PATIENT, as the patient forms the environment for the 
therapy to occur (figure 91). The features of a PATIENT are described in the 
ADEPT Ontology.
Figure 91: Patient
PATIENT
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The next layer is the TUMOUR. This is found within the PATIENT, and is the 
disease state that the treatment given will be directed against. It conceptually 
forms part of the PATIENT (figure 92). The part of the PATIENT which is not 
tumour is the patient’s physiology which may influence the treatment given.
Figure 92: Tumour
PATIENT
TUMOUR
The next layer is the TARGET (figure 93). This should be predominantly 
expressed in the tumour, but may also have a component of non-tumour 
expression. The area of overlap between TARGET and TUMOUR represents the 
parts of the tumour that express the target. There are however also parts of the 
tumour which do not express the target.
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Figure 93: Target
PATIENT
Tumour that does not 
express the target
Tumour that expresses 
the target
Target expressed in 
non-tumour tissue
The next component is the THERAPETIC (figure 94). The therapeutic can be 
described as a unique entity, as it has its own characteristics as outlined in the 
ADEPT Ontology. ADEPT has two molecules which constitute the 
‘THERAPEUTIC’. These are the antibody-enzyme, and the prodrug/drug. Both 
can be described in terms of structure, function, production, manipulation of 
product, in vitro characteristics and in vivo characteristics.
Figure 94: Therapeutic
PATIENT
TUMOUR
TARGET THERAPEUTIC
TUMOUR
TARGET
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THERAPY is the term used in the model and the Ontology for the administration 
of the THERAPEUTIC to the PATIENT (who has a TUMOUR and TARGET) 
(figure 95).
Figure 95: Therapy
PATIENT
TUMOUR
TARGET
' H E R A P E U r i C
The outcome components of THERAPY that can be represented in the model are 
delivery of therapeutic and effect.
Delivery of therapeutic involves the interaction o f the therapeutic with the 
PATIENT, and with the TARGET and the TUMOUR (figure 96). A targeted 
strategy is designed so that the maximal amount of therapeutic is delivered to the 
target on the tumour.
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Figure 96: Delivery of therapeutic
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TUMOUR
0  THERAPY
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TARGET
The effect may be one o f efficacy, which may occur in TUMOUR that has the 
TARGET, or it may be on tumour that does not have the TARGET, by a 
bystander effect (figure 97).
Figure 97: Efficacy
PATIENT
TUMOUR
THERAPEUTICTARGET
Targeted effect 
Bystander effect
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The effect may also be toxicity, which may occur when there is a TARGET that 
is outside the tumour, which is accessible to the therapeutic (cross-reactivity). It 
may also occur when the effect o f the treatment is not confined just to the 
TUMOUR and may radiate out to effect normal tissues, either by direct 
extension, Teak-back’ o f an active therapeutic. The third mechanism of toxicity 
is if  the THERAPEUTIC agent has its own toxic effect on non-tumour tissue in 
the patient (figure 98).
Figure 98: Toxicity
PATIENT
Target in non­
tumour tissues 
(cross-reactivity)
Toxic therapeutic or 
extension o f toxic 
effects from tumour 
into non-tumour tissue
This conceptual model therefore provides a simple visual representation o f the 
relationship between the 5 core superclasses of the Ontology. It is designed to 
facilitate the next stage o f development of developing an interactive database to 
store all the data from ADEPT, and to allow data queries.
TUMOUR
TOXICITY
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7.5 Discussion
The discussion of the ADEPT Ontology and Conceptual Model will focus on the 
three aims outlined at the beginning of the chapter. These included the concept 
that the Ontology and Conceptual Model could be used to organise data from 
ADEPT, that once the data was organised it may allow the identification of areas 
where more data could be acquired in a clinical trial setting and also to identify 
areas for rational improvement in ADEPT.
7.5.1 Organising data
The ADEPT Ontology attempts to name and, where possible, characterise all of 
the main components of ADEPT, with particular focus on the ADEPT clinical 
trials. Protege is a hierarchical Ontology tool designed to aid the organisation and 
accessibility of data. Protege has the additional flexibility of allowing the same 
data element to appear on different branches of the ‘tree’, thereby allowing a 
single query to generate the same data from different areas of the Ontology. 
Clinical trial data are, however, not always hierarchical, and at times this was 
problematic when constructing the Ontology. The development of a database 
should obviate this problem, as a database is not confined to hierarchical 
relationships. However, before a database can be designed, the components of it 
need to be identified. The Ontology was used to name, define and organise these 
components.
The ADEPT Ontology was designed to link to other Ontologies or databases 
where appropriate. For example the TUMOUR, TARGET and THERAPEUTIC 
superclasses could link via molecular profiling or structural and functional data 
to known genomic or proteomic databases and ontologies. It is important to 
create these links in order to access emerging data and information, and to 
maximise the opportunities for data acquisition and utilisation.
The Ontology was also designed to encompass commonly used terminology to 
facilitate cross-referencing and to enhance search facilities. For example, the 
inclusion of the MeSH classification in the TUMOUR superclass. The MeSH 
classification provides keyword associations, and is used for common search
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tools, such as Medline. By including a number of methods of describing the 
TUMOUR, the accessibility to other data trails is possible. This may ultimately 
lead to the acquisition of relevant data, and accessibility to shared data, in order 
to enhance overall knowledge. Data sharing is becoming an important concept as 
the volume of data generated world-wide escalates.
The Conceptual Model describes, in basic terms, the relationships between the 
five superclasses defined in the Ontology. It was designed to show how the 
components of the Ontology are related, and should therefore be useful in 
defining the relationships of these components into an ADEPT database. The 
majority of the terms used in the Ontology and the Conceptual Model are 
applicable not only to ADEPT but also to other targeted therapeutic strategies.
The ADEPT Ontology and Conceptual Model are therefore the initial step in the 
design of an ADEPT database, into which all of the data acquired on ADEPT 
could be entered, stored, organised and queried. A database for ADEPT would be 
extremely valuable, as it would facilitate the development of a complex 
therapeutic strategy by making the data more accessible. The development of the 
database was beyond the scope of this Ph.D and would present a large 
undertaking in terms of software engineering. Importantly, however, the 
Ontology and Conceptual Model will provide the framework for a relational 
database should this be undertaken.
7.5.2 Guiding mechanistic clinical trial design
One of the motivating reasons for developing an ADEPT Ontology and 
Conceptual Model was that it might help guide mechanistic clinical trial design. 
Clinical trials provide unique opportunities to test a new therapy in its ‘real-life’ 
setting. Obtaining maximal information during a clinical trial is critical to 
developing an understanding of the therapy, and to guiding rationale 
modifications to the system. This has to be balanced with an understanding that 
phase I clinical trials are performed on patients who have incurable cancer, have 
usually exhausted conventional treatment options, and who may have already in 
their ‘cancer journey’ had a variety of scans, tests, and invasive procedures 
performed.
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The Ontology and Model identify the five ‘superclasses’ as being PATIENT, 
TUMOUR, TARGET, THERAPEUTIC and THERAPY. Clinical trials should 
therefore, where possible, collect data on all of these components.
The data collected for the PATIENT superclass is listed in the Ontology, and 
involves collecting data on the ‘physiological’ state of the patient and the 
‘disease state’ of the patient. This data is now fairly standard for clinical trials.
The data collected on the TUMOUR has conventionally been based on a 
histological description, such as the tumour type, stage, grade, TNM 
classification, lymphovascular invasion. It is becoming more apparent that 
tumours should be also characterised based on their genomic or proteomic 
profile, as this may be more relevant for treatment responsiveness and tumour 
prognosis (Adlard et al, 2002; O’Neill and Song, 2003). It may be useful in 
current clinical trials to collect and store data on each tumour’s genomic or 
proteomic profile, for future reference, as it may be that certain genomic or 
proteomic features make a patient more or less likely to respond to a given 
treatment. This is the concept of ‘tailoring’ treatments to individuals, as opposed 
to giving the same treatment to everyone with the same tumour cell type. The 
increased accessibility to genomic and proteomic data is now making a more 
‘rationale’ approach theoretically possible.
Limited data is acquired on the microenvironment of the TUMOUR at the time 
of treatment. The development of functional imaging using PET may provide 
increasing opportunities to collect data non-invasively on the ‘functional state’ of 
a tumour. This may be in terms of glucose metabolism ([F-l 8] FDG), amino acid 
utilisation ([C-l 1]-methionine), DNA synthesis ([F-18]-3'-deoxy-3 
flourothymidine) or blood flow ([0-15] water) (Tewson and Krohn, 1998). This 
information may again determine the likelihood of treatment success, or may 
influence the prognosis of the patient.
In the ADEPT clinical trials presented in this thesis the data collected on the 
TARGET for each individual patient has been limited. All patients have serum 
CEA levels checked, and are ‘eligible’ for ADEPT if their CEA is between 10- 
lOOOpg/L. Only in patients with serum CEA levels < 10 pg/L, is
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immunohistochemistry performed on tumour specimens to ascertain the presence 
of tumour CEA. Immunohistochemistry is non-quantitative; however it does 
provide some data on the distribution of CEA in the tumour. 
Radioimmunoluminography (RILG) is a technique that can provide quantitative 
data on CEA distribution in tumour (Boxer et al, 1998). This can be performed 
on histological sections or tumour blocks. CEA levels estimated by RILG have 
been shown to correlate with levels of tumour localisation of an anti-CEA 
antibody in study of radioimmunoguided surgery (Boxer et al, 1998). It may be 
useful therefore to incorporate RILG assays for CEA in tumour on all patients in 
the ADEPT trials to assess if there is a correlation between antigen concentration 
and distribution with antibody localisation and treatment efficacy. This may aid 
in the more appropriate selection of patients for therapy. The limitation of this is 
that the tumour sections and blocks used for assessment of antigen distribution 
are usually obtained from the original surgical specimen, which may be taken 
months to years before the ADEPT treatment. It may not reflect the antigen 
distribution or accessibility in the tumour at the time of ADEPT treatment. At 
present there is no suitable non-invasive method of assessing this. Tumour 
biopsies can be performed and quantitative assessment of CEA obtained by 
RILG. However, tumour biopsies are invasive, associated with potential 
complications and only small samples of tissue are obtained. There is currently 
therefore no satisfactory way of assessing TARGET concentrations or 
accessibility in the tumours of patients receiving ADEPT.
The THERAPEUTIC will be discussed in the context of THERAPY, as this 
relates to when it is actually administered to the patient. The Ontology divides 
THERAPY (clinical trial) into protocol and outcomes. The measurement of 
outcomes is a key feature of mechanistic clinical trials. With regard to ADEPT 
the outcomes have been divided into three groups; delivery of therapeutic, 
mechanism and effect. The outcomes should be considered in terms of both 
antibody-enzyme and prodrug/drug.
The delivery of antibody-enzyme is assessed currently in clinical trials by the 
direct measurement of CPG2 enzyme activity in blood and in tumour biopsy 
samples, and by the assessment of biodistribution of radiolabelled antibody-
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enzyme. The measurement of CPG2 enzyme in blood gives an estimation of the 
half-life of antibody-enzyme, and is useful in guiding the timing of 
administration of prodrug, so as to minimise activation if prodrug in systemic 
tissues. The direct measurement of CPG2 enzyme in tumour is, however, more 
problematic as it depends upon attaining a sample of tumour via a tumour biopsy. 
This is an invasive procedure, usually performed under ultrasound guidance, but 
even with this assistance, viable tumour areas are not always obtained. The 
sample is usually very small, which limits the amount of information that can be 
obtained from it. A small sample is also difficult to analyse, as it will often have 
to be diluted further in the analysis process, and consequently the amount of 
enzyme activity within the sample may be less than the detection range of the 
assay used.
Radiolabelling antibody-enzyme provides, by SPECT analysis, a non-invasive 
means of assessing antibody-enzyme delivery. It does, however, also have 
limitations. The radiolabelling process may damage the antigen binding of the 
molecule, therefore reducing the ability of the radiolabelled molecule to reflect 
non-radiolabelled antibody-enzyme. In addition radioactivity is measured by this 
method, and so there is no discrimination between intact antibody-enzyme and 
non-functional fragments with radiolabel attached, or free radiolabel. Despite 
these limitations it has been shown to provide a reasonable estimate of tumour 
A5CP antibody-enzyme localisation when compared to the actual measured 
CPG2 activity from tumour biopsies. The rapid metabolism of MFECP1, due to 
its glycosylations, adds further difficulties for SPECT analysis. MFECP1 is 
rapidly cleared from non-tumour sites, particularly by the liver. CPG2 enzyme 
measurements confirm that clearance is associated with loss of enzyme activity 
in non-tumour sites. However, as radiolabel may be attached to multiple sites on 
the MFECP1 molecule, it will be present in non-tumour areas attached to non- 
functioning molecules, and not provide a good estimation of intact functional 
molecule in these sites.
Ideally a non-invasive method of assessing CPG2 function in the body is 
required. As CPG2 is responsible for the activation of prodrug it is a key issue to 
be able to quantitatively measure its presence in both tumour and normal tissues,
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in order to decide when prodrug should be administered, and also to maximise 
the likelihood of efficacy and minimise the likelihood of toxicity. There is no 
current satisfactory solution to this problem, and currently radiolabelling is 
continuing to be used, with the caveat for MFECP1 that tumour radioactivity 
may reflect actual antibody-enzyme localisation, but non-tumour radioactivity is 
likely to be a poor reflection of active enzyme.
Immunogenicity may affect delivery of the antibody-enzyme. ELISA has been 
used in both ADEPT clinical trials to measure ELAMA and HACPG2A. The 
ELISA studies performed in the ADEPT A5CP and ZD2767P trial suggested that 
all patients developed antibodies to A5CP after one administration. This limits 
the potential for repeat therapy. For MFECP1 there was no pre-existing positive 
control for MFE-23 for the ELISA assay, as although MFE-23 had previously 
been administered to 45 patients, none appeared to develop antibodies to it 
(Begent et al, 1996; Mayer et al, 2000). This required A5B7 to be used in the 
ELISA assay as a substitute for MFE-23. As discussed in chapter 4, as A5B7 
and MFE-23 may have different epitopes, this may not detect the presence of 
human anti-MFE-23 antibodies. The ability to detect antibodies against MFECP1 
would be very important if repeat therapy was to be administered.
With regard to the biodistribution of prodrug/ drug, with ZD2767P, the prodrug 
can be measured in blood by HPLC, but the drug has too short a chemical half- 
life to be measured. It would be desirable to be able to quantitatively measure the 
generation of active drug and its distribution. It is, however, difficult to design a 
tag that would preferentially be expressed on active drug and not on prodrug. The 
prodrug is expected to be widely distributed in the body. It is only when it is 
activated by enzyme that it forms a highly cytotoxic agent. It is of interest to 
identify the sites of activation of drug, and whether, once activated, it remains 
confined to tumour sites or ‘leaks’ into surrounding normal tissue.
The action of antibody-enzyme is antigen binding and an enzymatic reaction.
The ability to successfully bind antibody-enzyme to antigen is currently assessed 
by immunohistochemistry. Immunohistochemistry is, however, not quantitative, 
and whilst a positive result suggests that there has been antigen binding, a
363
negative result does not exclude it. A quantitative means of assessing binding 
would therefore be desirable.
The CPG2 enzyme needs to be functional in order to act to convert prodrug to 
drug. This is currently assessed by the measurement of CPG2 activity on tumour 
biopsies. The limitations of this method have been discussed above. A non- 
invasive means of assessing CPG2 function would therefore be desirable.
The measurement of drug activity is by the formation of DNA cross-links as 
detected on comet assay. The formation of DNA cross-links does not guarantee 
cytotoxicity as DNA repair mechanisms may correct the cross-links, and create 
‘resistance’ in the cancerous cells. The activity of DNA repair mechanisms may 
be assessed if serial biopsies were performed to look at DNA repair rates. This, 
however, is rarely practical in a clinical setting as most patients would be 
unwilling to have serial biopsies performed.
The effect of therapy is divided into efficacy and toxicity. As discussed in 
chapter 5 and 6, the assessment of efficacy by conventional anatomical 
imaging, such as by CT scans is limited. Functional imaging, such as with [F-18] 
FDG PET may however, provide an earlier and more sensitive assessment of 
response to therapy, and may represent a means of improving the assessment of 
efficacy in phase I clinical trials. As [F-18] FDG PET assesses the glucose 
metabolism of the cells it provides an indirect assessment of effect. More 
mechanism specific functional imaging may be useful such as radiotracers which 
are used to assess DNA synthesis.
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Table 60 lists the mechanistic studies that may be desirable for ADEPT.
Table 60: Desirable mechanistic studies for ADEPT
Superclass Measurement required
PATIENT
TUMOUR genomic and proteomic profile of tumour
assessment of tumour microenvironment by 
functional imaging
TARGET quantitative distribution/ accessibility of CEA in 
tumour
THERAPEUTIC/THERAPY
deliveryoftherapeutic non-invasive quantitative measurement of CPG2 
biodistribution in tumour and normal tissues
non-invasive quantitative measurement of drug 
activation and distribution of active drug in 
tumour and normal tissues
action measurement of DNA repair mechanism (serial 
biopsies)
effect assessment of effect on tumour (functional 
tumour imaging)
7.5.3 Identifying areas of improvement for ADEPT
The ADEPT Ontology and Conceptual Model were also theorised to be useful 
for identifying areas of potential improvement for ADEPT, and thereby with the 
data incorporated into them, rationally direct modifications to the system.
Again the 5 superclasses may be used to discuss areas of potential modification 
to ADEPT. The components of ADEPT that may therefore be modified are the 
PATIENT group, the TUMOUR, the TARGET, the THERAPEUTIC or the 
THERAPY (protocol).
The selection of the PATIENT group for ADEPT is likely to influence the 
outcome. Either the patient’s physiological characteristics or their tumour burden 
may be contributing to the success or failure of the system. For example, with the 
ADEPT MFECP1 clinical trial, the antibody-enzyme was glycosylated, and 
appeared to be cleared by the fiver. A patient therefore with impaired fiver 
function may clear the antibody-enzyme at a different rate than a patient with
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normal liver function. The current protocol states that a patient may have serum 
transaminase levels up to 5 times the upper limit of normal in the presence of 
liver metastasis. Changing these limits to exclude patients with this degree of 
liver impairment, and therefore setting a more stringent physiological 
environment, may limit the inter-patient variability in metabolism of antibody- 
enzyme that occurs.
The burden of tumour that a patient has may also influence the likelihood of 
ADEPT being efficacious. This may be because of the tumour burden’s influence 
on normal physiological function or because of the total number of tumour cells 
required to be killed to achieve a cure.
The TUMOUR chosen for ADEPT may influence the likelihood of ADEPT. 
Tumours with a poor blood supply are unlikely to be accessible to antibody- 
enzyme. Also those with intact DNA repair mechanism will be more resistant to 
the effects of alkylating agents.
The TARGET could also be modified. CEA is currently used, and has many 
favourable characteristics. It is common and usually abundant, it has a cell 
surface location, it does have non-tumour expression, but in a location which is 
usually inaccessible. Its disadvantage may be that is secreted into the circulation, 
which may reduce tumour localisation of antibody-enzyme. The discovery of 
many more targets using proteomics and genomics may lead to the identification 
of a target more favourable than CEA.
The THERAPEUTIC may be modified in a number of ways. The antibody- 
enzyme could be modified in terms of the antibody, the enzyme or the antibody- 
enzyme moiety. Changes such as antigen affinity, molecular size, 
immunogenicity, enzymatic reaction, presence of tags or glycosylations may all 
influence the likelihood of success of the therapy. Similarly there are many 
opportunities for modification of the prodrug/drug chosen. Characteristics such 
as half-life, size, solubility, stability, chemical structure and potency may all 
affect the likelihood of efficacy. For example the development of a drug which 
formed DNA cross-links that were not vulnerable to DNA repair mechanisms
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may improve the likelihood of efficacy of ADEPT, but it may also increase the 
potentially seriousness of toxicity.
The protocol used for THERAPY may also influence the likelihood of treatment 
efficacy. The dose of therapeutic used and the administration schedule may 
influence tumour and normal tissue biodistribution, and the likelihood of efficacy 
or toxicity. The timing of administration of prodrug in ADEPT is critical -  it 
must be at a time when there is active enzyme present in tumour and minimal or 
no enzyme present in normal tissues. There needs to be an adequate amount of 
enzyme in tumour and enough prodrug to generate sufficient quantities of drug 
for cytotoxicity.
The number of potential modifications to the ADEPT system is therefore very 
large, and deciding which modification may be beneficial is difficult. The 
acquisition and organisation of mechanistic data can be used as a means of 
directing this decision process. The formation of a relational database may help 
rationalise this decision. In addition the development of mathematical models 
based on in vitro or in vivo data has the potential to direct decisions regarding 
modifications to ADEPT.
7.6 Conclusion
An Ontology and Conceptual Model have been developed for the purpose of 
organising data relevant to ADEPT. They provide the framework for the 
development of a database that would have the additional advantages of allowing 
data queries and improved data accessibility. The principals of both the Ontology 
and Conceptual Model are applicable to other targeted therapies. Allowing 
access to data and linking to other databases is an important concept in ‘data 
sharing’ and should lead to enhancement of knowledge. The organisation of data 
relevant to ADEPT has introduced areas for improvement in both mechanistic 
clinical trial design in ADEPT, and potential areas for improvement in ADEPT 
therapy itself. In the future the development of mathematical models could be 
used to predict rational modifications to the ADEPT system by using complex 
data acquired, organised and accessible as a result of a relational ADEPT 
database.
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8 Conclusion
8.1 Background
The three hypotheses that have been addressed in this thesis are:
a) That a mechanistic trial design improves understanding and development 
o f ADEPT.
b) That a quantitative method o f metabolic response assessment in ADEPT 
may augment the assessment o f response in a phase I  clinical trial 
setting, and in particular it may aid in the interpretation o f radiological 
stable disease.
c) That the organisation o f the data collected in the ADEPT clinical trials 
into an Ontology and Conceptual Model o f ADEPT can direct 
mechanistic clinical trial design and identify areas for improvement in 
ADEPT.
These hypotheses will be discussed in detail below, with particular emphasis on 
my individual contribution to the work presented.
8.2 A mechanistic trial design improves understanding and development 
of ADEPT
This hypothesis explores the concept that designing phase I/II clinical trials in a
mechanistic fashion is an improvement on convention clinical trial design.
Conventional phase I/II clinical trials focus predominantly on dose escalation to
attain MTD. Once the MTD is defined efficacy may be assessed in a small cohort
of patients. Mechanistic clinical trial design aims to test that each component of a
therapy is functioning as proposed in a clinical trial setting. The trial design is
therefore often more complicated and patients may individually undergo more
investigations than in conventional trial designs, however the total number of
patients may be minimised by the ability to make decisions based on the data
collected. Mechanistic trials may potentially be safer for patients than standard
dose escalation schemes, as data attained from previous patients may guide the
dose escalation, and toxicities may be predicted or avoided. The therapy may be
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better understood and therefore more rationally developed based on the data 
acquired in a clinical trial setting. Therapies that do not produce efficacy may, 
instead of being discarded as ‘non-efficacious’ instead be modified appropriately 
and further developed.
There are, however, disadvantages to mechanistic clinical trial design. The 
clinical trial itself is often complex and expensive, requiring many specialised 
staff for the trial. Co-ordination between staff is required. The recruitment rate 
may therefore be much slower than with conventional trial design, and overall 
the trial may take longer to complete. The large amount of data generated 
requires interpretation during the trial in order that appropriate modifications 
may be made. An assumption is made that outcomes in individual patients may 
be translatable to other patients. Overall a significant amount of time is spent on 
developing each individual therapy; whereas it may be argued that the time may 
be spent developing new therapies.
The potential advantages and disadvantages of a mechanistic clinical trial design 
are listed in table 61.
Table 61: Mechanistic clinical trial design
Advantages Disadvantages
minimises number of patients required 
in clinical trial
many investigations performed in each 
individual patient (large burden to 
individual patients)
allows rational modifications to be 
made to therapy whilst trial is 
progressing
time-consuming and complex trial 
protocol
maximises information attained during 
clinical trial
requires co-ordination of many 
specialised medical and scientific staff 
expensive
minimises patient toxicities assumes that outcomes from individual 
patients are translatable to others
improves overall understanding of a 
therapy
large amount of data generated which 
may be difficult to interpret
accelerates development of a therapy each clinical trial may take longer than 
with a conventional trial design
unlikely to falsely discard a therapy as 
non-efficacious
significant time spent developing each 
individual therapy
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A mechanistic clinical trial approach was used for both ADEPT clinical trials 
presented in this thesis, and it has been demonstrated that this design did, in fact, 
improve understanding of ADEPT for both trials.
The first clinical trial (A5CP and ZD2767P) was designed to examine if the 
enhanced features of ZD2767P, including increased potency and a short half-life 
of it active drug, would provide an advantage in terms of efficacy and reduced 
toxicity compared to the previous prodrug, CMDA (chapter 2). In addition it 
was proposed that the increased potency of ZD2767P would obviate the 
requirement for a clearing antibody system, as even low levels of CPG2 in 
tumour regions may be sufficient to allow enough ZD2767D to be generated for 
cytotoxic effect.
Efficacy in this trial was not achieved. The collection of quantitative mechanistic 
data allowed an understanding of the reason for this. Without a clearing antibody 
system inadequate tumour specific targeting occurred with low tumour to normal 
tissue ratios and minimal tumour enzyme localisation (tumour CPG2 enzyme 
levels 0.01 U/g by tumour biopsy and gamma camera analysis). Toxicity 
occurred at doses of ZD2767P too low for therapeutic effect, and was likely to be 
due to activation of ZD2767P by circulating CPG2 enzyme. As a result of the 
mechanistic data acquired the part II phase of the study was not performed, as the 
likelihood of these patients attaining efficacy from ADEPT was small. Without 
the mechanistic clinical trial design 14 patients would have been treated at MTD 
to assess efficacy.
The other important mechanistic information attained from this trial was that the 
antibody-enzyme conjugate, A5CP, was almost universally immunogenic, 
thereby limiting its potential for use for repeat therapy. It was also found to be 
difficult to manufacture with significant variability occurring in enzyme activity 
and protein concentration of each batch, resulting in different pharmacokinetic 
and radiolabelling profiles. Based on this data, a decision was made to develop a 
new antibody-enzyme for use in ADEPT, with the aim of having the features 
identified as being important, including improved tumour targeting, reduced 
immunogenicity and a more consistent product after manufacture. Without the
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mechanistic data acquired from the trial these decisions could not have been 
made.
MFECP1, a genetically engineered fusion protein, was subsequently developed 
and manufactured for ADEPT, and a new clinical trial protocol was designed 
within two years of the previous trial ending. The aims of the clinical trial of 
MFECP1 and ZD2767P were to assess the safety and targeting ability of 
MFECP1, and to attempt to escalate the ZD2767P dose to levels likely to result 
in efficacy. Preliminary data has been presented in chapter 4 on the first 13 
patients treated with MFECP1 and ZD2767P. Again mechanistic studies were 
used to facilitate an understanding of function in the clinical trial setting. The 
preliminary data suggests that MFECP1 clears rapidly from the systemic 
circulation, as was proposed by preclinical data. The data from localisation of 
radiolabelled MFECP1 by quantitative SPECT imaging suggest there should be 
adequate levels of tumour CPG2 enzyme for prodrug activation, however this has 
yet to be confirmed by tumour biopsy. Prodrug dose escalation in continuing and 
it is predicted that the levels of ZD2767P required for efficacy may be obtained 
in a further 3 dose-doublings. Importantly, MFECP1 also appears to be 
associated with reduced immunogenicity compared to A5CP, which will have 
implications for repeated therapy.
The collection and analysis of quantitative mechanistic data has therefore been 
used throughout this thesis to assess if the design features of the components of 
ADEPT function in vivo as proposed. In this way limitations to the system have 
been understood and modifications proposed. These modifications have been 
rationally developed and implemented, which was only made possible due to the 
ability to collect mechanistic data on patients participating in the clinical trials. 
Mechanistic studies for ADEPT have therefore resulted, as hypothesised, in an 
improved understanding and development of ADEPT.
My clinical contribution to the ADEPT A5CP and ZD2767P clinical trial was in
the recruitment and consenting of patients for the trial and the day to day care of
patients on the trial. I co-ordinated the investigations performed on the patients,
including liaising with scientific staff, other medical departments, wards, nursing
staff and the patients. I analysed the gamma camera scans and [F-18] FDG PET
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scans on all patients. I co-ordinated the collection and recording of the trial data 
and it was my role to integrate and interpret this data. I was involved in decisions 
regarding dose escalation, patient recruitment, timing of treatment and protocol 
modifications. I supervised the data entry into the Case Report Forms, and was 
responsible for answering data queries. I presented updates to the local ethics 
committee and reported adverse events and serious adverse event as required by 
the trial protocol. I presented data at the AstraZeneca quarterly meeting and was 
an important contributor to the interim and final reports issued to AstraZeneca.
As part of the development process for MFECP1 and its preparation for use in 
the clinical trial, I performed radiolabelling studies using technetium carbonyl for 
MFECP1. The methods and results of these radiolabelling studies are presented 
in chapter 3 .1 performed all of the radiolabelling experiments, including 
stability studies, CEA binding studies and a biodistribution experiment.
For the MFECP1 and ZD2767P clinical trial I was actively involved in the 
clinical trial design, the writing of the protocol and submission of the protocol to 
the appropriate regulatory committees (CIRB, ARSAC, LREC). As with the first 
ADEPT trial I had a clinical responsibility for the recruitment, consenting and 
management of patients on the trial. I, again, co-ordinated the running of the 
trial, and managed the timings of investigations and the co-ordination of staff and 
patients. I performed all of the gamma camera and FDG PET analysis for the 
patients on the trial. I supervised data entry into the case report forms and was 
responsible for the notification of serious adverse events. I played an active role 
in treatment decisions including dose escalations, timing of treatments and 
protocol modifications. I played a significant role in the collation, integration and 
interpretation of the mechanistic data collected on the 13 patients reported in this 
thesis. I was a key contributor to the interim report issued to AstraZeneca.
The points of discussion and conclusions formed about both clinical trials are my 
own, and were developed in collaboration and consultation with Prof R Begent 
and other key senior scientific and clinical staff. The contribution of other 
scientists and clinical staff to both trials was essential and I gratefully 
acknowledge their work.
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8.3 A quantitative method of metabolic response assessment in ADEPT 
may augment the assessment of response in a phase I clinical trial 
setting, and in particular it may aid in the interpretation of 
radiological stable disease
The second hypothesis addressed in this thesis is based on the concept that the 
metabolic assessment of response in tumours may provide additional information 
when compared to conventional dimensional response assessment, particularly in 
a phase I/II clinical trial setting with non-optimised treatment being administered 
to heavily pre-treated patients with resistant tumours. It is in this setting that a 
sensitive assessment for therapeutic effect is required.
In order to test this hypothesis as part of the ADEPT clinical trials I had to first 
develop a method of quantitative response assessment for gamma camera [F-18] 
FDG PET and then test the method on a group of patients having conventional 
chemotherapy. The development of the automated region growing program was 
conjoint work with Dr Alan Green, in collaboration with Prof R Begent. The 
automated region growing program generates tumour volumes in a 
mathematically defined, reproducible and rapid manner, which provides a 
significant advantage over previous subjective methods of region drawing. Dr 
Green designed and implemented the program.
I planned, wrote and submitted to LREC the protocol for the clinical trial of 
using gamma camera [F-18] FDG PET to assess response to chemotherapy in 
patients with a broad range of tumour types receiving conventional first or 
second line chemotherapy. I was involved in the recruitment and consent of 
patients, and I co-ordinated the clinical trial. I designed the case report forms, 
supervised the data entry into these and provided annual reports on the trial’s 
progress to LREC. I analysed the [F-18] FDG PET scans using the methods 
outlined in chapter 5 .1 was responsible for the interpretation of the data and for 
the conclusions attained as a result of the data acquired.
The clinical trial demonstrated that the automated region growing program could
be applied to gamma camera [F-18] FDG PET scans, and that a statistical
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measure that accounted for both tumour size and intensity of [F-18] FDG uptake 
correlated best with conventional measures of response and provided an 
advantage over methods that account for intensity alone. The trial also showed 
that quantitative gamma camera [F-18] FDG PET could be used to predict 
response to chemotherapy after 2-4 weeks of treatment. Importantly an [F-18] 
FDG PET response at 2-4 weeks correlated not only with CT response at 9-12 
weeks, but also with overall patient survival. The trial also demonstrated that [F- 
18] FDG PET was useful for the assessment of patients with radiological stable 
disease, in whom it is often difficult to know if a therapy is efficacious.
Based on these results, I applied the VOI analysis, using the automated region 
growing program, to the [F-18] FDG PET scans performed on the patients who 
participated in the ADEPT clinical trials. I performed the analysis and I 
interpreted the [F-18] FDG data for these patients. In the ADEPT A5CP clinical 
trial the two patients who attained stable disease with ADEPT and had [F-18] 
FDG PET scans that could be analysed, both had an increase in VOI total counts, 
indicating a metabolic progression after therapy. In the ADEPT MFECP1 clinical 
trial, both patients with radiological stable disease and [F-18] FDG PET scans 
again progressed on metabolic imaging, although one of the patients had minimal 
progression, especially on the early [F-18] FDG PET scan. These results indicate 
limited efficacy of ADEPT in these patients, despite the patients attaining 
radiological stable disease.
These preliminary results indicate that metabolic imaging using [F-18] FDG PET 
may provide additional information on the response of tumours to ADEPT. The 
collection of more data would be valuable to further assess this. In particular the 
demonstration of a dose-response relationship between ZD2767P dose and 
tumour [F-18] FDG uptake would provide encouraging evidence for potential 
efficacy of ADEPT, even in the absence of a radiological response.
I have also demonstrated in this thesis that VOI analysis using the automated 
region growing program is a promising technique for the analysis of [F-18] FDG 
PET scans performed on gamma camera PET. It has the potential for wider 
application, in particular for quantitative response assessment of response to
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therapies using [F-18] FDG PET, and is likely to be applicable to dedicated PET 
systems as well as gamma camera PET.
8.4 The organisation of the data collected in the ADEPT clinical trials into 
an Ontology and Conceptual Model of ADEPT can direct mechanistic 
clinical trial design and identify areas for improvement in ADEPT
The third hypothesis for this thesis was that by organising the data collected on 
ADEPT, future clinical trial design could be improved and areas for 
enhancement of ADEPT could be identified. The ADEPT Ontology and 
Conceptual Model presented in chapter 7 is designed to form the framework for 
organising data on ADEPT. I developed the Ontology using Protege-2000, on 
open-source java based ontology tool. I designed and implemented the Ontology 
and the Conceptual Model. From the Ontology and Conceptual Model I was able 
to organise the data collected on ADEPT, in particular with reference to clinical 
trials. I was then able to identify several areas where improved clinical trial 
design may provide further information on ADEPT and to identify some 
preliminary areas for improvement in ADEPT.
This work should provide the foundation to developing a relational database to 
enter, store, organise and query the data, and to develop mathematical models of 
ADEPT in order that proposed modifications to ADEPT could be ‘tested’ prior to 
implementation.
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8.5 Conclusion
ADEPT was developed as a therapeutic strategy when it became apparent in the 
1980s that for most solid tumours systemically delivered chemotherapeutics were 
unlikely to achieve cure. Since then a much greater molecular understanding of 
the pathogenesis of cancer has developed, as has an understanding of the 
limitations of conventional chemotherapy. Despite these advances there remains 
the prospect of only palliation for the vast majority of patients who have 
advanced disease with most of the common solid tumour types.
The advantage of a two-step system of ADEPT is that by generating active drug 
specifically in tumour sites systemic toxicity is minimised and tumour 
cytotoxicity is maximised. Theoretically the large quantities of cytotoxic agent 
generated in tumour may be sufficient to overcome resistance mechanisms and 
attain cure.
ADEPT is a complex strategy as it encompasses two therapeutic systems, and 
there are a vast number of modifications that could be made to the system that 
may affect its likelihood of success. I have presented in this thesis two clinical 
trials of ADEPT, which have both been designed in a mechanistic fashion in 
order that a maximal amount of relevant data could be obtained on the 
functioning of ADEPT in a clinical trial setting. This has been for the purpose of 
guiding potential modifications to the ADEPT system.
A mechanistic approach has been successful in identifying the limitations of
therapy in the first ADEPT clinical trial presented in this thesis using A5CP and
ZD2767P. This trial had no clinical responses however the mechanistic data
allowed an understanding of why this occurred. The mechanistic data also
identified the areas in which ADEPT needed to be improved. The second
ADEPT clinical trial utilised a new targeting system, MFECP1, with potentially
enhanced tumour targeting, reduced immunogenicity and a more robust
production process. Data collected on the thirteen patients treated to date, shows
improved tumour to normal tissue ratios of enzyme compared with A5CP, and
therefore should allow escalation of prodrug doses to levels that may be
efficacious. That trial is continuing and further mechanistic data will be
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generated which should be able to enhance the understanding of ADEPT, and 
direct further modifications for the future.
The metabolic imaging of tumours using [F-18] FDG PET is emerging as a 
promising method of assessing response to therapies. I was involved in the 
development of an automated region growing algorithm to define tumour 
volumes and I designed a clinical trial to test the program in a cohort of patients 
receiving first or second line chemotherapy. I found that the use of statistics that 
took into account a change in tumour volume and metabolic activity correlated 
with patient response using conventional imaging and survival. This method was 
then applied to analysis of [F-18] FDG PET scans acquired in patients receiving 
ADEPT, and was particularly useful for the assessment of patients with 
radiological stable disease.
Mechanistic trial design leads to the generation of large amounts of data, and this 
data needs to be converted to information and then knowledge. It is becoming 
increasing difficult to store, recall, and analyse the vast quantities of data that are 
generated by mechanistic studies without the use of informatics to aid in the 
organisation and accessibility of this data. My development of an ADEPT 
Ontology and Conceptual Model was designed to initiate this process, by 
identifying the components of ADEPT, and broadly defining their relationships.
The Ontology serves to organise the data associated with ADEPT and can be 
used to identify components of ADEPT mechanistic clinical trial design that may 
be modified and improved. It highlights the potential complexity of ADEPT, 
particularly by identifying a number of possible alterations that may be made to 
the system. The future development of a relational database and ultimately of 
detailed mathematical models for ADEPT based on the framework provided by 
the Ontology and Conceptual Model should further facilitate the development of 
ADEPT for the future.
The concepts explored throughout this thesis of mechanistic clinical trial design 
and data organisation have used ADEPT, a complex therapeutic strategy, as the 
example. Many of the principles however, are widely applicable to phase I/II
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clinical trial design and rational therapeutic development, and should therefore 
translate to other therapeutic approaches.
In conclusion, this thesis has outlined how a mechanistic approach to ADEPT 
has been used to collect data on a complex therapeutic strategy in a clinical 
setting, and how mechanistic data can be organised to facilitate an understanding 
of ADEPT and to identify areas of potential improvement to the system. It is by 
generating and interpreting this data that rational change to the system may be 
made, thereby speeding up the development process and improving the 
likelihood of efficacy. Although ADEPT is a complex therapeutic strategy, this 
should not in itself be a barrier to its successful development. As our 
understanding of the complexity of the genome and proteome develops, our 
knowledge of the difficulties of curing common solid tumours also increases. It 
is therefore becoming increasingly likely that a complex strategy will be required 
to cure this common and potentially terminal disease.
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APPENDIX 1 -  SPECT analysis
Examples of the SPECT data entry and analysis spreadsheets are presented 
below with accompanying descriptions of the process of analysis.
Table 62: Data entry spreadsheet for SPECT analysis:
Thorax 4 Thorax24
slice counts no. pixels slice counts no. pixels
lung T45 8812 84 T45 1829 81
T47 7929 104 T60 1759 176
T50 4616 60 T61 1277 170
mean 86.1 counts/ipixel mean 11.4 counts/ pixel
liver 121 5732 36 121 1683 40
T33 3880 25 T28 935 28
T35 5144 30 T29 1659 42
mean 162.2 counts/pixel mean 38.9 counts/ pixel
heart T43 15818 72 T36 2222 56
T44 14041 63 T37 2101 48
T45 15316 64 T38 3475 72
mean 227.0 counts/ pixel mean 44.3 counts/ pixel
tumour 1 T32 2764 24 T31 369 21
T33 2350 18 T32 739 32
T34 2339 21 T33 655 35
mean 118.3 counts/ pixel mean 20.0 counts/ pixel
tumour 2 T24 3747 30 T17 1630 48
T26 4199 30 T20 1032 42
T27 5459 36 T21 712 35
mean 139.6 counts/ pixel mean 27.0 counts per pixel
Abbreviations: T -  thorax
Table 62 is an example of the data entry form used for the SPECT analysis. 
Regions of interest (ROI) are placed in triplicate on areas of lung, liver, heart and 
tumour for each scan. For each ROI the slice (and whether on the T -thorax scan 
or A -  abdominal scan) are recorded. Also recorded is the number of pixels 
drawn and the total counts in the ROI. The mean counts per pixel are then 
calculated for each organ (total counts in the 3 ROI divided by total number of 
pixels).
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Table 63: Analysis spreadsheet example
Patient ID 15 half-life 1-131 192.48 hrs
Injected dose (MBq) 232 MBq Total dose A5CP 5373 U
Date and time of injection 09/07/98 13:32 correction factor 0.002448 cps per pixel
time after injection acquisition time per frame
Thorax 4 (Tx 4)scan 4.5 hrs Tx4 scan 25 seconds
Thorax 24 (Tx 24) scan 25.8 hrs Tx 24 scan 30 seconds
scan
ID
mean
cts/pixel
acquisition
time(s)
cts
/sec/
pixel
activity
(MBq/ml)
time
after
m j(h)
decay
correction
factor
(To)
Activity at To 
(MBq/ml)
% inj 
dose/ kg
estimated CPG2 
activity (U/g)
lung Tx4 86.1 25 3.4 0.008 4.5 1.016 0.0086 3.7% 0.20 U/g
Tx24 11.4 30 0.4 0.001 25.8 1.097 0.0010 0.4% 0.02 U/g
liver Tx4 162.2 25 6.5 0.016 4.5 1.016 0.0161 7.0% 0.38 U/g
Tx24 38.9 30 1.3 0.003 25.8 1.097 0.0035 1.5% 0.08 U/g
heart Tx4 227.0 25 9.1 0.022 4.5 1.016 0.0236 9.7% 0.52 U/g
Tx24 44.3 30 1.5 0.004 25.8 1.097 0.0034 1.7% 0.09 U/g
tumourl Tx4 118.3 25 4.7 0.011 4.5 1.016 0.0118 5.1% 0.27 U/g
Tx24 20.0 30 0.7 0.002 25.8 1.097 0.0018 0.8% 0.04 U/g
tumour2 Tx4 139.6 25 5.6 0.014 4.5 1.016 0.0139 6.0% 0.32 U/g
Tx24 27.0 30 0.9 0.002 25.8 1.097 0.0024 1.0% 0.05 U/g
Abbreviations: Tx — thorax, U- units; h -  hour; s -  seconds; cts -  counts; inj -  injected; To- time zero
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This spreadsheet displayed in table 63 is representative of the data analysis used 
to quantitatively calculate the biodistribution of radiolabelled antibody-enzyme 
as part of the ADEPT clinical trials. The steps involved in the analysis are 
outlined below.
The mean counts per pixel are derived from the values obtained in the ROI data 
entry spreadsheet.
The acquisition time represents the time per frame used as part of the SPECT 
protocol.
The mean counts per pixel per second can be calculated by dividing the mean 
counts per pixel by the acquisition time (s).
The activity is the calculated by converting counts per pixel per second to MBq 
per ml based on a correction factor derived from phantom studies scanned with 
clinical SPECT parameters. The phantom contains a known amount of 
radioactivity, and thus the resultant conversion factor from counts per pixel per 
second to radioactivity per unit mass can be made. The conversion factor for I- 
131 on this camera is 0.002448 counts per second per pixel per ml.
A correction then needs to be made for the radioactive decay that occurs between 
scans due to the half-life of the radioisotope. The half-life of 1-131 is 192.48 
hours. The formula for decay correction is l/(EXP(LN(0.5)*time after 
injection[h]/half-life)), where EXP is exponential, and LN is log.
The decay correction factor can be used to correct the radioactivity per ml to 
the time of injection (To).
The percentage injected dose per kg of tissue is then calculated by dividing the 
radioactivity per ml in each tissue, by the injected 1-131 dose (232 MBq), 
converting to a percentage and then dividing by 1000 (to change from ml to kg). 
The enzyme units in the organs may then be estimated by multiplying the 
%injected dose per kg, by the injected A5CP dose (5373 U) and multiplying by 
1000 to convert from kg to grams.
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